{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting the script...\n"
     ]
    }
   ],
   "source": [
    "print(\"Starting the script...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import glob\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "env_path = '/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/OpenAI_key.env'\n",
    "load_dotenv(env_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----- Part 1: Process the TCGA sample sheet -----"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading the cleaned TCGA sample sheet...\n",
      "Sample sheet loaded. Total rows: 17773\n"
     ]
    }
   ],
   "source": [
    "print(\"Loading the cleaned TCGA sample sheet...\")\n",
    "sample_sheet_path = \"/home/chb3333/yulab/chb3333/data_extraction/wxs_sample_sheet_clean.tsv\"\n",
    "sample_df = pd.read_csv(sample_sheet_path, sep=\"\\t\")\n",
    "print(\"Sample sheet loaded. Total rows:\", len(sample_df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Filtering for TCGA projects...\n",
      "TCGA projects filtered. Rows after filtering: 10640\n"
     ]
    }
   ],
   "source": [
    "print(\"Filtering for TCGA projects...\")\n",
    "tcga_df = sample_df[sample_df[\"Project ID\"].str.contains(\"TCGA\", na=False)].copy()\n",
    "print(\"TCGA projects filtered. Rows after filtering:\", len(tcga_df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Normalizing sample types...\n"
     ]
    }
   ],
   "source": [
    "print(\"Normalizing sample types...\")\n",
    "def normalize_sample_type(sample_str):\n",
    "    parts = [s.strip() for s in str(sample_str).split(\",\")]\n",
    "    return \", \".join(sorted(parts))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sample types normalized.\n"
     ]
    }
   ],
   "source": [
    "tcga_df[\"Normalized Sample Type\"] = tcga_df[\"Sample Type\"].apply(normalize_sample_type)\n",
    "print(\"Sample types normalized.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Extracting TCGA Cancer Type Abbreviation...\n"
     ]
    }
   ],
   "source": [
    "print(\"Extracting TCGA Cancer Type Abbreviation...\")\n",
    "tcga_df[\"Cancer Type Abbrev\"] = tcga_df[\"Project ID\"].str.replace(\"TCGA-\", \"\", regex=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Merging full TCGA Cancer Type name from mapping file...\n",
      "TCGA mapping merge complete. Rows in tcga_df: 10640\n"
     ]
    }
   ],
   "source": [
    "print(\"Merging full TCGA Cancer Type name from mapping file...\")\n",
    "tcga_map_path = \"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/tcga_study_abbreviations.csv\"\n",
    "tcga_map_df = pd.read_csv(tcga_map_path)\n",
    "tcga_df = pd.merge(tcga_df, tcga_map_df, left_on=\"Cancer Type Abbrev\", right_on=\"Study Abbreviation\", how=\"left\")\n",
    "print(\"TCGA mapping merge complete. Rows in tcga_df:\", len(tcga_df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "tcga_df = tcga_df.drop(['Cancer Type Abbrev', \"File ID\", \"File Name\", \"Data Category\", \"Data Type\" ], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Project ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sample ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Abbreviation",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Name",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "be506ecc-484a-4c76-ae28-14881e03d7bb",
       "rows": [
        [
         "0",
         "TCGA-OV",
         "TCGA-42-2588",
         "TCGA-42-2588-10A, TCGA-42-2588-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "OV",
         "Ovarian serous cystadenocarcinoma"
        ],
        [
         "1",
         "TCGA-OV",
         "TCGA-20-1686",
         "TCGA-20-1686-01A, TCGA-20-1686-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "OV",
         "Ovarian serous cystadenocarcinoma"
        ],
        [
         "2",
         "TCGA-OV",
         "TCGA-09-0366",
         "TCGA-09-0366-10B, TCGA-09-0366-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "OV",
         "Ovarian serous cystadenocarcinoma"
        ],
        [
         "3",
         "TCGA-OV",
         "TCGA-13-0916",
         "TCGA-13-0916-10A, TCGA-13-0916-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "OV",
         "Ovarian serous cystadenocarcinoma"
        ],
        [
         "4",
         "TCGA-OV",
         "TCGA-61-1740",
         "TCGA-61-1740-01A, TCGA-61-1740-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "OV",
         "Ovarian serous cystadenocarcinoma"
        ],
        [
         "5",
         "TCGA-ESCA",
         "TCGA-R6-A8WG",
         "TCGA-R6-A8WG-10A, TCGA-R6-A8WG-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "6",
         "TCGA-ESCA",
         "TCGA-LN-A7HY",
         "TCGA-LN-A7HY-10A, TCGA-LN-A7HY-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "7",
         "TCGA-ESCA",
         "TCGA-IG-A97I",
         "TCGA-IG-A97I-10A, TCGA-IG-A97I-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "8",
         "TCGA-ESCA",
         "TCGA-2H-A9GM",
         "TCGA-2H-A9GM-11A, TCGA-2H-A9GM-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "9",
         "TCGA-ESCA",
         "TCGA-R6-A6XQ",
         "TCGA-R6-A6XQ-10A, TCGA-R6-A6XQ-01B",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "10",
         "TCGA-ESCA",
         "TCGA-S8-A6BW",
         "TCGA-S8-A6BW-10A, TCGA-S8-A6BW-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "11",
         "TCGA-ESCA",
         "TCGA-L5-A8NT",
         "TCGA-L5-A8NT-01A, TCGA-L5-A8NT-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "12",
         "TCGA-ESCA",
         "TCGA-L5-A8NE",
         "TCGA-L5-A8NE-11A, TCGA-L5-A8NE-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "13",
         "TCGA-ESCA",
         "TCGA-L5-A43E",
         "TCGA-L5-A43E-10A, TCGA-L5-A43E-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "14",
         "TCGA-ESCA",
         "TCGA-JY-A6F8",
         "TCGA-JY-A6F8-10A, TCGA-JY-A6F8-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "15",
         "TCGA-ESCA",
         "TCGA-RE-A7BO",
         "TCGA-RE-A7BO-01A, TCGA-RE-A7BO-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "16",
         "TCGA-ESCA",
         "TCGA-LN-A4A5",
         "TCGA-LN-A4A5-01A, TCGA-LN-A4A5-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "17",
         "TCGA-ESCA",
         "TCGA-L5-A43C",
         "TCGA-L5-A43C-01A, TCGA-L5-A43C-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "18",
         "TCGA-ESCA",
         "TCGA-JY-A938",
         "TCGA-JY-A938-01A, TCGA-JY-A938-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "19",
         "TCGA-ESCA",
         "TCGA-L5-A4OO",
         "TCGA-L5-A4OO-11A, TCGA-L5-A4OO-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "20",
         "TCGA-ESCA",
         "TCGA-V5-AASW",
         "TCGA-V5-AASW-01A, TCGA-V5-AASW-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "21",
         "TCGA-ESCA",
         "TCGA-L5-A8NH",
         "TCGA-L5-A8NH-01A, TCGA-L5-A8NH-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "22",
         "TCGA-ESCA",
         "TCGA-V5-A7RB",
         "TCGA-V5-A7RB-01A, TCGA-V5-A7RB-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "23",
         "TCGA-ESCA",
         "TCGA-IG-A625",
         "TCGA-IG-A625-10A, TCGA-IG-A625-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "24",
         "TCGA-ESCA",
         "TCGA-VR-A8ET",
         "TCGA-VR-A8ET-10B, TCGA-VR-A8ET-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "25",
         "TCGA-ESCA",
         "TCGA-R6-A6L4",
         "TCGA-R6-A6L4-10A, TCGA-R6-A6L4-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "26",
         "TCGA-ESCA",
         "TCGA-JY-A6FH",
         "TCGA-JY-A6FH-01A, TCGA-JY-A6FH-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "27",
         "TCGA-ESCA",
         "TCGA-VR-A8EY",
         "TCGA-VR-A8EY-01A, TCGA-VR-A8EY-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "28",
         "TCGA-ESCA",
         "TCGA-L5-A88V",
         "TCGA-L5-A88V-11A, TCGA-L5-A88V-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "29",
         "TCGA-ESCA",
         "TCGA-LN-A4A9",
         "TCGA-LN-A4A9-10A, TCGA-LN-A4A9-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "30",
         "TCGA-ESCA",
         "TCGA-2H-A9GO",
         "TCGA-2H-A9GO-01A, TCGA-2H-A9GO-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "31",
         "TCGA-ESCA",
         "TCGA-L5-A4ON",
         "TCGA-L5-A4ON-11A, TCGA-L5-A4ON-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "32",
         "TCGA-ESCA",
         "TCGA-XP-A8T6",
         "TCGA-XP-A8T6-10A, TCGA-XP-A8T6-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "33",
         "TCGA-ESCA",
         "TCGA-LN-A4A4",
         "TCGA-LN-A4A4-10A, TCGA-LN-A4A4-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "34",
         "TCGA-ESCA",
         "TCGA-L5-A893",
         "TCGA-L5-A893-11A, TCGA-L5-A893-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "ESCA",
         "Esophageal carcinoma"
        ],
        [
         "35",
         "TCGA-BRCA",
         "TCGA-AR-A24U",
         "TCGA-AR-A24U-01A, TCGA-AR-A24U-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "36",
         "TCGA-BRCA",
         "TCGA-AQ-A04J",
         "TCGA-AQ-A04J-01A, TCGA-AQ-A04J-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "37",
         "TCGA-BRCA",
         "TCGA-BH-A0HK",
         "TCGA-BH-A0HK-01A, TCGA-BH-A0HK-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "38",
         "TCGA-BRCA",
         "TCGA-A2-A04U",
         "TCGA-A2-A04U-10A, TCGA-A2-A04U-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "39",
         "TCGA-BRCA",
         "TCGA-BH-A202",
         "TCGA-BH-A202-10A, TCGA-BH-A202-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "40",
         "TCGA-BRCA",
         "TCGA-OL-A5RU",
         "TCGA-OL-A5RU-01A, TCGA-OL-A5RU-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "41",
         "TCGA-BRCA",
         "TCGA-E2-A154",
         "TCGA-E2-A154-01A, TCGA-E2-A154-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "42",
         "TCGA-BRCA",
         "TCGA-AR-A5QQ",
         "TCGA-AR-A5QQ-10A, TCGA-AR-A5QQ-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "43",
         "TCGA-BRCA",
         "TCGA-D8-A140",
         "TCGA-D8-A140-10A, TCGA-D8-A140-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "44",
         "TCGA-BRCA",
         "TCGA-AN-A0XV",
         "TCGA-AN-A0XV-10A, TCGA-AN-A0XV-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "45",
         "TCGA-BRCA",
         "TCGA-EW-A1OV",
         "TCGA-EW-A1OV-01A, TCGA-EW-A1OV-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "46",
         "TCGA-BRCA",
         "TCGA-OL-A66L",
         "TCGA-OL-A66L-01A, TCGA-OL-A66L-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "47",
         "TCGA-BRCA",
         "TCGA-D8-A1JU",
         "TCGA-D8-A1JU-10A, TCGA-D8-A1JU-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "48",
         "TCGA-BRCA",
         "TCGA-A2-A0YL",
         "TCGA-A2-A0YL-01A, TCGA-A2-A0YL-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ],
        [
         "49",
         "TCGA-BRCA",
         "TCGA-C8-A1HE",
         "TCGA-C8-A1HE-10A, TCGA-C8-A1HE-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BRCA",
         "Breast invasive carcinoma"
        ]
       ],
       "shape": {
        "columns": 7,
        "rows": 10640
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Project ID</th>\n",
       "      <th>Case ID</th>\n",
       "      <th>Sample ID</th>\n",
       "      <th>Sample Type</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Study Abbreviation</th>\n",
       "      <th>Study Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>TCGA-OV</td>\n",
       "      <td>TCGA-42-2588</td>\n",
       "      <td>TCGA-42-2588-10A, TCGA-42-2588-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>OV</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>TCGA-OV</td>\n",
       "      <td>TCGA-20-1686</td>\n",
       "      <td>TCGA-20-1686-01A, TCGA-20-1686-10A</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>OV</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TCGA-OV</td>\n",
       "      <td>TCGA-09-0366</td>\n",
       "      <td>TCGA-09-0366-10B, TCGA-09-0366-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>OV</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>TCGA-OV</td>\n",
       "      <td>TCGA-13-0916</td>\n",
       "      <td>TCGA-13-0916-10A, TCGA-13-0916-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>OV</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>TCGA-OV</td>\n",
       "      <td>TCGA-61-1740</td>\n",
       "      <td>TCGA-61-1740-01A, TCGA-61-1740-11A</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>OV</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10635</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-BS-A0T9</td>\n",
       "      <td>TCGA-BS-A0T9-01A, TCGA-BS-A0T9-10C</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10636</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-AJ-A3BK</td>\n",
       "      <td>TCGA-AJ-A3BK-10A, TCGA-AJ-A3BK-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10637</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-EY-A547</td>\n",
       "      <td>TCGA-EY-A547-01A, TCGA-EY-A547-10A</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10638</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-AX-A3FT</td>\n",
       "      <td>TCGA-AX-A3FT-01A, TCGA-AX-A3FT-10A</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10639</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-EY-A1GE</td>\n",
       "      <td>TCGA-EY-A1GE-01A, TCGA-EY-A1GE-10A</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10640 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Project ID       Case ID                           Sample ID  \\\n",
       "0        TCGA-OV  TCGA-42-2588  TCGA-42-2588-10A, TCGA-42-2588-01A   \n",
       "1        TCGA-OV  TCGA-20-1686  TCGA-20-1686-01A, TCGA-20-1686-10A   \n",
       "2        TCGA-OV  TCGA-09-0366  TCGA-09-0366-10B, TCGA-09-0366-01A   \n",
       "3        TCGA-OV  TCGA-13-0916  TCGA-13-0916-10A, TCGA-13-0916-01A   \n",
       "4        TCGA-OV  TCGA-61-1740  TCGA-61-1740-01A, TCGA-61-1740-11A   \n",
       "...          ...           ...                                 ...   \n",
       "10635  TCGA-UCEC  TCGA-BS-A0T9  TCGA-BS-A0T9-01A, TCGA-BS-A0T9-10C   \n",
       "10636  TCGA-UCEC  TCGA-AJ-A3BK  TCGA-AJ-A3BK-10A, TCGA-AJ-A3BK-01A   \n",
       "10637  TCGA-UCEC  TCGA-EY-A547  TCGA-EY-A547-01A, TCGA-EY-A547-10A   \n",
       "10638  TCGA-UCEC  TCGA-AX-A3FT  TCGA-AX-A3FT-01A, TCGA-AX-A3FT-10A   \n",
       "10639  TCGA-UCEC  TCGA-EY-A1GE  TCGA-EY-A1GE-01A, TCGA-EY-A1GE-10A   \n",
       "\n",
       "                               Sample Type  \\\n",
       "0      Blood Derived Normal, Primary Tumor   \n",
       "1      Primary Tumor, Blood Derived Normal   \n",
       "2      Blood Derived Normal, Primary Tumor   \n",
       "3      Blood Derived Normal, Primary Tumor   \n",
       "4       Primary Tumor, Solid Tissue Normal   \n",
       "...                                    ...   \n",
       "10635  Primary Tumor, Blood Derived Normal   \n",
       "10636  Blood Derived Normal, Primary Tumor   \n",
       "10637  Primary Tumor, Blood Derived Normal   \n",
       "10638  Primary Tumor, Blood Derived Normal   \n",
       "10639  Primary Tumor, Blood Derived Normal   \n",
       "\n",
       "                    Normalized Sample Type Study Abbreviation  \\\n",
       "0      Blood Derived Normal, Primary Tumor                 OV   \n",
       "1      Blood Derived Normal, Primary Tumor                 OV   \n",
       "2      Blood Derived Normal, Primary Tumor                 OV   \n",
       "3      Blood Derived Normal, Primary Tumor                 OV   \n",
       "4       Primary Tumor, Solid Tissue Normal                 OV   \n",
       "...                                    ...                ...   \n",
       "10635  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10636  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10637  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10638  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10639  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "\n",
       "                                 Study Name  \n",
       "0         Ovarian serous cystadenocarcinoma  \n",
       "1         Ovarian serous cystadenocarcinoma  \n",
       "2         Ovarian serous cystadenocarcinoma  \n",
       "3         Ovarian serous cystadenocarcinoma  \n",
       "4         Ovarian serous cystadenocarcinoma  \n",
       "...                                     ...  \n",
       "10635  Uterine Corpus Endometrial Carcinoma  \n",
       "10636  Uterine Corpus Endometrial Carcinoma  \n",
       "10637  Uterine Corpus Endometrial Carcinoma  \n",
       "10638  Uterine Corpus Endometrial Carcinoma  \n",
       "10639  Uterine Corpus Endometrial Carcinoma  \n",
       "\n",
       "[10640 rows x 7 columns]"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tcga_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "icd_df = pd.read_parquet(\"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/icd_codes/icd_data.parquet\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "PATIENT_ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "eff39b7c-81af-40db-a60a-5fa12bcad66c",
       "rows": [
        [
         "0",
         "TCGA-OR-A5J1",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0"
        ],
        [
         "1",
         "TCGA-OR-A5J2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "2",
         "TCGA-OR-A5J3",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "3",
         "TCGA-OR-A5J4",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "4",
         "TCGA-OR-A5J5",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "5",
         "TCGA-OR-A5J6",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "6",
         "TCGA-OR-A5J7",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "7",
         "TCGA-OR-A5J8",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "8",
         "TCGA-OR-A5J9",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "9",
         "TCGA-OR-A5JA",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "10",
         "TCGA-OR-A5JB",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "11",
         "TCGA-OR-A5JC",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "12",
         "TCGA-OR-A5JD",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "13",
         "TCGA-OR-A5JE",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "14",
         "TCGA-OR-A5JF",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "15",
         "TCGA-OR-A5JG",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "16",
         "TCGA-OR-A5JH",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "17",
         "TCGA-OR-A5JI",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "18",
         "TCGA-OR-A5JJ",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "19",
         "TCGA-OR-A5JK",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "20",
         "TCGA-OR-A5JL",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "21",
         "TCGA-OR-A5JM",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "22",
         "TCGA-OR-A5JO",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "23",
         "TCGA-OR-A5JP",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "24",
         "TCGA-OR-A5JQ",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "25",
         "TCGA-OR-A5JR",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "26",
         "TCGA-OR-A5JS",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "27",
         "TCGA-OR-A5JT",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "28",
         "TCGA-OR-A5JU",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "29",
         "TCGA-OR-A5JV",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "30",
         "TCGA-OR-A5JW",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "31",
         "TCGA-OR-A5JX",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "32",
         "TCGA-OR-A5JY",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "33",
         "TCGA-OR-A5JZ",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "34",
         "TCGA-OR-A5K0",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "35",
         "TCGA-OR-A5K1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "36",
         "TCGA-OR-A5K2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "37",
         "TCGA-OR-A5K3",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "38",
         "TCGA-OR-A5K4",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "39",
         "TCGA-OR-A5K5",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "40",
         "TCGA-OR-A5K6",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "41",
         "TCGA-OR-A5K8",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "42",
         "TCGA-OR-A5K9",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "43",
         "TCGA-OR-A5KB",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "44",
         "TCGA-OR-A5KO",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "45",
         "TCGA-OR-A5KP",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "46",
         "TCGA-OR-A5KQ",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "47",
         "TCGA-OR-A5KS",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0"
        ],
        [
         "48",
         "TCGA-OR-A5KT",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0"
        ],
        [
         "49",
         "TCGA-OR-A5KU",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 10953
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>PATIENT_ID</th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>TCGA-OR-A5J1</td>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>TCGA-OR-A5J2</td>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TCGA-OR-A5J3</td>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>TCGA-OR-A5J4</td>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>TCGA-OR-A5J5</td>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10948</th>\n",
       "      <td>TCGA-V4-A9F3</td>\n",
       "      <td>UVM</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10949</th>\n",
       "      <td>TCGA-V4-A9EY</td>\n",
       "      <td>UVM</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10950</th>\n",
       "      <td>TCGA-V4-A9E5</td>\n",
       "      <td>UVM</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10951</th>\n",
       "      <td>TCGA-WC-A883</td>\n",
       "      <td>UVM</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10952</th>\n",
       "      <td>TCGA-VD-AA8P</td>\n",
       "      <td>UVM</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10953 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         PATIENT_ID CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE\n",
       "0      TCGA-OR-A5J1                 ACC  C74.0            8370/1        C74.0\n",
       "1      TCGA-OR-A5J2                 ACC  C74.0            8370/3        C74.0\n",
       "2      TCGA-OR-A5J3                 ACC  C74.0            8370/3        C74.0\n",
       "3      TCGA-OR-A5J4                 ACC  C74.0            8370/3        C74.0\n",
       "4      TCGA-OR-A5J5                 ACC  C74.0            8370/3        C74.0\n",
       "...             ...                 ...    ...               ...          ...\n",
       "10948  TCGA-V4-A9F3                 UVM   None              None         None\n",
       "10949  TCGA-V4-A9EY                 UVM   None              None         None\n",
       "10950  TCGA-V4-A9E5                 UVM   None              None         None\n",
       "10951  TCGA-WC-A883                 UVM   None              None         None\n",
       "10952  TCGA-VD-AA8P                 UVM   None              None         None\n",
       "\n",
       "[10953 rows x 5 columns]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "icd_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df = pd.merge(tcga_df, icd_df, left_on=\"Case ID\", right_on=\"PATIENT_ID\", how=\"inner\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "merged_df = merged_df.drop(columns=['Project ID', 'Sample ID', 'Sample Type'])\n",
    "\n",
    "# Select only the desired columns\n",
    "result_df = merged_df[['Case ID', 'CANCER_TYPE_ACRONYM', 'ICD_10', 'ICD_O_3_HISTOLOGY', 'ICD_O_3_SITE', 'Normalized Sample Type']]\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Case ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "a16894cf-96a7-4eec-9760-b1858ad4bf3d",
       "rows": [
        [
         "0",
         "TCGA-42-2588",
         "OV",
         "C56.9",
         "8441/3",
         "C56.9",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "1",
         "TCGA-20-1686",
         "OV",
         "C56.9",
         "8441/3",
         "C56.9",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "2",
         "TCGA-09-0366",
         "OV",
         null,
         null,
         null,
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "3",
         "TCGA-13-0916",
         "OV",
         null,
         null,
         null,
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "4",
         "TCGA-61-1740",
         "OV",
         "C56.9",
         "8441/3",
         "C56.9",
         "Primary Tumor, Solid Tissue Normal"
        ]
       ],
       "shape": {
        "columns": 6,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Case ID</th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>TCGA-42-2588</td>\n",
       "      <td>OV</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>8441/3</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>TCGA-20-1686</td>\n",
       "      <td>OV</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>8441/3</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TCGA-09-0366</td>\n",
       "      <td>OV</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>TCGA-13-0916</td>\n",
       "      <td>OV</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>TCGA-61-1740</td>\n",
       "      <td>OV</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>8441/3</td>\n",
       "      <td>C56.9</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        Case ID CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0  TCGA-42-2588                  OV  C56.9            8441/3        C56.9   \n",
       "1  TCGA-20-1686                  OV  C56.9            8441/3        C56.9   \n",
       "2  TCGA-09-0366                  OV   None              None         None   \n",
       "3  TCGA-13-0916                  OV   None              None         None   \n",
       "4  TCGA-61-1740                  OV  C56.9            8441/3        C56.9   \n",
       "\n",
       "                Normalized Sample Type  \n",
       "0  Blood Derived Normal, Primary Tumor  \n",
       "1  Blood Derived Normal, Primary Tumor  \n",
       "2  Blood Derived Normal, Primary Tumor  \n",
       "3  Blood Derived Normal, Primary Tumor  \n",
       "4   Primary Tumor, Solid Tissue Normal  "
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Display the resulting dataframe\n",
    "result_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "group_cols = ['CANCER_TYPE_ACRONYM', 'ICD_10', 'ICD_O_3_HISTOLOGY', 'ICD_O_3_SITE', 'Normalized Sample Type']\n",
    "\n",
    "# Group by these columns and aggregate the Case IDs into a list\n",
    "grouped_df = result_df.groupby(group_cols, dropna=False)['Case ID'].apply(list).reset_index()\n",
    "\n",
    "\n",
    "# If you prefer a comma-separated string instead of a list, you can convert it as follows:\n",
    "grouped_df['Case IDs'] = grouped_df['Case ID'].apply(lambda ids: ', '.join(ids))\n",
    "\n",
    "# Drop the original 'Case ID' column (if only the aggregated version is needed)\n",
    "grouped_df = grouped_df.drop(columns=['Case ID'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "0135695f-a2f1-4185-a3a4-b377d987f06e",
       "rows": [
        [
         "0",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA-OR-A5KS, TCGA-OR-A5L2"
        ],
        [
         "1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA-OR-A5K6, TCGA-OR-A5LO, TCGA-OR-A5JY, TCGA-OR-A5JV, TCGA-OR-A5K3, TCGA-OR-A5KO, TCGA-OR-A5K0, TCGA-OR-A5J6, TCGA-OR-A5LC, TCGA-OR-A5LA, TCGA-OR-A5LG, TCGA-OR-A5LB, TCGA-OR-A5JM, TCGA-OR-A5KQ, TCGA-OR-A5JD, TCGA-P6-A5OF, TCGA-PK-A5HA, TCGA-OR-A5KY, TCGA-OR-A5L4, TCGA-OR-A5J9, TCGA-OR-A5JS, TCGA-PK-A5H9, TCGA-OR-A5JJ, TCGA-OR-A5JI, TCGA-OR-A5JF, TCGA-OR-A5LF, TCGA-OR-A5JH, TCGA-OR-A5JU, TCGA-OR-A5JL, TCGA-OR-A5KP, TCGA-OR-A5JO, TCGA-OR-A5K8, TCGA-OR-A5LN, TCGA-OR-A5KX, TCGA-OR-A5KW, TCGA-OR-A5L8, TCGA-OR-A5JW, TCGA-OR-A5JK, TCGA-OR-A5LR, TCGA-OR-A5JZ, TCGA-OU-A5PI, TCGA-OR-A5LD, TCGA-OR-A5JE, TCGA-OR-A5LH, TCGA-OR-A5K5, TCGA-OR-A5LJ, TCGA-OR-A5LL, TCGA-OR-A5JX, TCGA-OR-A5JQ, TCGA-PA-A5YG, TCGA-PK-A5H8, TCGA-OR-A5J4, TCGA-OR-A5J2, TCGA-OR-A5JG, TCGA-OR-A5J5, TCGA-OR-A5JT, TCGA-OR-A5LK, TCGA-OR-A5JB, TCGA-OR-A5KT, TCGA-OR-A5J3, TCGA-OR-A5L6, TCGA-OR-A5LS, TCGA-OR-A5LP, TCGA-OR-A5K1, TCGA-OR-A5LI, TCGA-OR-A5L1, TCGA-OR-A5J7, TCGA-OR-A5LT, TCGA-OR-A5L5, TCGA-OR-A5JR, TCGA-OR-A5K2, TCGA-OR-A5K4, TCGA-OR-A5KZ, TCGA-OR-A5JC, TCGA-OR-A5L3, TCGA-OR-A5LE"
        ],
        [
         "2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA-P6-A5OH, TCGA-OR-A5K9"
        ],
        [
         "3",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA-FD-A6TE, TCGA-K4-A6MB, TCGA-BT-A2LD, TCGA-DK-AA6T, TCGA-FD-A3SS, TCGA-FD-A6TH, TCGA-FD-A5BV, TCGA-E7-A7DU, TCGA-FD-A3SN, TCGA-K4-A5RH, TCGA-DK-A6AW, TCGA-GC-A3RD, TCGA-KQ-A41P"
        ],
        [
         "4",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA-BT-A20R, TCGA-BT-A20Q"
        ],
        [
         "5",
         "BLCA",
         "C67.0",
         "8130/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-4Z-AA89, TCGA-FD-A3B3, TCGA-4Z-AA7R"
        ],
        [
         "6",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A54R, TCGA-GC-A3BM, TCGA-DK-A3X1, TCGA-BT-A2LB, TCGA-BL-A0C8, TCGA-BL-A0C8, TCGA-DK-A6AV, TCGA-FD-A43P, TCGA-DK-AA74, TCGA-BL-A0C8, TCGA-4Z-AA86, TCGA-DK-A3WY, TCGA-DK-AA6L"
        ],
        [
         "7",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20X, TCGA-BT-A2LA"
        ],
        [
         "8",
         "BLCA",
         "C67.1",
         "8260/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-HQ-A2OF"
        ],
        [
         "9",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FD-A3SQ, TCGA-FD-A3B7, TCGA-4Z-AA7M, TCGA-DK-A3IK, TCGA-FD-A3SM, TCGA-ZF-A9RC, TCGA-UY-A9PA, TCGA-DK-AA6P, TCGA-DK-AA6R, TCGA-FD-A6TF, TCGA-FD-A62N, TCGA-DK-A3WX, TCGA-FD-A5BR, TCGA-GU-A763, TCGA-DK-A3IT, TCGA-FD-A43U, TCGA-DK-AA6X, TCGA-G2-A2EL, TCGA-2F-A9KP, TCGA-YF-AA3L, TCGA-R3-A69X, TCGA-FD-A3SJ, TCGA-DK-A6B0, TCGA-4Z-AA7W, TCGA-E7-A3X6, TCGA-UY-A9PB, TCGA-BT-A3PJ, TCGA-DK-AA71, TCGA-FD-A6TB, TCGA-GU-AATP, TCGA-DK-AA6S, TCGA-FD-A3B8, TCGA-DK-AA6W, TCGA-FD-A3B4, TCGA-PQ-A6FN, TCGA-ZF-AA54, TCGA-FJ-A871, TCGA-DK-A3IN, TCGA-DK-A3IL, TCGA-YF-AA3M, TCGA-FD-A6TG, TCGA-ZF-A9RG, TCGA-DK-A3IV, TCGA-DK-AA6U, TCGA-DK-A3X2, TCGA-E5-A2PC, TCGA-4Z-AA7N, TCGA-FD-A5BU, TCGA-FD-A3SO, TCGA-FD-A5BT, TCGA-DK-AA6M"
        ],
        [
         "10",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20W, TCGA-BT-A20O, TCGA-BT-A20V"
        ],
        [
         "11",
         "BLCA",
         "C67.2",
         "8130/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-XF-AAMQ, TCGA-BT-A42B, TCGA-UY-A9PF, TCGA-XF-AAML, TCGA-4Z-AA7Y, TCGA-FJ-A3Z9, TCGA-CF-A9FF, TCGA-4Z-AA7O, TCGA-FD-A6TA, TCGA-BT-A42C, TCGA-CF-A7I0"
        ],
        [
         "12",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-E7-A6ME, TCGA-FD-A43Y, TCGA-DK-AA75, TCGA-FD-A3N6, TCGA-UY-A9PD, TCGA-E7-A6MD, TCGA-KQ-A41Q, TCGA-FD-A6TK, TCGA-FD-A6TI, TCGA-GU-A764, TCGA-K4-AAQO, TCGA-DK-A6B1, TCGA-GV-A3QF, TCGA-FD-A5BZ, TCGA-FD-A6TD, TCGA-DK-AA76, TCGA-DK-A6B5"
        ],
        [
         "13",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20T, TCGA-G2-A2EO"
        ],
        [
         "14",
         "BLCA",
         "C67.3",
         "8130/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I4"
        ],
        [
         "15",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A3IU, TCGA-DK-A3IQ, TCGA-FD-A62S, TCGA-FD-A3SP, TCGA-FD-A3SR, TCGA-FD-A3N5, TCGA-DK-AA77, TCGA-FD-A3NA, TCGA-FD-A3B5, TCGA-FD-A3SL, TCGA-K4-A6FZ, TCGA-BT-A3PK, TCGA-DK-A6B6, TCGA-BL-A5ZZ, TCGA-KQ-A41S, TCGA-ZF-AA56, TCGA-ZF-A9RD, TCGA-DK-A6B2, TCGA-ZF-AA5P, TCGA-DK-A3WW, TCGA-BL-A13J, TCGA-DK-AA6Q, TCGA-ZF-A9R0, TCGA-K4-A4AB, TCGA-FD-A5BY, TCGA-FD-A5BS, TCGA-GV-A3QG, TCGA-GV-A3QI, TCGA-SY-A9G0, TCGA-ZF-A9RN, TCGA-FD-A6TC, TCGA-FD-A5C0, TCGA-FD-A43N, TCGA-4Z-AA82, TCGA-FD-A5C1, TCGA-K4-A5RI, TCGA-BL-A13J, TCGA-BL-A13J, TCGA-FD-A5BX, TCGA-ZF-AA52, TCGA-FD-A43S, TCGA-FD-A62P, TCGA-XF-AAN8, TCGA-2F-A9KT"
        ],
        [
         "16",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KO, TCGA-BT-A20J"
        ],
        [
         "17",
         "BLCA",
         "C67.4",
         "8130/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A5RJ, TCGA-BT-A42E, TCGA-FD-A3B6, TCGA-FD-A43X, TCGA-4Z-AA81"
        ],
        [
         "18",
         "BLCA",
         "C67.5",
         "8120/3",
         "C67.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FT-A3EE"
        ],
        [
         "19",
         "BLCA",
         "C67.6",
         "8120/3",
         "C67.6",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-KQ-A41N"
        ],
        [
         "20",
         "BLCA",
         "C67.9",
         "8010/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-ZF-AA4N"
        ],
        [
         "21",
         "BLCA",
         "C67.9",
         "8070/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A1HS"
        ],
        [
         "22",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-DK-A1A6"
        ],
        [
         "23",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-C4-A0EZ, TCGA-GV-A40G, TCGA-DK-A3IS, TCGA-GV-A40E, TCGA-DK-A2HX, TCGA-ZF-AA53, TCGA-HQ-A5ND, TCGA-E7-A7PW, TCGA-DK-A1A7, TCGA-GD-A3OQ, TCGA-C4-A0F0, TCGA-2F-A9KW, TCGA-UY-A78O, TCGA-4Z-AA87, TCGA-5N-A9KI, TCGA-C4-A0F6, TCGA-XF-A9SL, TCGA-XF-A9T3, TCGA-UY-A8OC, TCGA-GD-A76B, TCGA-YC-A9TC, TCGA-GC-A3I6, TCGA-SY-A9G5, TCGA-XF-AAMR, TCGA-XF-A9SY, TCGA-DK-A1AD, TCGA-XF-AAMJ, TCGA-5N-A9KM, TCGA-DK-A1A6, TCGA-CU-A3QU, TCGA-ZF-A9R3, TCGA-K4-A83P, TCGA-XF-A9T2, TCGA-E7-A97Q, TCGA-CU-A72E, TCGA-GC-A3RC, TCGA-UY-A9PH, TCGA-GU-AATO, TCGA-E7-A677, TCGA-ZF-A9R9, TCGA-XF-A8HD, TCGA-BL-A13I, TCGA-BL-A13I, TCGA-GU-A766, TCGA-XF-AAN0, TCGA-XF-A9SW, TCGA-DK-A1AB, TCGA-XF-AAMX, TCGA-ZF-A9RF, TCGA-ZF-A9RL, TCGA-K4-A4AC, TCGA-E7-A7XN, TCGA-LC-A66R, TCGA-CF-A8HX, TCGA-GC-A6I1, TCGA-XF-A9T0, TCGA-G2-A2EK, TCGA-ZF-AA4W, TCGA-GU-A762, TCGA-E7-A519, TCGA-XF-A9SP, TCGA-CU-A5W6, TCGA-FT-A61P, TCGA-XF-A8HF, TCGA-BT-A3PH, TCGA-YC-A89H, TCGA-KQ-A41O, TCGA-XF-A9SX, TCGA-GU-A42Q, TCGA-ZF-A9R5, TCGA-GU-AATQ, TCGA-XF-AAN4, TCGA-XF-AAMT, TCGA-ZF-AA4R, TCGA-GU-A767, TCGA-G2-AA3C, TCGA-XF-AAN5, TCGA-XF-A8HG, TCGA-E7-A85H, TCGA-H4-A2HQ, TCGA-LT-A5Z6, TCGA-ZF-A9R1, TCGA-DK-A1AF, TCGA-ZF-AA5N, TCGA-UY-A8OD, TCGA-4Z-AA7Q, TCGA-CU-A0YR, TCGA-C4-A0F7, TCGA-CU-A3KJ, TCGA-GU-A42P, TCGA-K4-A3WU, TCGA-DK-A1AA, TCGA-G2-A3IE, TCGA-GC-A3WC, TCGA-HQ-A2OE, TCGA-DK-A2I2, TCGA-E7-A678, TCGA-GC-A3OO, TCGA-XF-AAN3, TCGA-GV-A3JW, TCGA-G2-AA3B, TCGA-CF-A1HR, TCGA-DK-A1AE, TCGA-E7-A5KE, TCGA-E7-A5KF, TCGA-BT-A0S7, TCGA-FJ-A3Z7, TCGA-CF-A8HY, TCGA-XF-A8HE, TCGA-E7-A4XJ, TCGA-FJ-A3ZE, TCGA-GD-A6C6, TCGA-C4-A0F1, TCGA-GC-A4ZW, TCGA-GC-A6I3, TCGA-XF-A9SJ, TCGA-XF-A9SH, TCGA-G2-A2EJ, TCGA-XF-AAME, TCGA-DK-A1A3, TCGA-E5-A4TZ, TCGA-G2-AA3D, TCGA-KQ-A41R, TCGA-ZF-AA4X, TCGA-BL-A13I, TCGA-XF-A9T5, TCGA-E7-A3Y1, TCGA-UY-A9PE, TCGA-GV-A3QK, TCGA-GV-A3JV, TCGA-XF-AAMW, TCGA-ZF-AA51, TCGA-BT-A0YX, TCGA-ZF-AA4T, TCGA-XF-AAMH, TCGA-DK-A1AC, TCGA-4Z-AA84, TCGA-XF-A9SK, TCGA-DK-A1A5, TCGA-GC-A3RB, TCGA-PQ-A6FI, TCGA-XF-A8HH, TCGA-ZF-AA5H, TCGA-E7-A8O7, TCGA-ZF-AA58, TCGA-E7-A97P, TCGA-G2-A2EC, TCGA-GD-A3OP, TCGA-ZF-A9R4, TCGA-XF-AAMG, TCGA-XF-A9T8, TCGA-GC-A3YS, TCGA-K4-A3WS, TCGA-UY-A78M, TCGA-E5-A4U1, TCGA-G2-A2EF, TCGA-GD-A3OS, TCGA-ZF-A9RE, TCGA-DK-A3IM, TCGA-CF-A5U8, TCGA-UY-A78N, TCGA-ZF-AA4U, TCGA-GD-A2C5, TCGA-S5-A6DX, TCGA-ZF-A9RM, TCGA-XF-AAMF, TCGA-XF-AAN2, TCGA-G2-AA3F, TCGA-GV-A3JZ, TCGA-XF-AAN7, TCGA-G2-A3IB, TCGA-XF-A9SM, TCGA-CF-A5UA, TCGA-ZF-AA4V, TCGA-G2-A3VY, TCGA-ZF-A9R7, TCGA-GV-A3JX, TCGA-HQ-A5NE, TCGA-XF-A9SZ, TCGA-K4-A3WV, TCGA-XF-A9T4"
        ],
        [
         "24",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KQ, TCGA-UY-A78P, TCGA-UY-A8OB, TCGA-G2-A2ES, TCGA-BL-A3JM"
        ],
        [
         "25",
         "BLCA",
         "C67.9",
         "8130/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A47W, TCGA-XF-AAN1, TCGA-UY-A78K, TCGA-XF-A9T6, TCGA-LT-A8JT, TCGA-CF-A27C, TCGA-CF-A9FL, TCGA-XF-AAMY, TCGA-MV-A51V, TCGA-E7-A541, TCGA-2F-A9KR, TCGA-CF-A9FM, TCGA-CF-A3MF, TCGA-E7-A7DV, TCGA-CF-A3MG, TCGA-4Z-AA83, TCGA-CF-A9FH, TCGA-CF-A47X, TCGA-XF-A8HB, TCGA-S5-AA26, TCGA-XF-A9SV, TCGA-CF-A47S, TCGA-XF-AAMZ, TCGA-E7-A6MF, TCGA-E7-A4IJ, TCGA-H4-A2HO, TCGA-4Z-AA80, TCGA-CF-A47Y, TCGA-YC-A8S6, TCGA-ZF-A9R2, TCGA-CF-A3MH, TCGA-CF-A47V, TCGA-XF-A8HI, TCGA-4Z-AA7S, TCGA-CF-A3MI, TCGA-FJ-A3ZF, TCGA-CU-A0YO, TCGA-CU-A3YL, TCGA-CF-A47T, TCGA-UY-A78L, TCGA-DK-A2I1, TCGA-XF-A8HC, TCGA-XF-A9ST, TCGA-XF-A9SU, TCGA-XF-A9SI, TCGA-XF-A9SG, TCGA-GV-A6ZA"
        ],
        [
         "26",
         "BRCA",
         "C50.2",
         "8500/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18I"
        ],
        [
         "27",
         "BRCA",
         "C50.2",
         "8524/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-LD-A7W6"
        ],
        [
         "28",
         "BRCA",
         "C50.3",
         "8500/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18M, TCGA-BH-A18P"
        ],
        [
         "29",
         "BRCA",
         "C50.3",
         "8523/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18S"
        ],
        [
         "30",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A18V"
        ],
        [
         "31",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18V, TCGA-BH-A18U"
        ],
        [
         "32",
         "BRCA",
         "C50.5",
         "8500/3",
         "C50.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18G"
        ],
        [
         "33",
         "BRCA",
         "C50.8",
         "8022/3",
         "C50.8",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-Z7-A8R6"
        ],
        [
         "34",
         "BRCA",
         "C50.8",
         "8500/3",
         "C50.8",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18Q"
        ],
        [
         "35",
         "BRCA",
         "C50.9",
         "8010/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A7-A5ZV"
        ],
        [
         "36",
         "BRCA",
         "C50.9",
         "8013/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SK"
        ],
        [
         "37",
         "BRCA",
         "C50.9",
         "8200/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SB"
        ],
        [
         "38",
         "BRCA",
         "C50.9",
         "8211/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73X"
        ],
        [
         "39",
         "BRCA",
         "C50.9",
         "8401/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A2-A04W"
        ],
        [
         "40",
         "BRCA",
         "C50.9",
         "8480/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73W, TCGA-A2-A3KD, TCGA-C8-A12X, TCGA-D8-A27W, TCGA-D8-A1XV, TCGA-C8-A1HL, TCGA-C8-A8HQ, TCGA-D8-A1XC, TCGA-E9-A5UO, TCGA-OL-A66H, TCGA-AC-A8OR"
        ],
        [
         "41",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-E2-A15A, TCGA-E2-A15E, TCGA-E2-A15K"
        ],
        [
         "42",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-AR-A24U, TCGA-AQ-A04J, TCGA-BH-A0HK, TCGA-A2-A04U, TCGA-BH-A202, TCGA-OL-A5RU, TCGA-E2-A154, TCGA-D8-A140, TCGA-AN-A0XV, TCGA-EW-A1OV, TCGA-OL-A66L, TCGA-D8-A1JU, TCGA-C8-A1HE, TCGA-A2-A04R, TCGA-AR-A0TP, TCGA-A7-A26I, TCGA-EW-A1PB, TCGA-C8-A26V, TCGA-AN-A0XR, TCGA-A8-A08X, TCGA-AR-A1AX, TCGA-BH-A0EB, TCGA-A7-A0DB, TCGA-BH-A0W7, TCGA-BH-A0B4, TCGA-EW-A1P8, TCGA-A2-A0CV, TCGA-A8-A083, TCGA-B6-A0WY, TCGA-AN-A0XP, TCGA-A8-A07R, TCGA-A2-A04Q, TCGA-EW-A1P6, TCGA-C8-A27B, TCGA-A8-A06R, TCGA-B6-A0RH, TCGA-A2-A0YG, TCGA-A2-A0SU, TCGA-BH-A0EE, TCGA-D8-A1JH, TCGA-E2-A152, TCGA-EW-A1IZ, TCGA-OL-A5D6, TCGA-A1-A0SD, TCGA-BH-A0DK, TCGA-E2-A156, TCGA-A7-A56D, TCGA-E9-A1ND, TCGA-AR-A1AR, TCGA-A2-A1G4, TCGA-AN-A0FN, TCGA-GM-A2DA, TCGA-AR-A0TX, TCGA-BH-A0BP, TCGA-D8-A27P, TCGA-BH-A0AW, TCGA-E9-A1RF, TCGA-E9-A1R0, TCGA-A7-A6VY, TCGA-A2-A0CX, TCGA-AR-A0TZ, TCGA-A2-A25F, TCGA-E2-A15D, TCGA-OL-A5D7, TCGA-AC-A5EH, TCGA-AR-A0TR, TCGA-AQ-A1H2, TCGA-GM-A2DL, TCGA-EW-A1PD, TCGA-AN-A0XN, TCGA-AO-A03P, TCGA-D8-A1XW, TCGA-A7-A26I, TCGA-D8-A1JL, TCGA-LL-A5YN, TCGA-S3-A6ZH, TCGA-EW-A1P1, TCGA-B6-A0WW, TCGA-AN-A03Y, TCGA-D8-A1X5, TCGA-AN-A0AR, TCGA-A8-A09I, TCGA-C8-A1HO, TCGA-AO-A0JI, TCGA-BH-A0BD, TCGA-C8-A274, TCGA-B6-A1KC, TCGA-E2-A1L7, TCGA-A8-A06Q, TCGA-E9-A1R4, TCGA-A2-A0D4, TCGA-AC-A62V, TCGA-AR-A24Q, TCGA-AC-A8OP, TCGA-B6-A0WV, TCGA-D8-A27R, TCGA-D8-A1XB, TCGA-A2-A259, TCGA-D8-A1XL, TCGA-E2-A1IO, TCGA-A8-A08B, TCGA-BH-A0W5, TCGA-AO-A0JD, TCGA-3C-AALJ, TCGA-AO-A03O, TCGA-A8-A07F, TCGA-A1-A0SH, TCGA-A7-A6VV, TCGA-A2-A3XW, TCGA-B6-A0WT, TCGA-D8-A1Y3, TCGA-AR-A255, TCGA-B6-A0RT, TCGA-C8-A278, TCGA-BH-A6R8, TCGA-D8-A27K, TCGA-EW-A1PH, TCGA-3C-AALK, TCGA-EW-A6S9, TCGA-C8-A12Q, TCGA-E2-A15I, TCGA-A8-A0A9, TCGA-A2-A04X, TCGA-PL-A8LY, TCGA-E9-A24A, TCGA-B6-A0RG, TCGA-A1-A0SO, TCGA-C8-A12W, TCGA-A7-A26J, TCGA-AO-A03L, TCGA-GM-A3XL, TCGA-BH-A0DX, TCGA-A8-A07Z, TCGA-B6-A0I6, TCGA-B6-A0I6, TCGA-GM-A2DB, TCGA-E9-A247, TCGA-A8-A07G, TCGA-AN-A0XW, TCGA-BH-A0B1, TCGA-D8-A143, TCGA-D8-A1XR, TCGA-E2-A155, TCGA-D8-A1JJ, TCGA-E2-A1IG, TCGA-BH-A0B0, TCGA-D8-A1JG, TCGA-B6-A0RM, TCGA-BH-A0BM, TCGA-E2-A14V, TCGA-A2-A0ET, TCGA-AN-A0FL, TCGA-A2-A0EO, TCGA-A2-A1G0, TCGA-BH-A5J0, TCGA-C8-A138, TCGA-E2-A1B1, TCGA-C8-A1HN, TCGA-E2-A1IN, TCGA-BH-A0HN, TCGA-LD-A9QF, TCGA-A8-A09B, TCGA-E2-A574, TCGA-BH-A0H9, TCGA-C8-A131, TCGA-AC-A62X, TCGA-AN-A046, TCGA-A7-A4SF, TCGA-E2-A1L6, TCGA-AR-A24S, TCGA-A2-A0YT, TCGA-E9-A1R5, TCGA-A8-A07J, TCGA-A2-A0EV, TCGA-A8-A06X, TCGA-E2-A14N, TCGA-AO-A12A, TCGA-E2-A10C, TCGA-AN-A04C, TCGA-LL-A5YP, TCGA-AN-A0AM, TCGA-E2-A1II, TCGA-AO-A0JC, TCGA-A8-A07W, TCGA-D8-A1XY, TCGA-BH-A0DQ, TCGA-AN-A0XT, TCGA-LL-A73Z, TCGA-B6-A0I8, TCGA-AQ-A0Y5, TCGA-C8-A1HI, TCGA-A7-A0CD, TCGA-A7-A0DA, TCGA-A8-A091, TCGA-D8-A1XU, TCGA-B6-A0IK, TCGA-AR-A0U0, TCGA-EW-A6SD, TCGA-OL-A5RY, TCGA-E9-A1R2, TCGA-AN-A0AK, TCGA-AR-A252, TCGA-BH-A0EI, TCGA-E9-A22A, TCGA-A2-A25B, TCGA-BH-A0BW, TCGA-C8-A12Y, TCGA-AR-A0U3, TCGA-A2-A0CQ, TCGA-AR-A24K, TCGA-BH-A0H0, TCGA-AR-A0U2, TCGA-GM-A2DK, TCGA-BH-A0GZ, TCGA-BH-A0BL, TCGA-LL-A740, TCGA-B6-A0RO, TCGA-A2-A0T2, TCGA-E2-A15S, TCGA-A2-A0T1, TCGA-D8-A1JC, TCGA-A2-A3XU, TCGA-EW-A1P7, TCGA-C8-A1HJ, TCGA-AN-A0XU, TCGA-BH-A5IZ, TCGA-AO-A0JB, TCGA-BH-A0W4, TCGA-AN-A0AT, TCGA-A8-A07I, TCGA-A2-A0YM, TCGA-C8-A134, TCGA-B6-A1KI, TCGA-A1-A0SN, TCGA-E2-A15R, TCGA-S3-AA11, TCGA-AO-A128, TCGA-E2-A15T, TCGA-A8-A095, TCGA-D8-A1Y2, TCGA-UL-AAZ6, TCGA-A2-A0CL, TCGA-A8-A08P, TCGA-C8-A12M, TCGA-AR-A1AS, TCGA-E9-A1QZ, TCGA-A7-A6VX, TCGA-A8-A081, TCGA-BH-A0BQ, TCGA-A8-A093, TCGA-C8-A26X, TCGA-A2-A0ER, TCGA-A2-A04Y, TCGA-A2-A0D2, TCGA-D8-A1JA, TCGA-A7-A0CE, TCGA-C8-A12K, TCGA-A7-A26J, TCGA-AN-A0FS, TCGA-OL-A5RW, TCGA-A2-A0YC, TCGA-D8-A1JM, TCGA-AN-A0AL, TCGA-LL-A7SZ, TCGA-A8-A06T, TCGA-A8-A06U, TCGA-BH-A0C0, TCGA-A2-A0SV, TCGA-E9-A22G, TCGA-AR-A0TS, TCGA-A8-A06P, TCGA-B6-A0X5, TCGA-D8-A1JP, TCGA-AN-A0FD, TCGA-GM-A2DF, TCGA-AR-A0TW, TCGA-AN-A0FZ, TCGA-AN-A0FF, TCGA-C8-A12V, TCGA-AC-A23E, TCGA-A1-A0SP, TCGA-A2-A0EQ, TCGA-A2-A1FW, TCGA-C8-A1HK, TCGA-D8-A1X6, TCGA-A2-A0EY, TCGA-A8-A09C, TCGA-EW-A6SB, TCGA-A8-A07U, TCGA-A8-A08G, TCGA-BH-A0BV, TCGA-C8-A12T, TCGA-E2-A1IF, TCGA-D8-A1XA, TCGA-E2-A15A, TCGA-E2-A1B0, TCGA-AR-A24W, TCGA-A7-A26J, TCGA-A8-A06O, TCGA-D8-A1JE, TCGA-V7-A7HQ, TCGA-C8-A1HF, TCGA-C8-A137, TCGA-E2-A15E, TCGA-A2-A0D1, TCGA-AR-A24Z, TCGA-E2-A15K, TCGA-E2-A14Y, TCGA-AN-A0XO, TCGA-LD-A7W5, TCGA-D8-A1J9, TCGA-E2-A15C, TCGA-C8-A26Z, TCGA-OL-A6VR, TCGA-D8-A27N, TCGA-A8-A08H, TCGA-A8-A097, TCGA-AO-A03V, TCGA-AR-A1AH, TCGA-A2-A1G6, TCGA-E2-A1IK, TCGA-BH-A0AV, TCGA-A2-A0YJ, TCGA-A7-A26H, TCGA-C8-A12L, TCGA-UU-A93S, TCGA-E2-A1L9, TCGA-A8-A08O, TCGA-E9-A1R3, TCGA-E2-A570, TCGA-A2-A04P, TCGA-A2-A0CS, TCGA-LL-A8F5, TCGA-BH-A0HI, TCGA-EW-A1OZ, TCGA-E2-A1B6, TCGA-BH-A0C7, TCGA-S3-AA14, TCGA-B6-A0RS, TCGA-A2-A0T0, TCGA-AN-A0G0, TCGA-OL-A66I, TCGA-A8-A09N, TCGA-C8-A135, TCGA-A2-A0CT, TCGA-AO-A0JE, TCGA-D8-A1Y1, TCGA-AO-A1KP, TCGA-A8-A092, TCGA-AR-A1AO, TCGA-D8-A27L, TCGA-BH-A0E1, TCGA-E2-A573, TCGA-AR-A0TV, TCGA-A2-A04N, TCGA-AR-A250, TCGA-BH-A0B8, TCGA-E9-A243, TCGA-BH-A0BJ, TCGA-E2-A159, TCGA-E2-A14Z, TCGA-BH-A0HB, TCGA-C8-A1HG, TCGA-E9-A1R7, TCGA-D8-A141, TCGA-AO-A0JM, TCGA-BH-A0GY, TCGA-GM-A2DN, TCGA-D8-A13Z, TCGA-A7-A13E, TCGA-AR-A251, TCGA-A8-A07P, TCGA-BH-A0B9, TCGA-D8-A1Y0, TCGA-BH-A0DH, TCGA-E9-A22D, TCGA-AR-A1AP, TCGA-D8-A1XK, TCGA-AQ-A54O, TCGA-A2-A0CU, TCGA-D8-A1X9, TCGA-A2-A0T5, TCGA-D8-A1XQ, TCGA-AR-A1AY, TCGA-A8-A09G, TCGA-OL-A6VO, TCGA-AR-A254, TCGA-A8-A09M, TCGA-A8-A08R, TCGA-E2-A14X, TCGA-E9-A1RH, TCGA-A2-A4S3, TCGA-BH-A0BR, TCGA-AN-A0FY, TCGA-B6-A0IB, TCGA-E2-A15J, TCGA-E2-A1IE, TCGA-A2-A3Y0, TCGA-D8-A1XG, TCGA-A2-A0T3, TCGA-A2-A0SX, TCGA-BH-A0B3, TCGA-A7-A0D9, TCGA-D8-A1JK, TCGA-BH-A0HF, TCGA-AC-A7VB, TCGA-EW-A1P5, TCGA-B6-A0RE, TCGA-D8-A13Y, TCGA-B6-A0I5, TCGA-AC-A6NO, TCGA-E2-A15H, TCGA-AR-A24P, TCGA-AO-A03T, TCGA-D8-A1JF, TCGA-OL-A5D8, TCGA-A2-A0YH, TCGA-BH-A0HW, TCGA-GM-A2DM, TCGA-A2-A0T7, TCGA-BH-A0DE, TCGA-GM-A2DH, TCGA-AN-A0AS, TCGA-OL-A5S0, TCGA-E2-A9RU, TCGA-E2-A56Z, TCGA-C8-A275, TCGA-BH-A0DZ, TCGA-S3-AA0Z, TCGA-E2-A1LA, TCGA-E9-A1R6, TCGA-E9-A229, TCGA-E2-A14T, TCGA-PL-A8LZ, TCGA-AN-A0FW, TCGA-LL-A6FQ, TCGA-BH-A0AY, TCGA-D8-A1XM, TCGA-AN-A0XS, TCGA-E9-A1RB, TCGA-AC-A5XU, TCGA-AR-A1AU, TCGA-A8-A09D, TCGA-E9-A1RD, TCGA-EW-A1IY, TCGA-D8-A1J8, TCGA-C8-A12Z, TCGA-AO-A03R, TCGA-C8-A12U, TCGA-A7-A13D, TCGA-BH-A18H, TCGA-B6-A0X4, TCGA-C8-A12N, TCGA-AC-A8OQ, TCGA-C8-A12P, TCGA-E9-A1N8, TCGA-BH-A0W3, TCGA-AR-A24V, TCGA-A8-A090, TCGA-BH-A0HQ, TCGA-BH-A0DS, TCGA-AO-A0J4, TCGA-AO-A0J6, TCGA-A8-A099, TCGA-A7-A0DB, TCGA-EW-A1PA, TCGA-AR-A1AQ, TCGA-C8-A132, TCGA-A7-A13D, TCGA-AN-A04A, TCGA-BH-A0RX, TCGA-A2-A1FZ, TCGA-BH-A201, TCGA-A8-A085, TCGA-GM-A2DD, TCGA-A8-A09A, TCGA-AO-A0JF, TCGA-EW-A6SA, TCGA-E2-A1AZ, TCGA-B6-A1KF, TCGA-S3-A6ZF, TCGA-AQ-A1H3, TCGA-AQ-A04H, TCGA-BH-A0HY, TCGA-AN-A049, TCGA-BH-A0BC, TCGA-A2-A0D0, TCGA-A2-A0CW, TCGA-AN-A04D, TCGA-E9-A1RA, TCGA-A1-A0SF, TCGA-BH-A0E2, TCGA-OL-A66P, TCGA-A2-A0EM, TCGA-AO-A12D, TCGA-E2-A14Q, TCGA-A8-A094, TCGA-A7-A13D, TCGA-E2-A14P, TCGA-AO-A1KR, TCGA-E9-A1RG, TCGA-BH-A0HX, TCGA-LL-A5YO, TCGA-C8-A27A, TCGA-WT-AB41, TCGA-D8-A27M, TCGA-BH-A0H6, TCGA-D8-A147, TCGA-E2-A14W, TCGA-A2-A0CP, TCGA-PL-A8LX, TCGA-C8-A26W, TCGA-B6-A0RI, TCGA-A2-A0EU, TCGA-S3-AA15, TCGA-E9-A245, TCGA-BH-A0HO, TCGA-E9-A228, TCGA-C8-A12O, TCGA-A2-A0YE, TCGA-B6-A0I2, TCGA-AN-A041, TCGA-A8-A079, TCGA-A8-A08T, TCGA-E2-A150, TCGA-S3-AA17, TCGA-A2-A0D3, TCGA-AC-A6IW, TCGA-C8-A1HM, TCGA-A8-A08L, TCGA-AN-A0FV, TCGA-AN-A0FK, TCGA-E9-A227, TCGA-A7-A6VW, TCGA-AR-A24N, TCGA-A2-A0SW, TCGA-AO-A0JA, TCGA-EW-A1J6, TCGA-A8-A07L, TCGA-AC-A23C, TCGA-A2-A0YF, TCGA-A2-A1FX, TCGA-A8-A07B, TCGA-A2-A04T, TCGA-AN-A03X, TCGA-E2-A14O, TCGA-LL-A73Y, TCGA-E2-A15O, TCGA-A2-A0CM, TCGA-EW-A1J1, TCGA-A7-A0DB, TCGA-E2-A158, TCGA-A8-A09Q, TCGA-AR-A24L, TCGA-BH-A0B7, TCGA-B6-A0RN, TCGA-E9-A22E, TCGA-E9-A1NG, TCGA-B6-A0WS, TCGA-A1-A0SQ, TCGA-3C-AALI, TCGA-B6-A0RL, TCGA-D8-A1XT, TCGA-A7-A4SE, TCGA-AR-A256, TCGA-A7-A0CJ, TCGA-AR-A1AV, TCGA-A8-A08Z, TCGA-A8-A096, TCGA-E9-A226, TCGA-E2-A153, TCGA-A2-A25E, TCGA-D8-A1JI, TCGA-A1-A0SM, TCGA-A8-A075, TCGA-C8-A273, TCGA-BH-A42V, TCGA-AR-A1AN, TCGA-OL-A5RX, TCGA-OL-A5RZ, TCGA-AR-A0TQ, TCGA-A8-A06Z, TCGA-S3-AA10, TCGA-A8-A076, TCGA-AR-A1AJ, TCGA-E9-A1RE, TCGA-A1-A0SJ, TCGA-OL-A66O, TCGA-E9-A244, TCGA-OL-A5RV, TCGA-BH-A0EA, TCGA-AO-A1KT, TCGA-E2-A14R, TCGA-A8-A06Y, TCGA-A7-A5ZW, TCGA-D8-A1JD, TCGA-B6-A409, TCGA-E9-A248, TCGA-A2-A0ST, TCGA-LL-A6FR, TCGA-AN-A0FX, TCGA-AR-A0TT, TCGA-D8-A1XZ, TCGA-E9-A22H, TCGA-A1-A0SI, TCGA-EW-A1P3, TCGA-BH-A0E0, TCGA-B6-A0X1, TCGA-EW-A1OY, TCGA-EW-A2FS, TCGA-E2-A15P, TCGA-BH-A0E7, TCGA-BH-A0HU, TCGA-AR-A0TY, TCGA-E2-A1B4, TCGA-GM-A2DC, TCGA-D8-A27H, TCGA-B6-A1KN, TCGA-E2-A1BD, TCGA-A8-A08C, TCGA-AN-A0FT, TCGA-A2-A25C, TCGA-B6-A0I9, TCGA-AQ-A54N, TCGA-A7-A13E, TCGA-A8-A082, TCGA-D8-A145, TCGA-D8-A27F, TCGA-B6-A0IJ, TCGA-A7-A13F, TCGA-BH-A0H7, TCGA-A2-A04V, TCGA-S3-AA12, TCGA-B6-A0WZ, TCGA-AR-A0U1, TCGA-C8-A130, TCGA-AN-A0FJ, TCGA-AR-A1AW, TCGA-LL-A7T0, TCGA-AO-A0J2, TCGA-AR-A24R, TCGA-BH-A0BO, TCGA-A2-A1G1, TCGA-C8-A26Y, TCGA-D8-A1JB, TCGA-E2-A10A, TCGA-D8-A1XF, TCGA-A7-A13E, TCGA-AO-A12F, TCGA-D8-A142, TCGA-A8-A07O, TCGA-AR-A0TU, TCGA-B6-A401"
        ],
        [
         "43",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A1FE"
        ],
        [
         "44",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A1F6, TCGA-BH-A1FU, TCGA-BH-A203, TCGA-BH-A1FJ, TCGA-BH-A1FD, TCGA-BH-A0BS, TCGA-BH-A1FE, TCGA-BH-A0BF, TCGA-BH-A0DT, TCGA-A7-A13G, TCGA-BH-A18L, TCGA-BH-A0HA, TCGA-BH-A1EN, TCGA-BH-A1F8, TCGA-BH-A18T, TCGA-BH-A1F5, TCGA-BH-A1EY, TCGA-BH-A0DI, TCGA-BH-A0BZ, TCGA-E2-A1IU, TCGA-BH-A204, TCGA-AC-A2BM, TCGA-BH-A1ES, TCGA-A7-A0CH, TCGA-BH-A1EW, TCGA-BH-A18N, TCGA-A7-A13G, TCGA-GI-A2C8, TCGA-E2-A1LB, TCGA-AC-A2BK, TCGA-GM-A2DI, TCGA-BH-A0H3, TCGA-GM-A2D9, TCGA-BH-A0DO, TCGA-BH-A0AU, TCGA-BH-A1EV, TCGA-BH-A1EU, TCGA-BH-A208, TCGA-BH-A1FM, TCGA-AC-A23H, TCGA-BH-A0DV, TCGA-E2-A1LS, TCGA-BH-A18J, TCGA-E9-A1NH, TCGA-BH-A18R, TCGA-BH-A18F, TCGA-BH-A1ET, TCGA-BH-A1FH, TCGA-E2-A1LH, TCGA-BH-A0DG, TCGA-BH-A1F0, TCGA-BH-A0BT, TCGA-E2-A1LK, TCGA-BH-A18K, TCGA-BH-A0AZ, TCGA-BH-A1FL, TCGA-E2-A1LL, TCGA-BH-A1FG, TCGA-BH-A1FN, TCGA-BH-A0DD, TCGA-BH-A1EX"
        ],
        [
         "45",
         "BRCA",
         "C50.9",
         "8503/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-B6-A0IC, TCGA-EW-A2FW, TCGA-BH-A0HL, TCGA-D8-A1JS, TCGA-D8-A1X7"
        ],
        [
         "46",
         "BRCA",
         "C50.9",
         "8507/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SG, TCGA-D8-A1XS, TCGA-EW-A1PE, TCGA-EW-A2FV"
        ],
        [
         "47",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-PL-A8LV, TCGA-AR-A1AI, TCGA-EW-A1P4"
        ],
        [
         "48",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A209, TCGA-BH-A1FC"
        ],
        [
         "49",
         "BRCA",
         "C50.9",
         "8520/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-AC-A6IX"
        ]
       ],
       "shape": {
        "columns": 6,
        "rows": 731
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Case IDs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>726</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>727</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C55</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C55.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>728</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>729</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-N9-A4Q8, TCGA-N9-A4PZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>730</th>\n",
       "      <td>UVM</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>731 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0                   ACC  C74.0            8370/1        C74.0   \n",
       "1                   ACC  C74.0            8370/3        C74.0   \n",
       "2                   ACC  C74.0            8370/3        C74.0   \n",
       "3                  BLCA  C67.0            8120/3        C67.0   \n",
       "4                  BLCA  C67.0            8120/3        C67.0   \n",
       "..                  ...    ...               ...          ...   \n",
       "726                 UCS  C54.3            8980/3        C54.3   \n",
       "727                 UCS    C55            8950/3        C55.9   \n",
       "728                 UCS    NaN               NaN          NaN   \n",
       "729                 UCS    NaN               NaN          NaN   \n",
       "730                 UVM    NaN               NaN          NaN   \n",
       "\n",
       "                  Normalized Sample Type  \\\n",
       "0    Blood Derived Normal, Primary Tumor   \n",
       "1    Blood Derived Normal, Primary Tumor   \n",
       "2     Primary Tumor, Solid Tissue Normal   \n",
       "3    Blood Derived Normal, Primary Tumor   \n",
       "4     Primary Tumor, Solid Tissue Normal   \n",
       "..                                   ...   \n",
       "726  Blood Derived Normal, Primary Tumor   \n",
       "727  Blood Derived Normal, Primary Tumor   \n",
       "728  Blood Derived Normal, Primary Tumor   \n",
       "729   Primary Tumor, Solid Tissue Normal   \n",
       "730  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                              Case IDs  \n",
       "0    TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...  \n",
       "1    TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...  \n",
       "2    TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...  \n",
       "3    TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...  \n",
       "4    TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...  \n",
       "..                                                 ...  \n",
       "726                                       TCGA-N8-A4PM  \n",
       "727  TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...  \n",
       "728  TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...  \n",
       "729                         TCGA-N9-A4Q8, TCGA-N9-A4PZ  \n",
       "730  TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...  \n",
       "\n",
       "[731 rows x 6 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Translating Codes to Text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "file_path = \"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/icd_codes/ICD-O-3.2_MFin_17042019_web.csv\"\n",
    "\n",
    "# Load the Excel file\n",
    "morphology_description = pd.read_csv(file_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['Codes', 'Morphology_Description'], dtype='object')"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "morphology_description.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "file_path = \"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/icd_codes/ICD-O3 Topography.csv\"\n",
    "icd_o3 = pd.read_csv(file_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['icdo3_code', 'description'], dtype='object')"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "icd_o3.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(       Codes                             Morphology_Description\n",
       " 0     8000/0                                   Neoplasm, benign\n",
       " 1     8000/1    Neoplasm, uncertain whether benign or malignant\n",
       " 2     8000/3                                Neoplasm, malignant\n",
       " 3     8000/6                               Neoplasm, metastatic\n",
       " 4     8000/9  Neoplasm, malignant, uncertain whether primary...\n",
       " ...      ...                                                ...\n",
       " 1138  9985/3  Myelodysplastic syndrome with multilineage dys...\n",
       " 1139  9986/3    Myelodysplastic syndrome with isolated del (5q)\n",
       " 1140  9987/3      Therapy-related myelodysplastic syndrome, NOS\n",
       " 1141  9989/3                      Myelodysplastic syndrome, NOS\n",
       " 1142  9993/3  Myelodysplastic syndrome with ring sideroblast...\n",
       " \n",
       " [1143 rows x 2 columns],)"
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "morphology_description,\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "icd_mapping = dict(zip(icd_o3['icdo3_code'], icd_o3['description']))\n",
    "morph_mapping = dict(zip(morphology_description['Codes'], morphology_description['Morphology_Description']))\n",
    "\n",
    "# Translate ICD_10 and ICD_O_3_SITE codes using icd_o3 mapping\n",
    "grouped_df['ICD_10_desc'] = grouped_df['ICD_10'].map(icd_mapping)\n",
    "grouped_df['ICD_O_3_SITE_desc'] = grouped_df['ICD_O_3_SITE'].map(icd_mapping)\n",
    "\n",
    "# Translate ICD_O_3_HISTOLOGY codes using morphology_description mapping\n",
    "grouped_df['ICD_O_3_HISTOLOGY_desc'] = grouped_df['ICD_O_3_HISTOLOGY'].map(morph_mapping)\n",
    "\n",
    "study_abbrev = pd.read_csv(\"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/tcga_study_abbreviations.csv\")\n",
    "study_mapping = dict(zip(study_abbrev['Study Abbreviation'], study_abbrev['Study Name']))\n",
    "grouped_df['CANCER_TYPE_NAME'] = grouped_df['CANCER_TYPE_ACRONYM'].map(study_mapping)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "3b32a5ba-d660-4aef-b711-bad231188ec3",
       "rows": [
        [
         "0",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA-OR-A5KS, TCGA-OR-A5L2",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         null,
         "Adrenocortical carcinoma"
        ],
        [
         "1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA-OR-A5K6, TCGA-OR-A5LO, TCGA-OR-A5JY, TCGA-OR-A5JV, TCGA-OR-A5K3, TCGA-OR-A5KO, TCGA-OR-A5K0, TCGA-OR-A5J6, TCGA-OR-A5LC, TCGA-OR-A5LA, TCGA-OR-A5LG, TCGA-OR-A5LB, TCGA-OR-A5JM, TCGA-OR-A5KQ, TCGA-OR-A5JD, TCGA-P6-A5OF, TCGA-PK-A5HA, TCGA-OR-A5KY, TCGA-OR-A5L4, TCGA-OR-A5J9, TCGA-OR-A5JS, TCGA-PK-A5H9, TCGA-OR-A5JJ, TCGA-OR-A5JI, TCGA-OR-A5JF, TCGA-OR-A5LF, TCGA-OR-A5JH, TCGA-OR-A5JU, TCGA-OR-A5JL, TCGA-OR-A5KP, TCGA-OR-A5JO, TCGA-OR-A5K8, TCGA-OR-A5LN, TCGA-OR-A5KX, TCGA-OR-A5KW, TCGA-OR-A5L8, TCGA-OR-A5JW, TCGA-OR-A5JK, TCGA-OR-A5LR, TCGA-OR-A5JZ, TCGA-OU-A5PI, TCGA-OR-A5LD, TCGA-OR-A5JE, TCGA-OR-A5LH, TCGA-OR-A5K5, TCGA-OR-A5LJ, TCGA-OR-A5LL, TCGA-OR-A5JX, TCGA-OR-A5JQ, TCGA-PA-A5YG, TCGA-PK-A5H8, TCGA-OR-A5J4, TCGA-OR-A5J2, TCGA-OR-A5JG, TCGA-OR-A5J5, TCGA-OR-A5JT, TCGA-OR-A5LK, TCGA-OR-A5JB, TCGA-OR-A5KT, TCGA-OR-A5J3, TCGA-OR-A5L6, TCGA-OR-A5LS, TCGA-OR-A5LP, TCGA-OR-A5K1, TCGA-OR-A5LI, TCGA-OR-A5L1, TCGA-OR-A5J7, TCGA-OR-A5LT, TCGA-OR-A5L5, TCGA-OR-A5JR, TCGA-OR-A5K2, TCGA-OR-A5K4, TCGA-OR-A5KZ, TCGA-OR-A5JC, TCGA-OR-A5L3, TCGA-OR-A5LE",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA-P6-A5OH, TCGA-OR-A5K9",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "3",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA-FD-A6TE, TCGA-K4-A6MB, TCGA-BT-A2LD, TCGA-DK-AA6T, TCGA-FD-A3SS, TCGA-FD-A6TH, TCGA-FD-A5BV, TCGA-E7-A7DU, TCGA-FD-A3SN, TCGA-K4-A5RH, TCGA-DK-A6AW, TCGA-GC-A3RD, TCGA-KQ-A41P",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "4",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA-BT-A20R, TCGA-BT-A20Q",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "5",
         "BLCA",
         "C67.0",
         "8130/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-4Z-AA89, TCGA-FD-A3B3, TCGA-4Z-AA7R",
         "Trigone, bladder",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "6",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A54R, TCGA-GC-A3BM, TCGA-DK-A3X1, TCGA-BT-A2LB, TCGA-BL-A0C8, TCGA-BL-A0C8, TCGA-DK-A6AV, TCGA-FD-A43P, TCGA-DK-AA74, TCGA-BL-A0C8, TCGA-4Z-AA86, TCGA-DK-A3WY, TCGA-DK-AA6L",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "7",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20X, TCGA-BT-A2LA",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "8",
         "BLCA",
         "C67.1",
         "8260/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-HQ-A2OF",
         "Dome, bladder",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "9",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FD-A3SQ, TCGA-FD-A3B7, TCGA-4Z-AA7M, TCGA-DK-A3IK, TCGA-FD-A3SM, TCGA-ZF-A9RC, TCGA-UY-A9PA, TCGA-DK-AA6P, TCGA-DK-AA6R, TCGA-FD-A6TF, TCGA-FD-A62N, TCGA-DK-A3WX, TCGA-FD-A5BR, TCGA-GU-A763, TCGA-DK-A3IT, TCGA-FD-A43U, TCGA-DK-AA6X, TCGA-G2-A2EL, TCGA-2F-A9KP, TCGA-YF-AA3L, TCGA-R3-A69X, TCGA-FD-A3SJ, TCGA-DK-A6B0, TCGA-4Z-AA7W, TCGA-E7-A3X6, TCGA-UY-A9PB, TCGA-BT-A3PJ, TCGA-DK-AA71, TCGA-FD-A6TB, TCGA-GU-AATP, TCGA-DK-AA6S, TCGA-FD-A3B8, TCGA-DK-AA6W, TCGA-FD-A3B4, TCGA-PQ-A6FN, TCGA-ZF-AA54, TCGA-FJ-A871, TCGA-DK-A3IN, TCGA-DK-A3IL, TCGA-YF-AA3M, TCGA-FD-A6TG, TCGA-ZF-A9RG, TCGA-DK-A3IV, TCGA-DK-AA6U, TCGA-DK-A3X2, TCGA-E5-A2PC, TCGA-4Z-AA7N, TCGA-FD-A5BU, TCGA-FD-A3SO, TCGA-FD-A5BT, TCGA-DK-AA6M",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "10",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20W, TCGA-BT-A20O, TCGA-BT-A20V",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "11",
         "BLCA",
         "C67.2",
         "8130/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-XF-AAMQ, TCGA-BT-A42B, TCGA-UY-A9PF, TCGA-XF-AAML, TCGA-4Z-AA7Y, TCGA-FJ-A3Z9, TCGA-CF-A9FF, TCGA-4Z-AA7O, TCGA-FD-A6TA, TCGA-BT-A42C, TCGA-CF-A7I0",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "12",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-E7-A6ME, TCGA-FD-A43Y, TCGA-DK-AA75, TCGA-FD-A3N6, TCGA-UY-A9PD, TCGA-E7-A6MD, TCGA-KQ-A41Q, TCGA-FD-A6TK, TCGA-FD-A6TI, TCGA-GU-A764, TCGA-K4-AAQO, TCGA-DK-A6B1, TCGA-GV-A3QF, TCGA-FD-A5BZ, TCGA-FD-A6TD, TCGA-DK-AA76, TCGA-DK-A6B5",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "13",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20T, TCGA-G2-A2EO",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "14",
         "BLCA",
         "C67.3",
         "8130/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I4",
         null,
         null,
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "15",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A3IU, TCGA-DK-A3IQ, TCGA-FD-A62S, TCGA-FD-A3SP, TCGA-FD-A3SR, TCGA-FD-A3N5, TCGA-DK-AA77, TCGA-FD-A3NA, TCGA-FD-A3B5, TCGA-FD-A3SL, TCGA-K4-A6FZ, TCGA-BT-A3PK, TCGA-DK-A6B6, TCGA-BL-A5ZZ, TCGA-KQ-A41S, TCGA-ZF-AA56, TCGA-ZF-A9RD, TCGA-DK-A6B2, TCGA-ZF-AA5P, TCGA-DK-A3WW, TCGA-BL-A13J, TCGA-DK-AA6Q, TCGA-ZF-A9R0, TCGA-K4-A4AB, TCGA-FD-A5BY, TCGA-FD-A5BS, TCGA-GV-A3QG, TCGA-GV-A3QI, TCGA-SY-A9G0, TCGA-ZF-A9RN, TCGA-FD-A6TC, TCGA-FD-A5C0, TCGA-FD-A43N, TCGA-4Z-AA82, TCGA-FD-A5C1, TCGA-K4-A5RI, TCGA-BL-A13J, TCGA-BL-A13J, TCGA-FD-A5BX, TCGA-ZF-AA52, TCGA-FD-A43S, TCGA-FD-A62P, TCGA-XF-AAN8, TCGA-2F-A9KT",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "16",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KO, TCGA-BT-A20J",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "17",
         "BLCA",
         "C67.4",
         "8130/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A5RJ, TCGA-BT-A42E, TCGA-FD-A3B6, TCGA-FD-A43X, TCGA-4Z-AA81",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "18",
         "BLCA",
         "C67.5",
         "8120/3",
         "C67.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FT-A3EE",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "19",
         "BLCA",
         "C67.6",
         "8120/3",
         "C67.6",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-KQ-A41N",
         "Ureteric orifice",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "20",
         "BLCA",
         "C67.9",
         "8010/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-ZF-AA4N",
         "Bladder NOS",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "21",
         "BLCA",
         "C67.9",
         "8070/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A1HS",
         "Bladder NOS",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "22",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-DK-A1A6",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "23",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-C4-A0EZ, TCGA-GV-A40G, TCGA-DK-A3IS, TCGA-GV-A40E, TCGA-DK-A2HX, TCGA-ZF-AA53, TCGA-HQ-A5ND, TCGA-E7-A7PW, TCGA-DK-A1A7, TCGA-GD-A3OQ, TCGA-C4-A0F0, TCGA-2F-A9KW, TCGA-UY-A78O, TCGA-4Z-AA87, TCGA-5N-A9KI, TCGA-C4-A0F6, TCGA-XF-A9SL, TCGA-XF-A9T3, TCGA-UY-A8OC, TCGA-GD-A76B, TCGA-YC-A9TC, TCGA-GC-A3I6, TCGA-SY-A9G5, TCGA-XF-AAMR, TCGA-XF-A9SY, TCGA-DK-A1AD, TCGA-XF-AAMJ, TCGA-5N-A9KM, TCGA-DK-A1A6, TCGA-CU-A3QU, TCGA-ZF-A9R3, TCGA-K4-A83P, TCGA-XF-A9T2, TCGA-E7-A97Q, TCGA-CU-A72E, TCGA-GC-A3RC, TCGA-UY-A9PH, TCGA-GU-AATO, TCGA-E7-A677, TCGA-ZF-A9R9, TCGA-XF-A8HD, TCGA-BL-A13I, TCGA-BL-A13I, TCGA-GU-A766, TCGA-XF-AAN0, TCGA-XF-A9SW, TCGA-DK-A1AB, TCGA-XF-AAMX, TCGA-ZF-A9RF, TCGA-ZF-A9RL, TCGA-K4-A4AC, TCGA-E7-A7XN, TCGA-LC-A66R, TCGA-CF-A8HX, TCGA-GC-A6I1, TCGA-XF-A9T0, TCGA-G2-A2EK, TCGA-ZF-AA4W, TCGA-GU-A762, TCGA-E7-A519, TCGA-XF-A9SP, TCGA-CU-A5W6, TCGA-FT-A61P, TCGA-XF-A8HF, TCGA-BT-A3PH, TCGA-YC-A89H, TCGA-KQ-A41O, TCGA-XF-A9SX, TCGA-GU-A42Q, TCGA-ZF-A9R5, TCGA-GU-AATQ, TCGA-XF-AAN4, TCGA-XF-AAMT, TCGA-ZF-AA4R, TCGA-GU-A767, TCGA-G2-AA3C, TCGA-XF-AAN5, TCGA-XF-A8HG, TCGA-E7-A85H, TCGA-H4-A2HQ, TCGA-LT-A5Z6, TCGA-ZF-A9R1, TCGA-DK-A1AF, TCGA-ZF-AA5N, TCGA-UY-A8OD, TCGA-4Z-AA7Q, TCGA-CU-A0YR, TCGA-C4-A0F7, TCGA-CU-A3KJ, TCGA-GU-A42P, TCGA-K4-A3WU, TCGA-DK-A1AA, TCGA-G2-A3IE, TCGA-GC-A3WC, TCGA-HQ-A2OE, TCGA-DK-A2I2, TCGA-E7-A678, TCGA-GC-A3OO, TCGA-XF-AAN3, TCGA-GV-A3JW, TCGA-G2-AA3B, TCGA-CF-A1HR, TCGA-DK-A1AE, TCGA-E7-A5KE, TCGA-E7-A5KF, TCGA-BT-A0S7, TCGA-FJ-A3Z7, TCGA-CF-A8HY, TCGA-XF-A8HE, TCGA-E7-A4XJ, TCGA-FJ-A3ZE, TCGA-GD-A6C6, TCGA-C4-A0F1, TCGA-GC-A4ZW, TCGA-GC-A6I3, TCGA-XF-A9SJ, TCGA-XF-A9SH, TCGA-G2-A2EJ, TCGA-XF-AAME, TCGA-DK-A1A3, TCGA-E5-A4TZ, TCGA-G2-AA3D, TCGA-KQ-A41R, TCGA-ZF-AA4X, TCGA-BL-A13I, TCGA-XF-A9T5, TCGA-E7-A3Y1, TCGA-UY-A9PE, TCGA-GV-A3QK, TCGA-GV-A3JV, TCGA-XF-AAMW, TCGA-ZF-AA51, TCGA-BT-A0YX, TCGA-ZF-AA4T, TCGA-XF-AAMH, TCGA-DK-A1AC, TCGA-4Z-AA84, TCGA-XF-A9SK, TCGA-DK-A1A5, TCGA-GC-A3RB, TCGA-PQ-A6FI, TCGA-XF-A8HH, TCGA-ZF-AA5H, TCGA-E7-A8O7, TCGA-ZF-AA58, TCGA-E7-A97P, TCGA-G2-A2EC, TCGA-GD-A3OP, TCGA-ZF-A9R4, TCGA-XF-AAMG, TCGA-XF-A9T8, TCGA-GC-A3YS, TCGA-K4-A3WS, TCGA-UY-A78M, TCGA-E5-A4U1, TCGA-G2-A2EF, TCGA-GD-A3OS, TCGA-ZF-A9RE, TCGA-DK-A3IM, TCGA-CF-A5U8, TCGA-UY-A78N, TCGA-ZF-AA4U, TCGA-GD-A2C5, TCGA-S5-A6DX, TCGA-ZF-A9RM, TCGA-XF-AAMF, TCGA-XF-AAN2, TCGA-G2-AA3F, TCGA-GV-A3JZ, TCGA-XF-AAN7, TCGA-G2-A3IB, TCGA-XF-A9SM, TCGA-CF-A5UA, TCGA-ZF-AA4V, TCGA-G2-A3VY, TCGA-ZF-A9R7, TCGA-GV-A3JX, TCGA-HQ-A5NE, TCGA-XF-A9SZ, TCGA-K4-A3WV, TCGA-XF-A9T4",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "24",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KQ, TCGA-UY-A78P, TCGA-UY-A8OB, TCGA-G2-A2ES, TCGA-BL-A3JM",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "25",
         "BLCA",
         "C67.9",
         "8130/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A47W, TCGA-XF-AAN1, TCGA-UY-A78K, TCGA-XF-A9T6, TCGA-LT-A8JT, TCGA-CF-A27C, TCGA-CF-A9FL, TCGA-XF-AAMY, TCGA-MV-A51V, TCGA-E7-A541, TCGA-2F-A9KR, TCGA-CF-A9FM, TCGA-CF-A3MF, TCGA-E7-A7DV, TCGA-CF-A3MG, TCGA-4Z-AA83, TCGA-CF-A9FH, TCGA-CF-A47X, TCGA-XF-A8HB, TCGA-S5-AA26, TCGA-XF-A9SV, TCGA-CF-A47S, TCGA-XF-AAMZ, TCGA-E7-A6MF, TCGA-E7-A4IJ, TCGA-H4-A2HO, TCGA-4Z-AA80, TCGA-CF-A47Y, TCGA-YC-A8S6, TCGA-ZF-A9R2, TCGA-CF-A3MH, TCGA-CF-A47V, TCGA-XF-A8HI, TCGA-4Z-AA7S, TCGA-CF-A3MI, TCGA-FJ-A3ZF, TCGA-CU-A0YO, TCGA-CU-A3YL, TCGA-CF-A47T, TCGA-UY-A78L, TCGA-DK-A2I1, TCGA-XF-A8HC, TCGA-XF-A9ST, TCGA-XF-A9SU, TCGA-XF-A9SI, TCGA-XF-A9SG, TCGA-GV-A6ZA",
         "Bladder NOS",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "26",
         "BRCA",
         "C50.2",
         "8500/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18I",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "27",
         "BRCA",
         "C50.2",
         "8524/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-LD-A7W6",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "28",
         "BRCA",
         "C50.3",
         "8500/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18M, TCGA-BH-A18P",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "29",
         "BRCA",
         "C50.3",
         "8523/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18S",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "30",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A18V",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "31",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18V, TCGA-BH-A18U",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "32",
         "BRCA",
         "C50.5",
         "8500/3",
         "C50.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18G",
         "Lower outer quadrant of breast",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "33",
         "BRCA",
         "C50.8",
         "8022/3",
         "C50.8",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-Z7-A8R6",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "34",
         "BRCA",
         "C50.8",
         "8500/3",
         "C50.8",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18Q",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "35",
         "BRCA",
         "C50.9",
         "8010/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A7-A5ZV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "36",
         "BRCA",
         "C50.9",
         "8013/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SK",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "37",
         "BRCA",
         "C50.9",
         "8200/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SB",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "38",
         "BRCA",
         "C50.9",
         "8211/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73X",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "39",
         "BRCA",
         "C50.9",
         "8401/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A2-A04W",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "40",
         "BRCA",
         "C50.9",
         "8480/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73W, TCGA-A2-A3KD, TCGA-C8-A12X, TCGA-D8-A27W, TCGA-D8-A1XV, TCGA-C8-A1HL, TCGA-C8-A8HQ, TCGA-D8-A1XC, TCGA-E9-A5UO, TCGA-OL-A66H, TCGA-AC-A8OR",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "41",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-E2-A15A, TCGA-E2-A15E, TCGA-E2-A15K",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "42",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-AR-A24U, TCGA-AQ-A04J, TCGA-BH-A0HK, TCGA-A2-A04U, TCGA-BH-A202, TCGA-OL-A5RU, TCGA-E2-A154, TCGA-D8-A140, TCGA-AN-A0XV, TCGA-EW-A1OV, TCGA-OL-A66L, TCGA-D8-A1JU, TCGA-C8-A1HE, TCGA-A2-A04R, TCGA-AR-A0TP, TCGA-A7-A26I, TCGA-EW-A1PB, TCGA-C8-A26V, TCGA-AN-A0XR, TCGA-A8-A08X, TCGA-AR-A1AX, TCGA-BH-A0EB, TCGA-A7-A0DB, TCGA-BH-A0W7, TCGA-BH-A0B4, TCGA-EW-A1P8, TCGA-A2-A0CV, TCGA-A8-A083, TCGA-B6-A0WY, TCGA-AN-A0XP, TCGA-A8-A07R, TCGA-A2-A04Q, TCGA-EW-A1P6, TCGA-C8-A27B, TCGA-A8-A06R, TCGA-B6-A0RH, TCGA-A2-A0YG, TCGA-A2-A0SU, TCGA-BH-A0EE, TCGA-D8-A1JH, TCGA-E2-A152, TCGA-EW-A1IZ, TCGA-OL-A5D6, TCGA-A1-A0SD, TCGA-BH-A0DK, TCGA-E2-A156, TCGA-A7-A56D, TCGA-E9-A1ND, TCGA-AR-A1AR, TCGA-A2-A1G4, TCGA-AN-A0FN, TCGA-GM-A2DA, TCGA-AR-A0TX, TCGA-BH-A0BP, TCGA-D8-A27P, TCGA-BH-A0AW, TCGA-E9-A1RF, TCGA-E9-A1R0, TCGA-A7-A6VY, TCGA-A2-A0CX, TCGA-AR-A0TZ, TCGA-A2-A25F, TCGA-E2-A15D, TCGA-OL-A5D7, TCGA-AC-A5EH, TCGA-AR-A0TR, TCGA-AQ-A1H2, TCGA-GM-A2DL, TCGA-EW-A1PD, TCGA-AN-A0XN, TCGA-AO-A03P, TCGA-D8-A1XW, TCGA-A7-A26I, TCGA-D8-A1JL, TCGA-LL-A5YN, TCGA-S3-A6ZH, TCGA-EW-A1P1, TCGA-B6-A0WW, TCGA-AN-A03Y, TCGA-D8-A1X5, TCGA-AN-A0AR, TCGA-A8-A09I, TCGA-C8-A1HO, TCGA-AO-A0JI, TCGA-BH-A0BD, TCGA-C8-A274, TCGA-B6-A1KC, TCGA-E2-A1L7, TCGA-A8-A06Q, TCGA-E9-A1R4, TCGA-A2-A0D4, TCGA-AC-A62V, TCGA-AR-A24Q, TCGA-AC-A8OP, TCGA-B6-A0WV, TCGA-D8-A27R, TCGA-D8-A1XB, TCGA-A2-A259, TCGA-D8-A1XL, TCGA-E2-A1IO, TCGA-A8-A08B, TCGA-BH-A0W5, TCGA-AO-A0JD, TCGA-3C-AALJ, TCGA-AO-A03O, TCGA-A8-A07F, TCGA-A1-A0SH, TCGA-A7-A6VV, TCGA-A2-A3XW, TCGA-B6-A0WT, TCGA-D8-A1Y3, TCGA-AR-A255, TCGA-B6-A0RT, TCGA-C8-A278, TCGA-BH-A6R8, TCGA-D8-A27K, TCGA-EW-A1PH, TCGA-3C-AALK, TCGA-EW-A6S9, TCGA-C8-A12Q, TCGA-E2-A15I, TCGA-A8-A0A9, TCGA-A2-A04X, TCGA-PL-A8LY, TCGA-E9-A24A, TCGA-B6-A0RG, TCGA-A1-A0SO, TCGA-C8-A12W, TCGA-A7-A26J, TCGA-AO-A03L, TCGA-GM-A3XL, TCGA-BH-A0DX, TCGA-A8-A07Z, TCGA-B6-A0I6, TCGA-B6-A0I6, TCGA-GM-A2DB, TCGA-E9-A247, TCGA-A8-A07G, TCGA-AN-A0XW, TCGA-BH-A0B1, TCGA-D8-A143, TCGA-D8-A1XR, TCGA-E2-A155, TCGA-D8-A1JJ, TCGA-E2-A1IG, TCGA-BH-A0B0, TCGA-D8-A1JG, TCGA-B6-A0RM, TCGA-BH-A0BM, TCGA-E2-A14V, TCGA-A2-A0ET, TCGA-AN-A0FL, TCGA-A2-A0EO, TCGA-A2-A1G0, TCGA-BH-A5J0, TCGA-C8-A138, TCGA-E2-A1B1, TCGA-C8-A1HN, TCGA-E2-A1IN, TCGA-BH-A0HN, TCGA-LD-A9QF, TCGA-A8-A09B, TCGA-E2-A574, TCGA-BH-A0H9, TCGA-C8-A131, TCGA-AC-A62X, TCGA-AN-A046, TCGA-A7-A4SF, TCGA-E2-A1L6, TCGA-AR-A24S, TCGA-A2-A0YT, TCGA-E9-A1R5, TCGA-A8-A07J, TCGA-A2-A0EV, TCGA-A8-A06X, TCGA-E2-A14N, TCGA-AO-A12A, TCGA-E2-A10C, TCGA-AN-A04C, TCGA-LL-A5YP, TCGA-AN-A0AM, TCGA-E2-A1II, TCGA-AO-A0JC, TCGA-A8-A07W, TCGA-D8-A1XY, TCGA-BH-A0DQ, TCGA-AN-A0XT, TCGA-LL-A73Z, TCGA-B6-A0I8, TCGA-AQ-A0Y5, TCGA-C8-A1HI, TCGA-A7-A0CD, TCGA-A7-A0DA, TCGA-A8-A091, TCGA-D8-A1XU, TCGA-B6-A0IK, TCGA-AR-A0U0, TCGA-EW-A6SD, TCGA-OL-A5RY, TCGA-E9-A1R2, TCGA-AN-A0AK, TCGA-AR-A252, TCGA-BH-A0EI, TCGA-E9-A22A, TCGA-A2-A25B, TCGA-BH-A0BW, TCGA-C8-A12Y, TCGA-AR-A0U3, TCGA-A2-A0CQ, TCGA-AR-A24K, TCGA-BH-A0H0, TCGA-AR-A0U2, TCGA-GM-A2DK, TCGA-BH-A0GZ, TCGA-BH-A0BL, TCGA-LL-A740, TCGA-B6-A0RO, TCGA-A2-A0T2, TCGA-E2-A15S, TCGA-A2-A0T1, TCGA-D8-A1JC, TCGA-A2-A3XU, TCGA-EW-A1P7, TCGA-C8-A1HJ, TCGA-AN-A0XU, TCGA-BH-A5IZ, TCGA-AO-A0JB, TCGA-BH-A0W4, TCGA-AN-A0AT, TCGA-A8-A07I, TCGA-A2-A0YM, TCGA-C8-A134, TCGA-B6-A1KI, TCGA-A1-A0SN, TCGA-E2-A15R, TCGA-S3-AA11, TCGA-AO-A128, TCGA-E2-A15T, TCGA-A8-A095, TCGA-D8-A1Y2, TCGA-UL-AAZ6, TCGA-A2-A0CL, TCGA-A8-A08P, TCGA-C8-A12M, TCGA-AR-A1AS, TCGA-E9-A1QZ, TCGA-A7-A6VX, TCGA-A8-A081, TCGA-BH-A0BQ, TCGA-A8-A093, TCGA-C8-A26X, TCGA-A2-A0ER, TCGA-A2-A04Y, TCGA-A2-A0D2, TCGA-D8-A1JA, TCGA-A7-A0CE, TCGA-C8-A12K, TCGA-A7-A26J, TCGA-AN-A0FS, TCGA-OL-A5RW, TCGA-A2-A0YC, TCGA-D8-A1JM, TCGA-AN-A0AL, TCGA-LL-A7SZ, TCGA-A8-A06T, TCGA-A8-A06U, TCGA-BH-A0C0, TCGA-A2-A0SV, TCGA-E9-A22G, TCGA-AR-A0TS, TCGA-A8-A06P, TCGA-B6-A0X5, TCGA-D8-A1JP, TCGA-AN-A0FD, TCGA-GM-A2DF, TCGA-AR-A0TW, TCGA-AN-A0FZ, TCGA-AN-A0FF, TCGA-C8-A12V, TCGA-AC-A23E, TCGA-A1-A0SP, TCGA-A2-A0EQ, TCGA-A2-A1FW, TCGA-C8-A1HK, TCGA-D8-A1X6, TCGA-A2-A0EY, TCGA-A8-A09C, TCGA-EW-A6SB, TCGA-A8-A07U, TCGA-A8-A08G, TCGA-BH-A0BV, TCGA-C8-A12T, TCGA-E2-A1IF, TCGA-D8-A1XA, TCGA-E2-A15A, TCGA-E2-A1B0, TCGA-AR-A24W, TCGA-A7-A26J, TCGA-A8-A06O, TCGA-D8-A1JE, TCGA-V7-A7HQ, TCGA-C8-A1HF, TCGA-C8-A137, TCGA-E2-A15E, TCGA-A2-A0D1, TCGA-AR-A24Z, TCGA-E2-A15K, TCGA-E2-A14Y, TCGA-AN-A0XO, TCGA-LD-A7W5, TCGA-D8-A1J9, TCGA-E2-A15C, TCGA-C8-A26Z, TCGA-OL-A6VR, TCGA-D8-A27N, TCGA-A8-A08H, TCGA-A8-A097, TCGA-AO-A03V, TCGA-AR-A1AH, TCGA-A2-A1G6, TCGA-E2-A1IK, TCGA-BH-A0AV, TCGA-A2-A0YJ, TCGA-A7-A26H, TCGA-C8-A12L, TCGA-UU-A93S, TCGA-E2-A1L9, TCGA-A8-A08O, TCGA-E9-A1R3, TCGA-E2-A570, TCGA-A2-A04P, TCGA-A2-A0CS, TCGA-LL-A8F5, TCGA-BH-A0HI, TCGA-EW-A1OZ, TCGA-E2-A1B6, TCGA-BH-A0C7, TCGA-S3-AA14, TCGA-B6-A0RS, TCGA-A2-A0T0, TCGA-AN-A0G0, TCGA-OL-A66I, TCGA-A8-A09N, TCGA-C8-A135, TCGA-A2-A0CT, TCGA-AO-A0JE, TCGA-D8-A1Y1, TCGA-AO-A1KP, TCGA-A8-A092, TCGA-AR-A1AO, TCGA-D8-A27L, TCGA-BH-A0E1, TCGA-E2-A573, TCGA-AR-A0TV, TCGA-A2-A04N, TCGA-AR-A250, TCGA-BH-A0B8, TCGA-E9-A243, TCGA-BH-A0BJ, TCGA-E2-A159, TCGA-E2-A14Z, TCGA-BH-A0HB, TCGA-C8-A1HG, TCGA-E9-A1R7, TCGA-D8-A141, TCGA-AO-A0JM, TCGA-BH-A0GY, TCGA-GM-A2DN, TCGA-D8-A13Z, TCGA-A7-A13E, TCGA-AR-A251, TCGA-A8-A07P, TCGA-BH-A0B9, TCGA-D8-A1Y0, TCGA-BH-A0DH, TCGA-E9-A22D, TCGA-AR-A1AP, TCGA-D8-A1XK, TCGA-AQ-A54O, TCGA-A2-A0CU, TCGA-D8-A1X9, TCGA-A2-A0T5, TCGA-D8-A1XQ, TCGA-AR-A1AY, TCGA-A8-A09G, TCGA-OL-A6VO, TCGA-AR-A254, TCGA-A8-A09M, TCGA-A8-A08R, TCGA-E2-A14X, TCGA-E9-A1RH, TCGA-A2-A4S3, TCGA-BH-A0BR, TCGA-AN-A0FY, TCGA-B6-A0IB, TCGA-E2-A15J, TCGA-E2-A1IE, TCGA-A2-A3Y0, TCGA-D8-A1XG, TCGA-A2-A0T3, TCGA-A2-A0SX, TCGA-BH-A0B3, TCGA-A7-A0D9, TCGA-D8-A1JK, TCGA-BH-A0HF, TCGA-AC-A7VB, TCGA-EW-A1P5, TCGA-B6-A0RE, TCGA-D8-A13Y, TCGA-B6-A0I5, TCGA-AC-A6NO, TCGA-E2-A15H, TCGA-AR-A24P, TCGA-AO-A03T, TCGA-D8-A1JF, TCGA-OL-A5D8, TCGA-A2-A0YH, TCGA-BH-A0HW, TCGA-GM-A2DM, TCGA-A2-A0T7, TCGA-BH-A0DE, TCGA-GM-A2DH, TCGA-AN-A0AS, TCGA-OL-A5S0, TCGA-E2-A9RU, TCGA-E2-A56Z, TCGA-C8-A275, TCGA-BH-A0DZ, TCGA-S3-AA0Z, TCGA-E2-A1LA, TCGA-E9-A1R6, TCGA-E9-A229, TCGA-E2-A14T, TCGA-PL-A8LZ, TCGA-AN-A0FW, TCGA-LL-A6FQ, TCGA-BH-A0AY, TCGA-D8-A1XM, TCGA-AN-A0XS, TCGA-E9-A1RB, TCGA-AC-A5XU, TCGA-AR-A1AU, TCGA-A8-A09D, TCGA-E9-A1RD, TCGA-EW-A1IY, TCGA-D8-A1J8, TCGA-C8-A12Z, TCGA-AO-A03R, TCGA-C8-A12U, TCGA-A7-A13D, TCGA-BH-A18H, TCGA-B6-A0X4, TCGA-C8-A12N, TCGA-AC-A8OQ, TCGA-C8-A12P, TCGA-E9-A1N8, TCGA-BH-A0W3, TCGA-AR-A24V, TCGA-A8-A090, TCGA-BH-A0HQ, TCGA-BH-A0DS, TCGA-AO-A0J4, TCGA-AO-A0J6, TCGA-A8-A099, TCGA-A7-A0DB, TCGA-EW-A1PA, TCGA-AR-A1AQ, TCGA-C8-A132, TCGA-A7-A13D, TCGA-AN-A04A, TCGA-BH-A0RX, TCGA-A2-A1FZ, TCGA-BH-A201, TCGA-A8-A085, TCGA-GM-A2DD, TCGA-A8-A09A, TCGA-AO-A0JF, TCGA-EW-A6SA, TCGA-E2-A1AZ, TCGA-B6-A1KF, TCGA-S3-A6ZF, TCGA-AQ-A1H3, TCGA-AQ-A04H, TCGA-BH-A0HY, TCGA-AN-A049, TCGA-BH-A0BC, TCGA-A2-A0D0, TCGA-A2-A0CW, TCGA-AN-A04D, TCGA-E9-A1RA, TCGA-A1-A0SF, TCGA-BH-A0E2, TCGA-OL-A66P, TCGA-A2-A0EM, TCGA-AO-A12D, TCGA-E2-A14Q, TCGA-A8-A094, TCGA-A7-A13D, TCGA-E2-A14P, TCGA-AO-A1KR, TCGA-E9-A1RG, TCGA-BH-A0HX, TCGA-LL-A5YO, TCGA-C8-A27A, TCGA-WT-AB41, TCGA-D8-A27M, TCGA-BH-A0H6, TCGA-D8-A147, TCGA-E2-A14W, TCGA-A2-A0CP, TCGA-PL-A8LX, TCGA-C8-A26W, TCGA-B6-A0RI, TCGA-A2-A0EU, TCGA-S3-AA15, TCGA-E9-A245, TCGA-BH-A0HO, TCGA-E9-A228, TCGA-C8-A12O, TCGA-A2-A0YE, TCGA-B6-A0I2, TCGA-AN-A041, TCGA-A8-A079, TCGA-A8-A08T, TCGA-E2-A150, TCGA-S3-AA17, TCGA-A2-A0D3, TCGA-AC-A6IW, TCGA-C8-A1HM, TCGA-A8-A08L, TCGA-AN-A0FV, TCGA-AN-A0FK, TCGA-E9-A227, TCGA-A7-A6VW, TCGA-AR-A24N, TCGA-A2-A0SW, TCGA-AO-A0JA, TCGA-EW-A1J6, TCGA-A8-A07L, TCGA-AC-A23C, TCGA-A2-A0YF, TCGA-A2-A1FX, TCGA-A8-A07B, TCGA-A2-A04T, TCGA-AN-A03X, TCGA-E2-A14O, TCGA-LL-A73Y, TCGA-E2-A15O, TCGA-A2-A0CM, TCGA-EW-A1J1, TCGA-A7-A0DB, TCGA-E2-A158, TCGA-A8-A09Q, TCGA-AR-A24L, TCGA-BH-A0B7, TCGA-B6-A0RN, TCGA-E9-A22E, TCGA-E9-A1NG, TCGA-B6-A0WS, TCGA-A1-A0SQ, TCGA-3C-AALI, TCGA-B6-A0RL, TCGA-D8-A1XT, TCGA-A7-A4SE, TCGA-AR-A256, TCGA-A7-A0CJ, TCGA-AR-A1AV, TCGA-A8-A08Z, TCGA-A8-A096, TCGA-E9-A226, TCGA-E2-A153, TCGA-A2-A25E, TCGA-D8-A1JI, TCGA-A1-A0SM, TCGA-A8-A075, TCGA-C8-A273, TCGA-BH-A42V, TCGA-AR-A1AN, TCGA-OL-A5RX, TCGA-OL-A5RZ, TCGA-AR-A0TQ, TCGA-A8-A06Z, TCGA-S3-AA10, TCGA-A8-A076, TCGA-AR-A1AJ, TCGA-E9-A1RE, TCGA-A1-A0SJ, TCGA-OL-A66O, TCGA-E9-A244, TCGA-OL-A5RV, TCGA-BH-A0EA, TCGA-AO-A1KT, TCGA-E2-A14R, TCGA-A8-A06Y, TCGA-A7-A5ZW, TCGA-D8-A1JD, TCGA-B6-A409, TCGA-E9-A248, TCGA-A2-A0ST, TCGA-LL-A6FR, TCGA-AN-A0FX, TCGA-AR-A0TT, TCGA-D8-A1XZ, TCGA-E9-A22H, TCGA-A1-A0SI, TCGA-EW-A1P3, TCGA-BH-A0E0, TCGA-B6-A0X1, TCGA-EW-A1OY, TCGA-EW-A2FS, TCGA-E2-A15P, TCGA-BH-A0E7, TCGA-BH-A0HU, TCGA-AR-A0TY, TCGA-E2-A1B4, TCGA-GM-A2DC, TCGA-D8-A27H, TCGA-B6-A1KN, TCGA-E2-A1BD, TCGA-A8-A08C, TCGA-AN-A0FT, TCGA-A2-A25C, TCGA-B6-A0I9, TCGA-AQ-A54N, TCGA-A7-A13E, TCGA-A8-A082, TCGA-D8-A145, TCGA-D8-A27F, TCGA-B6-A0IJ, TCGA-A7-A13F, TCGA-BH-A0H7, TCGA-A2-A04V, TCGA-S3-AA12, TCGA-B6-A0WZ, TCGA-AR-A0U1, TCGA-C8-A130, TCGA-AN-A0FJ, TCGA-AR-A1AW, TCGA-LL-A7T0, TCGA-AO-A0J2, TCGA-AR-A24R, TCGA-BH-A0BO, TCGA-A2-A1G1, TCGA-C8-A26Y, TCGA-D8-A1JB, TCGA-E2-A10A, TCGA-D8-A1XF, TCGA-A7-A13E, TCGA-AO-A12F, TCGA-D8-A142, TCGA-A8-A07O, TCGA-AR-A0TU, TCGA-B6-A401",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "43",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A1FE",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "44",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A1F6, TCGA-BH-A1FU, TCGA-BH-A203, TCGA-BH-A1FJ, TCGA-BH-A1FD, TCGA-BH-A0BS, TCGA-BH-A1FE, TCGA-BH-A0BF, TCGA-BH-A0DT, TCGA-A7-A13G, TCGA-BH-A18L, TCGA-BH-A0HA, TCGA-BH-A1EN, TCGA-BH-A1F8, TCGA-BH-A18T, TCGA-BH-A1F5, TCGA-BH-A1EY, TCGA-BH-A0DI, TCGA-BH-A0BZ, TCGA-E2-A1IU, TCGA-BH-A204, TCGA-AC-A2BM, TCGA-BH-A1ES, TCGA-A7-A0CH, TCGA-BH-A1EW, TCGA-BH-A18N, TCGA-A7-A13G, TCGA-GI-A2C8, TCGA-E2-A1LB, TCGA-AC-A2BK, TCGA-GM-A2DI, TCGA-BH-A0H3, TCGA-GM-A2D9, TCGA-BH-A0DO, TCGA-BH-A0AU, TCGA-BH-A1EV, TCGA-BH-A1EU, TCGA-BH-A208, TCGA-BH-A1FM, TCGA-AC-A23H, TCGA-BH-A0DV, TCGA-E2-A1LS, TCGA-BH-A18J, TCGA-E9-A1NH, TCGA-BH-A18R, TCGA-BH-A18F, TCGA-BH-A1ET, TCGA-BH-A1FH, TCGA-E2-A1LH, TCGA-BH-A0DG, TCGA-BH-A1F0, TCGA-BH-A0BT, TCGA-E2-A1LK, TCGA-BH-A18K, TCGA-BH-A0AZ, TCGA-BH-A1FL, TCGA-E2-A1LL, TCGA-BH-A1FG, TCGA-BH-A1FN, TCGA-BH-A0DD, TCGA-BH-A1EX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "45",
         "BRCA",
         "C50.9",
         "8503/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-B6-A0IC, TCGA-EW-A2FW, TCGA-BH-A0HL, TCGA-D8-A1JS, TCGA-D8-A1X7",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast invasive carcinoma"
        ],
        [
         "46",
         "BRCA",
         "C50.9",
         "8507/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SG, TCGA-D8-A1XS, TCGA-EW-A1PE, TCGA-EW-A2FV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast invasive carcinoma"
        ],
        [
         "47",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-PL-A8LV, TCGA-AR-A1AI, TCGA-EW-A1P4",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "48",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A209, TCGA-BH-A1FC",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "49",
         "BRCA",
         "C50.9",
         "8520/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-AC-A6IX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast invasive carcinoma"
        ]
       ],
       "shape": {
        "columns": 10,
        "rows": 731
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Case IDs</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>726</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PM</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>727</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C55</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C55.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>728</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>729</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-N9-A4Q8, TCGA-N9-A4PZ</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>730</th>\n",
       "      <td>UVM</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uveal Melanoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>731 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0                   ACC  C74.0            8370/1        C74.0   \n",
       "1                   ACC  C74.0            8370/3        C74.0   \n",
       "2                   ACC  C74.0            8370/3        C74.0   \n",
       "3                  BLCA  C67.0            8120/3        C67.0   \n",
       "4                  BLCA  C67.0            8120/3        C67.0   \n",
       "..                  ...    ...               ...          ...   \n",
       "726                 UCS  C54.3            8980/3        C54.3   \n",
       "727                 UCS    C55            8950/3        C55.9   \n",
       "728                 UCS    NaN               NaN          NaN   \n",
       "729                 UCS    NaN               NaN          NaN   \n",
       "730                 UVM    NaN               NaN          NaN   \n",
       "\n",
       "                  Normalized Sample Type  \\\n",
       "0    Blood Derived Normal, Primary Tumor   \n",
       "1    Blood Derived Normal, Primary Tumor   \n",
       "2     Primary Tumor, Solid Tissue Normal   \n",
       "3    Blood Derived Normal, Primary Tumor   \n",
       "4     Primary Tumor, Solid Tissue Normal   \n",
       "..                                   ...   \n",
       "726  Blood Derived Normal, Primary Tumor   \n",
       "727  Blood Derived Normal, Primary Tumor   \n",
       "728  Blood Derived Normal, Primary Tumor   \n",
       "729   Primary Tumor, Solid Tissue Normal   \n",
       "730  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                              Case IDs           ICD_10_desc  \\\n",
       "0    TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...  Adrenal gland cortex   \n",
       "1    TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...  Adrenal gland cortex   \n",
       "2    TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...  Adrenal gland cortex   \n",
       "3    TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...      Trigone, bladder   \n",
       "4    TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...      Trigone, bladder   \n",
       "..                                                 ...                   ...   \n",
       "726                                       TCGA-N8-A4PM          Fundus uteri   \n",
       "727  TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...                   NaN   \n",
       "728  TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...                   NaN   \n",
       "729                         TCGA-N9-A4Q8, TCGA-N9-A4PZ                   NaN   \n",
       "730  TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...                   NaN   \n",
       "\n",
       "        ICD_O_3_SITE_desc            ICD_O_3_HISTOLOGY_desc  \\\n",
       "0    Adrenal gland cortex                               NaN   \n",
       "1    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "2    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "3        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "4        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "..                    ...                               ...   \n",
       "726          Fundus uteri               Carcinosarcoma, NOS   \n",
       "727            Uterus NOS             Mullerian mixed tumor   \n",
       "728                   NaN                               NaN   \n",
       "729                   NaN                               NaN   \n",
       "730                   NaN                               NaN   \n",
       "\n",
       "                 CANCER_TYPE_NAME  \n",
       "0        Adrenocortical carcinoma  \n",
       "1        Adrenocortical carcinoma  \n",
       "2        Adrenocortical carcinoma  \n",
       "3    Bladder Urothelial Carcinoma  \n",
       "4    Bladder Urothelial Carcinoma  \n",
       "..                            ...  \n",
       "726        Uterine Carcinosarcoma  \n",
       "727        Uterine Carcinosarcoma  \n",
       "728        Uterine Carcinosarcoma  \n",
       "729        Uterine Carcinosarcoma  \n",
       "730                Uveal Melanoma  \n",
       "\n",
       "[731 rows x 10 columns]"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df.to_parquet(\"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description/description_meta.parquet\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_ACRONYM",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "e102bc99-0f6e-4d8a-9a3b-9aa41231b23c",
       "rows": [
        [
         "0",
         "ACC",
         "C74.0",
         "8370/1",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA-OR-A5KS, TCGA-OR-A5L2",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         null,
         "Adrenocortical carcinoma"
        ],
        [
         "1",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA-OR-A5K6, TCGA-OR-A5LO, TCGA-OR-A5JY, TCGA-OR-A5JV, TCGA-OR-A5K3, TCGA-OR-A5KO, TCGA-OR-A5K0, TCGA-OR-A5J6, TCGA-OR-A5LC, TCGA-OR-A5LA, TCGA-OR-A5LG, TCGA-OR-A5LB, TCGA-OR-A5JM, TCGA-OR-A5KQ, TCGA-OR-A5JD, TCGA-P6-A5OF, TCGA-PK-A5HA, TCGA-OR-A5KY, TCGA-OR-A5L4, TCGA-OR-A5J9, TCGA-OR-A5JS, TCGA-PK-A5H9, TCGA-OR-A5JJ, TCGA-OR-A5JI, TCGA-OR-A5JF, TCGA-OR-A5LF, TCGA-OR-A5JH, TCGA-OR-A5JU, TCGA-OR-A5JL, TCGA-OR-A5KP, TCGA-OR-A5JO, TCGA-OR-A5K8, TCGA-OR-A5LN, TCGA-OR-A5KX, TCGA-OR-A5KW, TCGA-OR-A5L8, TCGA-OR-A5JW, TCGA-OR-A5JK, TCGA-OR-A5LR, TCGA-OR-A5JZ, TCGA-OU-A5PI, TCGA-OR-A5LD, TCGA-OR-A5JE, TCGA-OR-A5LH, TCGA-OR-A5K5, TCGA-OR-A5LJ, TCGA-OR-A5LL, TCGA-OR-A5JX, TCGA-OR-A5JQ, TCGA-PA-A5YG, TCGA-PK-A5H8, TCGA-OR-A5J4, TCGA-OR-A5J2, TCGA-OR-A5JG, TCGA-OR-A5J5, TCGA-OR-A5JT, TCGA-OR-A5LK, TCGA-OR-A5JB, TCGA-OR-A5KT, TCGA-OR-A5J3, TCGA-OR-A5L6, TCGA-OR-A5LS, TCGA-OR-A5LP, TCGA-OR-A5K1, TCGA-OR-A5LI, TCGA-OR-A5L1, TCGA-OR-A5J7, TCGA-OR-A5LT, TCGA-OR-A5L5, TCGA-OR-A5JR, TCGA-OR-A5K2, TCGA-OR-A5K4, TCGA-OR-A5KZ, TCGA-OR-A5JC, TCGA-OR-A5L3, TCGA-OR-A5LE",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "2",
         "ACC",
         "C74.0",
         "8370/3",
         "C74.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA-P6-A5OH, TCGA-OR-A5K9",
         "Adrenal gland cortex",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenocortical carcinoma"
        ],
        [
         "3",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA-FD-A6TE, TCGA-K4-A6MB, TCGA-BT-A2LD, TCGA-DK-AA6T, TCGA-FD-A3SS, TCGA-FD-A6TH, TCGA-FD-A5BV, TCGA-E7-A7DU, TCGA-FD-A3SN, TCGA-K4-A5RH, TCGA-DK-A6AW, TCGA-GC-A3RD, TCGA-KQ-A41P",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "4",
         "BLCA",
         "C67.0",
         "8120/3",
         "C67.0",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA-BT-A20R, TCGA-BT-A20Q",
         "Trigone, bladder",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "5",
         "BLCA",
         "C67.0",
         "8130/3",
         "C67.0",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-4Z-AA89, TCGA-FD-A3B3, TCGA-4Z-AA7R",
         "Trigone, bladder",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "6",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A54R, TCGA-GC-A3BM, TCGA-DK-A3X1, TCGA-BT-A2LB, TCGA-BL-A0C8, TCGA-BL-A0C8, TCGA-DK-A6AV, TCGA-FD-A43P, TCGA-DK-AA74, TCGA-BL-A0C8, TCGA-4Z-AA86, TCGA-DK-A3WY, TCGA-DK-AA6L",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "7",
         "BLCA",
         "C67.1",
         "8120/3",
         "C67.1",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20X, TCGA-BT-A2LA",
         "Dome, bladder",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "8",
         "BLCA",
         "C67.1",
         "8260/3",
         "C67.1",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-HQ-A2OF",
         "Dome, bladder",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "9",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FD-A3SQ, TCGA-FD-A3B7, TCGA-4Z-AA7M, TCGA-DK-A3IK, TCGA-FD-A3SM, TCGA-ZF-A9RC, TCGA-UY-A9PA, TCGA-DK-AA6P, TCGA-DK-AA6R, TCGA-FD-A6TF, TCGA-FD-A62N, TCGA-DK-A3WX, TCGA-FD-A5BR, TCGA-GU-A763, TCGA-DK-A3IT, TCGA-FD-A43U, TCGA-DK-AA6X, TCGA-G2-A2EL, TCGA-2F-A9KP, TCGA-YF-AA3L, TCGA-R3-A69X, TCGA-FD-A3SJ, TCGA-DK-A6B0, TCGA-4Z-AA7W, TCGA-E7-A3X6, TCGA-UY-A9PB, TCGA-BT-A3PJ, TCGA-DK-AA71, TCGA-FD-A6TB, TCGA-GU-AATP, TCGA-DK-AA6S, TCGA-FD-A3B8, TCGA-DK-AA6W, TCGA-FD-A3B4, TCGA-PQ-A6FN, TCGA-ZF-AA54, TCGA-FJ-A871, TCGA-DK-A3IN, TCGA-DK-A3IL, TCGA-YF-AA3M, TCGA-FD-A6TG, TCGA-ZF-A9RG, TCGA-DK-A3IV, TCGA-DK-AA6U, TCGA-DK-A3X2, TCGA-E5-A2PC, TCGA-4Z-AA7N, TCGA-FD-A5BU, TCGA-FD-A3SO, TCGA-FD-A5BT, TCGA-DK-AA6M",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "10",
         "BLCA",
         "C67.2",
         "8120/3",
         "C67.2",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20W, TCGA-BT-A20O, TCGA-BT-A20V",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "11",
         "BLCA",
         "C67.2",
         "8130/3",
         "C67.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-XF-AAMQ, TCGA-BT-A42B, TCGA-UY-A9PF, TCGA-XF-AAML, TCGA-4Z-AA7Y, TCGA-FJ-A3Z9, TCGA-CF-A9FF, TCGA-4Z-AA7O, TCGA-FD-A6TA, TCGA-BT-A42C, TCGA-CF-A7I0",
         "Lateral wall bladder",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "12",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-E7-A6ME, TCGA-FD-A43Y, TCGA-DK-AA75, TCGA-FD-A3N6, TCGA-UY-A9PD, TCGA-E7-A6MD, TCGA-KQ-A41Q, TCGA-FD-A6TK, TCGA-FD-A6TI, TCGA-GU-A764, TCGA-K4-AAQO, TCGA-DK-A6B1, TCGA-GV-A3QF, TCGA-FD-A5BZ, TCGA-FD-A6TD, TCGA-DK-AA76, TCGA-DK-A6B5",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "13",
         "BLCA",
         "C67.3",
         "8120/3",
         "C67.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BT-A20T, TCGA-G2-A2EO",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "14",
         "BLCA",
         "C67.3",
         "8130/3",
         "C67.3",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A2I4",
         null,
         null,
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "15",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-DK-A3IU, TCGA-DK-A3IQ, TCGA-FD-A62S, TCGA-FD-A3SP, TCGA-FD-A3SR, TCGA-FD-A3N5, TCGA-DK-AA77, TCGA-FD-A3NA, TCGA-FD-A3B5, TCGA-FD-A3SL, TCGA-K4-A6FZ, TCGA-BT-A3PK, TCGA-DK-A6B6, TCGA-BL-A5ZZ, TCGA-KQ-A41S, TCGA-ZF-AA56, TCGA-ZF-A9RD, TCGA-DK-A6B2, TCGA-ZF-AA5P, TCGA-DK-A3WW, TCGA-BL-A13J, TCGA-DK-AA6Q, TCGA-ZF-A9R0, TCGA-K4-A4AB, TCGA-FD-A5BY, TCGA-FD-A5BS, TCGA-GV-A3QG, TCGA-GV-A3QI, TCGA-SY-A9G0, TCGA-ZF-A9RN, TCGA-FD-A6TC, TCGA-FD-A5C0, TCGA-FD-A43N, TCGA-4Z-AA82, TCGA-FD-A5C1, TCGA-K4-A5RI, TCGA-BL-A13J, TCGA-BL-A13J, TCGA-FD-A5BX, TCGA-ZF-AA52, TCGA-FD-A43S, TCGA-FD-A62P, TCGA-XF-AAN8, TCGA-2F-A9KT",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "16",
         "BLCA",
         "C67.4",
         "8120/3",
         "C67.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KO, TCGA-BT-A20J",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "17",
         "BLCA",
         "C67.4",
         "8130/3",
         "C67.4",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-K4-A5RJ, TCGA-BT-A42E, TCGA-FD-A3B6, TCGA-FD-A43X, TCGA-4Z-AA81",
         "Posterior wall bladder",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "18",
         "BLCA",
         "C67.5",
         "8120/3",
         "C67.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-FT-A3EE",
         null,
         null,
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "19",
         "BLCA",
         "C67.6",
         "8120/3",
         "C67.6",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-KQ-A41N",
         "Ureteric orifice",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "20",
         "BLCA",
         "C67.9",
         "8010/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-ZF-AA4N",
         "Bladder NOS",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "21",
         "BLCA",
         "C67.9",
         "8070/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A1HS",
         "Bladder NOS",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "22",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-DK-A1A6",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "23",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-C4-A0EZ, TCGA-GV-A40G, TCGA-DK-A3IS, TCGA-GV-A40E, TCGA-DK-A2HX, TCGA-ZF-AA53, TCGA-HQ-A5ND, TCGA-E7-A7PW, TCGA-DK-A1A7, TCGA-GD-A3OQ, TCGA-C4-A0F0, TCGA-2F-A9KW, TCGA-UY-A78O, TCGA-4Z-AA87, TCGA-5N-A9KI, TCGA-C4-A0F6, TCGA-XF-A9SL, TCGA-XF-A9T3, TCGA-UY-A8OC, TCGA-GD-A76B, TCGA-YC-A9TC, TCGA-GC-A3I6, TCGA-SY-A9G5, TCGA-XF-AAMR, TCGA-XF-A9SY, TCGA-DK-A1AD, TCGA-XF-AAMJ, TCGA-5N-A9KM, TCGA-DK-A1A6, TCGA-CU-A3QU, TCGA-ZF-A9R3, TCGA-K4-A83P, TCGA-XF-A9T2, TCGA-E7-A97Q, TCGA-CU-A72E, TCGA-GC-A3RC, TCGA-UY-A9PH, TCGA-GU-AATO, TCGA-E7-A677, TCGA-ZF-A9R9, TCGA-XF-A8HD, TCGA-BL-A13I, TCGA-BL-A13I, TCGA-GU-A766, TCGA-XF-AAN0, TCGA-XF-A9SW, TCGA-DK-A1AB, TCGA-XF-AAMX, TCGA-ZF-A9RF, TCGA-ZF-A9RL, TCGA-K4-A4AC, TCGA-E7-A7XN, TCGA-LC-A66R, TCGA-CF-A8HX, TCGA-GC-A6I1, TCGA-XF-A9T0, TCGA-G2-A2EK, TCGA-ZF-AA4W, TCGA-GU-A762, TCGA-E7-A519, TCGA-XF-A9SP, TCGA-CU-A5W6, TCGA-FT-A61P, TCGA-XF-A8HF, TCGA-BT-A3PH, TCGA-YC-A89H, TCGA-KQ-A41O, TCGA-XF-A9SX, TCGA-GU-A42Q, TCGA-ZF-A9R5, TCGA-GU-AATQ, TCGA-XF-AAN4, TCGA-XF-AAMT, TCGA-ZF-AA4R, TCGA-GU-A767, TCGA-G2-AA3C, TCGA-XF-AAN5, TCGA-XF-A8HG, TCGA-E7-A85H, TCGA-H4-A2HQ, TCGA-LT-A5Z6, TCGA-ZF-A9R1, TCGA-DK-A1AF, TCGA-ZF-AA5N, TCGA-UY-A8OD, TCGA-4Z-AA7Q, TCGA-CU-A0YR, TCGA-C4-A0F7, TCGA-CU-A3KJ, TCGA-GU-A42P, TCGA-K4-A3WU, TCGA-DK-A1AA, TCGA-G2-A3IE, TCGA-GC-A3WC, TCGA-HQ-A2OE, TCGA-DK-A2I2, TCGA-E7-A678, TCGA-GC-A3OO, TCGA-XF-AAN3, TCGA-GV-A3JW, TCGA-G2-AA3B, TCGA-CF-A1HR, TCGA-DK-A1AE, TCGA-E7-A5KE, TCGA-E7-A5KF, TCGA-BT-A0S7, TCGA-FJ-A3Z7, TCGA-CF-A8HY, TCGA-XF-A8HE, TCGA-E7-A4XJ, TCGA-FJ-A3ZE, TCGA-GD-A6C6, TCGA-C4-A0F1, TCGA-GC-A4ZW, TCGA-GC-A6I3, TCGA-XF-A9SJ, TCGA-XF-A9SH, TCGA-G2-A2EJ, TCGA-XF-AAME, TCGA-DK-A1A3, TCGA-E5-A4TZ, TCGA-G2-AA3D, TCGA-KQ-A41R, TCGA-ZF-AA4X, TCGA-BL-A13I, TCGA-XF-A9T5, TCGA-E7-A3Y1, TCGA-UY-A9PE, TCGA-GV-A3QK, TCGA-GV-A3JV, TCGA-XF-AAMW, TCGA-ZF-AA51, TCGA-BT-A0YX, TCGA-ZF-AA4T, TCGA-XF-AAMH, TCGA-DK-A1AC, TCGA-4Z-AA84, TCGA-XF-A9SK, TCGA-DK-A1A5, TCGA-GC-A3RB, TCGA-PQ-A6FI, TCGA-XF-A8HH, TCGA-ZF-AA5H, TCGA-E7-A8O7, TCGA-ZF-AA58, TCGA-E7-A97P, TCGA-G2-A2EC, TCGA-GD-A3OP, TCGA-ZF-A9R4, TCGA-XF-AAMG, TCGA-XF-A9T8, TCGA-GC-A3YS, TCGA-K4-A3WS, TCGA-UY-A78M, TCGA-E5-A4U1, TCGA-G2-A2EF, TCGA-GD-A3OS, TCGA-ZF-A9RE, TCGA-DK-A3IM, TCGA-CF-A5U8, TCGA-UY-A78N, TCGA-ZF-AA4U, TCGA-GD-A2C5, TCGA-S5-A6DX, TCGA-ZF-A9RM, TCGA-XF-AAMF, TCGA-XF-AAN2, TCGA-G2-AA3F, TCGA-GV-A3JZ, TCGA-XF-AAN7, TCGA-G2-A3IB, TCGA-XF-A9SM, TCGA-CF-A5UA, TCGA-ZF-AA4V, TCGA-G2-A3VY, TCGA-ZF-A9R7, TCGA-GV-A3JX, TCGA-HQ-A5NE, TCGA-XF-A9SZ, TCGA-K4-A3WV, TCGA-XF-A9T4",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "24",
         "BLCA",
         "C67.9",
         "8120/3",
         "C67.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-2F-A9KQ, TCGA-UY-A78P, TCGA-UY-A8OB, TCGA-G2-A2ES, TCGA-BL-A3JM",
         "Bladder NOS",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "25",
         "BLCA",
         "C67.9",
         "8130/3",
         "C67.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-CF-A47W, TCGA-XF-AAN1, TCGA-UY-A78K, TCGA-XF-A9T6, TCGA-LT-A8JT, TCGA-CF-A27C, TCGA-CF-A9FL, TCGA-XF-AAMY, TCGA-MV-A51V, TCGA-E7-A541, TCGA-2F-A9KR, TCGA-CF-A9FM, TCGA-CF-A3MF, TCGA-E7-A7DV, TCGA-CF-A3MG, TCGA-4Z-AA83, TCGA-CF-A9FH, TCGA-CF-A47X, TCGA-XF-A8HB, TCGA-S5-AA26, TCGA-XF-A9SV, TCGA-CF-A47S, TCGA-XF-AAMZ, TCGA-E7-A6MF, TCGA-E7-A4IJ, TCGA-H4-A2HO, TCGA-4Z-AA80, TCGA-CF-A47Y, TCGA-YC-A8S6, TCGA-ZF-A9R2, TCGA-CF-A3MH, TCGA-CF-A47V, TCGA-XF-A8HI, TCGA-4Z-AA7S, TCGA-CF-A3MI, TCGA-FJ-A3ZF, TCGA-CU-A0YO, TCGA-CU-A3YL, TCGA-CF-A47T, TCGA-UY-A78L, TCGA-DK-A2I1, TCGA-XF-A8HC, TCGA-XF-A9ST, TCGA-XF-A9SU, TCGA-XF-A9SI, TCGA-XF-A9SG, TCGA-GV-A6ZA",
         "Bladder NOS",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "26",
         "BRCA",
         "C50.2",
         "8500/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18I",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "27",
         "BRCA",
         "C50.2",
         "8524/3",
         "C50.2",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-LD-A7W6",
         "Upper inner quadrant of breast",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "28",
         "BRCA",
         "C50.3",
         "8500/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18M, TCGA-BH-A18P",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "29",
         "BRCA",
         "C50.3",
         "8523/3",
         "C50.3",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18S",
         "Lower inner quadrant of breast",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "30",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A18V",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "31",
         "BRCA",
         "C50.4",
         "8500/3",
         "C50.4",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18V, TCGA-BH-A18U",
         "Upper outer quadrant of breast",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "32",
         "BRCA",
         "C50.5",
         "8500/3",
         "C50.5",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-BH-A18G",
         "Lower outer quadrant of breast",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "33",
         "BRCA",
         "C50.8",
         "8022/3",
         "C50.8",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-Z7-A8R6",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "34",
         "BRCA",
         "C50.8",
         "8500/3",
         "C50.8",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A18Q",
         "Overlapping lesion of breast",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "35",
         "BRCA",
         "C50.9",
         "8010/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A7-A5ZV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "36",
         "BRCA",
         "C50.9",
         "8013/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SK",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "37",
         "BRCA",
         "C50.9",
         "8200/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SB",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "38",
         "BRCA",
         "C50.9",
         "8211/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73X",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "39",
         "BRCA",
         "C50.9",
         "8401/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A2-A04W",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "40",
         "BRCA",
         "C50.9",
         "8480/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-D8-A73W, TCGA-A2-A3KD, TCGA-C8-A12X, TCGA-D8-A27W, TCGA-D8-A1XV, TCGA-C8-A1HL, TCGA-C8-A8HQ, TCGA-D8-A1XC, TCGA-E9-A5UO, TCGA-OL-A66H, TCGA-AC-A8OR",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast invasive carcinoma"
        ],
        [
         "41",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-E2-A15A, TCGA-E2-A15E, TCGA-E2-A15K",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "42",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-AR-A24U, TCGA-AQ-A04J, TCGA-BH-A0HK, TCGA-A2-A04U, TCGA-BH-A202, TCGA-OL-A5RU, TCGA-E2-A154, TCGA-D8-A140, TCGA-AN-A0XV, TCGA-EW-A1OV, TCGA-OL-A66L, TCGA-D8-A1JU, TCGA-C8-A1HE, TCGA-A2-A04R, TCGA-AR-A0TP, TCGA-A7-A26I, TCGA-EW-A1PB, TCGA-C8-A26V, TCGA-AN-A0XR, TCGA-A8-A08X, TCGA-AR-A1AX, TCGA-BH-A0EB, TCGA-A7-A0DB, TCGA-BH-A0W7, TCGA-BH-A0B4, TCGA-EW-A1P8, TCGA-A2-A0CV, TCGA-A8-A083, TCGA-B6-A0WY, TCGA-AN-A0XP, TCGA-A8-A07R, TCGA-A2-A04Q, TCGA-EW-A1P6, TCGA-C8-A27B, TCGA-A8-A06R, TCGA-B6-A0RH, TCGA-A2-A0YG, TCGA-A2-A0SU, TCGA-BH-A0EE, TCGA-D8-A1JH, TCGA-E2-A152, TCGA-EW-A1IZ, TCGA-OL-A5D6, TCGA-A1-A0SD, TCGA-BH-A0DK, TCGA-E2-A156, TCGA-A7-A56D, TCGA-E9-A1ND, TCGA-AR-A1AR, TCGA-A2-A1G4, TCGA-AN-A0FN, TCGA-GM-A2DA, TCGA-AR-A0TX, TCGA-BH-A0BP, TCGA-D8-A27P, TCGA-BH-A0AW, TCGA-E9-A1RF, TCGA-E9-A1R0, TCGA-A7-A6VY, TCGA-A2-A0CX, TCGA-AR-A0TZ, TCGA-A2-A25F, TCGA-E2-A15D, TCGA-OL-A5D7, TCGA-AC-A5EH, TCGA-AR-A0TR, TCGA-AQ-A1H2, TCGA-GM-A2DL, TCGA-EW-A1PD, TCGA-AN-A0XN, TCGA-AO-A03P, TCGA-D8-A1XW, TCGA-A7-A26I, TCGA-D8-A1JL, TCGA-LL-A5YN, TCGA-S3-A6ZH, TCGA-EW-A1P1, TCGA-B6-A0WW, TCGA-AN-A03Y, TCGA-D8-A1X5, TCGA-AN-A0AR, TCGA-A8-A09I, TCGA-C8-A1HO, TCGA-AO-A0JI, TCGA-BH-A0BD, TCGA-C8-A274, TCGA-B6-A1KC, TCGA-E2-A1L7, TCGA-A8-A06Q, TCGA-E9-A1R4, TCGA-A2-A0D4, TCGA-AC-A62V, TCGA-AR-A24Q, TCGA-AC-A8OP, TCGA-B6-A0WV, TCGA-D8-A27R, TCGA-D8-A1XB, TCGA-A2-A259, TCGA-D8-A1XL, TCGA-E2-A1IO, TCGA-A8-A08B, TCGA-BH-A0W5, TCGA-AO-A0JD, TCGA-3C-AALJ, TCGA-AO-A03O, TCGA-A8-A07F, TCGA-A1-A0SH, TCGA-A7-A6VV, TCGA-A2-A3XW, TCGA-B6-A0WT, TCGA-D8-A1Y3, TCGA-AR-A255, TCGA-B6-A0RT, TCGA-C8-A278, TCGA-BH-A6R8, TCGA-D8-A27K, TCGA-EW-A1PH, TCGA-3C-AALK, TCGA-EW-A6S9, TCGA-C8-A12Q, TCGA-E2-A15I, TCGA-A8-A0A9, TCGA-A2-A04X, TCGA-PL-A8LY, TCGA-E9-A24A, TCGA-B6-A0RG, TCGA-A1-A0SO, TCGA-C8-A12W, TCGA-A7-A26J, TCGA-AO-A03L, TCGA-GM-A3XL, TCGA-BH-A0DX, TCGA-A8-A07Z, TCGA-B6-A0I6, TCGA-B6-A0I6, TCGA-GM-A2DB, TCGA-E9-A247, TCGA-A8-A07G, TCGA-AN-A0XW, TCGA-BH-A0B1, TCGA-D8-A143, TCGA-D8-A1XR, TCGA-E2-A155, TCGA-D8-A1JJ, TCGA-E2-A1IG, TCGA-BH-A0B0, TCGA-D8-A1JG, TCGA-B6-A0RM, TCGA-BH-A0BM, TCGA-E2-A14V, TCGA-A2-A0ET, TCGA-AN-A0FL, TCGA-A2-A0EO, TCGA-A2-A1G0, TCGA-BH-A5J0, TCGA-C8-A138, TCGA-E2-A1B1, TCGA-C8-A1HN, TCGA-E2-A1IN, TCGA-BH-A0HN, TCGA-LD-A9QF, TCGA-A8-A09B, TCGA-E2-A574, TCGA-BH-A0H9, TCGA-C8-A131, TCGA-AC-A62X, TCGA-AN-A046, TCGA-A7-A4SF, TCGA-E2-A1L6, TCGA-AR-A24S, TCGA-A2-A0YT, TCGA-E9-A1R5, TCGA-A8-A07J, TCGA-A2-A0EV, TCGA-A8-A06X, TCGA-E2-A14N, TCGA-AO-A12A, TCGA-E2-A10C, TCGA-AN-A04C, TCGA-LL-A5YP, TCGA-AN-A0AM, TCGA-E2-A1II, TCGA-AO-A0JC, TCGA-A8-A07W, TCGA-D8-A1XY, TCGA-BH-A0DQ, TCGA-AN-A0XT, TCGA-LL-A73Z, TCGA-B6-A0I8, TCGA-AQ-A0Y5, TCGA-C8-A1HI, TCGA-A7-A0CD, TCGA-A7-A0DA, TCGA-A8-A091, TCGA-D8-A1XU, TCGA-B6-A0IK, TCGA-AR-A0U0, TCGA-EW-A6SD, TCGA-OL-A5RY, TCGA-E9-A1R2, TCGA-AN-A0AK, TCGA-AR-A252, TCGA-BH-A0EI, TCGA-E9-A22A, TCGA-A2-A25B, TCGA-BH-A0BW, TCGA-C8-A12Y, TCGA-AR-A0U3, TCGA-A2-A0CQ, TCGA-AR-A24K, TCGA-BH-A0H0, TCGA-AR-A0U2, TCGA-GM-A2DK, TCGA-BH-A0GZ, TCGA-BH-A0BL, TCGA-LL-A740, TCGA-B6-A0RO, TCGA-A2-A0T2, TCGA-E2-A15S, TCGA-A2-A0T1, TCGA-D8-A1JC, TCGA-A2-A3XU, TCGA-EW-A1P7, TCGA-C8-A1HJ, TCGA-AN-A0XU, TCGA-BH-A5IZ, TCGA-AO-A0JB, TCGA-BH-A0W4, TCGA-AN-A0AT, TCGA-A8-A07I, TCGA-A2-A0YM, TCGA-C8-A134, TCGA-B6-A1KI, TCGA-A1-A0SN, TCGA-E2-A15R, TCGA-S3-AA11, TCGA-AO-A128, TCGA-E2-A15T, TCGA-A8-A095, TCGA-D8-A1Y2, TCGA-UL-AAZ6, TCGA-A2-A0CL, TCGA-A8-A08P, TCGA-C8-A12M, TCGA-AR-A1AS, TCGA-E9-A1QZ, TCGA-A7-A6VX, TCGA-A8-A081, TCGA-BH-A0BQ, TCGA-A8-A093, TCGA-C8-A26X, TCGA-A2-A0ER, TCGA-A2-A04Y, TCGA-A2-A0D2, TCGA-D8-A1JA, TCGA-A7-A0CE, TCGA-C8-A12K, TCGA-A7-A26J, TCGA-AN-A0FS, TCGA-OL-A5RW, TCGA-A2-A0YC, TCGA-D8-A1JM, TCGA-AN-A0AL, TCGA-LL-A7SZ, TCGA-A8-A06T, TCGA-A8-A06U, TCGA-BH-A0C0, TCGA-A2-A0SV, TCGA-E9-A22G, TCGA-AR-A0TS, TCGA-A8-A06P, TCGA-B6-A0X5, TCGA-D8-A1JP, TCGA-AN-A0FD, TCGA-GM-A2DF, TCGA-AR-A0TW, TCGA-AN-A0FZ, TCGA-AN-A0FF, TCGA-C8-A12V, TCGA-AC-A23E, TCGA-A1-A0SP, TCGA-A2-A0EQ, TCGA-A2-A1FW, TCGA-C8-A1HK, TCGA-D8-A1X6, TCGA-A2-A0EY, TCGA-A8-A09C, TCGA-EW-A6SB, TCGA-A8-A07U, TCGA-A8-A08G, TCGA-BH-A0BV, TCGA-C8-A12T, TCGA-E2-A1IF, TCGA-D8-A1XA, TCGA-E2-A15A, TCGA-E2-A1B0, TCGA-AR-A24W, TCGA-A7-A26J, TCGA-A8-A06O, TCGA-D8-A1JE, TCGA-V7-A7HQ, TCGA-C8-A1HF, TCGA-C8-A137, TCGA-E2-A15E, TCGA-A2-A0D1, TCGA-AR-A24Z, TCGA-E2-A15K, TCGA-E2-A14Y, TCGA-AN-A0XO, TCGA-LD-A7W5, TCGA-D8-A1J9, TCGA-E2-A15C, TCGA-C8-A26Z, TCGA-OL-A6VR, TCGA-D8-A27N, TCGA-A8-A08H, TCGA-A8-A097, TCGA-AO-A03V, TCGA-AR-A1AH, TCGA-A2-A1G6, TCGA-E2-A1IK, TCGA-BH-A0AV, TCGA-A2-A0YJ, TCGA-A7-A26H, TCGA-C8-A12L, TCGA-UU-A93S, TCGA-E2-A1L9, TCGA-A8-A08O, TCGA-E9-A1R3, TCGA-E2-A570, TCGA-A2-A04P, TCGA-A2-A0CS, TCGA-LL-A8F5, TCGA-BH-A0HI, TCGA-EW-A1OZ, TCGA-E2-A1B6, TCGA-BH-A0C7, TCGA-S3-AA14, TCGA-B6-A0RS, TCGA-A2-A0T0, TCGA-AN-A0G0, TCGA-OL-A66I, TCGA-A8-A09N, TCGA-C8-A135, TCGA-A2-A0CT, TCGA-AO-A0JE, TCGA-D8-A1Y1, TCGA-AO-A1KP, TCGA-A8-A092, TCGA-AR-A1AO, TCGA-D8-A27L, TCGA-BH-A0E1, TCGA-E2-A573, TCGA-AR-A0TV, TCGA-A2-A04N, TCGA-AR-A250, TCGA-BH-A0B8, TCGA-E9-A243, TCGA-BH-A0BJ, TCGA-E2-A159, TCGA-E2-A14Z, TCGA-BH-A0HB, TCGA-C8-A1HG, TCGA-E9-A1R7, TCGA-D8-A141, TCGA-AO-A0JM, TCGA-BH-A0GY, TCGA-GM-A2DN, TCGA-D8-A13Z, TCGA-A7-A13E, TCGA-AR-A251, TCGA-A8-A07P, TCGA-BH-A0B9, TCGA-D8-A1Y0, TCGA-BH-A0DH, TCGA-E9-A22D, TCGA-AR-A1AP, TCGA-D8-A1XK, TCGA-AQ-A54O, TCGA-A2-A0CU, TCGA-D8-A1X9, TCGA-A2-A0T5, TCGA-D8-A1XQ, TCGA-AR-A1AY, TCGA-A8-A09G, TCGA-OL-A6VO, TCGA-AR-A254, TCGA-A8-A09M, TCGA-A8-A08R, TCGA-E2-A14X, TCGA-E9-A1RH, TCGA-A2-A4S3, TCGA-BH-A0BR, TCGA-AN-A0FY, TCGA-B6-A0IB, TCGA-E2-A15J, TCGA-E2-A1IE, TCGA-A2-A3Y0, TCGA-D8-A1XG, TCGA-A2-A0T3, TCGA-A2-A0SX, TCGA-BH-A0B3, TCGA-A7-A0D9, TCGA-D8-A1JK, TCGA-BH-A0HF, TCGA-AC-A7VB, TCGA-EW-A1P5, TCGA-B6-A0RE, TCGA-D8-A13Y, TCGA-B6-A0I5, TCGA-AC-A6NO, TCGA-E2-A15H, TCGA-AR-A24P, TCGA-AO-A03T, TCGA-D8-A1JF, TCGA-OL-A5D8, TCGA-A2-A0YH, TCGA-BH-A0HW, TCGA-GM-A2DM, TCGA-A2-A0T7, TCGA-BH-A0DE, TCGA-GM-A2DH, TCGA-AN-A0AS, TCGA-OL-A5S0, TCGA-E2-A9RU, TCGA-E2-A56Z, TCGA-C8-A275, TCGA-BH-A0DZ, TCGA-S3-AA0Z, TCGA-E2-A1LA, TCGA-E9-A1R6, TCGA-E9-A229, TCGA-E2-A14T, TCGA-PL-A8LZ, TCGA-AN-A0FW, TCGA-LL-A6FQ, TCGA-BH-A0AY, TCGA-D8-A1XM, TCGA-AN-A0XS, TCGA-E9-A1RB, TCGA-AC-A5XU, TCGA-AR-A1AU, TCGA-A8-A09D, TCGA-E9-A1RD, TCGA-EW-A1IY, TCGA-D8-A1J8, TCGA-C8-A12Z, TCGA-AO-A03R, TCGA-C8-A12U, TCGA-A7-A13D, TCGA-BH-A18H, TCGA-B6-A0X4, TCGA-C8-A12N, TCGA-AC-A8OQ, TCGA-C8-A12P, TCGA-E9-A1N8, TCGA-BH-A0W3, TCGA-AR-A24V, TCGA-A8-A090, TCGA-BH-A0HQ, TCGA-BH-A0DS, TCGA-AO-A0J4, TCGA-AO-A0J6, TCGA-A8-A099, TCGA-A7-A0DB, TCGA-EW-A1PA, TCGA-AR-A1AQ, TCGA-C8-A132, TCGA-A7-A13D, TCGA-AN-A04A, TCGA-BH-A0RX, TCGA-A2-A1FZ, TCGA-BH-A201, TCGA-A8-A085, TCGA-GM-A2DD, TCGA-A8-A09A, TCGA-AO-A0JF, TCGA-EW-A6SA, TCGA-E2-A1AZ, TCGA-B6-A1KF, TCGA-S3-A6ZF, TCGA-AQ-A1H3, TCGA-AQ-A04H, TCGA-BH-A0HY, TCGA-AN-A049, TCGA-BH-A0BC, TCGA-A2-A0D0, TCGA-A2-A0CW, TCGA-AN-A04D, TCGA-E9-A1RA, TCGA-A1-A0SF, TCGA-BH-A0E2, TCGA-OL-A66P, TCGA-A2-A0EM, TCGA-AO-A12D, TCGA-E2-A14Q, TCGA-A8-A094, TCGA-A7-A13D, TCGA-E2-A14P, TCGA-AO-A1KR, TCGA-E9-A1RG, TCGA-BH-A0HX, TCGA-LL-A5YO, TCGA-C8-A27A, TCGA-WT-AB41, TCGA-D8-A27M, TCGA-BH-A0H6, TCGA-D8-A147, TCGA-E2-A14W, TCGA-A2-A0CP, TCGA-PL-A8LX, TCGA-C8-A26W, TCGA-B6-A0RI, TCGA-A2-A0EU, TCGA-S3-AA15, TCGA-E9-A245, TCGA-BH-A0HO, TCGA-E9-A228, TCGA-C8-A12O, TCGA-A2-A0YE, TCGA-B6-A0I2, TCGA-AN-A041, TCGA-A8-A079, TCGA-A8-A08T, TCGA-E2-A150, TCGA-S3-AA17, TCGA-A2-A0D3, TCGA-AC-A6IW, TCGA-C8-A1HM, TCGA-A8-A08L, TCGA-AN-A0FV, TCGA-AN-A0FK, TCGA-E9-A227, TCGA-A7-A6VW, TCGA-AR-A24N, TCGA-A2-A0SW, TCGA-AO-A0JA, TCGA-EW-A1J6, TCGA-A8-A07L, TCGA-AC-A23C, TCGA-A2-A0YF, TCGA-A2-A1FX, TCGA-A8-A07B, TCGA-A2-A04T, TCGA-AN-A03X, TCGA-E2-A14O, TCGA-LL-A73Y, TCGA-E2-A15O, TCGA-A2-A0CM, TCGA-EW-A1J1, TCGA-A7-A0DB, TCGA-E2-A158, TCGA-A8-A09Q, TCGA-AR-A24L, TCGA-BH-A0B7, TCGA-B6-A0RN, TCGA-E9-A22E, TCGA-E9-A1NG, TCGA-B6-A0WS, TCGA-A1-A0SQ, TCGA-3C-AALI, TCGA-B6-A0RL, TCGA-D8-A1XT, TCGA-A7-A4SE, TCGA-AR-A256, TCGA-A7-A0CJ, TCGA-AR-A1AV, TCGA-A8-A08Z, TCGA-A8-A096, TCGA-E9-A226, TCGA-E2-A153, TCGA-A2-A25E, TCGA-D8-A1JI, TCGA-A1-A0SM, TCGA-A8-A075, TCGA-C8-A273, TCGA-BH-A42V, TCGA-AR-A1AN, TCGA-OL-A5RX, TCGA-OL-A5RZ, TCGA-AR-A0TQ, TCGA-A8-A06Z, TCGA-S3-AA10, TCGA-A8-A076, TCGA-AR-A1AJ, TCGA-E9-A1RE, TCGA-A1-A0SJ, TCGA-OL-A66O, TCGA-E9-A244, TCGA-OL-A5RV, TCGA-BH-A0EA, TCGA-AO-A1KT, TCGA-E2-A14R, TCGA-A8-A06Y, TCGA-A7-A5ZW, TCGA-D8-A1JD, TCGA-B6-A409, TCGA-E9-A248, TCGA-A2-A0ST, TCGA-LL-A6FR, TCGA-AN-A0FX, TCGA-AR-A0TT, TCGA-D8-A1XZ, TCGA-E9-A22H, TCGA-A1-A0SI, TCGA-EW-A1P3, TCGA-BH-A0E0, TCGA-B6-A0X1, TCGA-EW-A1OY, TCGA-EW-A2FS, TCGA-E2-A15P, TCGA-BH-A0E7, TCGA-BH-A0HU, TCGA-AR-A0TY, TCGA-E2-A1B4, TCGA-GM-A2DC, TCGA-D8-A27H, TCGA-B6-A1KN, TCGA-E2-A1BD, TCGA-A8-A08C, TCGA-AN-A0FT, TCGA-A2-A25C, TCGA-B6-A0I9, TCGA-AQ-A54N, TCGA-A7-A13E, TCGA-A8-A082, TCGA-D8-A145, TCGA-D8-A27F, TCGA-B6-A0IJ, TCGA-A7-A13F, TCGA-BH-A0H7, TCGA-A2-A04V, TCGA-S3-AA12, TCGA-B6-A0WZ, TCGA-AR-A0U1, TCGA-C8-A130, TCGA-AN-A0FJ, TCGA-AR-A1AW, TCGA-LL-A7T0, TCGA-AO-A0J2, TCGA-AR-A24R, TCGA-BH-A0BO, TCGA-A2-A1G1, TCGA-C8-A26Y, TCGA-D8-A1JB, TCGA-E2-A10A, TCGA-D8-A1XF, TCGA-A7-A13E, TCGA-AO-A12F, TCGA-D8-A142, TCGA-A8-A07O, TCGA-AR-A0TU, TCGA-B6-A401",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "43",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Metastatic, Solid Tissue Normal",
         "TCGA-BH-A1FE",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "44",
         "BRCA",
         "C50.9",
         "8500/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A1F6, TCGA-BH-A1FU, TCGA-BH-A203, TCGA-BH-A1FJ, TCGA-BH-A1FD, TCGA-BH-A0BS, TCGA-BH-A1FE, TCGA-BH-A0BF, TCGA-BH-A0DT, TCGA-A7-A13G, TCGA-BH-A18L, TCGA-BH-A0HA, TCGA-BH-A1EN, TCGA-BH-A1F8, TCGA-BH-A18T, TCGA-BH-A1F5, TCGA-BH-A1EY, TCGA-BH-A0DI, TCGA-BH-A0BZ, TCGA-E2-A1IU, TCGA-BH-A204, TCGA-AC-A2BM, TCGA-BH-A1ES, TCGA-A7-A0CH, TCGA-BH-A1EW, TCGA-BH-A18N, TCGA-A7-A13G, TCGA-GI-A2C8, TCGA-E2-A1LB, TCGA-AC-A2BK, TCGA-GM-A2DI, TCGA-BH-A0H3, TCGA-GM-A2D9, TCGA-BH-A0DO, TCGA-BH-A0AU, TCGA-BH-A1EV, TCGA-BH-A1EU, TCGA-BH-A208, TCGA-BH-A1FM, TCGA-AC-A23H, TCGA-BH-A0DV, TCGA-E2-A1LS, TCGA-BH-A18J, TCGA-E9-A1NH, TCGA-BH-A18R, TCGA-BH-A18F, TCGA-BH-A1ET, TCGA-BH-A1FH, TCGA-E2-A1LH, TCGA-BH-A0DG, TCGA-BH-A1F0, TCGA-BH-A0BT, TCGA-E2-A1LK, TCGA-BH-A18K, TCGA-BH-A0AZ, TCGA-BH-A1FL, TCGA-E2-A1LL, TCGA-BH-A1FG, TCGA-BH-A1FN, TCGA-BH-A0DD, TCGA-BH-A1EX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "45",
         "BRCA",
         "C50.9",
         "8503/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-B6-A0IC, TCGA-EW-A2FW, TCGA-BH-A0HL, TCGA-D8-A1JS, TCGA-D8-A1X7",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast invasive carcinoma"
        ],
        [
         "46",
         "BRCA",
         "C50.9",
         "8507/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-A1-A0SG, TCGA-D8-A1XS, TCGA-EW-A1PE, TCGA-EW-A2FV",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast invasive carcinoma"
        ],
        [
         "47",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Blood Derived Normal, Primary Tumor",
         "TCGA-PL-A8LV, TCGA-AR-A1AI, TCGA-EW-A1P4",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "48",
         "BRCA",
         "C50.9",
         "8510/3",
         "C50.9",
         "Primary Tumor, Solid Tissue Normal",
         "TCGA-BH-A209, TCGA-BH-A1FC",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast invasive carcinoma"
        ],
        [
         "49",
         "BRCA",
         "C50.9",
         "8520/3",
         "C50.9",
         "Blood Derived Normal, Metastatic",
         "TCGA-AC-A6IX",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast invasive carcinoma"
        ]
       ],
       "shape": {
        "columns": 10,
        "rows": 731
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_ACRONYM</th>\n",
       "      <th>ICD_10</th>\n",
       "      <th>ICD_O_3_HISTOLOGY</th>\n",
       "      <th>ICD_O_3_SITE</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Case IDs</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/1</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ACC</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>8370/3</td>\n",
       "      <td>C74.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>BLCA</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>8120/3</td>\n",
       "      <td>C67.0</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>726</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>8980/3</td>\n",
       "      <td>C54.3</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N8-A4PM</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>727</th>\n",
       "      <td>UCS</td>\n",
       "      <td>C55</td>\n",
       "      <td>8950/3</td>\n",
       "      <td>C55.9</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>728</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>729</th>\n",
       "      <td>UCS</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>TCGA-N9-A4Q8, TCGA-N9-A4PZ</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>730</th>\n",
       "      <td>UVM</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Uveal Melanoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>731 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    CANCER_TYPE_ACRONYM ICD_10 ICD_O_3_HISTOLOGY ICD_O_3_SITE  \\\n",
       "0                   ACC  C74.0            8370/1        C74.0   \n",
       "1                   ACC  C74.0            8370/3        C74.0   \n",
       "2                   ACC  C74.0            8370/3        C74.0   \n",
       "3                  BLCA  C67.0            8120/3        C67.0   \n",
       "4                  BLCA  C67.0            8120/3        C67.0   \n",
       "..                  ...    ...               ...          ...   \n",
       "726                 UCS  C54.3            8980/3        C54.3   \n",
       "727                 UCS    C55            8950/3        C55.9   \n",
       "728                 UCS    NaN               NaN          NaN   \n",
       "729                 UCS    NaN               NaN          NaN   \n",
       "730                 UVM    NaN               NaN          NaN   \n",
       "\n",
       "                  Normalized Sample Type  \\\n",
       "0    Blood Derived Normal, Primary Tumor   \n",
       "1    Blood Derived Normal, Primary Tumor   \n",
       "2     Primary Tumor, Solid Tissue Normal   \n",
       "3    Blood Derived Normal, Primary Tumor   \n",
       "4     Primary Tumor, Solid Tissue Normal   \n",
       "..                                   ...   \n",
       "726  Blood Derived Normal, Primary Tumor   \n",
       "727  Blood Derived Normal, Primary Tumor   \n",
       "728  Blood Derived Normal, Primary Tumor   \n",
       "729   Primary Tumor, Solid Tissue Normal   \n",
       "730  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                              Case IDs           ICD_10_desc  \\\n",
       "0    TCGA-OR-A5L9, TCGA-OR-A5J1, TCGA-OR-A5KU, TCGA...  Adrenal gland cortex   \n",
       "1    TCGA-OR-A5J8, TCGA-OR-A5KV, TCGA-OR-A5JP, TCGA...  Adrenal gland cortex   \n",
       "2    TCGA-OR-A5KB, TCGA-PK-A5HC, TCGA-PK-A5HB, TCGA...  Adrenal gland cortex   \n",
       "3    TCGA-DK-A2I6, TCGA-GV-A3QH, TCGA-FD-A62O, TCGA...      Trigone, bladder   \n",
       "4    TCGA-BT-A20U, TCGA-BT-A20N, TCGA-BT-A20P, TCGA...      Trigone, bladder   \n",
       "..                                                 ...                   ...   \n",
       "726                                       TCGA-N8-A4PM          Fundus uteri   \n",
       "727  TCGA-N5-A4RO, TCGA-N7-A4Y8, TCGA-N5-A4R8, TCGA...                   NaN   \n",
       "728  TCGA-N9-A4Q7, TCGA-NF-A4X2, TCGA-QM-A5NM, TCGA...                   NaN   \n",
       "729                         TCGA-N9-A4Q8, TCGA-N9-A4PZ                   NaN   \n",
       "730  TCGA-V4-A9ET, TCGA-YZ-A980, TCGA-V4-A9EW, TCGA...                   NaN   \n",
       "\n",
       "        ICD_O_3_SITE_desc            ICD_O_3_HISTOLOGY_desc  \\\n",
       "0    Adrenal gland cortex                               NaN   \n",
       "1    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "2    Adrenal gland cortex        Adrenal cortical carcinoma   \n",
       "3        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "4        Trigone, bladder  Transitional cell carcinoma, NOS   \n",
       "..                    ...                               ...   \n",
       "726          Fundus uteri               Carcinosarcoma, NOS   \n",
       "727            Uterus NOS             Mullerian mixed tumor   \n",
       "728                   NaN                               NaN   \n",
       "729                   NaN                               NaN   \n",
       "730                   NaN                               NaN   \n",
       "\n",
       "                 CANCER_TYPE_NAME  \n",
       "0        Adrenocortical carcinoma  \n",
       "1        Adrenocortical carcinoma  \n",
       "2        Adrenocortical carcinoma  \n",
       "3    Bladder Urothelial Carcinoma  \n",
       "4    Bladder Urothelial Carcinoma  \n",
       "..                            ...  \n",
       "726        Uterine Carcinosarcoma  \n",
       "727        Uterine Carcinosarcoma  \n",
       "728        Uterine Carcinosarcoma  \n",
       "729        Uterine Carcinosarcoma  \n",
       "730                Uveal Melanoma  \n",
       "\n",
       "[731 rows x 10 columns]"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "chatgpt_query_info = grouped_df[['CANCER_TYPE_NAME', 'ICD_10_desc', 'ICD_O_3_HISTOLOGY_desc', 'ICD_O_3_SITE_desc', 'Normalized Sample Type']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#chatgpt_query_info_deduplicated = chatgpt_query_info.drop_duplicates()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "chatgpt_query_info_deduplicated = chatgpt_query_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "424a7b6d-b555-428d-860f-dc6cd2136372",
       "rows": [
        [
         "0",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         null,
         "Adrenal gland cortex",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "1",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenal gland cortex",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "2",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenal gland cortex",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "3",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Trigone, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "4",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Trigone, bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "5",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Trigone, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "6",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Dome, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "7",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Dome, bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "8",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Dome, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "9",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Lateral wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "10",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Lateral wall bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "11",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Lateral wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "12",
         "Bladder Urothelial Carcinoma",
         null,
         "Transitional cell carcinoma, NOS",
         null,
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "13",
         "Bladder Urothelial Carcinoma",
         null,
         "Transitional cell carcinoma, NOS",
         null,
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "14",
         "Bladder Urothelial Carcinoma",
         null,
         "Papillary transitional cell carcinoma",
         null,
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "15",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Posterior wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "16",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Posterior wall bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "17",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Posterior wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "18",
         "Bladder Urothelial Carcinoma",
         null,
         "Transitional cell carcinoma, NOS",
         null,
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "19",
         "Bladder Urothelial Carcinoma",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Ureteric orifice",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "20",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "21",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "22",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Metastatic"
        ],
        [
         "23",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "24",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "25",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "26",
         "Breast invasive carcinoma",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper inner quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "27",
         "Breast invasive carcinoma",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Upper inner quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "28",
         "Breast invasive carcinoma",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Lower inner quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "29",
         "Breast invasive carcinoma",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Lower inner quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "30",
         "Breast invasive carcinoma",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper outer quadrant of breast",
         "Metastatic, Solid Tissue Normal"
        ],
        [
         "31",
         "Breast invasive carcinoma",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper outer quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "32",
         "Breast invasive carcinoma",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Lower outer quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "33",
         "Breast invasive carcinoma",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Overlapping lesion of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "34",
         "Breast invasive carcinoma",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Overlapping lesion of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "35",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "36",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "37",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "38",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "39",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "40",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "41",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Metastatic"
        ],
        [
         "42",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "43",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Metastatic, Solid Tissue Normal"
        ],
        [
         "44",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "45",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "46",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "47",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "48",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "49",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Metastatic"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 715
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>714</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>715 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 CANCER_TYPE_NAME           ICD_10_desc  \\\n",
       "0        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "1        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "2        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "3    Bladder Urothelial Carcinoma      Trigone, bladder   \n",
       "4    Bladder Urothelial Carcinoma      Trigone, bladder   \n",
       "..                            ...                   ...   \n",
       "710        Uterine Carcinosarcoma           Endometrium   \n",
       "711        Uterine Carcinosarcoma           Endometrium   \n",
       "712        Uterine Carcinosarcoma            Myometrium   \n",
       "713        Uterine Carcinosarcoma          Fundus uteri   \n",
       "714        Uterine Carcinosarcoma                   NaN   \n",
       "\n",
       "               ICD_O_3_HISTOLOGY_desc     ICD_O_3_SITE_desc  \\\n",
       "0                                 NaN  Adrenal gland cortex   \n",
       "1          Adrenal cortical carcinoma  Adrenal gland cortex   \n",
       "2          Adrenal cortical carcinoma  Adrenal gland cortex   \n",
       "3    Transitional cell carcinoma, NOS      Trigone, bladder   \n",
       "4    Transitional cell carcinoma, NOS      Trigone, bladder   \n",
       "..                                ...                   ...   \n",
       "710             Mullerian mixed tumor           Endometrium   \n",
       "711               Carcinosarcoma, NOS           Endometrium   \n",
       "712             Mullerian mixed tumor            Myometrium   \n",
       "713               Carcinosarcoma, NOS          Fundus uteri   \n",
       "714             Mullerian mixed tumor            Uterus NOS   \n",
       "\n",
       "                  Normalized Sample Type  \n",
       "0    Blood Derived Normal, Primary Tumor  \n",
       "1    Blood Derived Normal, Primary Tumor  \n",
       "2     Primary Tumor, Solid Tissue Normal  \n",
       "3    Blood Derived Normal, Primary Tumor  \n",
       "4     Primary Tumor, Solid Tissue Normal  \n",
       "..                                   ...  \n",
       "710   Primary Tumor, Solid Tissue Normal  \n",
       "711  Blood Derived Normal, Primary Tumor  \n",
       "712  Blood Derived Normal, Primary Tumor  \n",
       "713  Blood Derived Normal, Primary Tumor  \n",
       "714  Blood Derived Normal, Primary Tumor  \n",
       "\n",
       "[715 rows x 5 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chatgpt_query_info_deduplicated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "chatgpt_query_info_deduplicated = chatgpt_query_info_deduplicated.rename(columns={'Normalized Sample Type': 'Normalized_Sample_Type'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_chatgpt_query_info = chatgpt_query_info_deduplicated.fillna(\"UNKOWN\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "CANCER_TYPE_NAME",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_10_desc",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_HISTOLOGY_desc",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "ICD_O_3_SITE_desc",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized_Sample_Type",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "344537eb-011a-4506-a7ac-b73f0b3178c8",
       "rows": [
        [
         "0",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         "UNKOWN",
         "Adrenal gland cortex",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "1",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenal gland cortex",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "2",
         "Adrenocortical carcinoma",
         "Adrenal gland cortex",
         "Adrenal cortical carcinoma",
         "Adrenal gland cortex",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "3",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Trigone, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "4",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Transitional cell carcinoma, NOS",
         "Trigone, bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "5",
         "Bladder Urothelial Carcinoma",
         "Trigone, bladder",
         "Papillary transitional cell carcinoma",
         "Trigone, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "6",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Dome, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "7",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Transitional cell carcinoma, NOS",
         "Dome, bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "8",
         "Bladder Urothelial Carcinoma",
         "Dome, bladder",
         "Papillary adenocarcinoma, NOS",
         "Dome, bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "9",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Lateral wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "10",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Transitional cell carcinoma, NOS",
         "Lateral wall bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "11",
         "Bladder Urothelial Carcinoma",
         "Lateral wall bladder",
         "Papillary transitional cell carcinoma",
         "Lateral wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "12",
         "Bladder Urothelial Carcinoma",
         "UNKOWN",
         "Transitional cell carcinoma, NOS",
         "UNKOWN",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "13",
         "Bladder Urothelial Carcinoma",
         "UNKOWN",
         "Transitional cell carcinoma, NOS",
         "UNKOWN",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "14",
         "Bladder Urothelial Carcinoma",
         "UNKOWN",
         "Papillary transitional cell carcinoma",
         "UNKOWN",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "15",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Posterior wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "16",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Transitional cell carcinoma, NOS",
         "Posterior wall bladder",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "17",
         "Bladder Urothelial Carcinoma",
         "Posterior wall bladder",
         "Papillary transitional cell carcinoma",
         "Posterior wall bladder",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "19",
         "Bladder Urothelial Carcinoma",
         "Ureteric orifice",
         "Transitional cell carcinoma, NOS",
         "Ureteric orifice",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "20",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "21",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Squamous cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "22",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Metastatic"
        ],
        [
         "23",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "24",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Transitional cell carcinoma, NOS",
         "Bladder NOS",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "25",
         "Bladder Urothelial Carcinoma",
         "Bladder NOS",
         "Papillary transitional cell carcinoma",
         "Bladder NOS",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "26",
         "Breast invasive carcinoma",
         "Upper inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper inner quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "27",
         "Breast invasive carcinoma",
         "Upper inner quadrant of breast",
         "Infiltrating lobular mixed with other types of carcinoma",
         "Upper inner quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "28",
         "Breast invasive carcinoma",
         "Lower inner quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Lower inner quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "29",
         "Breast invasive carcinoma",
         "Lower inner quadrant of breast",
         "Infiltrating duct mixed with other types of carcinoma",
         "Lower inner quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "30",
         "Breast invasive carcinoma",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper outer quadrant of breast",
         "Metastatic, Solid Tissue Normal"
        ],
        [
         "31",
         "Breast invasive carcinoma",
         "Upper outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Upper outer quadrant of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "32",
         "Breast invasive carcinoma",
         "Lower outer quadrant of breast",
         "Infiltrating duct carcinoma, NOS",
         "Lower outer quadrant of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "33",
         "Breast invasive carcinoma",
         "Overlapping lesion of breast",
         "Pleomorphic carcinoma",
         "Overlapping lesion of breast",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "34",
         "Breast invasive carcinoma",
         "Overlapping lesion of breast",
         "Infiltrating duct carcinoma, NOS",
         "Overlapping lesion of breast",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "35",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "36",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Large cell neuroendocrine carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "37",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Adenoid cystic carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "38",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Tubular adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "39",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Apocrine adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "40",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Mucinous adenocarcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "41",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Metastatic"
        ],
        [
         "42",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "43",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Metastatic, Solid Tissue Normal"
        ],
        [
         "44",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Infiltrating duct carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "45",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Intraductal papillary adenocarcinoma with invasion",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "46",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Invasive micropapillary carcinoma of breast",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "47",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ],
        [
         "48",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Medullary carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Primary Tumor, Solid Tissue Normal"
        ],
        [
         "49",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Metastatic"
        ],
        [
         "50",
         "Breast invasive carcinoma",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Lobular carcinoma, NOS",
         "Breast NOS (excludes Skin of breast C44.5)",
         "Blood Derived Normal, Primary Tumor"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 704
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CANCER_TYPE_NAME</th>\n",
       "      <th>ICD_10_desc</th>\n",
       "      <th>ICD_O_3_HISTOLOGY_desc</th>\n",
       "      <th>ICD_O_3_SITE_desc</th>\n",
       "      <th>Normalized_Sample_Type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>UNKOWN</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Adrenal cortical carcinoma</td>\n",
       "      <td>Adrenal gland cortex</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Transitional cell carcinoma, NOS</td>\n",
       "      <td>Trigone, bladder</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Endometrium</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Myometrium</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Carcinosarcoma, NOS</td>\n",
       "      <td>Fundus uteri</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>714</th>\n",
       "      <td>Uterine Carcinosarcoma</td>\n",
       "      <td>UNKOWN</td>\n",
       "      <td>Mullerian mixed tumor</td>\n",
       "      <td>Uterus NOS</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>704 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                 CANCER_TYPE_NAME           ICD_10_desc  \\\n",
       "0        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "1        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "2        Adrenocortical carcinoma  Adrenal gland cortex   \n",
       "3    Bladder Urothelial Carcinoma      Trigone, bladder   \n",
       "4    Bladder Urothelial Carcinoma      Trigone, bladder   \n",
       "..                            ...                   ...   \n",
       "710        Uterine Carcinosarcoma           Endometrium   \n",
       "711        Uterine Carcinosarcoma           Endometrium   \n",
       "712        Uterine Carcinosarcoma            Myometrium   \n",
       "713        Uterine Carcinosarcoma          Fundus uteri   \n",
       "714        Uterine Carcinosarcoma                UNKOWN   \n",
       "\n",
       "               ICD_O_3_HISTOLOGY_desc     ICD_O_3_SITE_desc  \\\n",
       "0                              UNKOWN  Adrenal gland cortex   \n",
       "1          Adrenal cortical carcinoma  Adrenal gland cortex   \n",
       "2          Adrenal cortical carcinoma  Adrenal gland cortex   \n",
       "3    Transitional cell carcinoma, NOS      Trigone, bladder   \n",
       "4    Transitional cell carcinoma, NOS      Trigone, bladder   \n",
       "..                                ...                   ...   \n",
       "710             Mullerian mixed tumor           Endometrium   \n",
       "711               Carcinosarcoma, NOS           Endometrium   \n",
       "712             Mullerian mixed tumor            Myometrium   \n",
       "713               Carcinosarcoma, NOS          Fundus uteri   \n",
       "714             Mullerian mixed tumor            Uterus NOS   \n",
       "\n",
       "                  Normalized_Sample_Type  \n",
       "0    Blood Derived Normal, Primary Tumor  \n",
       "1    Blood Derived Normal, Primary Tumor  \n",
       "2     Primary Tumor, Solid Tissue Normal  \n",
       "3    Blood Derived Normal, Primary Tumor  \n",
       "4     Primary Tumor, Solid Tissue Normal  \n",
       "..                                   ...  \n",
       "710   Primary Tumor, Solid Tissue Normal  \n",
       "711  Blood Derived Normal, Primary Tumor  \n",
       "712  Blood Derived Normal, Primary Tumor  \n",
       "713  Blood Derived Normal, Primary Tumor  \n",
       "714  Blood Derived Normal, Primary Tumor  \n",
       "\n",
       "[704 rows x 5 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_chatgpt_query_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# template = \"\"\"\n",
    "# response = client.chat.completions.create(\n",
    "#   model=\"gpt-4o\",\n",
    "#   messages=[\n",
    "#     {{\n",
    "#       \"role\": \"system\",\n",
    "#       \"content\": [\n",
    "#         {{\n",
    "#           \"type\": \"text\",\n",
    "#           \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
    "#         }}\n",
    "#       ]\n",
    "#     }},\n",
    "#     {{\n",
    "#       \"role\": \"user\",\n",
    "#       \"content\": [\n",
    "#         {{\n",
    "#           \"type\": \"text\",\n",
    "#           \"text\": \"Describe how {CANCER_TYPE_NAME} (per ICD-10: {ICD_10_desc}) impacts survival, focusing on:\\n- Tumor Origin: How {ICD_O_3_SITE_desc} influences metastatic patterns, patient survival, and treatment accessibility.\\n- Histology: How {ICD_O_3_HISTOLOGY_desc} interacts with mutation profiles to drive outcomes.\\n- Sampling Bias: Limitations of {Normalized_Sample_Type} in genomic analysis.\\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\\n\\nFor each aspect, explain step by step:\\n- How it influences survival (positive/negative)\\n- Biological rationale without excessive jargon\\n- Potential biases in genomic interpretation\\n\\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n",
    "#         }}\n",
    "#       ]\n",
    "#     }}\n",
    "#   ],\n",
    "#   response_format={{ \"type\": \"text\" }},\n",
    "#   temperature=1,\n",
    "#   max_completion_tokens=2048,\n",
    "#   top_p=1,\n",
    "#   frequency_penalty=0,\n",
    "#   presence_penalty=0\n",
    "# )\n",
    "# \"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "response = client.chat.completions.create(\n",
      "  model=\"gpt-4o\",\n",
      "  messages=[\n",
      "    {\n",
      "      \"role\": \"system\",\n",
      "      \"content\": [\n",
      "        {\n",
      "          \"type\": \"text\",\n",
      "          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    {\n",
      "      \"role\": \"user\",\n",
      "      \"content\": [\n",
      "        {\n",
      "          \"type\": \"text\",\n",
      "          \"text\": \"Describe how Adrenocortical carcinoma (per ICD-10: Adrenal gland cortex) impacts survival, focusing on:\n",
      "- Tumor Origin: How Adrenal gland cortex influences metastatic patterns, patient survival, and treatment accessibility.\n",
      "- Histology: How UNKOWN interacts with mutation profiles to drive outcomes.\n",
      "- Sampling Bias: Limitations of Blood Derived Normal, Primary Tumor in genomic analysis.\n",
      "- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n",
      "\n",
      "For each aspect, explain step by step:\n",
      "- How it influences survival (positive/negative)\n",
      "- Biological rationale without excessive jargon\n",
      "- Potential biases in genomic interpretation\n",
      "\n",
      "Conclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n",
      "        }\n",
      "      ]\n",
      "    }\n",
      "  ],\n",
      "  response_format={ \"type\": \"text\" },\n",
      "  temperature=1,\n",
      "  max_completion_tokens=2048,\n",
      "  top_p=1,\n",
      "  frequency_penalty=0,\n",
      "  presence_penalty=0\n",
      ")\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# prompts = []\n",
    "# for index, row in final_chatgpt_query_info.iterrows():\n",
    "#     prompt_filled = template.format(\n",
    "#         CANCER_TYPE_NAME=row[\"CANCER_TYPE_NAME\"],\n",
    "#         ICD_10_desc=row[\"ICD_10_desc\"],\n",
    "#         ICD_O_3_SITE_desc=row[\"ICD_O_3_SITE_desc\"],\n",
    "#         ICD_O_3_HISTOLOGY_desc=row[\"ICD_O_3_HISTOLOGY_desc\"],\n",
    "#         Normalized_Sample_Type=row[\"Normalized_Sample_Type\"]\n",
    "#     )\n",
    "#     prompts.append(prompt_filled)\n",
    "\n",
    "# # Now 'prompts' is a list where each element is a fully formatted prompt.\n",
    "# print(prompts[0])  # Print the first prompt as an example."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from openai import OpenAI"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# client = OpenAI(api_key=os.getenv(\"OPENAI_API_KEY\"))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def get_response(prompt):\n",
    "#     try:\n",
    "#         response = openai.ChatCompletion.create(\n",
    "#             model=\"gpt-4o\",\n",
    "#             messages=[\n",
    "#                 {\n",
    "#                     \"role\": \"system\",\n",
    "#                     \"content\": [\n",
    "#                         {\n",
    "#                             \"type\": \"text\",\n",
    "#                             \"text\": (\n",
    "#                                 \"You are an expert oncologist specializing in cancer survival. \"\n",
    "#                                 \"You are explaining complex oncological and genomic factors to another expert \"\n",
    "#                                 \"in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge \"\n",
    "#                                 \"of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations \"\n",
    "#                                 \"and ensure biological clarity while emphasizing survival impact.\"\n",
    "#                             )\n",
    "#                         }\n",
    "#                     ]\n",
    "#                 },\n",
    "#                 {\n",
    "#                     \"role\": \"user\",\n",
    "#                     \"content\": [\n",
    "#                         {\n",
    "#                             \"type\": \"text\",\n",
    "#                             \"text\": prompt\n",
    "#                         }\n",
    "#                     ]\n",
    "#                 }\n",
    "#             ],\n",
    "#             response_format={\"type\": \"text\"},\n",
    "#             temperature=1,\n",
    "#             max_tokens=2048,\n",
    "#             top_p=1,\n",
    "#             frequency_penalty=0,\n",
    "#             presence_penalty=0\n",
    "#         )\n",
    "#         return response\n",
    "#     except Exception as e:\n",
    "#         print(f\"Error processing prompt: {e}\")\n",
    "#         return None\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing prompt 1/704...\n",
      "ChatCompletion(id='chatcmpl-BAiDlUHNHkknGlvawXAMOwjM0XPKx', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Adrenal Gland Cortex\\n\\n**Influence on Survival:**\\nAdrenocortical carcinoma (ACC) originates in the adrenal cortex, which is crucial for hormone production, particularly glucocorticoids, mineralocorticoids, and androgens. The origin significantly affects metastatic patterns, often spreading early to the liver, lungs, and peritoneum due to abundant vascularization of the adrenal glands.\\n\\n**Biological Rationale:**\\nThe adrenal gland's function in hormone secretion plays a critical role in the metabolic and immune environment, potentially enhancing tumor spread. Thus, the complex regulation of hormones by tumors influences cachexia and immunosuppression, further impacting mortality rates.\\n\\n**Treatment Accessibility:**\\nTreatment options are limited, often constrained by early metastasis and the tumor’s resistance to conventional chemotherapy. Surgical resection is the mainstay, but complete removal is challenging due to local invasiveness.\\n\\n**Potential Biases:**\\nThe localized and aggressive nature of ACC implies that early dissemination might not be adequately captured in initial genomic analyses, leading to an underestimation of its metastatic potential and consequent survival estimates.\\n\\n### Histology \\n\\n**Influence on Survival:**\\nThe histological profile of ACC, characterized by its unknown interaction patterns, suggests a heterogeneous nature that complicates prognosis. Anaplastic changes correlate with more aggressive behavior and poorer outcomes.\\n\\n**Biological Rationale:**\\nHistological examination reveals insights into tumor biology, including cell organization, mitotic count, and necrosis, which influence tumor grading. A higher grade results in a more negative prognosis, attributable to increased growth rate and metastatic propensity.\\n\\n**Potential Biases:**\\nPathological assessment might not always capture the genetic diversity within tumor mass, potentially misconstruing mutation impact. Analyzing insufficient biopsy material can overlook aggressive subpopulations.\\n\\n### Sampling Bias\\n\\n**Limitations of Blood Derived Normal, Primary Tumor in Genomic Analysis:**\\n \\n- **Primary Tumor Sample Bias:** Tissue sampling from primary tumors may not reflect the heterogeneity across metastatic sites. Tumors often exhibit intratumoral heterogeneity, resulting in missed mutational clones during initial biopsy reliance.\\n  \\n- **Blood-Derived Samples:** These are limited by their dilution effect, as circulating tumor DNA often represents a small fraction of all cell-free DNA, potentially missing key mutations.\\n\\n### Key Genes\\n\\n1. **TP53**: Central to regulating cell cycle arrest and apoptosis. Mutations lead to unchecked cellular division, directly worsening prognosis.\\n\\n2. **CTNNB1**: This gene, essential for Wnt signaling, when mutated, drives malignancy via uncontrolled cellular proliferation. Aberrant pathways are linked to poor survival rates.\\n\\n3. **MEN1**: Often implicated in multiple endocrine neoplasia, mutations result in dysfunctional tumor suppressor pathways, enhancing cell growth and survival.\\n\\n4. **ZNRF3**: Negative regulator of Wnt signaling. Loss of function mutations contribute to enhanced Wnt pathway activity, promoting tumor growth.\\n\\n5. **CDKN2A**: Encodes for p16, a cyclin-dependent kinase inhibitor. Mutations prevent cell cycle regulation, aiding uncontrolled cell division.\\n\\n6. **RB1**: Tumor suppressor linked to cell cycle regulation. Deactivation leads to unregulated progression through the cell cycle, favoring tumor growth.\\n\\n7. **TERT**: Regulates telomere length. Mutations can enable indefinite replication, a hallmark of cancer malignancy.\\n\\n8. **PRKAR1A**: Involves cyclic AMP signaling, mutations lead to tumoral growth through disrupted signaling cascades.\\n\\n**Biological Mechanisms:**\\nSurvival impact arises from mechanisms like evasion of apoptosis (TP53), increased proliferative capacity (CTNNB1, RB1), and disrupted reparative processes (TERT, MEN1).\\n\\n**Potential Interpretation Bias:**\\nGenomic analyses might overemphasize certain pathway changes without accounting for tumor microenvironment influence on gene expression. Intratumoral heterogeneity can further muddle gene impact assessment.\\n\\n### Conclusion: Key Survival Risk Factors\\n\\nSynthesizing the outlined factors reveals that ACC survival is critically contingent upon the tumor’s metastatic propensity, influenced largely by its origin and genetic profile, particularly mutations in key oncogenes and tumor suppressors. The unique histological features and inherent treatment resistance, compounded by sampling biases, underscore the necessity for comprehensive mutational and histological analyses. Clinically, identifying mutations early could stratify patients for targeted therapies, addressing key biological pathways altered in ACC, potentially improving outcomes significantly.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741892965, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=921, prompt_tokens=442, total_tokens=1363, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 2/704...\n",
      "ChatCompletion(id='chatcmpl-BAiE42qkiupRADZ3fgeMvF75S9CmL', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"To provide a comprehensive analysis of how Adrenocortical carcinoma (ACC) impacts survival, we need to address each component methodically: tumor origin, histology, sampling biases, and key genes.\\n\\n### Tumor Origin\\n1. **Influence on Survival:**\\n   - **Metastatic Patterns:** ACC originates from the adrenal gland cortex, a site responsible for hormone production, such as cortisol. This predisposes the cancer to a high rate of hematogenous spread, leading to early metastases in the liver, lungs, and bones, which markedly reduces survival prospects.\\n   - **Treatment Accessibility:** The adrenal gland’s location beneath the diaphragmatic level can complicate surgical intervention, the cornerstone for potential curative treatment.\\n\\n2. **Biological Rationale:**\\n   - The endocrine function of the adrenal cortex influences systemic hormonal imbalances, exacerbating cancer progression and impairing metabolic functions, further affecting patient outcomes negatively.\\n\\n3. **Biases in Interpretation:**\\n   - The adrenal gland serves a critical role in systemic physiology; thus, the effects of localized tumorigenesis can be underestimated when extrapolating data from different primary sites, potentially skewing survival analysis.\\n\\n### Histology\\n1. **Influence on Survival:**\\n   - The aggressive histological nature of ACC, characterized by high mitotic rates and necrosis, correlates with poor prognosis.\\n\\n2. **Biological Rationale:**\\n   - Tumor cells' ability to evade apoptosis and rapidly proliferate are hallmarks driven by complex mutation profiles, including defects in the TP53 and RB1 pathways.\\n\\n3. **Potential Biases:**\\n   - Analyzing histological data without molecular profiling limits the comprehension of aggressive phenotypes, as genomic alterations may provide better insight into prognosis.\\n\\n### Sampling Bias\\n1. **Influence on Survival:**\\n   - Sampling bias can skew genomic data interpretation — Blood Derived Normals (BDN) might not capture tumor heterogeneity present in primary tumor samples.\\n\\n2. **Biological Rationale:**\\n   - BDNs may lack mutations present only in cancerous tissues, leading to an underestimation of tumor-specific oncogenic drivers.\\n\\n3. **Potential Biases:**\\n   - Primary tumor samples provide a comprehensive genomic landscape but may not reflect metastatic behavior or immune interactions affecting survival.\\n\\n### Key Genes\\n1. **Influence on Survival:**\\n   - Certain genes are paramount in dictating survival outcomes by interfering with cellular processes such as proliferation, immune evasion, and apoptosis.\\n\\n2. **Biological Mechanisms:**\\n   - **TP53:** Regulates genomic stability; mutations here lead to unchecked cellular proliferation.\\n   - **IGF2:** Involved in cell growth; overexpression promotes aggressive tumor behavior.\\n   - **CTNNB1 (β-catenin):** Part of the Wnt signaling pathway, its activation is linked to increased tumor invasiveness.\\n   - **MEN1:** Tumor suppressor; mutations are associated with multiple endocrine neoplasia, affecting survival negatively.\\n   - **TERT:** Implicated in telomere lengthening, providing cancer cells with replicative immortality.\\n   - **RB1:** Loss promotes unregulated cell cycle entry, contributing to aggressive tumor phenotypes.\\n   - **PRKAR1A:** Related to cyclic AMP signaling, affecting apoptosis and proliferation.\\n\\n3. **Potential Biases:**\\n   - These genes’ roles might vary between studies due to inter-sample or inter-institutional variability, complicating survival predictions.\\n\\n### Synthesis of Key Survival Risk Factors\\nSynthesizing these insights, the most significant risk factors for low survival in ACC include its aggressive histological features, high propensity for metastasis, challenging localization for complete surgical resection, and critical genomic alterations leading to dysregulated cell proliferation and hormone imbalance. Clinically, a multi-disciplinary approach, integrating precise surgical, hormonal, and targeted genetic therapies, becomes essential in improving survival outcomes. Understanding the genomic landscape is vital for individualizing treatment strategies, thus enhancing prognosis for ACC patients.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741892984, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=817, prompt_tokens=443, total_tokens=1260, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 3/704...\n",
      "ChatCompletion(id='chatcmpl-BAiETUp2RXtklp2JWf9Bs2E3YRQg1', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin: Adrenal Gland Cortex**\\n\\n1. **Influences on Metastatic Patterns and Survival:**\\n   - **Origin Context:** Adrenocortical carcinoma (ACC) arises from the cortex of the adrenal gland, responsible for producing steroid hormones like cortisol. This hormonal activity can influence tumor behavior and patient symptoms.\\n   - **Metastatic Propensity:** The adrenal cortex's rich vascular network facilitates hematogenous spread, commonly metastasizing to the liver, lungs, and bones, contributing to poor prognosis.\\n   - **Survival Impact:** ACC's propensity for early metastasis results in a high mortality rate, with a 5-year survival often below 40%, largely dependent on stage at diagnosis.\\n\\n2. **Treatment Accessibility:**\\n   - **Surgical Challenges:** Complete surgical resection is often the most effective treatment but is limited by tumor size and spread. Incomplete resections lead to poorer outcomes.\\n   - **Therapeutic Limitations:** Limited efficacy of chemotherapy and the need for targeted therapies complicate treatment options, directly impacting survival.\\n\\n**Histology and Mutation Interaction**\\n\\n1. **Histological Characteristics:**\\n   - **Cellular Features:** ACCs often display high mitotic rates, necrosis, and cell pleomorphism, indicative of aggressive behavior.\\n   - **Survival Implications:** Tumors with more aggressive histopathological features correlate with worse survival outcomes.\\n\\n2. **Mutation Profiles:**\\n   - Mutations in genes like TP53, CTNNB1, and MEN1 are typical, with pathways affecting cell cycle regulation and Wnt signaling.\\n   - **Survival Impact:** Mutations can confer resistance to apoptosis (cell death) and enhance proliferative capacities, worsening prognosis.\\n   \\n**Sampling Bias in Genomic Analysis**\\n\\n1. **Primary Tumor Limitations:**\\n   - **Sampling Bias:** Biopsies may not fully represent tumor heterogeneity, potentially overlooking subclonal populations driving aggression.\\n   - **Genomic Insights:** Divergent genomic profiles between primary and metastatic sites can lead to underestimation of mutation prevalence impacting survival predictions.\\n\\n2. **Solid Tissue Normal Biases:**\\n   - Using adjacent normal tissue for genomic comparisons may introduce biases in differential expression analysis, sometimes normal tissues undergo molecular alterations due to tumor proximity, skewing results.\\n\\n**Key Survival-Associated Genes:**\\n\\n1. **TP53:**\\n   - **Function:** Tumor suppressor; regulates the cell cycle and apoptosis.\\n   - **Impact:** Mutations lead to unchecked cell division, contributing to aggressive tumor behavior and poor survival.\\n\\n2. **CTNNB1:**\\n   - **Function:** Wnt signaling pathway; impacts cell proliferation.\\n   - **Impact:** Mutations lead to constitutive signaling, enhancing proliferation and tumor metastasis.\\n\\n3. **MEN1:**\\n   - **Function:** Tumor suppressor; impacts gene transcription.\\n   - **Impact:** Mutations are linked to hormonal dysregulation adding complexity to tumor control and psychiatric stress in patients.\\n\\n4. **ZNRF3:**\\n   - **Function:** Negative regulator of Wnt signaling.\\n   - **Impact:** Loss-of-function mutations activate Wnt, aiding tumor proliferation and metastasis.\\n\\n5. **IGF2:**\\n   - **Function:** Mitogenic signaling; overexpressed in many cancers.\\n   - **Impact:** Promotes cell growth and survival, hindering tumor control once metastasis occurs.\\n\\n**Conclusion: Synthesis of Key Survival Risk Factors**\\n\\nAdrenal cortical carcinoma's poor survival outcomes are driven by a combination of aggressive histological features, metastatic capacity, and complex mutation landscapes. The tumor’s origin in the hormonally active adrenal cortex exacerbates systemic manifestations and complicates treatment options. Key genes, prominently involving pathways such as p53 and Wnt, materially affect cellular behaviors leading to unchecked proliferation and survival, notwithstanding surgical and therapeutic interventions.\\n\\nUnderstanding biases in genomic analyses, particularly concerning tumor heterogeneity and microenvironment influences, emphasizes the need for comprehensive, accurately representative sampling methodologies. Clinical strategies focusing on early detection, controlled surgical excision, and advanced genetic therapies might modestly improve survival, but further research and therapy development remain crucial.\\n\\nImplementing precision medicine approaches that consider these intricate factors and optimize clinical decision-making could ultimately advance patient outcomes in ACC.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893009, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=867, prompt_tokens=443, total_tokens=1310, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 4/704...\n",
      "ChatCompletion(id='chatcmpl-BAiEvFIJjXaR0NzoUnU5NFAbrvVXG', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Impact of Trigone, Bladder on Survival\\n\\n**Influence on Survival:**\\n\\n- The trigone area of the bladder is anatomically located at the base, near the urethral orifices and ureters, making tumors in this area prone to early invasion into surrounding tissues.\\n- This anatomical positioning increases the risk for lymphatic spread and potential metastasis to local and distant sites, often leading to poorer survival outcomes due to advanced disease at diagnosis.\\n\\n**Biological Rationale:**\\n\\n- The proximity of the trigone to critical urinary tract structures means that even small tumors can cause substantial functional disruptions, complicating surgical interventions and contributing to more aggressive disease manifestations.\\n\\n**Potential Biases:**\\n\\n- Retrospective studies often disproportionately include aggressive cases from this region, potentially skewing our understanding of survival for trigonal bladder cancer. Therefore, careful selection and analysis of cohorts are critical.\\n\\n### Histology: Interaction of Transitional Cell Carcinoma, NOS with Mutation Profiles\\n\\n**Influence on Survival:**\\n\\n- Transitional cell carcinoma, NOS is the most common histologic type in bladder cancer, with a well-studied but variable response to treatment based on its mutation profile.\\n\\n**Biological Rationale:**\\n\\n- Specific mutation profiles (e.g., in FGFR3, TP53) dramatically impact tumor behavior:\\n  - **FGFR3 mutations** typically correlate with less aggressive, superficial tumors with better survival.\\n  - **TP53 mutations** are linked to higher grade, advanced tumors that are often resistant to chemotherapy, negatively impacting survival.\\n\\n**Potential Biases:**\\n\\n- Histopathological assessments can be subjective, and variations in interpretation might influence mutation identification and subsequent treatment decisions.\\n\\n### Sampling Bias in Genomic Analysis\\n\\n**Limitations of Blood Derived Normal and Primary Tumor Sampling:**\\n\\n- Blood-derived normal samples often serve as references in genomic comparison but may lack tumor-specific mutational context.\\n- Primary tumor samples, when not representative of the tumor heterogeneity, might ignore subclonal populations, missing potentially critical drivers of disease progression and survival.\\n\\n**Potential Biases:**\\n\\n- Sampling bias can lead to under-representation of certain mutations, particularly those present in small, aggressive subpopulations, skewing data towards less aggressive mutation profiles.\\n\\n### Key Survival-Associated Genes\\n\\n1. **TP53:** Regulates cell cycle and apoptosis. Mutations lead to loss of tumor suppressor function, increasing survival disadvantage due to resistance to therapy and higher grade tumors.\\n\\n2. **RB1:** Loss affects cell cycle control, promoting unchecked cellular proliferation and correlating with poorer survival outcomes.\\n\\n3. **FGFR3:** Typically associated with better prognosis, mutations suggest non-invasive disease, often seen in low-grade tumors with limited survival impact when appropriately managed.\\n\\n4. **PIK3CA:** Involved in cell growth pathways, mutations typically confer resistance to apoptosis, contributing to potential therapeutic resistance and negative survival implications.\\n\\n5. **ARID1A:** Disruptions in chromatin remodeling, leading to genomic instability and potentially more aggressive cancer phenotypes with poorer survival.\\n\\n6. **ERBB2/HER2:** Overexpression correlates with aggressive tumor growth and poorer outcomes, though targeted therapies can improve survival.\\n\\n7. **TSC1/TSC2:** Mutations in these genes can lead to mTOR pathway activation, driving tumor progression and negatively affecting survival.\\n\\n8. **MDM2:** Amplification leads to inactivation of TP53, contributing to poor survival outcomes due to unchecked cellular proliferation.\\n\\n**Synthesis of Key Survival Risk Factors:**\\n\\nBladder urothelial carcinoma originating in the trigone poses distinct challenges given its anatomical context that predisposes to aggressive disease. The histological and genetic composition of these tumors, particularly involving mutations in TP53 and RB1, significantly influence patient prognosis. Furthermore, sampling biases, especially in genetic studies, can lead to misinterpretation of the mutational landscape. Accurate understanding and management thus require a nuanced approach integrating site-specific, histologic, and molecular characteristics to optimize patient outcomes and improve survival. Recognizing and addressing these factors is crucial for personalized treatment strategies.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893037, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=832, prompt_tokens=449, total_tokens=1281, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 5/704...\n",
      "ChatCompletion(id='chatcmpl-BAiFFu18bgV7xysNIYbXnD4cekPp2', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin: Trigone, Bladder\\n\\n### Metastatic Patterns and Survival Impact\\n1. **Localization and Metastatic Propensity**:\\n   - The trigone area of the bladder, located at the base near the ureters and urethra, poses a unique challenge due to its proximity to critical structures. Tumors originating here can more readily invade nearby tissues, particularly the ureters and lymphatic system, which increases the risk of metastasis.\\n   - **Impact on Survival**: The increased metastatic potential due to anatomical considerations generally results in poorer survival outcomes because of earlier dissemination and more aggressive disease.\\n\\n2. **Treatment Accessibility**:\\n   - Surgery and local therapies must consider the trigone's proximity to ureters, which complicates resection and increases the likelihood of incomplete tumor removal or damage to urinary function.\\n   - **Impact on Survival**: This limits the intensity or scope of local treatments, often leading to suboptimal management and reduced survival.\\n\\n### Biological Rationale\\n- The trigone’s rich vascular and lymphatic networks facilitate faster spread of neoplastic cells, emphasizing the metastatic burden and disease complexity influencing prognosis severely.\\n\\n## Histology: Transitional Cell Carcinoma, NOS\\n\\n### Mutation Profiles and Outcomes\\n1. **Histological Influence**:\\n   - Transitional cell carcinoma, NOS is characterized by high-grade mutations often involving p53, FGFR3, and others.\\n   - **Survival Impact**: The mutation burden often correlates with treatment resistance and aggressive disease behavior, affecting survival.\\n\\n2. **Comprehensive Genomic Interactions**:\\n   - Mutation profiles can affect pathways related to cell cycle regulation and apoptosis, reducing therapeutic response efficacy.\\n   - **Impact on Survival**: High mutation rates typically indicate poor differentiation, correlating with lower survival rates due to treatment resistance.\\n\\n### Biological Rationale\\n- Key mutations disrupt regulatory pathways crucial for apoptosis and proliferation control, leading to unchecked cell growth and malignancy.\\n\\n## Sampling Bias: Primary Tumor, Solid Tissue Normal\\n\\n### Limitations in Genomic Analysis\\n1. **Sampling Biases**:\\n   - Bias may arise if normal tissues are not truly representative of the genetic landscape, or heterogeneous tumors are poorly sampled.\\n   - **Impact on Survival Analysis**: Misinterpretation of genomic data can skew survival predictions as mutated pathways or genes may be under-represented.\\n\\n2. **Variability in Expression**:\\n   - Intratumoral heterogeneity can lead to variability in detected mutations and expression levels.\\n   - **Impact on Genomic Interpretation**: This complicates tumor behavior predictions, potentially leading to sub-optimal treatment strategies.\\n\\n## Key Genes Affecting Survival\\n\\n1. **TP53**: Encodes p53, a tumor suppressor involved in DNA repair and apoptosis.\\n   - **Mechanism**: Mutations lead to apoptosis inhibition, increasing resistance and aggressiveness.\\n   - **Survival Risk**: Strongly negative impact; prevalent in resistant tumors.\\n\\n2. **FGFR3**: Often mutated in bladder cancers, involved in cell growth and survival pathways.\\n   - **Mechanism**: Mutation enhances proliferative signaling.\\n   - **Survival Impact**: Holistically dependent on mutation; can be therapeutic targets if alterations are actionable.\\n\\n3. **KMT2D**: Histone modification gene affecting chromatin dynamics.\\n   - **Mechanism**: Altered expression leads to dysregulated gene expression pathways.\\n   - **Survival Impact**: Negative influence, often signifies progression.\\n\\n4. **CDKN2A**: Regulates cell cycle inhibitors like p16 and ARF.\\n   - **Mechanism**: Inactivation promotes unchecked cell cycle progression.\\n   - **Survival Risk**: Significantly negative as it supports uncontrolled proliferation.\\n\\n5. **PIK3CA**: Part of the PI3K/AKT pathway involved in proliferation and survival.\\n   - **Mechanism**: Mutations enhance cell survival, often linking to poor prognosis.\\n   - **Survival Impact**: Negative, due to proliferation reliance.\\n\\n6. **ERBB2 Her2/neu**: Associated with enhanced cellular signalling and modular control.\\n   - **Mechanism**: Overexpression leads to enhanced proliferative and survival pathways.\\n   - **Survival Impact**: Mixed impact; while aggressive, can be targeted therapeutically for benefit.\\n\\n## Conclusion: Key Survival Risk Factors\\n\\n### Clinical Insights\\n- **Anatomical Considerations**: Tumors at the trigone emphasize an increased risk of aggressive behavior due to location.\\n- **Histological and Genetic Complexity**: High mutation load contributes to treatment resistance and rapid progression, demanding personalized treatment strategies.\\n- **Sampling and Interpretation Bias**: Accurate genomic profiling is critical to therapy adjustments and improving survival outcomes.\\n\\nIn conclusion, the integration of tumor location, histological characteristics, and genetic insights provides a comprehensive framework for understanding and improving patient survival in bladder urothelial carcinoma. Tailoring treatment plans to these nuanced dynamics holds the promise of optimizing clinical outcomes and extending survival.\\n\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893057, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1018, prompt_tokens=449, total_tokens=1467, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 6/704...\n",
      "ChatCompletion(id='chatcmpl-BAiFaxlibCUuxyb9fbNoEPwDh5mcl', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Trigone, Bladder\\n\\n**Influences on Survival:**\\n\\n1. **Anatomical Considerations**: The trigone is a triangular region at the base of the bladder, close to the ureters and urethra. Tumors originating in this zone are more prone to invade the muscle layer early and can involve nearby structures, leading to poorer prognosis due to potential complications and earlier metastasis to regional lymph nodes.\\n\\n2. **Metastatic Patterns**: Due to its location, trigone tumors may have a higher propensity for local regional spread and involvement of lymphatic nodes. This early lymphatic spread can lead to poorer survival outcomes, as regional lymph node involvement is a significant negative prognostic factor.\\n\\n3. **Treatment Accessibility**: Trigone tumors might be less accessible for complete surgical resection compared to those on the bladder dome or lateral walls, especially if they involve the ureteric orifices, leading to increased surgical complexity and potential incomplete tumor clearance.\\n\\n### Histology: Papillary Transitional Cell Carcinoma\\n\\n**Influence on Survival:**\\n\\n1. **Histological Subtype**: Papillary transitional cell carcinoma (TCC) is often associated with better initial prognosis compared to more infiltrative types. However, its habituation for recurrence and progression to high-grade disease is a significant survival concern.\\n\\n2. **Mutation Profiles**: Common mutations in FGFR3, PIK3CA, and HRAS are associated with papillary TCC. FGFR3 mutations are typically linked to low-grade, non-muscle invasive tumors with better initial survival, but they require monitoring due to potential for recurrence and eventual progression to muscle-invasive disease.\\n\\n### Sampling Bias: Blood Derived Normal, Primary Tumor\\n\\n**Influence on Genomic Interpretation:**\\n\\n1. **Blood-Derived Normal Limitations**: Using blood-derived normal samples can introduce bias in interpreting tumor-specific mutations, potentially confounding germline with somatic mutations. This can lead to overestimation of mutation burden or misidentification of driver mutations.\\n\\n2. **Primary Tumor Bias**: Sampling from primary tumors may not capture the heterogeneity within the entire tumor mass or between primary and metastatic sites, leading to incomplete understanding of the tumor's mutational landscape.\\n\\n### Key Genes: Survival-Associated\\n\\n1. **TP53**: Commonly mutated in bladder cancer, linked to impaired apoptosis. Loss leads to genomic instability, contributing to aggressiveness and poor survival.\\n\\n2. **RB1**: Alterations are associated with disruption of cell cycle control, leading to increased tumor proliferation and worse outcomes.\\n\\n3. **FGFR3**: Mutations often seen in low-grade tumors with generally better outcomes, though not exempt from later progression risks.\\n\\n4. **PIK3CA**: Mutations here influence PI3K/AKT pathway, promoting cell growth and possibly contributing to resistance to certain therapies.\\n\\n5. **ERBB2 (HER2)**: Overexpressed or amplified in some bladder cancers, associated with aggressive disease and potentially targetable for therapy.\\n\\n6. **TSC1**: Mutations may affect mTOR signaling, with implications for targeted therapies and survival outcomes.\\n\\n### Synthesis\\n\\n**Key Survival Risk Factors:**\\n\\n- **Local Invasion and Metastasis**: Anatomical challenges due to tumor origin lead to early dissemination.\\n- **Histological Variability**: Papillary TCC with FGFR3 mutations offers a dichotomy of initial favorable outcome with latent risk of progression.\\n- **Sampling Bias**: Misinterpreted genomic profiles due to sampling strategies can misconstrue prognostic predictions.\\n- **Genetic Contributions**: Mutations in TP53, RB1, and proliferation pathways like PI3K/AKT significantly influence survival dynamics by fostering aggressive tumor behaviors.\\n\\n**Clinical Impact:**\\n\\nUnderstanding the intricate interplay between these factors is imperative for developing personalized treatment regimens that can improve survival by targeting specific pathways and utilizing strategic surgical and adjuvant interventions. Emphasizing molecular profiling in clinical practice allows for tailored approaches, potentially mitigating the innate survival risks associated with bladder urothelial carcinoma in the trigone region.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893078, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=841, prompt_tokens=449, total_tokens=1290, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 7/704...\n",
      "ChatCompletion(id='chatcmpl-BAiFxJdRsotsnoSOgtaeAa1kLeZcB', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To understand the survival impact of Bladder Urothelial Carcinoma, particularly at the bladder dome, requires a detailed examination of tumor origin, histology, genetic alterations, and potential sampling biases.\\n\\n### Tumor Origin: Bladder Dome\\n\\n1. **Influence on Metastasis and Survival:**  \\n   - The bladder dome is located superiorly, making transitional cell carcinoma that originates here typically present with deeper muscle invasion due to anatomical proximity to surrounding structures and accumulation of occult metastases.\\n   - The potential for earlier local and distant spread can contribute to poorer prognoses and a more complex treatment approach, often requiring radical interventions like cystectomy and systemic therapy.\\n\\n2. **Biological Rationale:**  \\n   - Tumors at the bladder dome may have more immediate access to lymphatic drainage systems, increasing the potential for metastasis.\\n   - Anatomically, the proximity to the upper urinary tracts can facilitate early urothelial spread and invasion into other tissues.\\n\\n3. **Impact on Treatment Accessibility:**  \\n   - Because dome-originating tumors often require more aggressive interventions, there can be limitations to treatment accessibility linked to patient comorbidities or lack of surgical facilities specialized for extensive resections.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n1. **Influence on Mutation Profiles and Outcomes:**  \\n   - Transitional Cell Carcinoma (TCC), particularly those labeled as \"NOS\" (Not Otherwise Specified), signifies a standard, often aggressive phenotype that typically exhibits mutations in genes like TP53 and FGFR3.\\n   - This can lead to diverse behaviors: TP53 mutations often correlate with high-grade, muscle-invasive cancers, implying poorer outcomes, while FGFR3 alterations are linked to low-grade tumors, presenting better prognostic indicators.\\n\\n2. **Biological Rationale:**  \\n   - TP53 mutations impede apoptosis, fostering unchecked cellular proliferation and tumor survival, whereas FGFR3 mutations can sometimes be therapeutically exploited with inhibitors to reduce tumor aggressiveness.\\n\\n### Sampling Bias: Limitations in Genomic Analysis\\n\\n1. **Blood-Derived Normal vs. Primary Tumor:**  \\n   - Blood-derived samples might not capture tumor-specific genetic alterations, leading to underrepresentation of driver mutations or misrepresentations of somatic vs. germline changes.\\n   - Primary tumor samples are essential for detecting intra-tumoral heterogeneity, which informs targeted therapeutic strategies and prognosis but can be limited by sampling procedures that might miss critical subclonal populations.\\n\\n2. **Impact on Survival Analysis:**  \\n   - Misinterpretation of genomic data due to sampling bias can lead to suboptimal treatments or missed detection of actionable mutations, influencing survival outcomes adversely.\\n\\n### Key Genes Influencing Survival\\n\\n1. **TP53:** Central in maintaining genomic integrity; mutations are often associated with advanced, aggressive disease phenotypes.\\n2. **FGFR3:** Alterations here, more frequent in low-grade tumors, may suggest better prognosis and targeted treatment opportunities.\\n3. **RB1:** Loss of function can lead to uncontrolled cell cycle progression, commonly seen in aggressive bladder cancers.\\n4. **PIK3CA:** Activating mutations support oncogenic pathways influencing cellular survival and proliferation.\\n5. **ERBB2 (HER2):** Amplification correlates with aggressive tumor behavior and can be targeted therapeutically.\\n6. **TSC1:** Inactivation leads to mTOR pathway deregulation, affecting cellular growth control, tied to poorer outcomes.\\n7. **EZH2:** Overexpression promotes cancer progression through epigenetic modifications, indicating aggressive disease.\\n\\n### Conclusion: Synthesis of Survival Risk Factors\\n\\nIntegrating our understanding of tumor origin, histology, and genetics reveals that survival in bladder urothelial carcinoma is significantly influenced by the site of origin, specific mutation profiles within the histological context, and the potential for sampling biases. Clinically, addressing the specific molecular landscape of each tumor—acknowledging anatomical and histological aggressiveness—allows for more personalized treatments that can mitigate these survival risks, enhancing outcomes. Understanding these intertwined aspects fosters improved prognostic assessments and maximizes therapeutic efficacy tailored to individual patient profiles.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893101, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=830, prompt_tokens=445, total_tokens=1275, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 8/704...\n",
      "ChatCompletion(id='chatcmpl-BAiGJo9E3gnq7ElmGuC5OyWf9RkX9', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Dome of the Bladder\\n\\n1. **Influence on Metastatic Patterns and Survival:**\\n   - **Metastatic Patterns:** The location of a urothelial carcinoma at the dome of the bladder can potentially influence metastatic spread due to its proximity to the peritoneum. Tumors here may have a greater propensity for transcoelomic dissemination, possibly affecting peritoneal surfaces. This can result in metastasis that challenges early detection and management, adversely impacting survival rates.\\n   - **Patient Survival:** Tumors located at the dome may present with distinct clinical challenges, such as increased difficulty in achieving complete surgical resection with negative margins if invaded outside the bladder. The anatomical peculiarity can translate to altered surgical approaches, impacting recurrence and survival directly.\\n   - **Treatment Accessibility:** Tumors at the dome could complicate straightforward access during endoscopic procedures due to their anatomical position, potentially limiting treatment options and impacting outcomes negatively.\\n\\n2. **Biological Rationale:**\\n   - Anatomical location plays a critical role in the surgical removal and dissemination pathway of cancer, impacting both immediate treatment efficacy and long-term survival outcomes.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n1. **Influence on Mutation Profiles and Outcomes:**\\n   - **Mutation Profiles:** Transitional cell carcinoma (TCC), NOS, is predominantly associated with alterations in key pathways, including FGFR3 and TP53 mutations. These mutations drive varying responses to therapy and recurrence risks. Mutations in FGFR3, often seen in non-invasive papillary tumors, are associated with a better prognosis, whereas TP53 mutations correlate with a more aggressive course and poorer survival.\\n   - **Outcomes:** The aggressiveness and response to chemotherapy differ markedly based on these mutations, with TP53 alterations often leading to resistance, complicating the management and negatively influencing survival rates.\\n\\n2. **Biological Rationale:**\\n   - Genetic mutations fundamentally alter cell proliferation and response to apoptosis, dictating how extensively and aggressively a tumor progresses, directly correlating with patient survival.\\n\\n### Sampling Bias: Limitations in Genomic Analysis\\n\\n1. **Primary Tumor vs. Solid Tissue Normal:**\\n   - **Limitations:** Genomic analysis often juxtaposes primary tumor samples against \\'normal\\' tissues, which might not be truly normal due to field cancerization or prior environmental exposures. This \"normal\" tissue might harbor pre-neoplastic changes, skewing results.\\n   - **Impact:** Such biases can lead to overestimations of oncogenic mutations, mistaking incidental findings as drivers. These biases complicate the understanding of true mutation frequencies, potentially leading to misdirected therapeutic targets.\\n\\n2. **Biological Rationale:**\\n   - Accurately distinguishing between driver mutations and passenger effects requires precise sampling, as misinterpretations can widely skew survival-associated therapeutic strategies.\\n\\n### Key Survival-Associated Genes\\n\\n1. **FGFR3 (Fibroblast Growth Factor Receptor 3):** \\n   - *Survival Impact:* Mutations here often indicate a more favorable prognosis, linked to superficial tumors.\\n   - *Mechanism:* Drives cellular growth and differentiation; less likely to invade deeply.\\n\\n2. **TP53 (Tumor Protein p53):**\\n   - *Survival Impact:* Strongly associated with high-grade, invasive tumors; poor survival.\\n   - *Mechanism:* Inactivates cell cycle checkpoints, apoptosis, facilitating unchecked growth.\\n\\n3. **PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha):**\\n   - *Survival Impact:* Often mutated in bladder cancer, associated with various growth signals.\\n   - *Mechanism:* Activates AKT pathway, promoting survival and proliferation.\\n\\n4. **ERBB2 (HER2/Neu):**\\n   - *Survival Impact:* Overexpression/mutations can predict aggressive cancer phenotypes.\\n   - *Mechanism:* Enhances proliferation and survival via receptor signaling.\\n\\n5. **TSC1 (Tuberous Sclerosis 1):**\\n   - *Survival Impact:* Mutations lead to mTOR pathway activation, impacting survival negatively.\\n   - *Mechanism:* Loss results in deregulated cell growth and metabolism.\\n\\n6. **CDKN2A (Cyclin Dependent Kinase Inhibitor 2A):**\\n   - *Survival Impact:* Loss of function is associated with advanced disease and poor prognosis.\\n   - *Mechanism:* Regulates cell cycle progression; loss fuels proliferative states.\\n\\n### Synthesis and Clinical Insights\\n\\n- Integrating these elements signals a complex landscape. Tumor origin, notably at the bladder dome, presents anatomical barriers influencing dissemination and treatment efficacy. Histological subtleties, expressed through genetic mutations, significantly alter tumor behavior, steering survival probabilities.\\n- Sampling biases remain critical in decoding genomic data, as misinterpretations can mislead clinical applications and prognostications.\\n- Clinically, insight into these gene pathways emphasizes personalized therapeutic strategies, potentially enhancing survival through targeted treatments. Understanding these multifactorial influences is paramount for elevating patient-specific oncological care.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893123, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1038, prompt_tokens=445, total_tokens=1483, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 9/704...\n",
      "ChatCompletion(id='chatcmpl-BAiGhrkPKxgUkdW0ENbn0mWMhd2Aa', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin: Impact of the Bladder Dome on Survival\\n\\n### Metastatic Patterns\\n1. **Metastatic Pathway**: Bladder Urothelial Carcinoma originating from the dome might present with a unique dissemination pattern compared to other bladder locations. The dome's position allows for potential early peritoneal seeding and lymphatic spread, influencing metastasis distribution.\\n2. **Survival Impact**: This early potential for widespread metastasis can lead to a poorer prognosis due to the increased difficulty in achieving complete resection and control of metastatic sites.\\n3. **Treatment Accessibility**: If the cancer involves peritoneal surfaces or upper urinary tract regions accessed via the dome, it might complicate surgical and systemic treatment approaches, thus affecting patient survival negatively.\\n\\n## Histology: Papillary Adenocarcinoma and Mutation Profiles\\n\\n### Interaction and Outcome\\n1. **Histological Features**: Papillary adenocarcinoma implies glandular differentiation, often arising from metaplasia or chronic irritation. This histology may correlate with distinct mutation profiles like FGFR3 or PIK3CA mutations.\\n2. **Survival Influence**: Generally, papillary features, if low-grade, may predict better outcomes; high-grade or invasive patterns worsen prognosis. The presence of favorable mutations (e.g., FGFR3) typically denotes better response to targeted therapies, thus positively influencing survival.\\n3. **Genomic-Driven Outcomes**: Mutations can drive therapeutic options; FGFR3 targeting can improve outcomes in mutation-positive tumors.\\n\\n## Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n### Limitations in Genomic Analysis\\n1. **Bias Potential**: Using blood-derived normals as baselines in genomic studies of bladder cancer can introduce bias, as the circulating free DNA may not accurately reflect tumoral heterogeneity or specific mutations present in the tumor itself.\\n2. **Survival Impact**: Incorrect genomic profiling may lead to suboptimal therapeutic strategies being chosen if the nuances of primary tumor mutations are underrepresented.\\n3. **Rationale**: Primary tumors tend to harbor actionable mutations critical for personalized treatment strategies, thereby emphasizing the importance of direct tumor sampling in accurate survival predictions.\\n\\n## Key Genes Associated with Survival\\n\\n### Selected Genes\\n1. **FGFR3**: Mutations in FGFR3 are often associated with low-grade, non-invasive tumors—better survival rates due to susceptibility to targeted therapies.\\n2. **TP53**: Mutational loss or alteration often denotes aggressive disease, poor prognosis due to impaired apoptotic pathways.\\n3. **PIK3CA**: Similar to FGFR3, mutations in PIK3CA may allow targeted intervention strategies.\\n4. **KDM6A**: Mutations can correlate with less aggressive disease; better survival outcomes have been noted.\\n5. **RB1**: Associated with elevated tumor progression risk; mutations here mark poorer outcomes.\\n6. **ERBB2 (HER2)**: Overexpression/amplification could guide targeted treatment, impacting survival positively if treated.\\n7. **CDKN2A**: Loss here is a marker for aggressive behavior and poor prognosis due to unchecked cell proliferation.\\n\\n### Biological Mechanisms\\n- **Proliferation/Apoptosis**: Genes like TP53 and RB1 regulate cell cycle and apoptosis, crucial for survival determination.\\n- **Immune Evasion**: Mutations (e.g., in TP53) can also impact immune surveillance mechanisms, altering responses to immunotherapy.\\n- **Signal Transduction**: Alterations in PIK3CA and FGFR3 drive pathway activations susceptible to targeted blockade.\\n\\n## Conclusion: Synthesis of Survival Risk Factors\\n\\n- **Key Insights**: Tumor origin at the bladder dome implies complex dissemination influencing prognostic outcomes, worsened by specific histological and mutational profiles (e.g., TP53). Choosing treatment strategies that align with the genetic landscape is paramount for improved survival, highlighting the importance of comprehensive genomic profiling devoid of sampling bias.\\n- **Clinically Relevant Impact**: Understanding the interplay between genetic mutations, histological cues, and tumor localization allows for tailored treatment strategies, which can significantly optimize patient survival outcomes in bladder urothelial carcinoma. Precision medicine approaches thus remain pivotal in this context.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893147, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=861, prompt_tokens=448, total_tokens=1309, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 10/704...\n",
      "ChatCompletion(id='chatcmpl-BAiGytl7HR7Muj12PylTADEMt7SxK', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin\\n**Influence on Survival:**  \\n- The lateral wall of the bladder provides an anatomical context through which urothelial carcinoma may spread locally or distantly. Tumors in this location may invade adjacent structures such as the prostate or bowel, and given its position, there is a high potential for involvement of local lymph nodes, impacting metastatic spread.\\n- **Biological Rationale:**  \\n  As bladder urothelial carcinomas arise from the urothelial lining, they inherently have access to vascular and lymphatic pathways. Tumors in the lateral wall are near key vascular and lymphatic channels, facilitating metastasis. This proximity means that any local spread could rapidly progress to more severe stages.\\n- **Biases in Genomic Interpretation:**  \\n  Tumor sampling from this area may underrepresent heterogeneity if the samples lack peripheral invasion zones, skewing genomic data towards non-representative mutation profiles.\\n\\n## Histology\\n**Influence on Survival:**  \\n- Transitional cell carcinoma, NOS, is the typical histology seen in bladder cancer. Its heterogeneity in differentiation and architectural patterns affects prognostication and treatment outcomes.\\n- **Biological Rationale:**  \\n  The pleomorphic nature and variable differentiation in transitional cell carcinoma mean a wide range of genetic mutations and epigenetic changes drive the tumor's behavior, influencing treatment resistance and progression.\\n- **Biases in Genomic Interpretation:**  \\n  Sampling biases may arise when primary tumors of this histology are assessed without considering the diverse clonal architecture, leading to a lack of understanding of key driver mutations.\\n\\n## Sampling Bias\\n**Influence on Survival:**  \\n- Genomic studies often rely on blood-derived normal samples for baseline comparisons, which may not reflect tumor-specific mutations, impacting the accuracy of survival-associated findings.\\n- **Biological Rationale:**  \\n  Blood-derived normals lack somatic mutations present in urothelial tissues, introducing noise and potential false negatives for mutation calls that could be clinically significant.\\n- **Potential Bias:**  \\n  Primary tumors are heterogeneous; hence, single-sample biases might fail to capture the genetic diversity, affecting the identification of genes with true prognostic roles.\\n\\n## Key Genes and Biological Mechanisms\\n1. **TP53:**  \\n   - **Influence on Survival:** Mutations often result in poor prognosis due to resistance to chemotherapy and increased genomic instability.\\n   - **Biological Mechanism:** P53 is a crucial regulator of apoptosis, ensuring DNA damage repair before cell division.\\n\\n2. **FGFR3:**  \\n   - **Influence on Survival:** Mutational activation is generally associated with lower-grade, non-invasive tumors, which paradoxically suggests better initial prognosis.\\n   - **Biological Mechanism:** Promotes cell proliferation and survival pathways.\\n\\n3. **PIK3CA:**  \\n   - **Influence on Survival:** Mutations activate PI3K/AKT pathway, contributing to tumor growth and survival, often linked with advanced disease.\\n   - **Biological Mechanism:** Regulates cell growth, metabolism, and survival processes.\\n\\n4. **ERBB2 (HER2):**  \\n   - **Influence on Survival:** Overexpression correlates with aggressive disease and reduced survival.\\n   - **Biological Mechanism:** Drives proliferation and inhibits apoptosis.\\n\\n5. **CDKN2A:**  \\n   - **Influence on Survival:** Loss results in poorer outcomes due to unchecked cell cycle progression.\\n   - **Biological Mechanism:** Encodes tumor suppressors that regulate cell cycle progression.\\n\\n6. **RB1:**  \\n   - **Influence on Survival:** Loss of function mutations are linked to disease progression and poor survival.\\n   - **Biological Mechanism:** Critical in cell cycle control.\\n\\n7. **TSC1:**  \\n   - **Influence on Survival:** Mutations can impact mTOR pathway activity, altering cellular metabolism and growth, positively associated with some therapeutic responses.\\n   - **Biological Mechanism:** Regulates mTOR pathway, which is key in controlling cell growth and division.\\n\\n## Conclusion\\n**Synthesis of Key Risk Factors:**\\n- **Prognostic indicators** based on tumor biology, such as location and traditional histological grades, intimately dictate metastatic potential and survival. Lateral wall bladder cancer's connection to key lymphovascular areas plays a critical role in aggressive spread.\\n- **Genomic insights** such as mutations in TP53, FGFR3, and ERBB2 contribute to oncogenic processes, highlighting the need for tailored therapeutic strategies.\\n- **Potential biases** in sampling underscore the importance of comprehensive profiling to truly capture tumor heterogeneity and identify actionable targets.\\n\\n**Clinically Relevant Insights:**\\n- Effective management of bladder urothelial carcinoma requires a nuanced understanding of its origin, biology, and potential biases inherent in genomic assessments.\\n- Personalized therapeutic approaches based on precise genetic profiling can significantly impact survival outcomes, demanding integration of molecular data into clinical practice.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893164, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=986, prompt_tokens=447, total_tokens=1433, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 11/704...\n",
      "ChatCompletion(id='chatcmpl-BAiHM1Xe4wAz5Y8mgRh53DlzW3EP3', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin and Impact on Survival\\n\\n1. **Lateral Wall Bladder and Metastatic Pattern**\\n   - **Influence on Survival:** Tumors originating in the lateral wall of the bladder often have a unique spatial relationship with lymphatic drainage pathways and nearby tissues, influencing metastatic patterns.\\n   - **Biological Rationale:** Their proximity to lateral vesical vessels might facilitate early dissemination to regional lymph nodes or distant organs, potentially worsening prognosis. The vascular and lymphatic network can create pathways for metastatic spread.\\n   - **Treatment Accessibility:** Surgical approaches can be challenging depending on the lateral wall\\'s involvement, possibly limiting effective resection and contributing to poorer outcomes.\\n   - **Survival Outcome:** Generally, lateral wall tumors can present with less favorable survival metrics due to these factors.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n2. **Mutation Profiles and Outcome**\\n   - **Influence on Survival:** As the most common histological type, transitional cell carcinoma (TCC) interacts with specific genetic mutations that can significantly impact prognosis.\\n   - **Biological Rationale:** TCC is often associated with mutations in genes such as FGFR3, which, while sometimes indicating a low-grade non-invasive tumor, can complicate treatment if the disease becomes invasive. Other mutations like TP53 often indicate high-grade, aggressive forms with poorer outcomes.\\n   - **Survival Outcome:** Overall, patients with TCC have variable survival outcomes based on the mutational landscape, but aggressive forms driven by poor gene mutation profiles tend to have worse prognoses.\\n\\n### Sampling Bias\\n\\n3. **Limitations in Primary Tumor and Solid Tissue Normal Analysis**\\n   - **Influence on Survival:** The genomic variability within the primary tumor and between tumor and normal tissue can be misconstrued due to sampling bias.\\n   - **Biological Rationale:** Heterogeneity within the tumor might result in underrepresentation of aggressive clones when biopsies do not capture the most malignant sections.\\n   - **Potential Biases:** Solid tissue normal samples may not be perfectly \"normal,\" thus confounding differential analysis and survival predictions.\\n   - **Survival Impact:** Such biases can lead to underestimation of tumor aggressiveness, affecting treatment choices and survival predictions negatively.\\n\\n### Key Genes Influencing Survival\\n\\n4. **Key Genes and Their Mechanisms**\\n   - **TP53:** Mutation here often signals aggressive disease through disrupted cell cycle regulation and impaired DNA repair; associated with reduced survival.\\n   - **FGFR3:** While mutations can be associated with non-aggressive tumors, if invasive, they complicate management; thus affecting survival inversely.\\n   - **ERBB2 (HER2):** Overexpression or mutation activates growth pathways, contributing to aggressive behavior and reduced survival.\\n   - **PIK3CA:** Mutations here can lead to dysregulated cell proliferation and survival signaling, increasing malignancy potential.\\n   - **TERT:** Mutations linked to unchecked cellular proliferation via telomere maintenance mechanisms; negatively impact survival.\\n   - **CDKN2A:** Loss of function leads to disrupted cell cycle control, promoting tumor growth and poor outcomes.\\n   - **RB1:** Loss or dysfunction here impairs cell cycle checkpoint control, common in aggressive variants.\\n   - **MIR21:** Overexpression of this microRNA leads to enhanced oncogenic signaling; often correlates with poor prognosis.\\n\\n### Conclusion: Synthesis of Key Survival Risk Factors\\n\\nThe survival impact in bladder urothelial carcinoma, especially from a lateral wall origin, is multifactorial. Factors include the aggressive nature and metastatic propensity facilitated by anatomical and histological features, compounded by specific genetic alterations. Accurate genomic profiling is essential yet complicated by sampling biases; comprehensively understanding mutations such as TP53, FGFR3, and others provides critical insight into prognosis and targeted therapy. By resolving these complexities, clinicians can tailor interventions to improve survival outcomes, highlighting the necessity of precision oncology in managing urothelial carcinoma.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893188, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=797, prompt_tokens=447, total_tokens=1244, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 12/704...\n",
      "ChatCompletion(id='chatcmpl-BAiHm4xKUtQ5hsD8s86P3oSPN0Lsx', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='1. **Tumor Origin: Lateral Wall Bladder**\\n\\n   - **Influence on Survival**: Tumor location in the lateral wall of the bladder can impact survival through its proximity to the pelvic lymph nodes and surrounding musculature, potentially influencing metastatic patterns. Tumors in this area are more likely to invade muscle layers and spread to lymph nodes, which generally corresponds to a more advanced stage at diagnosis and poorer prognosis.\\n   \\n   - **Biological Rationale**: The lateral wall’s anatomical structure facilitates easier access for cancer cells to invade muscular layers and lymphatic channels, increasing metastatic potential compared to tumors originating in more superficial or non-muscular areas.\\n   \\n   - **Treatment Accessibility**: Anatomical complexity may challenge surgical approaches, influencing the ability to achieve clear margins during resection, potentially complicating treatment and negatively impacting survival.\\n\\n2. **Histology: Papillary Transitional Cell Carcinoma**\\n\\n   - **Influence on Survival**: Papillary transitional cell carcinoma often presents as a more superficial, exophytic growth that may initially imply a better prognosis due to non-invasive characteristics. However, its progression can be dynamic.\\n   \\n   - **Mutation Profiles**: Specific mutations such as FGFR3, frequently found in non-invasive papillary carcinomas, are associated with favorable outcomes when compared to other histological variants. Such mutations often lead to less aggressive growth patterns.\\n   \\n   - **Biological Rationale**: Mutations and histological aspects contribute to differences in cellular growth regulation and responsiveness to therapies, shaping overall survival outcomes.\\n\\n3. **Sampling Bias: Blood Derived Normal, Primary Tumor**\\n\\n   - **Limitations on Genomic Analysis**: Using blood-derived normal samples to identify tumor-specific mutations can introduce a sampling bias due to the heterogeneity of cancer tissues compared to peripheral blood. \\n   \\n   - **Implication on Survival Analysis**: Misinterpretation of genomic data may arise due to these biases, leading to inappropriate treatment decisions and survivorship predictions if somatic mutations are mischaracterized.\\n   \\n   - **Biological Rationale**: The heterogeneity of tumor samples is critical, as primary tumors often present mixed cell populations that could obscure the driver mutations impacting survival.\\n\\n4. **Key Genes Influencing Survival**\\n\\n   - **TP53**: Integral in regulating the cell cycle and apoptosis. TP53 mutations typically correlate with poor prognosis due to impaired cellular apoptosis and increased likelihood of genetic instability.\\n   \\n   - **FGFR3**: Mutations often found in low-grade tumors and associated with a favorable prognosis due to typically slower progression and responsiveness to targeted therapies.\\n   \\n   - **PIK3CA**: Linked to cell growth and survival pathways; mutations can lead to increased proliferation and tumor aggressiveness.\\n   \\n   - **ERBB2 (HER2)**: Overexpression in some bladder cancers can lead to aggressive tumor behavior; however, it also presents a targetable pathway for therapeutic interventions, potentially improving survival.\\n   \\n   - **CDKN2A**: Encodes proteins p16INK4a and p14ARF, which regulate the cell cycle; its loss or mutation often predicts aggressive disease and poorer outcomes.\\n   \\n   - **RB1**: Critical for cell cycle control; losses or mutations correlate with high-grade tumors and worse survival due to unchecked progression of the cell cycle.\\n   \\n5. **Synthesis of Key Survival Risk Factors**\\n\\n   Integrating insights from tumor origin, histology, sampling biases, and genetic factors, the major survival determinants in bladder urothelial carcinoma, particularly originating from the lateral wall, include the potential for muscle invasion, specific histological variant mutational profiles, and accurate genetic evaluation. Treatment strategies must be nuanced to address these complexities. Comprehensive genomic profiling and anatomically-informed intervention strategies remain crucial to optimizing patient outcomes. Emphasizing targeted therapies for specific genetic alterations holds promise in elevating survival rates, particularly for tumors exhibiting high-risk mutation profiles or advanced stage.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893214, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=792, prompt_tokens=447, total_tokens=1239, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 13/704...\n",
      "ChatCompletion(id='chatcmpl-BAiI4O8IOLkxBGqBRcYBsrLOA98Iz', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Bladder Urothelial Carcinoma (ICD-10: UNKOWN)\\n\\n**Influence on Survival and Biological Rationale:**\\n\\n1. **Metastatic Patterns:**\\n   - **Influence:** The unknown specific categorization can sometimes suggest a broader spread of metastatic sites due to a failure in early specific identification, potentially leading to less targeted surveillance and intervention.\\n   - **Biological Rationale:** As an epithelial-origin tumor, bladder urothelial carcinoma typically spreads to lymph nodes, liver, lungs, and bone, altering patient outcomes through aggressive metastatic spread.\\n   - **Survival Impact:** Negative. The unclear diagnosis might delay targeted treatment, allowing more time for the cancer to disseminate.\\n\\n2. **Treatment Accessibility:**\\n   - **Influence:** The unknown classification often limits access to specific treatment protocols typically applied to well-characterized subtypes.\\n   - **Biological Rationale:** Without clear subtype information, treatment might rely on more generic, potentially less effective chemotherapy regimens.\\n   - **Survival Impact:** Negative. Lack of precise therapeutic targeting can lead to reduced efficacy and poorer patient outcomes.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n**Influence on Survival and Biological Rationale:**\\n\\n1. **Interaction with Mutation Profiles:**\\n   - **Influence:** Common mutations such as those in TP53, FGFR3, and PIK3CA have prognostic significance.\\n   - **Biological Rationale:** \\n     - TP53 mutations often result in loss of cell cycle control and can indicate higher grade tumors.\\n     - FGFR3 mutations are typically associated with lower-grade tumors with a more favorable prognosis.\\n   - **Survival Impact:** Mixed. Specific mutations correlate with either aggressive disease (TP53) or less aggressive disease (FGFR3), impacting survival differently.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n**Influence on Genomic Interpretation and Survival:**\\n\\n1. **Sampling Bias:**\\n   - **Influence:** Blood-derived normal tissue may not capture tumor heterogeneity, possibly leading to incomplete genomic profiling.\\n   - **Biological Rationale:** Tumor samples show the heterogeneous tumor environment, which is crucial for understanding driver mutations, while blood-derived normals lack this complexity.\\n   - **Survival Impact:** Negative. Misinterpretation or incomplete characterization can lead to less effective, non-tailored treatments.\\n\\n### Key Genes: Survival-Associated and Biological Mechanisms\\n\\n1. **TP53:**\\n   - **Mechanism:** Regulates cell cycle and apoptosis.\\n   - **Survival Impact:** Mutations often lead to poorer prognosis due to resistance to apoptosis.\\n\\n2. **FGFR3:**\\n   - **Mechanism:** Affects cell growth and division.\\n   - **Survival Impact:** Generally, mutations confer a better prognosis.\\n\\n3. **PIK3CA:**\\n   - **Mechanism:** Part of the PI3K/AKT pathway, critical for cell survival.\\n   - **Survival Impact:** Mutations can lead to increased proliferation.\\n\\n4. **RB1:**\\n   - **Mechanism:** Controls cell cycle progression.\\n   - **Survival Impact:** Mutations often associated with high-grade, aggressive tumors.\\n\\n5. **ERBB2 (HER2):**\\n   - **Mechanism:** Cell growth and differentiation.\\n   - **Survival Impact:** Overexpression can imply aggressive tumor behavior.\\n\\n6. **TSC1:**\\n   - **Mechanism:** Regulation of mTOR pathway.\\n   - **Survival Impact:** Alterations can drive tumor independence and progression.\\n\\n7. **ARID1A:**\\n   - **Mechanism:** Chromatin remodeling.\\n   - **Survival Impact:** Loss-of-function mutations often correlate with poorer outcomes.\\n\\n8. **CDKN2A:**\\n   - **Mechanism:** Involved in cell cycle arrest.\\n   - **Survival Impact:** Loss of function may lead to unchecked cellular proliferation.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nIn summary, the survival impact of bladder urothelial carcinoma is closely tied to a combination of tumor origin classifications, histological identification of mutational profiles, and biases inherent to sampling methods. Key genes such as TP53, FGFR3, and others have varied impacts based on their biological functions, from cell cycle regulation to signaling pathways that influence tumor aggressiveness and treatment response. Clinical decision-making is significantly enhanced by understanding these factors, allowing for more personalized and potentially effective interventions that directly address genomic and phenotypic tumor characteristics, thereby optimizing patient survival outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893232, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=928, prompt_tokens=445, total_tokens=1373, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 14/704...\n",
      "ChatCompletion(id='chatcmpl-BAiIRm6n8PU7ECAB0ddsH6kC3EH7A', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='## Tumor Origin and Impact on Survival\\n\\n**Influence on Metastatic Patterns**: The origin of bladder urothelial carcinoma, often referred to under ICD-10 as \"UNKNOWN\" due to unspecified nuances, primarily affects the urothelium lining the bladder. This origin predisposes tumors to local invasion and metastasis primarily to regional lymph nodes, bones, liver, and lungs. Locally advanced and metastatic cases exhibit poorer survival due to limited resectability and the aggressive nature of dissemination.\\n\\n**Influence on Survival**: Due to the proximity to vital structures and potential for early dissemination, unknown specifics of origin can hinder timely intervention, impacting survival negatively.\\n\\n**Treatment Accessibility**: Diagnosis labeled as \"UNKNOWN\" can delay targeted therapy decisions due to unclear tumor origin, impacting treatment efficacy and subsequent survival.\\n\\n**Biological Rationale**: Origin impacts the pathophysiology through inherent tendencies for invasive growth, fostering an environment conducive to early metastasis, lowering overall survival rates. The unknown classification often complicates definitive therapeutic strategies.\\n\\n## Histology and Mutation Profiles\\n\\n**Transitional Cell Carcinoma, NOS**: As the most common histological type, transitional cell carcinoma manifests with a variety of mutation profiles, most notably involving FGFR3, TP53, and TERT. These mutations directly influence cellular behavior including uncontrolled proliferation and resistance to apoptosis.\\n\\n**Influence on Survival**: The presence of specific mutations, particularly TP53 mutations, might predict poorer survival due to their association with aggressive tumor behavior.\\n\\n**Biological Rationale**: FGFR3 mutations are often linked with low-grade tumors, while TP53 alterations are associated with higher-grade lesions and worse outcomes. Such mutations impact DNA repair mechanisms, cell cycle control, and apoptotic pathways, driving divergent survival outcomes.\\n\\n## Sampling Bias in Genomic Analysis\\n\\n**Limitations of Primary Tumor and Solid Tissue Normal**: Sampling biases confound comprehensive genomic landscapes due to tumor heterogeneity and microenvironmental influences. Solid tissue samples may not fully reflect the full mutational burden or the clonal diversity present within or between metastatic lesions.\\n\\n**Influence on Survival**: Incomplete mutation detection can lead to missed therapeutic targets or overestimation of therapeutic efficacy, thereby adversely affecting survival predictions.\\n\\n**Biological Rationale**: The inherent heterogeneity means that genomic insights derived solely from primary tumors without consideration of metastatic diversity could lead to suboptimal treatment strategies, impacting patient survival adversely.\\n\\n## Key Genes and Their Impact\\n\\n1. **TP53**: Involved in DNA damage response and cell cycle regulation. Mutations lead to loss of tumor suppressor function, driving aggressive growth and resistance to apoptosis, thus negatively impacting survival.\\n\\n2. **FGFR3**: Receptor tyrosine kinase gene often mutated in low-grade tumors, typically conferring a better prognosis due to its prevalence in non-invasive bladder cancers.\\n\\n3. **TERT**: Promoter mutations lead to telomerase reactivation, contributing to cellular immortalization and potential metastasis, resulting in poorer survival outcomes.\\n\\n4. **RB1**: Mutations affect cell cycle regulation, linked to high-grade tumors with worse prognosis due to loss of cell cycle control.\\n\\n5. **PIK3CA**: Mutations can activate carcinogenic signaling pathways, influencing cell growth and survival, often related to invasive phenotype and adverse prognosis.\\n\\n6. **CDKN2A**: Alterations lead to disrupted cell cycle arrest, promoting tumorigenesis, often associated with higher-grade lesions and reduced survival.\\n\\n## Conclusion and Synthesis of Survival Risk Factors\\n\\nSurvival in bladder urothelial carcinoma is intricately linked to the complex interplay of tumor origin, histology, sampling biases, and gene mutations. \"UNKNOWN\" origins and high-grade histologies with adverse mutation profiles like TP53 and RB1 exacerbate survival challenges by promoting aggressive tumor behaviors and diminishing the effectiveness of existing treatments. Recognizing these patterns enables stratification for therapeutic targeting and highlights the necessity for comprehensive genomic profiling to guide precision oncology. Understanding these dynamics facilitates improved patient stratification and treatment customization, ultimately impacting survival positively by enabling more informed clinical decision-making.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893255, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=831, prompt_tokens=445, total_tokens=1276, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 15/704...\n",
      "ChatCompletion(id='chatcmpl-BAiIh0hSCaCst9p4V5hDhiR9L993A', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin and Its Impact on Survival**\\n\\n- **Influence on Survival:**\\n  Tumor origin, particularly an unknown designation like \"UNKOWN\" for bladder urothelial carcinoma, significantly influences survival due to variability in metastatic patterns and treatment accessibility. Patients with unclear tumor origins may experience delayed diagnosis, hindering timely intervention. This results often in advanced disease at presentation and a generally poorer prognosis.\\n  \\n- **Biological Rationale:**\\n  The origin of bladder tumors often determines their metastatic spread. Urothelial carcinomas typically metastasize via lymphatic vessels to regional nodes and potentially to the liver, lungs, and bones. The lack of clarity in tumor origin (\"UNKOWN\") complicates predictions of specific metastatic pathways and complicates treatment planning.\\n\\n- **Potential Biases:**\\n  When tumor origin is not clearly defined, genomic analyses can be biased because important context-related genetic markers might be overlooked or misinterpreted, leading to suboptimal treatment recommendations.\\n\\n**Histology and Mutation Profiles**\\n\\n- **Influence on Survival:**\\n  Papillary transitional cell carcinoma (TCC) is a common histologic subtype of bladder cancer. It is associated with specific mutation profiles that can either enhance or undermine survival, depending on the nature of the mutations.\\n\\n- **Biological Rationale:**\\n  Papillary TCC tends to display mutations in genes such as FGFR3 and PIK3CA, which promote cell proliferation and survival. Though these mutations may initially indicate a superficial bladder cancer with better prognosis, progression or co-existing mutations can complicate outcomes, such as TP53 mutations, which are associated with poor differentiation and aggressive behavior.\\n\\n- **Potential Biases:**\\n  The histological classification may bias genomic data interpretation if the mutational analysis is not contextually integrated with histology, leading to generalized rather than personalized treatment plans.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\n- **Influence on Survival:**\\n  Utilizing blood-derived normal samples and primary tumors for genomic comparison introduces biases that may affect survival predictions and therapeutic decisions.\\n\\n- **Biological Rationale:**\\n  Blood-derived samples may not fully capture the tumor heterogeneity or the tumor microenvironment\\'s influence, potentially skewing mutation and expression profiles. Primary tumors may not reflect metastatic sites\\' genetic makeup, missing driver mutations essential for prognosis and treatment.\\n\\n- **Potential Biases:**\\n  The reliance solely on primary tumor samples might ignore clonal heterogeneity especially in advanced cancers, leading to misinterpretation of survival data and risk stratification.\\n\\n**Key Survival-Associated Genes**\\n\\n1. **TP53**: Known for its tumor suppressor role, mutations often result in unchecked cellular proliferation and reduced apoptosis, leading to poorer survival.\\n\\n2. **FGFR3**: Common in non-muscle-invasive bladder cancers, mutations here often correlate with better outcomes when not associated with other aggressive mutations.\\n\\n3. **PIK3CA**: Alterations lead to enhanced cell survival and growth signaling, influencing variable survival depending on co-altering genes.\\n\\n4. **CDKN2A**: Loss results in loss of cell cycle regulation, significantly affecting survival especially when coupled with invasive phenotypes.\\n\\n5. **RB1**: Key in cell cycle control; mutations correlate with aggressive tumor characteristics and poorer survival.\\n\\n6. **ERCC2**: Its dysfunction affects DNA repair, influencing response to chemotherapy and patient survival.\\n\\n7. **E2F1**: Overexpression is linked to uncontrolled cell proliferation, often signaling advanced disease and reduced survival.\\n\\n8. **ARID1A**: Mutations are commonly associated with increased genomic instability and poor outcomes.\\n\\n**Conclusion: Synthesis of Key Survival Risk Factors**\\n\\nIn conclusion, the survival impact in bladder urothelial carcinoma is intricately connected to the interplay of tumor origin, histology, key genetic mutations, and the limitations posed by sampling biases. Clinically, recognizing the tumor\\'s genetic landscape alongside its origin and histological characteristics guides more accurate prognostication and treatment strategies, ultimately optimizing patient survival. Embracing a multifaceted approach that integrates genomic with histologic data reduces biases and enhances precision in oncology care delivery, emphasizing the necessity of personalized therapeutic regimens.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893271, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=841, prompt_tokens=445, total_tokens=1286, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 16/704...\n",
      "ChatCompletion(id='chatcmpl-BAiIxRKsdnzUTBnFO8Ivscpt8PATG', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin: Impact on Survival**\\n\\n1. **Tumor Location (Posterior Wall Influence):**\\n   - **Metastatic Patterns:** The posterior wall of the bladder consists of a rich supply of blood vessels and lymphatics, potentially facilitating early dissemination of cancer cells. This regional anatomy can contribute to an increased likelihood of regional lymph node involvement and distant metastasis, which negatively impacts survival.\\n   - **Patient Survival:** Tumors originating from the posterior wall may have delayed detection compared to more anterior tumors, as they might cause symptoms like hematuria later in progression. Delayed detection often results in diagnoses at more advanced stages, decreasing survival odds.\\n   - **Treatment Accessibility:** The posterior wall location can complicate surgical access, making complete surgical resection more challenging. Suboptimal resections can result in residual disease, increasing recurrence risk and worsening survival prospects.\\n\\n**Histology: Transitional Cell Carcinoma, NOS**\\n\\n1. **Mutation Profiles and Outcomes:**\\n   - Transitional cell carcinoma (TCC) is the most common histologic subtype of bladder cancer, characterized by genetic alterations like FGFR3 mutations, TP53 alterations, and TERT promoter mutations. FGFR3 mutations are generally associated with low-grade tumors and better prognosis, whereas TP53 mutations correlate with high-grade tumors and poor outcomes.\\n   - **Survival Impact:** The interplay of these mutations delineates the aggressiveness of the tumor; TCCs with a preponderance of TP53 and RB1 mutations usually signify a more aggressive clinical course and poorer survival, whereas FGFR3 mutations alone might indicate a more indolent disease.\\n   - **Biological Mechanisms:** TP53 mutations disrupt apoptosis and cell cycle control, facilitating unchecked proliferation, while FGFR3 mutations enhance cell signaling pathways that promote growth but can often be targeted therapeutically.\\n\\n**Sampling Bias: Influence on Genomic Analysis**\\n\\n1. **Blood Derived Normal vs. Primary Tumor:**\\n   - **Sample Limitations:** Using blood-derived normal samples can lead to misinterpretation if the infiltrating tumor cells or circulating tumor DNA is not adequately represented. This may result in either false negative or false positive findings in genetic testing.\\n   - **Bias Introduction:** Tumor heterogeneity is a key issue when relying on primary tumor samples. A sample might not capture all subclonal populations, leading to an incomplete genomic landscape that neglects minor yet potentially aggressive clones. This underestimation of tumor aggression can misguide treatment decisions, impacting survival negatively.\\n\\n**Key Genes: Survival-Associated Mechanisms**\\n\\n1. **FGFR3, TP53, TERT, RB1, PI3KCA, E2F3, ERBB2:**\\n   - **FGFR3:** Activates growth pathways; can be targeted with tyrosine kinase inhibitors if mutated, offering potential therapeutic benefit and improved survival.\\n   - **TP53:** A tumor suppressor gene; mutations disrupt apoptosis and cell cycle arrest, contributing to aggressive tumor behavior and poorer survival.\\n   - **TERT:** Mutation in the promoter region leads to telomerase activation, contributing to cellular immortality, enhancing survival negatively via tumor persistence.\\n   - **RB1:** Mutations result in loss of cell cycle control; heavily linked with higher grade, poorer prognosis.\\n   - **PI3KCA:** Part of the PI3K/AKT pathway; mutations lead to increased signaling involved in cell survival and growth, often correlating with advanced disease.\\n   - **E2F3:** Overexpression drives proliferation, associated with tumor aggressiveness.\\n   - **ERBB2 (HER2):** Overexpression/amplification relates to enhanced growth signaling; targeted therapy has potential yet variable efficacy.\\n\\n**Conclusion: Synthesis of Survival Risk Factors**\\n\\n- **Key Factors:** Tumor origin impacts metastatic spread, detection time, and surgical outcomes. Histological type and its associated mutation profile guide tumor behavior and potential response to therapy. Accurate genomic analysis requires overcoming sampling biases to ensure targeted treatment strategies.\\n- **Clinical Relevance:** Understanding these factors aids in personalizing treatment plans, which can significantly affect survival outcomes. Recognition of genetic signatures such as TP53 and FGFR3 mutations facilitates stratification of treatment protocols, helping in stratifying patients for aggressive versus conservative management strategies.\\n- **Overall Impact:** Integrating these insights into clinical practice improves prognostication, resource allocation, and ultimately, enhances tailored therapeutic approaches to improve patient survival in urothelial carcinoma.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893287, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=899, prompt_tokens=447, total_tokens=1346, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 17/704...\n",
      "ChatCompletion(id='chatcmpl-BAiJNsiKjqBSf5XdCb19IQLKJdLCO', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Posterior Wall Bladder\\n\\n1. **Metastatic Patterns**: Tumors originating from the posterior wall of the bladder often exhibit distinct metastatic behavior. The posterior location can allow tumors easier access to pelvic lymph nodes and the vertebral venous plexus, influencing early lymphatic and hematogenous spread. This facilitates metastases to bones and distant lymph nodes, potentially leading to a poorer prognosis.\\n\\n2. **Survival Influence**: Tumors with such metastatic potential generally correlate with lower survival rates due to increased likelihood of aggressive spread before diagnosis. Early intervention is crucial but often challenging due to anatomical complexity.\\n\\n3. **Treatment Accessibility**: Surgical approaches, such as cystectomy, might be more complex due to proximity to other pelvic structures. This can limit surgical options and increase reliance on systemic therapies, which might not be as effective alone in metastatic settings.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n1. **Mutation Profiles**: Transitional cell carcinoma (TCC) typically displays mutations in genes such as TP53, FGFR3, and TERT. The presence of TP53 mutations often indicates genomic instability and aggressive tumor behavior, generally associated with poorer outcomes.\\n\\n2. **Survival Influence**: FGFR3 mutations, on the other hand, could be indicative of a more indolent course, particularly in low-grade tumors, and might correlate with slightly better survival rates due to targeted therapy options.\\n\\n3. **Biological Rationale**: The histological identification of TCC is essential for understanding underlying genetic and epigenetic mutations driving tumor progression, influencing treatment strategies accordingly.\\n\\n### Sampling Bias: Primary Tumor vs. Solid Tissue Normal\\n\\n1. **Genomic Analysis Limitations**: Genomic profiling often suffers from biases due to varied sampling locations. Primary tumor samples might not fully represent heterogeneity, missing subclones that could affect metastasis and drug resistance. Conversely, solid tissue normal may not be completely unaffected by the tumor microenvironment.\\n\\n2. **Survival Influence**: These biases can impact the apparent effectiveness of therapies due to mischaracterization of the tumor's genetic landscape, potentially leading to suboptimal treatment plans and thus affecting survival rates adversely.\\n\\n### Key Genes Associated with Survival\\n\\n1. **TP53**: Regulates cell cycle and apoptosis. Mutations often lead to aggressive tumor phenotypes and poor prognosis due to a loss of tumor suppressor functions.\\n\\n2. **FGFR3**: Mutations generally associated with lower-grade tumors and better prognosis due to less aggressive behavior and availability of targeted therapies.\\n\\n3. **TERT**: Promotes telomere maintenance leading to unlimited replicative potential. Its mutations often portend worse outcomes by enabling sustained tumor growth.\\n\\n4. **PIK3CA**: Involved in cell growth and survival; mutations can contribute to oncogenic signaling, often associated with reduced survival due to enhanced proliferative capabilities.\\n\\n5. **HER2/ERBB2**: Overexpression in bladder cancer has been linked to aggressive disease and poorer survival, providing a target for specific treatments which may improve outcomes.\\n\\n6. **CDKN2A**: Loss typically leads to dysregulation of cell cycle control, contributing to rapid progression and poorer survival metrics.\\n\\n### Conclusion: Synthesis of Survival Risk Factors\\n\\nUnderstanding the intricate interplay of tumor origin, histology, genetic mutations, and sampling biases is essential for determining bladder urothelial carcinoma's impact on survival. Posterior wall tumors' proclivity for early metastasis, combined with aggressive genetic mutations like TP53 and TERT, generally suggests a more challenging prognosis. Histological factors, along with the potential of sampling bias, underline the importance of comprehensive genomic profiling to inform treatment strategies. Clinically, recognizing these patterns enables more nuanced risk stratification, guiding personalized therapeutic approaches to ultimately improve patient survival outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893313, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=775, prompt_tokens=447, total_tokens=1222, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 18/704...\n",
      "ChatCompletion(id='chatcmpl-BAiJfAVxopr0bR40s1Am7qWa9udE3', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin and Its Impact on Survival\\n\\n**Posterior Wall Bladder Influence:**\\n\\n1. **Metastatic Patterns:**  \\n   - Tumors originating in the posterior wall of the bladder have a higher likelihood of early invasion to proximal structures such as the prostate or seminal vesicles. This proximity can facilitate earlier progression to advanced stages, thus potentially reducing survival rates. \\n\\n2. **Patient Survival:**  \\n   - The anatomical origin impacts the likelihood of early detection. Tumors in less visible or accessible regions might be diagnosed later, often leading to poorer outcomes due to the advanced disease stage at detection.\\n\\n3. **Treatment Accessibility:**  \\n   - Tumors located on the posterior wall may be challenging to access surgically or via cystoscopic interventions, potentially impacting treatment efficacy and necessitating more aggressive or systemic therapies that come with higher morbidity.\\n\\n### Histology and Mutation Profiles\\n\\n**Papillary Transitional Cell Carcinoma:**\\n\\n1. **Mutation Interaction:**  \\n   - This histology is commonly associated with genetic alterations in FGFR3, RAS, and TP53. FGFR3 mutations, often found in low-grade tumors, have been associated with better prognosis, whereas high-grade tumors with TP53 mutations typically forecast poorer outcomes due to aggressive behavior.\\n\\n2. **Survival Influence:**  \\n   - The dual nature of papillary carcinoma allows for survival disparities; lower-grade tumors usually show a favorable prognosis, while higher grades are more aggressive and less responsive to standard treatments.\\n\\n3. **Biological Basis:**  \\n   - Histological variability leads to diverse cellular environments influencing tumor behavior – for instance, FGFR3 mutations promote cell proliferation but can also be targeted with precision therapies, potentially improving outcomes.\\n\\n### Sampling Bias and Genomic Analysis\\n\\n**Blood-Derived Normal, Primary Tumor Limitations:**\\n\\n1. **Sampling Bias in Genomic Analysis:**  \\n   - Genetic analysis using blood-derived normal (germline) samples compared to primary tumors can miss somatic mutations present only in tumor tissue. This can lead to incomplete mutation profiles, obscuring potential therapeutic targets and prognostic markers.\\n\\n2. **Biological Implications:**  \\n   - Primary tumor samples may be heterogeneous, possessing multiple subclonal populations; blood-based sampling might fail to capture this variability. Thus, genomic data might underrepresent certain mutation pathways crucial for survival predictions.\\n\\n### Key Survival-Associated Genes\\n\\n1. **TP53:**  \\n   - Acts as a tumor suppressor, pivotal in cell cycle regulation and apoptosis. Mutations often correlate with aggressive disease phenotypes and poor survival.\\n\\n2. **FGFR3:**  \\n   - Promotes cellular proliferation and survival. Mutant forms are typically present in less aggressive cancers with a relatively favorable prognosis, serving as targets for FGFR inhibitors.\\n\\n3. **PIK3CA:**  \\n   - Part of the PI3K/AKT pathway, it influences cell growth and survival, with mutations correlating with oncogenic potential and therapy resistance.\\n\\n4. **ARID1A:**  \\n   - Alterations in this chromatin remodeling gene can lead to deficient DNA repair mechanisms, contributing to tumorigenesis and treatment challenges.\\n\\n5. **ERBB2 (HER2):**  \\n   - Although less common, overexpression can influence metastatic potential and response to targeted therapies, impacting overall survival.\\n\\n6. **RB1:**  \\n   - Tumor suppressor involved in cell cycle control; loss of function enhances cell proliferation capacity, often seen in high-grade tumors with shorter survival periods.\\n\\n### Synthesis and Clinically Relevant Insights\\n\\n**Key Survival Risk Factors:**\\n\\n- The anatomical origin of bladder urothelial carcinoma significantly influences metastatic risk and treatment feasibility, impacting survival negatively when diagnosis and intervention are delayed.\\n- Histological characteristics, particularly in papillary transitional cell carcinoma, along with specific mutation profiles, dictate the biological trajectory of disease and subsequent therapeutic strategies.\\n- Sampling biases can skew genomic interpretations, highlighting the necessity of comprehensive multi-source sampling for accurate prognostic and therapeutic insights.\\n- Understanding the distinct roles of key genes offers potential therapeutic avenues, emphasizing the relevance of personalized medicine in improving patient outcomes.\\n\\nThe integration of these factors underscores the complexity of bladder cancer progression and survival, advocating for tailored diagnostic and treatment approaches to optimize patient survival prospects.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893331, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=856, prompt_tokens=447, total_tokens=1303, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 19/704...\n",
      "ChatCompletion(id='chatcmpl-BAiJzxHC5OQu6HliuuoZRSNcDQIpc', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Bladder Urothelial Carcinoma at the ureteric orifice may demonstrate unique metastatic routes due to its proximity to vascular and lymphatic channels. This can facilitate early dissemination to regional lymph nodes and distant sites, generally worsening prognosis.\\n- **Patient Survival:** The anatomical site may lead to more rapid disease progression, influencing both overall survival (OS) and progression-free survival (PFS).\\n- **Treatment Accessibility:** The location can impact surgical accessibility and resection outcomes, potentially reducing the efficacy of standard treatments like TURBT (transurethral resection of bladder tumor).\\n\\n**Biological Rationale:**\\n- The ureteric orifice's integration into the urinary tract provides a conduit for early metastatic spread, which biologically predicates a more aggressive disease course.\\n  \\n**Genomic Interpretation Biases:**\\n- Tumors here may be under-represented in general bladder cancer studies, skewing genomic databases and tumor profiling efforts.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n- **Transitional Cell Carcinoma, NOS:** The nonspecific nature of this histological classification implies a standard urothelial phenotype, which could mask subtypes with distinct molecular characteristics and prognostic impacts.\\n\\n**Biological Rationale:**\\n- Certain mutations typical in this histology, like FGFR3 or TP53 alterations, influence pathways like cell proliferation or apoptosis resistance. Their presence correlates negatively or positively with survival depending on downstream impacts on tumor behavior.\\n\\n**Genomic Interpretation Biases:**\\n- Histological simplifications can lead to misclassifications, affecting the accuracy of survival predictions based on shared mutation profiles within a diverse histological category.\\n\\n### Sampling Bias\\n\\n**Limitations of Blood Derived Normal, Primary Tumor:**\\n- **Influence on Survival:** Differences between primary tumor samples and adjacent non-tumor tissue versus systemic blood-derived normals can lead to misinterpretations of mutation backgrounds and tumor-specific adaptations.\\n  \\n**Biological Rationale:**\\n- Tumor microenvironment interactions and clonal heterogeneity may be underrepresented when primarily relying on blood-derived normal samples for comparative genomic studies.\\n\\n**Genomic Interpretation Biases:**\\n- Potential underestimation of intratumoral diversity and environmental influences might result in generalized findings that do not account for intricate tumor dynamics affecting survival.\\n\\n### Key Genes\\n\\n1. **TP53:** Often mutated, influencing genomic instability and resistance to apoptosis, associated with worse prognosis.\\n2. **FGFR3:** Mutations often correlate with papillary tumors that exhibit relatively better outcomes due to less aggressive behavior.\\n3. **PIK3CA:** Pertinent in oncogenic signaling pathways; its deregulation is indicative of poor survival due to enhanced proliferative capacity.\\n4. **ERBB2 (Her2):** Amplification in some bladder cancers predicting aggressive progression and shorter OS.\\n5. **CDKN2A:** Deletions or mutations disrupt cell cycle control, associated with higher grade tumors and poorer survival.\\n6. **TSC1/TSC2:** Mutations here impact mTOR pathway signaling, influencing cellular growth and survival, potentially offering targeted treatment avenues.\\n7. **RB1:** Loss impacts cell cycle regulation, often found in muscle-invasive and advanced disease correlating with shorter survival.\\n\\n**Biological Mechanisms:**\\n\\nEach gene influences pathways critical to tumor biology, such as cellular growth, apoptosis, and immune evasion. The presence or alteration in these genes directly impacts tumor susceptibility to treatment and natural disease course.\\n\\n### Conclusion\\n\\nKey survival risk factors in bladder urothelial carcinoma include anatomical site considerations, specific histological and genetic profiles, and the influence of sampling biases on genomic data. Clinically, recognizing the interplay of these factors can assist in developing personalized treatment plans, potentially improving survival outcomes by targeting specific pathways or correcting sampling methods for more accurate profiling. The integration of detailed genetic and histological data into clinical practice will enhance predictive accuracy and treatment efficiency, offering patients tailored therapeutic strategies based on individual tumor biology.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893351, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=816, prompt_tokens=449, total_tokens=1265, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 20/704...\n",
      "ChatCompletion(id='chatcmpl-BAiKH8tVVenpmGnJpHC3cUUI8Xsva', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Bladder Urothelial Carcinoma (BUC), classified as Bladder NOS, often originates in the urothelium, facilitating spread via lymphatics to regional and distant nodes, particularly the pelvic lymph nodes, lungs, liver, and bones. Metastasis generally indicates a poor prognosis due to limited treatment efficacy.\\n- **Survival Impact:** Regional and distant metastasis substantially lower survival rates (five-year survival drops significantly with metastatic spread). Treatments are less effective in late stages, making early detection pivotal.\\n- **Treatment Accessibility:** Accessibility can be restricted by socioeconomic factors influencing early detection and timely treatment, which are crucial as radical cystectomy or trimodal therapy has higher success if applied in early stages.\\n\\n**Biological Rationale:**\\n- **Urothelial Behavior:** Tumor cells can transition through epithelial-mesenchymal transition (EMT), enhancing metastatic propensity.\\n- **Early Detection Impact:** Tumor stage at diagnosis is crucial; localized disease has far better prognostic outcomes.\\n\\n**Potential Biases:**\\n- **Detection Bias:** Stage and metastatic burden may be underestimated in initial evaluations, skewing survival statistics negatively.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n- **Carcinoma, NOS & Mutation Interactions:** Non-specific histology (NOS) means variable prognosis; however, certain mutations (e.g., FGFR3) often correlate with low-grade, papillary tumors that have a more favorable prognosis than high-grade tumors. Conversely, TP53 mutations often indicate aggressive, high-grade disease.\\n\\n**Biological Rationale:**\\n- **Differentiation and Mutations:** Tumors with poorly differentiated features often harbor mutations like TP53, promoting unchecked proliferation and thus affecting survival negatively.\\n\\n**Potential Biases:**\\n- **Homogeneity Assumptions:** There is a risk of oversimplifying heterogeneity in NOS classifications, leading to imprecise therapeutic targets.\\n\\n### Sampling Bias\\n\\n**Influence on Survival:**\\n- **Blood Derived Normal vs. Primary Tumor Sampling:** Blood-derived samples may not capture the intra-tumoral heterogeneity or specific somatic mutations integral to treatment and prognosis.\\n\\n**Biological Rationale:**\\n- **Tumor-Specific Mutations:** Blood samples might fail to detect crucial mutations present only in the tumor microenvironment, missing key drivers of invasion and metastasis.\\n\\n**Potential Biases:**\\n- **Genomic Under-representation:** This approach may lead to incorrect assumptions about mutation prevalence or actionability in tumors, affecting understanding of prognosis.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes:**\\n1. **TP53:** Mutations lead to defective apoptosis, allowing prolonged cell survival and increased resistance to therapy; common in aggressive tumors.\\n2. **FGFR3:** Often found in less aggressive, low-grade tumors, promoting cell growth; therapeutic target with tyrosine kinase inhibitors.\\n3. **TSC1/TSC2:** Mutations can dysregulate mTOR signaling, influencing tumor metabolism and growth, contributing to aggressive behavior.\\n4. **PIK3CA:** Mutations enhance proliferation through Akt signaling, often correlating with reduced survival.\\n5. **RB1:** Loss facilitates unregulated cell cycle progression, typically associated with high-grade tumors and poorer outcomes.\\n6. **ERBB2 (HER2):** Overexpression signifies aggressive growth; known target for monoclonal antibody therapy, emphasis on personalized treatment.\\n7. **MDM2:** Amplification leads to p53 inactivation, impacting cellular apoptosis negatively.\\n8. **CDKN2A/B:** Loss of function mutations encourage unchecked cell division, linking to poor prognosis.\\n\\n**Biological Mechanisms:**\\n- **Proliferation:** Genes like PIK3CA and FGFR3 regulate pathways enhancing cell cycle progression.\\n- **Immune Response:** Mutations influencing immune evasion often denote aggressiveness.\\n- **Apoptosis Regulation:** TP53, MDM2 involvement in apoptosis alterations directly correlates with tumor robustness and survival likelihood.\\n\\n### Conclusion\\n\\nIn summary, Bladder Urothelial Carcinoma’s survival outcomes are critically impacted by the interplay of metastatic behavior, histological complexity, and genetic mutations. While advancements in molecular profiling improve understanding, sampling biases persist as a challenge. Prognostic assessments must incorporate genetic and environmental factors to optimize treatment strategies effectively. Clinically, early detection and personalized therapy, steered by genetic insights, are pivotal in improving survival rates, underscoring the urgency in integrating genomics into routine oncological practice.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893369, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=926, prompt_tokens=445, total_tokens=1371, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 21/704...\n",
      "ChatCompletion(id='chatcmpl-BAiKarHgMzxBeo2jN2ZQqG1GuXKlm', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin: Bladder NOS**\\n\\n1. **Metastatic Patterns and Survival Impact**:\\n   - **Influence on Metastasis**: Bladder NOS refers to carcinomas originating from the bladder without specific subtype differentiation. These tumors can metastasize through the lymphatic system and bloodstream, primarily targeting regional lymph nodes, bones, lungs, and liver. The degree of metastasis heavily influences survival, with distant metastases generally leading to poorer prognoses.\\n   - **Treatment Accessibility**: Lack of specificity in tumor origin (NOS) might impact treatment decisions due to uncertainty in the most aggressive treatment pathway, potentially affecting curative outcomes and contributing to survival discrepancies.\\n\\n2. **Biological Rationale**:\\n   - **Tumor Behavior**: The general categorization under NOS might obscure differences in biological behavior across subtypes, which can lead to under- or overtreatment.\\n   - **Impact on Survival**: Unspecific classification can complicate precise prognostic assessments and treatment personalization.\\n\\n**Histology and Mutation Profiles: Squamous Cell Carcinoma, NOS**\\n\\n1. **Interaction and Outcomes**:\\n   - **Histological Influence**: Squamous cell carcinoma (SCC) in the bladder is less common than urothelial carcinoma and tends to arise from chronic irritation and inflammation. Tumors are often less responsive to conventional chemotherapies, leading to poorer survival outcomes.\\n   - **Mutation Profiles**: SCC may exhibit unique mutations in pathways related to keratinocyte proliferation and differentiation, further complicating treatment.\\n\\n2. **Biological Mechanism**:\\n   - **Mutational Landscape**: Key mutations in genes like TP53 and CDKN2A might drive carcinogenesis, affecting cell cycle regulation and apoptosis—potentially reducing survival through more aggressive tumor growth.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\n1. **Bias Concerns**:\\n   - **Blood-Derived Normal vs. Primary Tumor Sampling**: Differences in genomic profiles between blood and tumor samples could introduce bias, causing either an underestimation or misinterpretation of tumor-specific mutations if mismatched samples are compared.\\n   - **Biological Relevance**: Blood samples might lack tumor heterogeneity insights, crucial for identifying actionable mutations affecting survival.\\n\\n2. **Biological and Clinical Implications**:\\n   - **Potential for Misleading Results**: Non-representative sampling could lead to inappropriate treatment strategies by misjudging tumor aggressiveness or potential therapeutic targets.\\n\\n**Key Genes Influencing Survival**\\n\\n1. **Identifying Crucial Genes**:\\n   - **TP53**: Commonly mutated in bladder cancer, influences apoptosis and cell cycle control. Mutations in TP53 can lead to unchecked tumor growth and poor survival prognoses.\\n   - **FGFR3**: Mutations commonly found in low-grade, non-invasive tumors. While promoting proliferation, outcomes may vary with therapeutic targeting potential.\\n   - **PIK3CA**: Involved in cell growth and survival signaling pathways. Mutations can contribute to cancer progression but also present therapeutic opportunities.\\n   - **CDKN2A (p16)**: Loss of function in this gene can lead to dysregulated cell cycle progression and is often associated with aggressive disease and worse survival.\\n   - **ERBB2 (HER2)**: Overexpression or amplification can lead to enhanced agresiviness, yet offers potential targets for therapy, impacting survival positively if targeted effectively.\\n   - **RB1**: Disruption affects cell cycle control, promoting unsupervised cellular proliferation.\\n   - **ERCC2**: Involves DNA repair mechanism; mutations may lead to genomic instability.\\n   - **TSC1**: Tumor suppressor gene; mutations may cause unfavorable responses to certain therapies impacting survival.\\n\\n**Synthesis of Key Survival Risk Factors**\\n\\n1. **Integrated Understanding**:\\n   - **Survival Impacts**: Specific genetic mutations, tumor origin and histology (NOS distinctions), and sampling biases collectively inform therapeutic directions and prognostic expectations.\\n   - **Clinical Insights**: Understanding and mitigating these factors through precision medicine can enhance survival outcomes by tailoring treatment protocols to genetic profiles and tumor-specific characteristics.\\n   - **Patient Survival Impact**: Improved stratification of bladder carcinoma will allow for more targeted treatments, better utilization of molecular data, and more consistent survival predictions, ultimately aiming at improving patient-specific outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893388, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=879, prompt_tokens=446, total_tokens=1325, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 22/704...\n",
      "ChatCompletion(id='chatcmpl-BAiKtSPArGU5OXiksWE54PQhAhohb', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Step-by-step Analysis:**\\n\\n1. **Bladder NOS and Metastatic Patterns:**\\n   - **Influence on Survival:**\\n     - Classified as Bladder NOS (not otherwise specified), urothelial carcinoma, commonly impacts survival negatively due to its potential for wide metastatic dissemination.\\n     - Primary metastasis typically targets the lungs, liver, and bones, complicating treatment efficacy.\\n   - **Biological Rationale:**\\n     - Originating from urothelial cells in the bladder mucosa, the carcinoma tends to invade local tissues early, eventually penetrating into vascular networks, facilitating distant metastasis.\\n   - **Impact on Treatment Access:**\\n     - As a heterogeneous disease with non-specific classification, treatment approaches are often broad-spectrum, which can delay targeted interventions critical for improving survival outcomes.\\n\\n### Histology\\n\\n**Step-by-step Analysis:**\\n\\n1. **Transitional Cell Carcinoma, NOS and Mutation Profiles:**\\n   - **Influence on Survival:**\\n     - The transitional cell histology, majorly characterized by variability in differentiation status, affects survival differently. Poor differentiation often correlates with worse prognosis.\\n   - **Biological Rationale:**\\n     - Mutation profiles such as those in TP53 or FGFR3 can either lead to rapid tumor progression (TP53 mutations) or more indolent growth (FGFR3 mutations), directly impacting survival outcomes.\\n   - **Interaction with Treatment:**\\n     - Certain mutations confer sensitivity or resistance to chemotherapy, impacting overall survival.\\n\\n### Sampling Bias\\n\\n**Step-by-step Analysis:**\\n\\n1. **Limitations of Blood Derived Normal, Metastatic Sampling:**\\n   - **Influence on Survival:**\\n     - Biased sampling can obscure true mutational landscape, misleading treatment decisions.\\n   - **Biological Rationale:**\\n     - Blood-derived samples might miss intratumoral heterogeneity, resulting in a skewed understanding of tumor biology.\\n   - **Potential Consequences:**\\n     - Leads to underestimation of certain mutations actively driving progression or treatment resistance.\\n\\n### Key Genes\\n\\n**Step-by-step Analysis:**\\n\\n1. **Identifying Survival-Associated Genes:**\\n   - **TP53:** Often mutated, promoting unregulated cell cycle progression and poor response to DNA-damaging agents.\\n   - **FGFR3:** Mutations often associated with non-invasive tumors, usually indicating a better prognosis.\\n   - **PIK3CA:** Influences pathways leading to cellular proliferation and survival. Mutations can promote resistance to certain therapies.\\n   - **ERBB2 (HER2):** Amplification can drive aggressive tumor growth; however, presents a targetable feature.\\n   - **CDKN2A:** Regulates cell cycle progression; loss/mutation associated with high-grade tumors and poor prognosis.\\n   - **NOTCH1/2:** Involved in cell differentiation and apoptosis; mutations may enhance invasive capabilities or treatment resistance.\\n   - **MET:** Overexpression linked to increased invasiveness and poorer outcomes due to enhanced metastatic potential.\\n\\n   **Mechanisms Involved:**\\n   - **Proliferation:** Many mutations (TP53, PIK3CA) directly or indirectly increase cellular replication rates, overwhelming reparative and immune responses.\\n   - **Immune Response Modulation:** Changes in expression of genes like CDKN2A and NOTCH might impact immune evasion, influencing survival.\\n   - **Apoptosis Regulation:** Variations in these genes can promote apoptosis resistance, an essential survival determinant.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n- **Clinically Relevant Insights:**\\n  - Integration of tumor origin, specific histological features, and mutational profiles unveils high-risk survival scenarios. Knowledge of genetic mutations aids in precision treatment planning.\\n  - Identifying and addressing sampling biases in genomics analysis remains critical for accurate treatment response predictions.\\n  \\n- **Impact on Survival:**\\n  - Improved survival correlates with precision medicine approaches tailored to the unique molecular profiles of tumors, while improper classification or inadequate sampling can mislead therapeutic direction.\\n  \\nUltimately, addressing these oncological and genomic intricacies enhances personalized treatment strategies, potentially improving outcomes for patients with Bladder Urothelial Carcinoma.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893407, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=850, prompt_tokens=445, total_tokens=1295, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 23/704...\n",
      "ChatCompletion(id='chatcmpl-BAiLEMptd98s5D1Gwtse72kf7fuRz', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin: Impact on Survival\\n\\n**Influence on Survival:**\\n- **Primary Tumor Origin:** Bladder Urothelial Carcinoma (BUC), or Bladder NOS per ICD-10, originates in the urethelial cells lining the bladder. As a higher-grade malignancy tends to present as flat or papillary carcinoma.\\n- **Metastatic Patterns:** The urothelial origin aids in hematogenous and lymphatic spread, primarily to distant organs such as the liver, lungs, and bones. Early metastasis significantly diminishes survival prospects.\\n- **Treatment Accessibility:** Region-specific treatment strategies play a pivotal role. BUC can benefit from aggressive localized treatments like Transurethral Resection of Bladder Tumor (TURBT) combined with intravesical chemotherapy if detected early.\\n\\n**Biological Rationale:**\\n- **Apical Architecture and Invasive Potential:** The urothelial's transitional characteristics and architecture confer some resilience against superficial damage but permit tumor cells to invade deeper tissues, leading to complex metastatic behaviors.\\n- **Immune Modulation:** The bladder's exposure to the external environment implies a unique immune microenvironment, sometimes allowing tumors to evade immune surveillance.\\n\\n## Histology: Role of Transitional Cell Carcinoma (TCC), NOS\\n\\n**Influence on Survival:**\\n- **Mutation Profiles:** TCC NOS can harbor mutations in pivotal genes like TP53 and FGFR3, significantly altering cell cycle regulation and contributing to both tumor aggressiveness and therapeutic challenges.\\n\\n**Biological Rationale:**\\n- **Adaptability and Proliferation:** TCC's histological nature allows cells to stretch and compress, influencing tumor dormancy versus proliferation states and impacting how conventional therapies, including radiation and chemotherapeutics, may penetrate.\\n\\n## Sampling Bias: Limitations of Blood-Derived Normal and Primary Tumor\\n\\n**Influence on Survival:**\\n- **Genomic Analysis Limitations:** Blood-derived normal tissues might not reflect urothelial cellular microenvironment, skewing mutation detection and leading to potential misinterpretations of clonal diversity and therapeutic resistance.\\n\\n**Biological Rationale:**\\n- **Stromal Influence and Tumor Microenvironment (TME):** Primary tumor sampling is necessary but inherently limited due to the spatial heterogeneity and TME impact on gene expression profiles, omitting clonal selection and adaptation nuances.\\n\\n## Key Genes Impacting Survival\\n\\n**Survival-Associated Genes:**\\n1. **TP53:** Critical in controlling cell division and apoptosis. Mutations often result in unchecked proliferation.\\n2. **FGFR3:** Frequently mutated, linked to mitogenic signaling and therapy resistance; manifests in low-grade tumors.\\n3. **PIK3CA:** Alters PI3K/AKT pathway, directly influencing growth survival pathways.\\n4. **RB1:** Loss of this gene can disrupt cell cycle control, contributing to retinoblastoma protein dysfunctions.\\n5. **ERBB2 (HER2):** Overexpression can amplify growth signals; potential target for monoclonal antibody therapy.\\n6. **CDKN2A:** Influences both cell cycle and senescence; deleted or mutated in aggressive forms.\\n7. **MDM2:** Regulates TP53, mutations can undermine tumor suppressor mechanisms.\\n8. **HRAS:** Element of MAPK pathway, promotes proliferation and survival, particularly when mutated.\\n\\n**Biological Mechanisms:**\\n- **Proliferation and Apoptosis:** Many of these genes directly affect cellular growth regulation and programmed cell death.\\n- **Immune Response Modulation:** Some genes influence immune checkpoints and could inform about immune evasion strategies employed by tumors.\\n\\n## Synthesis of Key Survival Risk Factors\\n\\n**Clinically Relevant Insights:**\\n- **Diagnosing the histological characteristics early with an aligned genomic profile can lead to custom therapeutic strategies offering better outcomes.**\\n- **Molecular subtyping of genes reveals variability in TME adaptations, impacting overall prognosis and targeted therapy efficacy.**\\n- **Addressing metastatic risks via early intervention, immune checkpoint inhibitors, or targeted FGFR inhibitors improves survival chances.**\\n\\n**Impact on Patient Survival:**\\n- Understanding the oncogenic driving mutations, histological adaptability, and sensitivity to immune modulation can directly impact survival rates through more personalized treatment plans, contributing to longer remission periods and, ultimately, increased overall survival.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893428, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=876, prompt_tokens=445, total_tokens=1321, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 24/704...\n",
      "ChatCompletion(id='chatcmpl-BAiLadiuuZbW9AKq8IGhM5uDSbVs8', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Bladder NOS\\n\\n1. **Influence on Survival**: Bladder Urothelial Carcinoma, categorized as Bladder NOS (Not Otherwise Specified), can significantly impact patient survival due to its broad categorization that may include a variety of histological subtypes. The unspecified nature often complicates targeted treatment decisions which can adversely affect outcomes.\\n\\n2. **Metastatic Patterns**: Being categorized as NOS often means a delay in specific diagnostic detailing, which can influence metastasis detection. The primary sites for metastases are the lungs, liver, and bones, which are pivotal in determining treatment course and survival rates. Earlier and accurate classification improves prognosis as targeted therapies can delay metastasis.\\n\\n3. **Treatment Accessibility**: Bladder NOS implies limited initial characterization, potentially reducing treatment precision. Access to advanced genomic profiling and multidisciplinary management becomes crucial in improving survival.\\n\\n4. **Biases**: The general classification of NOS can lead to initial therapeutic misdirection, where more specific subtypes might respond differently to standard urothelial carcinoma treatments.\\n\\n### Histology: Transitional Cell Carcinoma, NOS\\n\\n1. **Survival Influence**: This type largely defines overall survival in bladder cancer due to its prevalence and variability in aggressiveness. Prognosis is driven significantly by the grade and stage of the tumor at diagnosis.\\n\\n2. **Mutation Interactions**: Common mutations include TP53 alterations and FGFR3, which differ starkly in their prognostic implications. For instance, FGFR3 mutations are associated with better outcomes in non-muscle invasive forms, whereas TP53 mutations indicate a poor prognosis due to their role in genomic stability.\\n\\n3. **Biological Rationale**: Transitional cell carcinoma generally demonstrates varied environmental and lifestyle interaction at a cellular level, influencing mutation frequency and oncogenesis.\\n\\n4. **Potential Biases**: Histological assessment can be subjectively biased, impacting initial treatment strategies, which affects survival. Observer variability and lack of detailed molecular profiling can skew interpretations.\\n\\n### Sampling Bias: Limitations in Genomic Analysis\\n\\n1. **Primary Tumor vs. Solid Tissue Normal**: Distinguishing between somatic and germline mutations requires accurate sampling. Sampling bias often occurs when only primary tumors are analyzed, potentially omitting normal tissue comparison for baseline mutation assessment.\\n\\n2. **Survival Impact**: Inaccurate genomic profiling can lead to inappropriate targeting of therapies that may not address the primary oncogenic drivers, affecting survival outcomes.\\n\\n3. **Biological Rationale**: Proper comparison ensures identification of driver mutations versus passenger mutations, key in tailoring adjuvant therapies.\\n\\n4. **Biases**: Over-reliance on primary tumor biopsies without matched normal tissue results in biased mutation identification, leading efforts away from effective personalized treatments.\\n\\n### Key Genes\\n\\n1. **TP53**: Involved in DNA repair, apoptosis, and tumor suppression. Mutations often correlate with aggressive disease and poorer survival.\\n\\n2. **FGFR3**: Mutations are common in low-grade tumors affecting receptor tyrosine kinase pathways, associated with improved outcomes in superficial disease.\\n\\n3. **PIK3CA**: Part of the PI3K/AKT pathway, its mutations often result in proliferative advantages to tumor cells, correlating with variable survival implications depending on co-existing mutations.\\n\\n4. **ERBB2 (HER2)**: Overexpression/amplification leads to aggressive tumor biology, but also offers therapeutic targets, potentially improving survival.\\n\\n5. **CDKN2A**: Its loss is associated with cell cycle deregulation, contributing to worse survival, primarily through facilitating unrestrained cellular proliferation.\\n\\n6. **TSC1**: Mutation or inactivation may confer sensitivity to mTOR inhibitors, presenting therapeutic options that could extend survival.\\n\\n7. **EP300**: Alters chromatin state and transcription regulation; mutations can lead to disrupted gene expression networks, impacting progression and survival.\\n\\n8. **ARID1A**: Loss frequently observed in high-grade tumors, impacts chromatin remodeling, associated with poor prognosis but suggests vulnerability to specific therapeutic approaches.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nUnderstanding these factors highlights the importance of precise histological classification, comprehensive genomic profiling including driver mutation identification, and the need for reducing sampling biases. Treatment strategies tailored to conquer mutation-specific pathways can greatly influence survival positively. Key clinical insights include the necessity of early and detailed diagnosis alongside personalized therapy plans guided by molecular and histologic specifics, ultimately enhancing overall patient survival outcomes in bladder urothelial carcinoma.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893450, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=913, prompt_tokens=445, total_tokens=1358, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 25/704...\n",
      "ChatCompletion(id='chatcmpl-BAiLrkCtrob6rxiSgROdBs2ohSYsJ', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"To comprehensively understand the impact of Bladder Urothelial Carcinoma (Bladder NOS) on survival, we must break down the factors into distinct yet interconnected components: tumor origin, histology, sampling biases, and key genomic alterations.\\n\\n### Tumor Origin\\n\\n1. **Influence on Survival**: \\n   - Bladder Urothelial Carcinoma, specifically categorized as Bladder NOS, often indicates a potential for aggressive behavior and unpredictable metastatic patterns. Such tumors are inclined to spread through the lymphatic system and invade local and distant organs, affecting survival negatively.\\n   \\n2. **Biological Rationale**:\\n   - The origin in the bladder’s urothelial tissue means that carcinoma can penetrate deeply into the bladder wall, progressing to surrounding tissues. This invasive nature complicates treatment and influences prognosis.\\n\\n3. **Metastatic Patterns and Treatment Accessibility**:\\n   - Due to the urological location, treatment may be further limited by the tumor's early resistance to conventional therapies, which include systemic chemotherapy and immunotherapy.\\n\\n### Histology\\n\\n1. **Influence on Survival**: \\n   - **Papillary Transitional Cell Carcinoma**: The histological subtype typically signifies more favorable outcomes compared to flat, invasive variants, mainly due to generally lower histopathological grades.\\n   \\n2. **Mutation Profiles**:\\n   - Mutations such as FGFR3 are prevalent in papillary variants, often associated with low-grade lesions and hence better prognosis. However, TP53 mutations, indicative of a more aggressive nature, often confer worse outcomes.\\n\\n3. **Biological Rationale**:\\n   - Histological assessment impacts detection of recurrence and progression, which crucially determines treatment response and survival outcome.\\n\\n### Sampling Bias: Genomic Analysis\\n\\n1. **Influence on Survival**:\\n   - Limitations of relying on blood-derived normal samples compared to primary tumor samples can skew analyses concerning mutations that influence treatment response and the understanding of intratumoral heterogeneity.\\n\\n2. **Biological Rationale**:\\n   - Genomic complexity in Bladder NOS necessitates primary tumor sampling to capture the full mutational landscape. Blood samples may not reflect intratumoral complexities and can misrepresent the prevalence of mutations important for prognosis and treatment.\\n\\n3. **Potential Bias in Interpretation**:\\n   - Sampling biases can result in under- or over-representation of certain mutations, complicating therapeutic decisions that rely on precision medicine approaches.\\n\\n### Key Genes and Their Mechanisms\\n\\n1. **FGFR3**: Involved in cell growth and angiogenesis, mutations in FGFR3 correlate with non-muscle invasive bladder cancer, often resulting in better survival. \\n\\n2. **TP53**: Integral to DNA repair and apoptosis, mutations often signify more aggressive disease and poor survival due to impeded tumor suppressor functions.\\n\\n3. **PIK3CA**: Part of the PI3K/AKT pathway, mutations can drive proliferation, with aberrant activation contributing to aggressive tumor behavior.\\n\\n4. **ERBB2 (HER2)**: Overexpression can lead to increased proliferation and tumor growth, often associated with poor survival in advanced stages.\\n\\n5. **CDKN2A**: Its inactivation results in deregulation of the cell cycle, promoting unchecked cellular proliferation, which is unfavorable.\\n\\n6. **RB1**: Loss of function results in cell cycle dysregulation, contributing to a more invasive phenotype and decreased survival.\\n\\n7. **TSC1/TSC2**: Tumor suppressors related to mTOR pathway regulation; mutations can disrupt cellular growth control mechanisms, thereby affecting survival.\\n\\n### Synthesis of Survival Risk Factors\\n\\n- **Clinical Insights**: Treatment strategies should be tailored according to histological and genetic profiles, such as targeting FGFR3 in papillary carcinomas or using checkpoint inhibitors where immune evasion genetics (e.g., PD-L1 expression) are present.\\n  \\n- **Survival Impact**: Accurate characterization of tumor origin and histological subtype through comprehensive genomic profiling can optimize treatment pathways and improve prognostic accuracy.\\n\\nBy integrating this complex oncological and genetic knowledge, clinicians can better predict patient outcomes, personalize therapies, and ultimately aim to enhance survival in individuals diagnosed with Bladder Urothelial Carcinoma.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893467, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=856, prompt_tokens=445, total_tokens=1301, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 26/704...\n",
      "ChatCompletion(id='chatcmpl-BAiMDq0LQzSqaWUfbHlQdp4Pprh8f', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Upper Inner Quadrant of Breast\\n\\n1. **Influence on Survival and Metastatic Patterns:**\\n   - **Localization**: The upper inner quadrant's lymphatic drainage patterns may lead to less frequent nodal involvement initially, as compared to tumors in other quadrants, potentially contributing to a more favorable prognosis in early stages.\\n   - **Metastatic Spread**: Tumors originating here may demonstrate distinct metastatic patterns due to proximity to the internal mammary chain. This can influence the sites of secondary tumor deposits, potentially impacting survival negatively if initially underappreciated in treatment planning.\\n\\n2. **Treatment Accessibility:**\\n   - **Surgical Accessibility**: Location can influence ease of achieving clear surgical margins, with potential survival impact if more extensive surgery or adjuvant therapy is required.\\n   - **Radiation Therapy**: Due to proximity to vital structures, doses may need cautious balancing to minimize collateral damage, influencing locoregional control and hence survival.\\n\\n### Histology: Infiltrating Duct Carcinoma, NOS (Not Otherwise Specified)\\n\\n1. **Influence on Survival:**\\n   - **Histological Aggressiveness**: As the most common form of breast cancer, it presents a baseline for survival comparisons, with varying grades affecting outcomes. High-grade tumors correlate with elevated recurrence risks, negatively impacting survival.\\n   \\n2. **Mutation Profile Interactions:**\\n   - **Common Mutations**: Often harbor mutations in genes like TP53 and PIK3CA, impacting cell cycle regulation and growth pathways. These mutations can dictate aggressive tumor phenotypes and treatment resistance, leading to poorer survival outcomes.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n1. **Limitations on Genomic Analysis:**\\n   - **Blood vs. Tumor Samples**: Blood-derived normal samples provide a baseline for germline comparisons but may miss somatic mutations crucial to the tumoral genomic landscape. This can limit the detection of driver mutations in tumor tissue, skewing prognostic evaluations.\\n   \\n2. **Impact on Survival Prediction:**\\n   - Genomic studies relying solely on blood or limited tissue samples may overlook heterogeneity and clonal evolution within the tumor, potentially underestimating aggressive behavior and thus offering an incomplete survival prediction.\\n\\n### Key Genes Impacting Survival\\n\\n1. **BRCA1/2**: \\n   - **Mechanism**: Involved in DNA repair pathway integrity. Mutations can lead to genomic instability, increasing secondary oncogenic mutations, often correlating with poor survival due to aggressive cancer phenotypes.\\n   \\n2. **TP53**: \\n   - **Mechanism**: Critical regulator of cell cycle and apoptosis. Mutations lead to unchecked cell proliferation and resistance to chemotherapeutics, aligning with adverse survival outcomes.\\n   \\n3. **PIK3CA**: \\n   - **Mechanism**: Part of the PI3K/AKT signaling pathway, influencing cellular growth and survival. Mutations have been associated with endocrine therapy resistance and variable survival outcomes.\\n   \\n4. **HER2 (ERBB2)**: \\n   - **Mechanism**: Oncogene that encodes a receptor tyrosine kinase, amplification leads to aggressive tumor growth. Targeted therapies can improve survival significantly, illustrating its dual role in prognosis and therapeutic targeting.\\n   \\n5. **CDH1**: \\n   - **Mechanism**: Associated with cell adhesion, mutations can enhance metastatic potential due to loss of epithelial integrity, commonly linking to worse survival stats.\\n   \\n6. **ESR1**: \\n   - **Mechanism**: Encodes estrogen receptor, mutations or overexpression usually denote hormonal therapy applicability but can also indicate endocrine resistance mechanisms, influencing survival negatively in such cases.\\n\\n### Conclusion\\n\\n**Synthesis of Key Survival Risk Factors:**\\n- Tumor localization in the upper inner quadrant has unique metastatic implications and surgical considerations, both of which influence survival dynamics.\\n- Histological type and associated mutation profiles of infiltrating duct carcinomas fundamentally drive treatment responses and survival likelihood, underscoring their clinical significance.\\n- Genomic analyses must account for sampling biases to avoid testimonial survival optimism or pessimism.\\n- The interplay of key genes like BRCA1/2, TP53, and HER2 showcases that precise genomic characterization influences not only survival prognostication but also theragnostic pathways.\\n\\nSuch integrated understanding is vital for tailored therapeutic approaches, aiming for optimal survival outcomes and informed clinical decision-making.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893489, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=902, prompt_tokens=446, total_tokens=1348, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 27/704...\n",
      "ChatCompletion(id='chatcmpl-BAiMh66PuNzUzAATLpr2wVOfJIHke', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"To address the impacts on survival concerning Breast invasive carcinoma, particularly from the upper inner quadrant of the breast, we must take a structured approach dissecting each factor logically. \\n\\n### Tumor Origin: Upper Inner Quadrant Influence\\n1. **Impact on Survival**:\\n   - **Metastatic Patterns**: Breast cancer originating from the upper inner quadrant may show different drainage patterns, predominantly towards the internal mammary nodes rather than axillary nodes. This alternate drainage route can affect both diagnostic visibility and survival outcomes since typical screening emphasizes axillary examination.\\n   - **Patient Survival**: The internal mammary node involvement may be less accessible during surgery, potentially leading to under-treatment.\\n   - **Treatment Accessibility**: Standard surgical treatments like sentinel lymph node dissection might miss metastases in these nodes, impacting long-term survival negatively.\\n\\n2. **Biological Rationale**:\\n   - The upper inner quadrant possesses distinct lymphatic drainage paths, which influences metastatic spread. This unique configuration might delay detection of metastatic nodes, complicating treatment strategies.\\n\\n3. **Biases in Interpretation**:\\n   - Most genomic and clinical data focus on axillary node involvement due to its prevalence, possibly underestimating the significance of internal mammary node involvement due to less frequent direct sampling or imaging.\\n\\n### Histology: Infiltrating Lobular Mixed Carcinoma\\n1. **Impact on Survival**:\\n   - **Interaction with Mutation Profiles**: Infiltrating lobular carcinoma (ILC), especially mixed types, exhibit different mutation spectra compared to ductal types, potentially affecting response to therapy and therapy-driven pathways like hormone response.\\n   - **Outcomes**: Mixed histology can convolute prognostic predictions due to varied mutation impacts across the tumor, potentially leading to mixed therapeutic results.\\n\\n2. **Biological Rationale**:\\n   - ILC tumors typically have mutations in CDH1 (E-cadherin), impacting cell adhesion and metastatic propensity. Mixed histology might also carry mutations from ductal carcinoma profiles influencing heterogeneity in treatment response.\\n\\n3. **Biases in Interpretation**:\\n   - Histological mixed tumors may exhibit variable genomic features at different foci, potentially leading to sampling bias if analysis doesn't capture the full heterogeneity.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n1. **Impact on Survival**:\\n   - **Genomic Analysis**: Blood-derived normals can miss somatic mutations present exclusively in the tumor, potentially underestimating tumor complexity and misjudging prognosis.\\n\\n2. **Biological Rationale**:\\n   - Normal tissue controls from blood might not capture all somatic mutations given the differences between hematopoietic tissue and solid tumors.\\n\\n3. **Biases in Interpretation**:\\n   - The disparity in genetic material between blood and tumor tissue can lead to incomplete mutation profiles, skewing understanding of the tumor genome's impact on survival.\\n\\n### Key Survival-Associated Genes\\n1. **PTEN, TP53, BRCA1/2**: \\n   - **PTEN**: Tumor suppressor, regulates PI3K pathway. Loss can lead to unchecked proliferation.\\n   - **TP53**: Maintains genomic stability; mutations lead to evasion of apoptosis.\\n   - **BRCA1/2**: Involved in DNA repair; mutations heighten susceptibility to aggressive disease phenotypes.\\n\\n2. **PIK3CA, ESR1, ERBB2 (HER2)**:\\n   - **PIK3CA**: Mutation leads to activation of PI3K/AKT signaling.\\n   - **ESR1**: Estrogen receptor affects hormone therapy response and survival.\\n   - **ERBB2**: Overexpression relates to therapy targets (e.g., trastuzumab), crucial for prognosis and treatment.\\n\\n3. **AKT1**: \\n   - Important in cell cycle progression, seen frequently altered in breast cancer impacting survival.\\n\\n### Conclusion\\nIn conclusion, survival in breast invasive carcinoma, especially from the upper inner quadrant, is intricately linked to the tumor's anatomical origin, histological features, sampling biases, and specific genomic mutations. Clinically, understanding the unique metastatic patterns due to tumor origin is critical for targeted treatment planning and node evaluation. Histological diversity and precise genomic profiling are crucial to determine appropriate treatment regimens. Addressing sampling biases ensures accurate genomic interpretation, fundamental in prognostication and personalized medicine. Emphasizing these factors provides comprehensive insights to improve survival outcomes and therapy effectiveness.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893519, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=904, prompt_tokens=450, total_tokens=1354, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 28/704...\n",
      "ChatCompletion(id='chatcmpl-BAiMzISuYNcDvPxY1gMMF25p7XKeG', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin: Lower Inner Quadrant of Breast**\\n\\n1. **Influence on Metastatic Patterns and Survival**: The origin of the tumor in the lower inner quadrant of the breast can significantly influence metastatic patterns and survival rates in breast cancer patients. Tumors in this quadrant are closer to the internal mammary lymph nodes compared to those in other quadrants. Metastasis to these nodes often signals an advanced disease state, potentially worsening the prognosis due to less accessibility for surgical interventions and radiation therapy.\\n\\n2. **Biological Rationale**: Tumors in this region often demonstrate a propensity to metastasize to less common nodal basins, which can complicate both early detection and comprehensive nodal management. As a result, the anatomical location might obscure early metastatic processes from usual imaging techniques, delaying the diagnosis of nodal involvement and affecting survival negatively.\\n\\n3. **Treatment Accessibility**: The lower inner quadrant's proximity to other major body structures can complicate surgical accessibility, impacting the ease and success rate of interventions like mastectomy or lymph node dissection. Complex surgery might result in incomplete excision or require more aggressive treatment, potentially influencing survival negatively.\\n\\n**Histology: Infiltrating Duct Carcinoma, NOS**\\n\\n1. **Influence on Mutation Profiles and Outcomes**: Infiltrating duct carcinoma is the most common histological type of breast cancer and involves heterogeneous mutation profiles, varying from patient to patient. This heterogeneity affects the uniformity of treatment response, as particular mutations can drive resistance to standard therapies.\\n\\n2. **Biological Rationale**: Histological heterogeneity in infiltrating duct carcinoma frequently associates with diverse mutation profiles in key pathways like PI3K/AKT, and TP53. These variations underpin differences in cell proliferation, evasion of apoptosis, and impacts on survival.\\n\\n3. **Influence on Outcomes**: If the tumor exhibits mutations that drive growth and resistance to apoptosis, these features can lead to poorer prognostic outcomes and a more aggressive disease course, thus negatively affecting survival.\\n\\n**Sampling Bias: Limitations in Genomic Analysis**\\n\\n1. **Influence on Genomic Interpretation**: Sampling biases in genomic analysis often arise from the predominance of studies using primary tumors or solid tissue normals. This could neglect the detection of sub-clonal populations driving metastasis and drug resistance.\\n\\n2. **Biological Rationale**: By focusing solely on primary tumor tissue, there is a risk of under-representing heterogeneity and variant profiles that could be critical for understanding metastatic progression and therapy resistance.\\n\\n3. **Survival Impact**: Misinterpretation of genomic data due to limited sampling might lead to sub-optimal treatment choices, with significant implications for survival outcomes.\\n\\n**Key Genes Associated with Survival**\\n\\n1. **TP53**: Acts as a tumor suppressor, regulating cell cycle and apoptosis. Mutations often lead to lack of cell cycle arrest, decreased apoptosis, and consequently poorer survival.\\n\\n2. **PIK3CA**: Frequently mutated in breast cancer, leading to hyperactive PI3K/AKT signaling, driving proliferation and survival signals, impacting survival outcomes negatively due to enhanced tumor growth.\\n\\n3. **BRCA1/BRCA2**: Loss-of-function mutations impair DNA repair mechanisms, potentially resulting in increased genomic instability and worsening prognosis.\\n\\n4. **HER2 (ERBB2)**: Gene amplification leads to enhanced signaling for proliferation, but targeted therapy can significantly improve outcomes when HER2 mutation is moderated.\\n\\n5. **ESR1**: Mutations in estrogen receptors can influence endocrine therapy responsiveness, impacting survival variably depending on the mutation.\\n\\n6. **CDH1**: Responsible for cell adhesion; mutations often result in loss of cell cohesion, promoting invasion and metastasis, adversely affecting survival.\\n\\n7. **Ki-67**: Marker for proliferation; high levels indicate active tumor growth, usually correlating with aggressive disease and poorer survival.\\n\\n8. **PD-L1**: Expression levels can modulate immune evasion; high expression could influence the effectiveness of immunotherapy, impacting survival positively if treatment is successful.\\n\\n**Synthesis of Key Survival Risk Factors**\\n\\nUnderstanding the interplay of anatomical origins with node involvement, histological heterogeneity, genomic biases, and pivotal genetic mutations provides a comprehensive framework for assessing survival risk in breast cancer patients. Clinically, accounting for these variables contributes to more personalized, targeted strategies that improve survival outcomes. Enhancing genomic analysis, integrating precision medicine approaches, and acknowledging anatomical and histological variations are paramount in improving prognostic assessments and personalizing treatment modalities for better patient survival.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893537, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=925, prompt_tokens=446, total_tokens=1371, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 29/704...\n",
      "ChatCompletion(id='chatcmpl-BAiNJO5Otd8HPSpJnOT62rLdByUHU', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Tumors originating in the lower inner quadrant of the breast may have unique lymphatic drainage patterns leading to a slightly different metastatic pathway, potentially involving internal mammary nodes earlier than other quadrants.\\n- **Patient Survival:** While exact survival impact is less clear, tumors in this region can present diagnostic challenges, which can delay detection and treatment initiation.\\n- **Treatment Accessibility:** The anatomical position may complicate surgical approaches, impacting the extent of resection and subsequent adjuvant treatment planning.\\n\\n**Biological Rationale:**\\n- **Lymphatic Drainage:** The lower inner breast's proximity to central thoracic lymph nodes might facilitate early spread internally before external symptoms prompt diagnosis.\\n- This anatomical nuance necessitates vigilance in imaging, particularly involving the mediastinum and internal mammary chains during staging workup.\\n\\n**Biases:**\\n- **Detection Bias:** Variability in lymphatic spread patterns can affect staging accuracy, potentially leading to misclassification of disease extent.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n- **Infiltrating Duct with Other Types:** These mixed histological subtypes often exhibit diverse biological behaviors, potentially complicating prognosis.\\n- **Mutation Profiles:** Heterogeneity in histological subtypes often correlates with diverse mutation signatures, impacting response to targeted therapies.\\n\\n**Biological Rationale:**\\n- **Driver Mutations:** Mixed histology often presents with varied mutation landscapes that can lead to differential activation of oncogenic pathways. This affects both the aggressiveness of the tumor and its responsiveness to systemic therapies.\\n  \\n**Biases:**\\n- **Sampling Bias:** Tumor heterogeneity in mixed histological cases might result in under-diagnosing aggressive subcomponents if the biopsy is not representative.\\n\\n### Sampling Bias\\n\\n**Influence on Survival:**\\n- **Primary Tumor vs. Solid Tissue Normal:** Discrepancies in genomic analysis can occur when only primary tumor data is available, potentially underestimating mutational burdens or epigenetic changes present in micrometastatic disease.\\n\\n**Biological Rationale:**\\n- **Genomic Complexity:** Primary tumors might not encapsulate the full mutation spectrum, especially when early micro-metastases exist with divergent evolution pathways.\\n  \\n**Biases:**\\n- **Underrepresentation:** There’s a risk of underestimating metastatic potential if sampling does not account for heterogeneity across tumor sites.\\n\\n### Key Genes\\n\\n**Influence on Survival:**\\n- **Genes and Mechanisms:**\\n  - **TP53:** Tumor suppressor gene mutations often lead to loss of apoptotic regulation, facilitating tumor aggressiveness.\\n  - **BRCA1/BRCA2:** Mutations linked to repair of DNA damage, pivotal in maintaining genomic stability, can be prognostic indicators, especially regarding sensitivity to DNA-damaging agents.\\n  - **PIK3CA:** Oncogene alterations are common, promoting cell proliferation and survival, influencing responses to PI3K inhibitors.\\n  - **HER2 (ERBB2):** Overexpression leads to increased signaling for growth, directly impacting prognosis and treatment strategies with targeted therapies like trastuzumab.\\n  - **ESR1:** Estrogen receptor status, influencing hormone therapy responsiveness, significant for survival stratification.\\n  - **CDH1:** E-cadherin mutations in lobular components may relate to adhesion defects, affecting metastatic potential.\\n  - **PTEN:** Loss impacts PI3K/AKT signaling, contributing to unchecked cellular proliferation and survival.\\n\\n**Biological Rationale:**\\n- **Mutational Impact:** Each gene impacts pivotal cellular mechanisms, ranging from apoptosis to proliferation control, reflecting on tumor behavior and treatment response.\\n\\n**Biases:**\\n- **Interpretation Variability:** Dependence on primary tumor samples could skew genomic landscapes, missing vital mutations present in metastases.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n- **Clinical Insights:** Understanding the original tumor's anatomy, histology subtype, key genomic alterations, and recognizing sampling biases offers foundational insights into tailoring personalized treatments.\\n- **Survival Impact:** Variations in metastatic pathways, histology-driven genetics, and specific gene mutations collectively shape prognostic outcomes and therapeutic decisions, directly translating to patient survival optimization.\\n\\nThis structured approach to identifying and interpreting biological factors provides a comprehensive understanding necessary to drive meaningful clinical decision-making, ultimately influencing cancer survival outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893557, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=889, prompt_tokens=449, total_tokens=1338, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 30/704...\n",
      "ChatCompletion(id='chatcmpl-BAiNc86LwUQkdUAxmcFggsmS0GFVC', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin: Upper Outer Quadrant of Breast**\\n\\n1. **Influence on Survival:**\\n   - Positive Influence: The upper outer quadrant often leads to earlier detection due to higher breast tissue density, improving prognosis.\\n   - Negative Impact: However, this quadrant is richer in lymphatic vessels, increasing metastatic risk primarily to axillary lymph nodes.\\n\\n2. **Biological Rationale:**\\n   - Tumors in this area often present more detectably in self-examinations and screenings, facilitating early-stage interventions.\\n   - High lymphatic density facilitates early lymph node involvement, posing a challenge in complete eradication and requiring aggressive treatment.\\n\\n3. **Interpretational Biases:**\\n   - Studies often have sampling biases, with more urban or healthcare-accessible populations skewing data towards more favorable outcomes due to regular screenings.\\n\\n**Histology: Infiltrating Duct Carcinoma (IDC), NOS**\\n\\n1. **Survival Influence:**\\n   - Negative: IDC, NOS typically exhibits more aggressive molecular features and may correlate with worse overall survival than non-specific histologies.\\n   - Interaction with Mutations: Frequently associated with aberrations in pathways such as HER2 or ER, affecting treatment responses.\\n\\n2. **Biological Rationale:**\\n   - Its propensity for abnormal glandular invasion leads to significant tissue architecture disruption.\\n   - These architectural changes are often accompanied by key oncogenic mutations, increasing potential for chemoresistance.\\n\\n3. **Interpretational Biases:**\\n   - Non-specific categorization (NOS) might mask heterogeneity in outcomes, potentially overlooking variations driven by subtle molecular phenotypes.\\n\\n**Sampling Bias: Metastatic, Solid Tissue Normal**\\n\\n1. **Sampling Bias Influence:**\\n   - Positive: Offers a baseline for comparing tumorous vs. non-tumorous tissue.\\n   - Negative: Metastatic sites may introduce variability in gene expression profiles, complicating interpretation.\\n\\n2. **Biological Rationale:**\\n   - The assumption of normal tissue can be misleading when adjacent tumorous infiltration affects gene expression signatures.\\n\\n3. **Bias Implication:**\\n   - Assumptions of 'normalcy' may skew understanding of tumor-specific mutations, hindering precise molecular targeting.\\n\\n**Key Genes**\\n\\n1. **TP53:**\\n   - Impact: Negative due to its role in cell cycle regulation. Mutations lead to loss of apoptosis control, facilitating unchecked proliferation.\\n   \\n2. **BRCA1/2:**\\n   - Impact: Both positive when functional, due to their DNA repair roles. Mutations heighten genomic instability, lowering survival odds.\\n   \\n3. **HER2 (ERBB2):**\\n   - Impact: Negative, as overexpression correlates with aggressive forms of cancer. Targeting with specific treatments can improve outcomes.\\n   \\n4. **PIK3CA:**\\n   - Impact: Potentially negative due to its pathway's involvement in cellular growth, often leading to therapeutic resistance when mutated.\\n   \\n5. **CDH1:**\\n   - Impact: Negative; mutations disrupt cell adhesion, enhancing metastatic risk.\\n   \\n6. **ESR1:**\\n   - Impact: Positive when wild-type given effective endocrine therapies, though resistance mutations pose ongoing challenges.\\n\\n**Synthesis of Key Survival Risk Factors:**\\n\\nThe survival landscape for breast cancer, particularly from the upper outer quadrant, intertwines anatomical origin, histological traits, and genetic backgrounds. Early detection mediated by more accessible tumor locations, combined with targeted genetic therapies, advances survival. Histological aggressiveness demands nuanced treatment stratification informed by genetic mutation patterns like those in PIK3CA or TP53. Sampling biases, particularly within metastatic contexts, necessitate rigorous validation across diverse populations to ensure comprehensive risk assessment. Overall, personalized therapy leveraging genomic insights remains critical in extending patient survival, underscoring the need for integrated, multifactorial analysis.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893576, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=775, prompt_tokens=446, total_tokens=1221, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 31/704...\n",
      "ChatCompletion(id='chatcmpl-BAiNqpzz8siI7N1rvaTqbP35JSbpn', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Positive/Negative Impact:** The upper outer quadrant (UOQ) of the breast is a common origin point for breast cancers, often associated with better survival rates due to earlier detection.\\n- **Biological Rationale:** Tumors in the UOQ typically have better accessibility for physical exams and mammographic screening, allowing earlier diagnosis. Moreover, the relative abundance of lymphatic drainage from the upper outer quadrant often leads to a more patterned route of metastasis, predominantly involving axillary lymph nodes, allowing targeted surgical and therapeutic interventions.\\n- **Potential Biases:** The prevalence of tumors arising from the UOQ might lead to overrepresentation in studies, potentially skewing data to suggest better survival outcomes due to early detection and management rather than intrinsic tumor characteristics.\\n\\n### Histology\\n\\n**Interaction with Mutation Profiles:**\\n- **Infiltrating Duct Carcinoma, NOS:**\\n  - **Impact on Survival:** May exhibit varied survival outcomes dependent on specific mutation profiles, often impacting cellular differentiation and response to treatment.\\n  - **Biological Rationale:** As a common subtype of breast cancer, infiltrating duct carcinoma, not otherwise specified (NOS), can exhibit mutations in genes like TP53, PIK3CA, and HER2/ERBB2, impacting pathways like cell proliferation, apoptosis, and immune evasion. These mutations can lead to a heterogeneous response to therapy and variable prognosis.\\n- **Potential Biases:** Histological classification at initial biopsy may not fully represent tumor heterogeneity, leading to incomplete mutational analysis and treatment planning.\\n\\n### Sampling Bias\\n\\n**Limitations in Genomic Analysis:**\\n- **Primary Tumor vs. Solid Tissue Normal:**\\n  - **Impact on Survival:** Inaccuracies in genomic comparisons can misestimate the true burden of mutations driving survival.\\n  - **Biological Rationale:** Using solid tissue normal as a control may overlook tumor-associated genetic deviations specific to the tumor microenvironment or systemic influences, skewing interpretations of the tumor's genomic landscape.\\n- **Potential Biases:** The selection of primary tumor versus adjacent normal tissue for genomic studies may not account for field cancerization effects, which can underestimate mutational drivers that influence systemic disease progression and treatment resistance.\\n\\n### Key Genes\\n\\n1. **TP53:**\\n   - **Mechanism:** Tumor suppressor gene regulating the cell cycle and apoptosis; mutations negatively impact survival by allowing unchecked proliferation.\\n2. **PIK3CA:**\\n   - **Mechanism:** Part of the PI3K/AKT pathway, promoting cell growth and survival. Mutations can lead to resistance against targeted therapies.\\n3. **BRCA1/BRCA2:**\\n   - **Mechanism:** Crucial in DNA repair via homologous recombination; dysfunction increases the risk for aggressive cancer phenotypes.\\n4. **HER2/ERBB2:**\\n   - **Mechanism:** Receptor tyrosine-protein kinase involved in cell signaling; overexpression often results in poor prognosis but also offers targeted therapy options.\\n5. **ESR1:**\\n   - **Mechanism:** Estrogen receptor mediating hormonal growth stimuli; mutations complicate hormone therapy effectiveness.\\n6. **PTEN:**\\n   - **Mechanism:** Tumor suppressor involved in cell cycle regulation; loss enhances metastatic potential and therapy resistance.\\n7. **GATA3:**\\n   - **Mechanism:** Transcription factor important for luminal cell differentiation; mutations can indicate a favorable response to hormonal therapies.\\n8. **CDH1 (E-cadherin):**\\n   - **Mechanism:** Involved in cell adhesion; loss is associated with invasive carcinomas and negative prognostic significance.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n- **Clinically Relevant Insights:**\\n  - Tumor origin in the UOQ, while facilitating early detection, can mask intrinsic aggressive biology when observed purely via histological classification.\\n  - The interaction of common histological features with key genetic mutations underscores the personalized nature of treatment strategies and prognostic evaluations.\\n  - Accurate genomic interpretation requires addressing potential sampling biases and understanding the biological roles of key genes in survival outcomes.\\n  \\n- **Impact on Patient Survival:**\\n  - Understanding the nuanced interplay between anatomical origins, histological diversity, molecular mutations, and sampling biases is crucial for developing targeted treatments and improving survival outcomes for patients with breast invasive carcinoma. Identifying and addressing biases in current research methodologies can vastly enhance therapeutic precision and efficacy.\\n\\n\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893590, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=910, prompt_tokens=446, total_tokens=1356, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 32/704...\n",
      "ChatCompletion(id='chatcmpl-BAiO6MF484Ccszl69rRSsV9TN5Sqt', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Lower Outer Quadrant of Breast\\n\\n1. **Impact on Survival**:\\n   - Breast tumors originating in the lower outer quadrant (LOQ) generally have a better prognosis compared to inner quadrant tumors, primarily due to anatomical and vascular factors influencing metastatic spread.\\n   - LOQ tumors are diagnosed more easily due to accessibility, potentially leading to earlier treatment and improved outcomes.\\n\\n2. **Metastatic Patterns**:\\n   - Tumors in the LOQ tend to metastasize first to axillary lymph nodes, which are more accessible for surgical management, thus potentially improving survival rates.\\n   - Comparatively, tumors in the medial quadrant may spread to internal mammary nodes, which are harder to detect and treat.\\n\\n3. **Treatment Accessibility**:\\n   - The physical location allows for efficient surgical intervention and axillary dissection, optimizing treatment strategies and potentially leading to higher survival rates.\\n\\n---\\n\\n### Histology: Infiltrating Ductal Carcinoma, NOS\\n\\n1. **Influence on Outcomes**:\\n   - Infiltrating ductal carcinoma (IDC), NOS represents the most common histological subtype, generally associated with intermediate prognosis depending on grade, stage, and molecular subtype.\\n\\n2. **Interaction with Mutations**:\\n   - IDC frequently associates with mutations in TP53, PIK3CA, and GATA3, each influencing tumor aggressiveness and patient survival.\\n   - For example, TP53 mutations often correlate with poorer outcomes due to the protein’s role in apoptosis and genomic stability.\\n\\n3. **Biological Rationale**:\\n   - In IDC, disrupted ductal architecture facilitates invasion, while genetic instability leads to heterogeneity in metastatic potential, complicating prognosis.\\n\\n---\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n1. **Limitations**:\\n   - Using blood-derived normal comparisons in genomic studies can introduce biases as somatic mutations specific to tumor tissue may not be detectable, limiting insights into tumor-specific genomic alterations.\\n\\n2. **Genomic Analysis**:\\n   - Primary tumor sampling offers a direct assessment of mutational burden but may miss spatial heterogeneity, affecting the understanding of resistance mechanisms and influencing treatment strategies.\\n\\n3. **Bias Impact**:\\n   - Disparities in sampling can lead to underestimations of actionable mutations, impacting therapeutic decision-making and patient survival.\\n\\n---\\n\\n### Key Genes and Survival\\n\\n1. **TP53**:\\n   - Role: Tumor suppressor involved in DNA repair, apoptosis.\\n   - Impact: Mutations often indicate a poor prognosis due to compromised cellular repair mechanisms.\\n\\n2. **PIK3CA**:\\n   - Role: Part of the PI3K/AKT pathway, involved in cell proliferation and survival.\\n   - Impact: Mutations may confer increased growth potential, influencing treatment resistance.\\n\\n3. **BRCA1/2**:\\n   - Role: DNA repair via homologous recombination.\\n   - Impact: Germline mutations correlate with aggressive phenotypes but offer therapeutic targets like PARP inhibitors.\\n\\n4. **GATA3**:\\n   - Role: Transcription factor in luminal differentiation.\\n   - Impact: Mutations can affect gene expression profiles, influencing treatment responsiveness.\\n\\n5. **HER2 (ERBB2)**:\\n   - Role: Growth factor receptor.\\n   - Impact: Overexpression predicts response to targeted therapies but typically indicates worse survival without such therapies.\\n\\n6. **ESR1**:\\n   - Role: Estrogen receptor, critical in ER-positive breast cancer growth.\\n   - Impact: Mutations can lead to endocrine therapy resistance, complicating treatment approaches.\\n\\n7. **FGFR**:\\n   - Role: Receptor tyrosine kinase, involved in signal transduction.\\n   - Impact: Alterations in this pathway can contribute to tumor progression and drug resistance.\\n\\n---\\n\\n### Conclusion: Key Survival Risk Factors\\n\\nThe survival outlook for breast invasive carcinoma, particularly originating in the LOQ, depends intricately on anatomical, histological, and genetic factors. The accessibility of LOQ tumors improves early detection and treatment outcomes, while the histological classification of IDC dictates mutation interactions influencing prognosis.\\n\\nSampling biases in genomic analysis can obscure the full spectrum of actionable mutations, underlining the importance of comprehensive tissue analysis. Critical gene alterations, as outlined, provide actionable insights that drive personalized treatment strategies aimed at improving patient survival. An integrative approach, acknowledging these multifaceted variables, is essential for optimizing clinical interventions and advancing survival outcomes in breast cancer patients.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893606, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=900, prompt_tokens=446, total_tokens=1346, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 33/704...\n",
      "ChatCompletion(id='chatcmpl-BAiOPwtRnP5nUfLfOZ31NEbSrR7Wl', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Overlapping Lesion of Breast\\n\\n1. **Survival Influence**: Overlapping lesions in breast cancer may indicate a complex tumor involving multiple quadrants, which can complicate surgical intervention and may increase the potential for local recurrence and metastatic spread, negatively impacting survival.\\n\\n2. **Biological Rationale**: Such lesions suggest that the cancer does not have a single point of origin, which might lead to a heterogeneous tumor microenvironment. This heterogeneity can foster varied metastatic pathways as different areas contribute distinct biological behaviors, complicating management strategies.\\n\\n3. **Treatment and Metastatic Patterns**: The presence of tumors in multiple regions makes complete surgical resection challenging, potentially leaving cancerous tissue behind, which contributes to lower survival rates.\\n\\n4. **Potential Biases**: Biopsies from overlapping lesions might underestimate the tumor's true heterogeneity, leading to suboptimal treatment planning. Moreover, radiographic assessments may miss micrometastases in less easily visible zones, affecting survival predictions.\\n\\n### Histology: Pleomorphic Carcinoma\\n\\n1. **Survival Influence**: Pleomorphic carcinoma is characterized by extreme cellular atypia and aggressive behavior, contributing to poor prognosis and reduced survival due to its rapid progress and resistance to conventional therapies.\\n\\n2. **Biological Rationale**: The marked heterogeneity in cell morphology is reflective of genetic instability and a high mutation burden, which promotes an aggressive phenotype. This can lead to rapid progression and poor response to treatments, thereby reducing survival times.\\n\\n3. **Mutation Interaction**: High mutation rates might engage in complex interactions where certain oncogenic pathways, like those involving p53 or HER2, drive the aggressive nature, limiting the effectiveness of standard treatments.\\n\\n4. **Potential Biases**: Histological evaluations may underrepresent heterogeneity if biopsy samples do not capture the full spectrum of cellular diversity, potentially leading to less effective treatment regimens recommended based on incomplete data.\\n\\n### Sampling Bias: Blood Derived Normal, Primary Tumor\\n\\n1. **Survival Influence**: Using blood-derived normal tissues as a control in genomic analyses can introduce biases, as these do not account for the tumor’s immediate influence on surrounding normal breast tissues, which might harbor field changes affecting prognosis.\\n\\n2. **Biological Rationale**: Blood samples reflect systemic rather than localized genomic changes, which can lead to misleading conclusions about the mutational landscape of the primary tumor. \\n\\n3. **Potential Biases**: Blood-derived norms may fail to identify certain somatic mutations or epigenetic changes that occur in the local breast tissue environment, leading to underestimation of tumor aggressiveness and misjudgement in survival prognosis.\\n\\n### Key Genes Associated with Survival\\n\\n1. **TP53**: Mutations in TP53 are common in breast cancer and typically indicate poor prognosis because they impair the cell's ability to undergo apoptosis, allowing for unchecked proliferation.\\n\\n2. **BRCA1/2**: Mutations in these genes are linked with hereditary breast cancer and can lead to poor survival outcomes due to higher risks of recurrence and aggressive disease forms. Their roles in DNA repair deficiency contribute to genomic instability.\\n\\n3. **PIK3CA**: Mutations here lead to activation of the PI3K/AKT pathway, promoting cell growth and survival independently of normal regulatory controls, correlating with reduced survival.\\n\\n4. **HER2**: Amplification or overexpression of HER2 is associated with aggressive cancer phenotypes and poorer outcomes, though targeted therapies have improved the prognosis.\\n\\n5. **CDH1**: Loss-of-function mutations affect cell adhesion (via E-cadherin), contributing to higher invasiveness and metastatic potential, generally resulting in worse patient survival.\\n\\n6. **HER3 (ERBB3)**: Overexpression promotes survival pathways and resistance to certain therapies, impacting overall treatment success and thereby influencing survival negatively.\\n\\n7. **PTEN**: Loss of PTEN function leads to unchecked PI3K/AKT signaling, promoting survival and growth of cancer cells, typically linked with poor prognosis.\\n\\n### Synthesis\\n\\nIn summary, survival in breast invasive carcinoma, especially with overlapping lesions, is detrimentally affected by biological complexity and treatment challenges arising from tumor heterogeneity, aggressive histological subtypes like pleomorphic carcinoma, and inherent genetic mutations. These factors contribute to poorer survival outcomes, driven by difficulties in achieving comprehensive local control and addressing systemic disease. By understanding and addressing genetic mutations such as those in TP53, BRCA1/2, and PI3KCA, treatment strategies can be better tailored to individual genetic profiles, offering potential pathways to improve survival through precision medicine approaches. Such insights offer critical guidance in optimizing therapeutic interventions for personalized cancer management, aiming to enhance patient survival outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893625, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=954, prompt_tokens=441, total_tokens=1395, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 34/704...\n",
      "ChatCompletion(id='chatcmpl-BAiOmX3ylr9YpvglyWF6OBi1TqqhH', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To understand the impact of \"Overlapping lesion of breast\" in breast invasive carcinoma on survival, we should examine four key areas: tumor origin, histology, sampling bias, and key genes.\\n\\n### Tumor Origin: Overlapping Lesions of the Breast\\n\\n1. **Influence on Survival:**\\n   - \"Overlapping lesions\" refer to tumors arising in multiple locations within the breast, often indicating extensive local spread, which can complicate disease management.\\n   - This presentation potentially leads to a higher risk of micrometastases, impacting survival negatively due to difficulty in achieving full surgical clearance and higher likelihood of distant metastasis over time.\\n\\n2. **Biological Rationale:**\\n   - The overlapping distribution implies a more heterogeneous tumor microenvironment, which might enhance metastatic efficiency through diverse cellular interactions and increased genetic variability.\\n   - Tumors in varied regions also suggest greater intratumoral heterogeneity, complicating targeted therapies and hence influencing survival outcomes unfavorably.\\n\\n3. **Impact on Treatment:**\\n   - The extensive nature can limit surgical options, increasing reliance on systemic therapies, which might not be as effective alone in totally eradicating the cancer cells.\\n   - There\\'s often increased difficulty in monitoring and assessing treatment responses in such complex presentations.\\n\\n### Histology: Infiltrating Duct Carcinoma, NOS\\n\\n1. **Influence on Survival:**\\n   - The term \"NOS\" (Not Otherwise Specified) in IDC indicates a lack of detailed differentiation features, suggesting a varied molecular background that can affect prognosis.\\n   - Histological grading helps gauge aggressive potential but remains limited if underlying gene expressions aren\\'t fully elucidated.\\n\\n2. **Biological Rationale:**\\n   - IDC is characterized by proliferation through ductal and lobular structures, with its behavior being highly reliant on underlying mutation profiles like BRCA1/2 or PIK3CA.\\n   - The variability in mutation spectra, like those affecting hormone receptor status, dictates responses to respective endocrine and cytotoxic therapies.\\n\\n3. **Genomic Interaction:**\\n   - NOS classification can mask specific aggressive genomic subtypes potentially unresponsive to standard hormone therapies, thereby worsening survival without appropriate profiling.\\n   \\n### Sampling Bias: Primary Tumor vs. Solid Tissue Normal\\n\\n1. **Influence on Survival:**\\n   - Sampling bias, particularly in genomic analyses, can arise when primary tumors are not representative of the metastatic clones, leading to possible misinterpretation of results.\\n   - Relying solely on primary tumor sampling may overlook crucial genomic evolutions that occurred during metastasis, skewing survival predictions.\\n\\n2. **Biological Rationale:**\\n   - Solid tissue \\'normal’ comparisons might miss early oncogenic alterations present even before histological changes manifest, not depicting an accurate baseline.\\n\\n3. **Bias Consequences:**\\n   - If primary tumors and metastatic sites differ significantly in genomic profiles, treatments tailored to primary-based mutation data might fail, affecting long-term survival.\\n   \\n### Key Genes: Survival-Associated\\n\\n1. **BRCA1/2:**\\n   - **Influence**: Homologous recombination repair deficiency increases sensitivity to PARP inhibitors, generally improving outcomes when applicable.\\n   - **Mechanism**: Both genes are crucial for DNA repair processes; their mutations lead to genomic instability driving aggressive cancer behaviors.\\n\\n2. **PIK3CA:**\\n   - **Influence**: Common mutation in breast cancer that may predict sensitivity to PI3K inhibitors, modifying survival outcomes.\\n   - **Mechanism**: It activates signaling pathways that promote cell growth and survival; targeted therapies can enhance prognosis if implemented accurately.\\n\\n3. **TP53:**\\n   - **Influence**: Mutations often correlate with poorer prognosis due to impaired apoptosis and enhanced tumorigenic potential.\\n   - **Mechanism**: TP53 acts as a tumor suppressor; dysfunction leads to unregulated cell cycle progression and survival.\\n\\n4. **ERBB2 (HER2):**\\n   - **Influence**: Overexpression signifies a highly aggressive subtype, but it is responsive to HER2-targeted therapies, improving survival.\\n   - **Mechanism**: HER2 promotes proliferation and inhibits apoptosis, crucial for cellular growth signaling.\\n\\n5. **CDH1:**\\n   - **Influence**: Loss influences cell adhesion, increasing metastatic risk, particularly in lobular carcinoma types.\\n   - **Mechanism**: CDH1 is key for epithelial cell adhesion; its loss facilitates invasion and metastasis.\\n\\n6. **PTEN:**\\n   - **Influence**: Mutation or loss correlates with poorer outcomes due to unchecked PI3K/AKT pathway activation.\\n   - **Mechanism**: PTEN acts as a tumor suppressor, regulating cell cycle progression and apoptosis.\\n\\n### Conclusion: Synthesis of Key Survival Risk Factors\\n\\n- **Summary**: The interplay between tumor origin (overlapping lesions), comprehensive histological profiling, and detailed genomic analysis is critical for tailoring treatment strategies. Understanding intratumoral heterogeneity and accurately profiling the genomic landscape beyond primary tumors ensures adequate therapeutic responses, ultimately impacting survival positively.\\n  \\n- **Clinically Relevant Insights**: Efforts to personalize breast cancer treatment should focus on integrating comprehensive genomic profiling into clinical practice, especially for complex cases like overlapping lesions. Addressing sampling bias and ensuring robust histological characterization can guide more effective intervention strategies.\\n\\nIn supporting broader oncologic strategies, all these factors emphasize devising integrative models that harmonize phenotypic and genotypic data to improve the precision of survival predictions in breast cancer patients.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893648, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1119, prompt_tokens=446, total_tokens=1565, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 35/704...\n",
      "ChatCompletion(id='chatcmpl-BAiP8etOtGAFJuwkRyDixXBsxdhwD', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\n\\n1. **Metastatic Patterns**: Breast NOS indicates a primary breast origin, excluding cutaneous (skin) involvement. It generally disperses via lymphatics and bloodstream, primarily targeting bones, lungs, liver, and brain. Metastasis profoundly impacts survival negatively due to organ dysfunction and treatment complexity.\\n\\n2. **Patient Survival and Treatment Accessibility**: Earlier detection with localized disease correlates with better survival outcomes (stage I-II). However, disparities in healthcare can hinder timely diagnosis and access to treatments, negatively influencing survival, particularly in underserved populations.\\n\\n**Biological Rationale:**\\n\\n- The absence of skin involvement suggests a more profound tumor origin impacting deeper tissue layers, primarily through enriched lymphovasculature in these regions facilitating rapid systemic dissemination.\\n  \\n**Potential Biases**:\\n\\n- Diagnostic ambiguities in defining tumor origin could lead to misclassification, impacting survival statistics and treatment decisions.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n\\n1. **Carcinoma, NOS**: This broad classification often lacks specific histological characterization, leading to variable survival predictions. Histopathological details like grade and subtypes (e.g., ductal vs. lobular) significantly influence prognosis and treatment response.\\n\\n**Biological Rationale:**\\n\\n- Histology influences cell architecture, proliferation rates, and cellular invasiveness. Without detailed profiling, predicting tumor behavior and therapeutic responses remains challenging.\\n\\n**Potential Biases**:\\n\\n- Non-specific classification (NOS) might overlook distinct features pertinent to targeted therapies or prognostic assessment.\\n\\n### Sampling Bias\\n\\n**Influence on Survival:**\\n\\n1. **Blood-Derived Normal vs. Primary Tumor Samples**: Blood samples may miss tumor-specific mutations, limiting detection of actionable genetic alterations crucial for targeted therapy and survival prediction.\\n\\n**Biological Rationale:**\\n\\n- Blood-derived cells often lack tumor microenvironment interactions captured in primary tumor samples, leading to incomplete analysis of tumor-host interactions and potentially skewed data.\\n\\n**Potential Biases**:\\n\\n- Genomic data skewed by the heterogeneity of sampling sites may result in misidentification of driver mutations or misinterpretation of their prevalence in patient populations.\\n\\n### Key Genes\\n\\n1. **TP53**: Mutations lead to impaired DNA repair and apoptosis, elevating cancer progression risks.\\n   \\n2. **BRCA1/2**: Germline mutations compromise genomic integrity, increasing susceptibility and altering survival outcomes depending on mutation status.\\n   \\n3. **HER2 (ERBB2)**: Overexpression amplifies proliferative signals; targeted therapies can vastly improve survival.\\n   \\n4. **PIK3CA**: Affects cell growth and survival pathways; mutations are targetable, impacting treatment choice.\\n   \\n5. **PTEN**: Tumor suppressor with roles in cell cycle regulation; its loss correlates with aggressive behavior and poor survival.\\n   \\n6. **CDH1**: E-cadherin loss enhances invasiveness; impacts prognosis particularly in lobular breast cancer.\\n   \\n7. **ESR1**: Estrogen receptor gene; mutation status affects response to hormone therapy, influencing disease trajectory.\\n  \\n**Biological Rationale:**\\n\\n- These genes modulate processes such as proliferation, apoptosis, cell signaling, or adhesion. Dysregulation can lead to unchecked growth, therapeutic resistance, and metastasis, thus distinctly affecting survival.\\n\\n### Conclusion\\n\\nKey risk factors impacting breast carcinoma survival include metastatic potential, histopathological nuances, genetic profile, and treatment accessibility. Clinically, comprehensive profiling integrating tumor origin, histology, and specific mutations is essential to tailor treatments. Recognizing sampling biases and ensuring robust genetic analysis can enhance precision oncology approaches, with significant survival benefits. Mechanistic insights into crucial genes aid in developing new therapies and enhancing existing protocols, directly influencing patient outcomes favorably.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893670, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=771, prompt_tokens=458, total_tokens=1229, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 36/704...\n",
      "ChatCompletion(id='chatcmpl-BAiPMNVrJKohnj2SCKhHampfD8jE4', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin:\\nBreast invasive carcinoma, particularly Breast NOS (excluding skin of breast), typically originates from breast epithelial tissues. Understanding its origin is crucial for assessing metastatic patterns, treatment accessibility, and patient survival.\\n\\n1. **Metastatic Patterns**: Invasive breast carcinoma commonly metastasizes to regional lymph nodes, lungs, bones, liver, and brain. The specific pathways are influenced by the origin of tumor cells and their interaction with surrounding microenvironments.\\n   \\n   - **Survival Influence**: Metastases in vital organs like the liver or brain often result in poorer survival outcomes due to the difficulty of treating such distant sites and the consequential increase in systemic disease burden. \\n\\n   - **Biological Rationale**: Tumor origin affects cellular traits like adhesion and motility, dictating metastatic routes and influencing survival negatively as metastatic competence evolves.\\n\\n2. **Treatment Accessibility**: The tumor's location and extent of spread determine the feasibility of surgical options and the application of local therapies such as radiotherapy.\\n   \\n   - **Survival Influence**: Limited intervention options due to advanced spread often correlate with reduced survival rates.\\n\\n### Histology:\\n\\nLarge cell neuroendocrine carcinoma (LCNEC) of the breast is rare. Histological features and mutation profiles heavily influence patient outcomes.\\n\\n1. **Histological Impact**: LCNEC is aggressive with high mitotic rates and poor differentiation.\\n\\n   - **Survival Influence**: Due to its aggressive nature, LCNEC typically leads to unfavorable prognoses with short survival times.\\n\\n   - **Mutation Profiles**: Frequent mutations in genes like TP53 and RB1 relate to cell cycle dysregulation and increased tumor aggressiveness.\\n   \\n2. **Biological Rationale**: Poorly differentiated tumors exhibit rapid proliferation, overwhelming the body's ability to contain cancerous growth, thereby negatively affecting survival.\\n\\n### Sampling Bias:\\n\\nSampling methods significantly affect genomic analyses and subsequent survival predictions.\\n\\n1. **Blood Derived Normal vs. Primary Tumor**:\\n\\n   - **Survival Influence**: Primary tumor samples provide direct genetic profiles of cancer cells, crucial for understanding tumor behavior and survival implications but are harder to obtain safely, limiting comprehensive analysis.\\n   \\n   - **Biological Rationale**: Blood-derived normal samples can confound results as they don't directly reflect tumor-specific genetic alterations, impacting accuracy in associating genetic mutations with survival outcomes.\\n\\n2. **Limitations**: Biases may misrepresent tumor heterogeneity, leading to incomplete survival risk assessments.\\n\\n### Key Genes:\\n\\nSeveral genes are integral to breast cancer survival, influencing diverse biological pathways.\\n\\n1. **TP53**: Mutation leads to loss of apoptotic control, enhancing cell survival and resistance to therapy, thereby worsening prognosis.\\n\\n2. **BRCA1/2**: Involvement in DNA repair processes; mutations increase susceptibility to cancers but offer targeted therapy options, affecting survival positively through personalized treatments.\\n\\n3. **PIK3CA**: Affects cell growth and proliferation; mutations often lead to aggressive tumor behavior, negatively impacting survival unless targeted with specific inhibitors.\\n\\n4. **ERBB2 (HER2)**: Overexpression/amplification associates with aggressive disease; however, targeted therapies like trastuzumab improve survival significantly.\\n\\n5. **ESR1**: Encodes Estrogen Receptor. Hormone receptor status guides endocrine therapies, impacting survival by tailoring treatment to tumor biology.\\n\\n6. **CDH1**: Loss of E-cadherin function contributes to invasive abilities, driving metastasis and negatively impacting prognosis.\\n\\n7. **AKT1**: Mutations activate cell survival pathways, promoting oncogenic states and therapy resistance, generally leading to poorer outcomes.\\n\\n### Synthesis:\\n\\nIntegrating all factors, breast invasive carcinoma outcomes are guided by tumor origin's influence on metastasis, histological aggressiveness, genetic mutations, and sample reliability. Key insights:\\n\\n- **Metastatic Competency**: Tumor origin and histology direct metastatic potential, critical for survival predictions.\\n- **Genomic Precision**: Precise mutation identification guides therapeutic choices, with biases in sampling potentially skewing survival estimations.\\n  \\nUnderstanding these factors reinforces the necessity of tailored therapeutic strategies and emphasizes the impact of accurate genomic profiling on improving patient survival. Personalized interventions, especially those targeting specific genetic alterations, represent a pivotal advance in increasing breast cancer survival rates.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893684, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=875, prompt_tokens=460, total_tokens=1335, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 37/704...\n",
      "ChatCompletion(id='chatcmpl-BAiPj7i7qSgxplqsEBZ4iRftar7Ti', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='## Tumor Origin\\n\\nBreast invasive carcinoma, classified under Breast NOS (excluding the skin of the breast C44.5), primarily originates within the ductal or lobular tissues of the breast. This classification directly influences metastatic patterns, treatment strategies, and survival outcomes:\\n\\n1. **Metastatic Patterns**: Breast NOS cases tend to metastasize primarily to bones, lungs, liver, and brain. The nature of these metastatic patterns significantly alters disease prognosis. Metastasis to bones might suggest a more indolent course, while brain metastases typically indicate more aggressive disease and lower survival rates.\\n\\n2. **Patient Survival**: The site of origin within breast tissues, whether ductal or lobular, impacts the biology of the disease. Ductal carcinomas often have a more aggressive course, particularly when associated with high-grade tumor characteristics.\\n\\n3. **Treatment Accessibility**: Breast NOS can impact access to personalized therapies that target specific biomolecular features, like hormone receptor status or HER2 expression, which are crucial in optimizing treatment regimens and improving survival.\\n\\n## Histology\\n\\nAdenoid cystic carcinoma of the breast, although rare, represents a unique histological subtype with distinct clinical behavior:\\n\\n1. **Mutation Profiles**: This subtype typically exhibits genomic stability relative to other more common invasive ductal carcinomas. Mutations such as MYB-NFIB fusion are characteristic and not commonly associated with traditional breast cancer pathways like estrogen receptor mutations.\\n\\n2. **Survival Outcomes**: These tumors generally demonstrate indolent growth and a favorable prognosis, though they may be difficult to target with standard breast cancer therapies due to differences in their genetic landscape.\\n\\n## Sampling Bias\\n\\nThe use of Blood Derived Normal and Primary Tumor samples presents several limitations in genomic analyses:\\n\\n1. **Blood Derived Normal**: May not reflect the comprehensive genetic heterogeneity present within tumor tissues, potentially leading to underrepresentation of key somatic mutations.\\n\\n2. **Primary Tumor**: Focusing only on primary tumors can miss sub-clonal populations present in metastatic sites, skewing genomic interpretation and survival analysis by neglecting evolutionary tumor dynamics.\\n\\n## Key Genes\\n\\nIdentifying genes associated with breast cancer survival is critical for understanding prognosis and targeting therapeutic interventions:\\n\\n1. **TP53**: Mutations in this tumor suppressor gene are associated with aggressive tumor behavior and poor survival outcomes. TP53 plays a role in DNA repair, apoptosis regulation, and overall genomic stability.\\n\\n2. **BRCA1/BRCA2**: Germline mutations confer higher lifetime risk for breast cancer and significantly affect survival, particularly due to associations with early onset and increased bilateral incidence. Their functions in homologous recombination repair are crucial for maintaining genomic integrity.\\n\\n3. **PIK3CA**: Common in breast cancers, mutations lead to aberrant activation of the PI3K/AKT pathway, promoting tumor growth and resistance to apoptosis, impacting overall survival negatively.\\n\\n4. **ERBB2 (HER2)**: Overexpression leads to aggressive tumor characteristics. However, it is a target for effective therapies like Trastuzumab, which improve survival outcomes.\\n\\n5. **ESR1**: Alterations in estrogen receptor genes can alter response to hormone therapies, affecting survival outcomes positively when properly targeted.\\n\\n6. **CDH1**: Relevant in lobular carcinoma, mutations here can influence cell adhesion, promoting metastasis and altering clinical outcomes.\\n\\n7. **PTEN**: A tumor suppressor inversely related to PI3K/AKT pathway activation, with mutations leading to unchecked cellular proliferation.\\n\\n## Conclusion\\n\\nBreast invasive carcinoma survival is intricately linked to tumor origin, histological subtype, and key genetic alterations. Metastatic potential, differences in treatment accessibility and responsiveness, and personalized therapeutic strategies play a central role in determining outcomes. By recognizing biases in genomic sampling and exploiting actionable mutations, clinicians can better stratify risks, thereby enhancing personalized treatment strategies, ultimately improving patient survival. Crucially, combining genetic insights with clinical features remains the cornerstone of addressing survival disparities in breast cancer patients.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893707, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=817, prompt_tokens=458, total_tokens=1275, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 38/704...\n",
      "ChatCompletion(id='chatcmpl-BAiQ731BkBetN2qnriMYi1odDMXH2', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin:\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Tumors originating in the breast (Breast NOS) have a propensity to metastasize to axillary lymph nodes, bones, liver, and lungs, each with unique implications for survival. More advanced stages correlate with poorer outcomes.\\n- **Patient Survival:** The survival rate is heavily dependent on early detection and treatment. Localized tumors have significantly higher survival rates compared to those with distal spread.\\n- **Treatment Accessibility:** There is variability in treatment accessibility based on socioeconomic factors, impacting survival. Advanced therapies may not be equally available globally, influencing overall survival rates.\\n\\n**Biological Rationale:**\\n- **Local Invasion and Growth:** The breast tissue provides a rich environment for local invasion, particularly affecting lymphatic spread. Anatomical proximity facilitates metastatic spread, critically impacting prognostic outcomes.\\n\\n**Bias in Interpretation:**\\n- **Clinical Diagnosis Bias:** The classification of breast cancer can sometimes overlook underrepresented subtypes, skewing survival data interpretation.\\n\\n### Histology:\\n**Influence on Survival:**\\n- **Tubular Adenocarcinoma Profile:** This subtype generally presents a better prognosis due to lower grades and slower progression. It involves well-differentiated cells, suggesting less aggressive behavior.\\n\\n**Biological Rationale:**\\n- **Cell Differentiation:** Better-differentiated tumor cells (as seen in tubular patterns) are less likely to proliferate rapidly, thereby prolonging survival.\\n\\n**Bias in Interpretation:**\\n- **Over-representation of Common Histologies:** Rare subtypes might be underrepresented in clinical trials, affecting the perceived efficacy of treatments.\\n\\n### Sampling Bias:\\n**Influence on Survival:**\\n- **Sample Source Impact:** Using blood-derived normal samples can miss certain somatic mutations present in the tumor but not in peripheral blood, potentially misrepresenting actionable mutations.\\n\\n**Biological Rationale:**\\n- **Genomic Heterogeneity:** Tumors can exhibit significant intratumor heterogeneity, impacting treatment response prediction and survival estimations.\\n\\n**Bias in Interpretation:**\\n- **Sampling Bias:** Biased sampling might underrate the presence of mutation-driven heterogeneity, leading to over/underestimation of survival-associated mutations.\\n\\n### Key Genes:\\n**Influence on Survival:**\\n- **Common Survival-Associated Genes in Breast Cancer:**\\n  1. **BRCA1/BRCA2:** Mutations impair DNA repair, increasing cancer risk but provide treatment targets like PARP inhibitors.\\n  2. **TP53:** Tumor suppressor gene loss often entails poor prognosis due to unchecked cell proliferation.\\n  3. **HER2:** Overexpression drives aggressive cancer phenotype but offers targeted therapy options (e.g., trastuzumab).\\n  4. **ESR1:** Related to estrogen receptor expression, influencing responsiveness to hormone therapies.\\n  5. **PIK3CA:** Mutations activate the PI3K pathway, a target for PI3K inhibitors, impacting treatment response.\\n  6. **CDH1:** Loss of function relates to cellular adhesion alteration, facilitating metastasis.\\n  7. **GATA3:** Influences gene expression relevant to luminal subtype, positively impacting survival.\\n\\n**Biological Rationale:**\\n- **Proliferation and Survival Pathways:** These genes regulate key pathways such as cell cycle, apoptosis, and DNA repair mechanisms that directly impact tumor progression and patient survival.\\n\\n**Bias in Interpretation:**\\n- **Genomic Variability:** Somatic mutations exhibit variability in expression and impact across different individuals, complicating survival estimations.\\n\\n### Conclusion:\\n**Synthesis and Clinical Insights:**\\n- **Key Survival Factors:** Early detection, tumor subtype, molecular targets, and individual genetic variability are pivotal in dictating survival outcomes.\\n- **Clinical Relevance:** Integrating genomic insights with histological and clinical data aids in tailoring personalized therapies, which can significantly optimize survival. Accessibility to cutting-edge treatments and thorough genomic profiling further influence patient prognosis and treatment efficacy. The consistency in leveraging personalized medicine frameworks remains crucial in improving overall survival outcomes for patients diagnosed with breast invasive carcinomas.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893731, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=832, prompt_tokens=459, total_tokens=1291, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 39/704...\n",
      "ChatCompletion(id='chatcmpl-BAiQNckUS34Fv2vlYjBVuRw0EI75o', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**1. Influence on Survival:**\\n   - **Metastatic Patterns:** Breast invasive carcinoma, not involving the skin (ICD-10: Breast NOS excluding C44.5), primarily begins in the breast ducts or lobules and has the potential to metastasize to lymph nodes, bones, liver, lungs, and brain.\\n   - **Patient Survival:** Metastatic locations influence survival; brain metastases are often associated with poorer prognoses compared to other sites.\\n   - **Treatment Accessibility:** The availability and choice of treatments are influenced by the type and extent of metastasis. Hormone receptor-positive or HER2-positive tumors may benefit from targeted therapies, influencing survival positively.\\n\\n**2. Biological Rationale:**\\n   - **Spread Mechanisms:** The tendency of certain breast tissues to allow cancer cells to enter systemic circulation influences metastatic likelihood and subsequent survival impacts.\\n\\n**3. Interpretation Biases:**\\n   - Metastatic capability may not be fully captured in initial diagnostic samples, leading to variability in survival predictions based on incomplete initial assessments.\\n\\n### Histology\\n\\n**1. Influence on Survival:**\\n   - **Apocrine Adenocarcinoma Interaction:** This rare subtype often shows androgen receptor expression and unique mutation profiles that impact response to endocrine therapies.\\n   - **Mutation Profiles:** Common mutations include AR, TP53, and others that affect hormone signaling pathways, potentially providing different treatment options and prognostic value.\\n\\n**2. Biological Rationale:**\\n   - **Hormone Pathway Alteration:** Variations in receptor status and specific mutations directly influence tumor growth rates, treatment responses, and consequently survival outcomes.\\n\\n**3. Interpretation Biases:**\\n   - Under-representation of rare histological subtypes in studies may lead to a lack of tailored treatment guidelines, affecting survival interpretation.\\n\\n### Sampling Bias\\n\\n**1. Limitations of Blood-Derived Normal vs. Primary Tumor Genomic Analysis:**\\n   - **Survival Influence:** Variability in detecting all genetic alterations may skew survival predictions.\\n   - **Biological Rationale:** Blood samples may not reflect tumor heterogeneity, missing mutations present in tumor tissue, influencing perceived treatment efficacy.\\n\\n**2. Interpretation Biases:**\\n   - **Normal Tissue Comparison:** Using blood-derived normal samples for comparison assumes uniformity in non-cancerous tissue, potentially misestimating mutation significance.\\n\\n### Key Genes and Mechanisms\\n\\n**1. TP53:**\\n   - **Mechanism:** Tumor suppressor, regulates apoptosis. Mutations can lead to unchecked cell growth.\\n   - **Survival Impact:** Often associated with poor outcomes due to aggressive tumor profiles.\\n\\n**2. BRCA1/BRCA2:**\\n   - **Mechanism:** DNA repair pathways. Mutations increase genomic instability.\\n   - **Survival Impact:** Linked to hereditary breast cancers; impacts choices in prophylactic and therapeutic strategies.\\n\\n**3. PIK3CA:**\\n   - **Mechanism:** Part of the PI3K/AKT pathway, influences cell proliferation and survival.\\n   - **Survival Impact:** Mutations may confer resistance to certain treatments, necessitating specific targeted therapies.\\n\\n**4. HER2:**\\n   - **Mechanism:** Growth factor receptor, involved in cell signaling pathways.\\n   - **Survival Impact:** Overexpression is associated with more aggressive tumors, but also a target for effective therapies like trastuzumab.\\n\\n**5. ESR1:**\\n   - **Mechanism:** Estrogen receptor gene, crucial in hormone signaling.\\n   - **Survival Impact:** Mutations may alter efficacy of endocrine therapies, impacting long-term survival.\\n\\n**6. CDH1:**\\n   - **Mechanism:** Codes for E-cadherin, maintains cell-cell adhesion.\\n   - **Survival Impact:** Loss of function facilitates metastasis and is correlated with poor outcomes.\\n\\n### Conclusion\\n\\nSurvival in breast invasive carcinoma is intricately linked to tumor origin, histological subtype, and the key mutations present. Understanding the heterogeneity within tumors and the biological ramifications of key mutations allows for more personalized and effective treatment strategies. Sampling biases can impede accurate survival predictions, necessitating comprehensive and multifaceted diagnostic approaches. Clinically significant insights, such as targeting specific mutations (HER2, ESR1), leveraging histological details, and acknowledging sample limitations, are imperative for enhancing survival outcomes in breast cancer patients.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893747, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=884, prompt_tokens=460, total_tokens=1344, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 40/704...\n",
      "ChatCompletion(id='chatcmpl-BAiQgeWQSJwu9RWC2rPNzJKT864Be', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Sure, let's break down the impact on survival of Breast invasive carcinoma from the specified perspectives.\\n\\n### Tumor Origin\\n\\n**Influence on Survival:**\\n- Breast NOS (not otherwise specified, excludes skin of breast) refers to primary breast cancer but excludes cutaneous (skin-related) origins. Its origin influences potential pelvic or peritoneal metastasis.\\n- **Metastatic Patterns:** Tumors originating from breast tissues, such as the ductal or lobular epithelium, have typical metastatic patterns, commonly involving bones, liver, lungs, and brain. The unique metastatic profile affects survival negatively, as treatment strategies and prognostication are often contingent on knowing which organ systems may become involved.\\n\\n**Biological Rationale:**\\n- **Ductal Origin:** Carcinomas originating in the breast ducts often metastasize early, complicating treatment due to already established systemic disease. \\n- **Lobular Origin:** Lobular carcinomas are known for diffused metastatic patterns and often require more aggressive systemic therapy.\\n\\n**Treatment Accessibility:**\\n- Depending on origin, hormonal receptor status and HER2 (a genetic marker) dictate treatment, i.e., ER/PR positive allows for endocrine therapy, HER2 positive for targeted therapy, impacting survival positively.\\n\\n**Potential Biases:**\\n- Generalization in 'NOS' categories may overshadow subtype nuances critical for personalized treatment regimens.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n- **Mucinous Adenocarcinoma:** This subtype often correlates with a better prognosis compared to other forms such as invasive ductal carcinoma.\\n\\n**Biological Rationale:**\\n- These tumors are generally low-grade due to their less aggressive nature and interaction with genetic mutations like lower HER2 overexpression.\\n- The mucinous nature usually indicates a distinct growth pattern and reduced invasiveness.\\n\\n**Potential Biases:**\\n- Histological sampling might overlook tumor heterogeneity leading to underestimating aggressiveness.\\n\\n### Sampling Bias\\n\\n- **Blood Derived Normal (BDN):** While useful for comparative mutational analysis, BDN might not account for somatic mosaicism or mutations not reflected in normal blood cells, potentially missing private mutations crucial for personalized medicine.\\n- **Primary Tumor Samples:** May not capture metastasized or heterogeneous tumor regions, underrepresenting the full genomic landscape and potentially impacting survival predictions.\\n\\n### Key Genes\\n\\n1. **BRCA1/BRCA2 (DNA Repair):** Mutations here can lead to defective DNA repair mechanisms, increasing genetic instability and impacting survival negatively. Tumors with such mutations may respond to PARP inhibitors.\\n2. **PIK3CA (Cell Signaling):** Common in ER-positive cancers; impacts proliferation. Mutations may confer resistance to some hormonal therapies but make tumors more amenable to PI3K inhibitors.\\n3. **TP53 (Apoptosis and DNA repair):** Loss-of-function mutations can inhibit apoptosis, promoting survival of malignant cells and negatively affecting outcomes.\\n4. **ERBB2/HER2 (Cell Growth):** HER2 amplification correlates with accelerated growth, metastasis, and poor prognosis; however, targeted therapies like trastuzumab significantly improve survival.\\n5. **TPD52 (Cell Proliferation):** Overexpression relates to increased proliferation and poor survival; a potential target for therapies in active research.\\n6. **CDH1 (Cell Adhesion):** Loss in lobular carcinomas affects cell adhesion and promotes metastatic spread, yet provides distinctive lines for AI-based image diagnosis.\\n7. **RB1 (Cell Cycle Regulation):** Alterations lead to unchecked cell cycle progression, increasing tumor aggressiveness.\\n\\n### Conclusion\\n\\nTo consolidate, the survival impact of breast invasive carcinoma (NOS, excluding skin) is a multifaceted interplay between tumor origin and its metastatic potential, histological subtypes with unique mutation profiles, and the inherent biases in genomic sampling. Clinically, understanding these dynamics aids in optimizing targeted treatments, enhancing survival, and tailoring follow-up care. Innovations in genomic profiling and personalized therapy are essential in mitigating current biases, thus leading to improved surveillance and patient-specific interventions.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893766, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=827, prompt_tokens=460, total_tokens=1287, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 41/704...\n",
      "ChatCompletion(id='chatcmpl-BAiQtJPMDDMEpCoS4NMu5qk41ZBC3', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin**\\n\\n**Influence on Survival:**  \\nBreast invasive carcinoma, particularly Breast NOS which excludes skin of the breast (ICD-10: C50 excluding C44.5), typically arises from the epithelial cells of breast glands, leading to distinct metastatic behavior. This origin is crucial in determining metastatic spread primarily to the axillary lymph nodes, lungs, liver, bones, and brain, influencing patient prognosis and survival negatively due to potential organ dysfunction and complications in these sites.\\n\\n**Biological Rationale:**  \\nBreast NOS tumors generally exhibit a pattern of metastasis reflecting the natural expansion of malignant breast epithelial cells that are capable of epithelial-mesenchymal transition (EMT). This transition enhances their motility and invasive capacities, allowing them to traverse tissue planes and enter lymphatic and vascular systems.\\n\\n**Potential Biases:**  \\nTumor origin can shape treatment plans and access. For instance, tumors with distinct primary sites can be more operable if they haven't invaded local skin or tissues. Cases excluding skin invasion may present differently, potentially impacting survival analysis and interpretations in genomic studies.\\n\\n---\\n\\n**Histology**\\n\\n**Influence on Survival:**  \\nInfiltrating duct carcinoma, NOS, which is the most common histological subtype, directly impacts survival through its relatively aggressive biological behavior and heterogeneous mutation profiles, leading to varied responses to therapy.\\n\\n**Biological Rationale:**  \\nThis carcinoma subtype often exhibits mutations in genes such as TP53 and PI3K pathways, driving unchecked cell proliferation and survival. The diverse histological patterns lead to a variable prognosis, depending heavily on genetic alterations' roles in driving tumor aggressiveness and resistance to treatments.\\n\\n**Potential Biases:**  \\nHistological analyses can be skewed due to sampling differences. Variability in tumor grading (e.g., poorly differentiated cells) might not be uniformly captured in genomic analyses, causing genetic aberrations specific to certain histological types to be underrepresented.\\n\\n---\\n\\n**Sampling Bias**\\n\\n**Influence on Survival:**  \\nUtilizing Blood Derived Normal or Metastatic samples introduces specific biases. These samples might not comprehensively reflect primary tumor mutation status or microenvironment influences, skewing survival prognostications.\\n\\n**Biological Rationale:**  \\nBlood-derived samples primarily reflect circulating tumor DNA or cells, which could misrepresent the integral tumor mutational landscape. Similarly, metastatic target site differences might not capture primary tumor characteristics fully, leading to potential over- or underestimation of survival-linked mutations.\\n\\n**Potential Biases:**  \\nSampling limitations inherently confine the mutational spectrum observed, often focusing on metastatic processes rather than initial tumor-genesis mechanisms. This may bias studies towards mutations associated with metastatic fitness rather than resistance to initial treatment modalities.\\n\\n---\\n\\n**Key Genes**\\n\\n1. **BRCA1/2**: Integral in DNA repair, their malfunction via mutations leads to genomic instability, increasing tumor aggressiveness and reducing survival.\\n   \\n2. **TP53**: A key tumor suppressor gene, mutations here lead to uncontrolled proliferation and impaired apoptosis, adversely affecting survival.\\n\\n3. **PIK3CA**: Often mutated in breast cancer, activating this pathway supports survival and growth through enhanced cellular proliferation and metabolism.\\n\\n4. **HER2**: Overexpression leads to aggressive cell growth; while HER2 targeting therapies exist, not all patients respond uniformly, influencing survival variably.\\n\\n5. **ESR1 (Estrogen Receptor 1)**: Mutations can drive estrogen-independent growth, complicating hormone therapy efficacy, and adversely impacting outcomes.\\n\\n6. **AKT1**: Part of the PI3K/AKT/mTOR pathway, mutations here enhance tumor survival and resistance to apoptosis.\\n\\n7. **CDH1**: Loss-of-function mutations compromise cell adhesion, increasing metastatic potential and decreasing survival prospects.\\n\\n8. **PTEN**: Tumor suppressor gene whose loss enhances PI3K/AKT pathway activation, promoting survival and therapy resistance.\\n\\n**Biological Mechanisms:**  \\nThese genes collectively regulate key processes, including DNA repair (BRCA1/2), cell cycle control (TP53), signal transduction (PIK3CA, AKT1), and hormone sensitivity (ESR1), directly linking their mutational status to survival outcomes.\\n\\n---\\n\\n**Conclusion: Key Survival Risk Factors**  \\n\\nBreast invasive carcinoma survival is intricately tied to tumor origin and histological presentation, both of which dictate metastatic patterns and treatment efficacy. Genomic insights, tempered by potential sampling biases, highlight the significance of mutations in key genes influencing DNA repair, proliferative signaling, and apoptotic pathways. Clinically, understanding these dynamics allows for a more nuanced approach to prognosis and personalized treatment strategies, with the explicit goal of improving survival outcomes through targeted therapies and comprehensive genomic profiling strategies.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893779, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=953, prompt_tokens=461, total_tokens=1414, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 42/704...\n",
      "ChatCompletion(id='chatcmpl-BAiR4JzRaCoGIvBoMbSHkMr3K2aW6', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival**: Breast invasive carcinoma, particularly Breast NOS (Not Otherwise Specified), influences survival predominantly through its metastatic patterns and the accessibility of treatments. Unlike skin cancers, which might spread distinctly, Breast NOS often follows a more predictable path of dissemination, typically affecting regional lymph nodes and further spreading to bone, liver, and lungs, impacting survival negatively if not caught early.\\n\\n**Biological Rationale**: The primary origin site, the breast tissue itself, is highly glandular, providing a fertile ground for cancer cell proliferation and subsequent mutation accumulation. These characteristics enable certain tumors to develop aggressive tendencies.\\n\\n**Access and Treatment Bias**: Treatment accessibility can be a challenge, as variations in molecular subtypes require specific therapies, such as endocrine therapy or HER2-targeted treatments. The availability of such targeted therapies can significantly alter survival outcomes.\\n\\n### Histology\\n\\n**Influence on Survival**: Infiltrating duct carcinoma, NOS, being the most common breast cancer type, comprises a broad spectrum of genetic profiles and histological grades that influence prognosis. Higher grades are associated with poorer survival due to increased cellular atypia and rapid proliferation rates.\\n\\n**Biological Rationale**: The heterogeneity of the infiltrating duct carcinoma reflects different mutation landscapes, often including mutations in TP53, PIK3CA, and HER2 amplification, leading to aggressive tumor behaviors and treatment resistance.\\n\\n**Mutation Profile Interaction**: Comprehensive profiling of these tumors often reveals a multitude of driver mutations and pathways involved, which can be challenging to target collectively, impacting patient outcomes negatively.\\n\\n### Sampling Bias\\n\\n**Influence on Survival Analysis**: The reliance on Blood Derived Normal and Primary Tumor samples in genomic analyses can introduce biases. Blood samples may not capture the tumor's full heterogeneity or microenvironment influences, leading to an incomplete understanding of potential metastases or recurrences.\\n\\n**Biological Rationale**: Primary tumors often fail to reflect the full scope of cancer evolution, as metastases may harbor additional mutations or epigenetic changes not present in the primary site, skewing treatment decisions and survival predictions.\\n\\n**Genomic Interpretation Bias**: The limited sampling scope can lead to underestimation of actionable mutations present in secondary sites, resulting in suboptimal treatment stratifications.\\n\\n### Key Genes\\n\\n1. **TP53**:\\n   - **Influence**: Mutations in TP53 are associated with worse survival due to apoptosis bypass and increased genomic instability.\\n   - **Mechanism**: Regulates cell cycle and apoptosis; loss of function leads to unchecked cellular proliferation.\\n\\n2. **PIK3CA**:\\n   - **Influence**: Mutations indicate potential responsiveness to PI3K inhibitors; mixed impact on survival depending on therapeutic access.\\n   - **Mechanism**: Part of the PI3K/AKT/mTOR pathway promoting growth and survival.\\n\\n3. **HER2 (ERBB2)**:\\n   - **Influence**: Amplification leads to aggressive cancer but is targetable by monoclonal antibodies improving outcomes.\\n   - **Mechanism**: Involved in cell growth and differentiation signaling.\\n\\n4. **BRCA1/2**:\\n   - **Influence**: Presents risk for hereditary breast cancer; impacts treatment strategy with PARP inhibitors improving survival for mutation carriers.\\n   - **Mechanism**: Role in DNA repair processes.\\n\\n5. **ESR1**:\\n   - **Influence**: Estrogen receptor positivity suggests potential for endocrine therapies; predictive of responsiveness and hence survival.\\n   - **Mechanism**: Drives tumor growth in estrogen-responsive cancers.\\n\\n6. **CDH1 (E-cadherin)**:\\n   - **Influence**: Mutations associated with lobular breast cancer; loss may increase metastatic potential.\\n   - **Mechanism**: Cell adhesion protein; loss aids in tissue invasion.\\n\\n7. **PTEN**:\\n   - **Influence**: Loss of function mutations lead to PI3K pathway activation, with mixed survival impacts depending on therapeutic intervention.\\n   - **Mechanism**: Negative regulator of the PI3K pathway, affecting cell cycle and apoptosis.\\n\\n8. **Ki-67**:\\n   - **Influence**: High levels correlate with poor prognosis due to indicates high proliferation.\\n   - **Mechanism**: A proliferation marker reflecting growth rate.\\n\\n### Conclusion\\n\\nIn synthesizing these factors, survival in breast invasive carcinoma (Breast NOS) critically depends on the interplay between tumor origin and histology, the presence of key genetic alterations, and the method of sample analysis. Clinically, understanding the tumor's specific genetic landscape and its heterogeneity is crucial for personalized treatment strategies, directly impacting patient survival. Effective treatment approaches can mitigate the negative survival impact of certain aggressive genomic features, emphasizing the need for a comprehensive diagnostic and therapeutic framework tailored to each patient's unique cancer profile. This underscores the importance of precision oncology in improving outcomes and transitioning from generalized to personalized cancer care strategies.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893790, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1001, prompt_tokens=461, total_tokens=1462, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 43/704...\n",
      "ChatCompletion(id='chatcmpl-BAiRNzl4le2RIy9p1mhJ5I0GES6aI', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Certainly, let's dissect each component related to Breast invasive carcinoma, focusing on its impact on survival through a structured analysis:\\n\\n### Tumor Origin: Breast NOS (Excludes Skin of Breast)\\n\\n1. **Influences on Metastatic Patterns and Patient Survival**:\\n   - **Influence**: Breast invasive carcinoma primarily arises from the ducts or lobules of the breast tissue. The exclusion of skin of the breast (C44.5) narrows the focus to these common sites of origin, which markedly affects its metastatic patterns.\\n   - **Biological Rationale**: These carcinomas often metastasize to axillary lymph nodes, lungs, bones, and liver. The spread is facilitated by anatomical proximity and hematogenous dissemination patterns through lymphatic channels.\\n   - **Impact on Survival**: The propensity for such spread, particularly when axillary nodes are involved, often correlates with poorer survival outcomes due to systemic disease dissemination. \\n\\n2. **Treatment Accessibility**:\\n   - **Influence**: Treatment protocols primarily involve surgery, radiation, and systemic therapy, which are influenced by tumor origin. Excluding non-ductal/non-lobular origins like skin precludes certain surgical interventions.\\n   - **Biological Rationale**: The therapeutic approach, such as hormone receptor status (ER/PR) and HER2-like characteristics, stems from the tissue origin, impacting individualized treatment efficacy and survival.\\n\\n### Histology: Infiltrating Duct Carcinoma, NOS\\n\\n1. **Interaction with Mutation Profiles**:\\n   - **Influence**: Histological classification informs mutation analysis with infiltrating duct carcinoma frequently associated with mutations in genes like TP53, PIK3CA, and others.\\n   - **Biological Rationale**: These mutations drive cancer proliferation, invasion, and resistance to apoptosis. For instance, PIK3CA mutations can enhance oncogenic signaling pathways.\\n   - **Survival Impact**: These histo-genomic interactions can predict aggressiveness and potential resistance to therapy, influencing overall survival expectations negatively.\\n\\n### Sampling Bias: Metastatic, Solid Tissue Normal\\n\\n1. **Limitations in Genomic Analysis**:\\n   - **Influence**: Sampling bias arises when metastatic tissues are compared with limited 'solid tissue normal', which may not entirely represent the patient's baseline genetic environment.\\n   - **Biological Rationale**: Solid tissue normal samples often taken from non-involved areas might miss early mutational landscapes, skewing the interpretation of genomic data.\\n   - **Bias in Genomic Interpretation**: These biases can lead to over- or underestimation of mutation frequencies and their impact on survival, potentially affecting decision-making in therapeutic interventions.\\n\\n### Key Genes and Their Roles\\n\\n1. **TP53**:\\n   - **Mechanism**: Tumor suppressor, involved in DNA repair and apoptosis. Mutations can lead to unchecked cell division.\\n   - **Survival**: Negative impact due to increased mutation burden and potential for aggressive disease.\\n\\n2. **BRCA1/BRCA2**:\\n   - **Mechanism**: Involved in DNA repair processes. Mutations heighten genomic instability.\\n   - **Survival**: Poorer outcomes due to higher risk of additional genomic aberrations.\\n\\n3. **PIK3CA**:\\n   - **Mechanism**: Activates AKT/mTOR pathway, promoting proliferation and survival.\\n   - **Survival**: Mixed impact based on association with tumor subtype and targeted therapy responsiveness.\\n\\n4. **HER2**:\\n   - **Mechanism**: Growth factor receptor; overexpression leads to aggressive tumor growth.\\n   - **Survival**: Historically negative; however, targeted therapies like trastuzumab improve outcomes significantly.\\n\\n5. **CDH1**:\\n   - **Mechanism**: Encodes E-cadherin, important for cell adhesion. Mutations can promote invasive growth.\\n   - **Survival**: Generally adverse due to increased likelihood of metastatic behavior.\\n\\n### Conclusion\\n\\nIn synthesizing these insights, the survival impact of breast invasive carcinoma is heavily predicated on tumor origin, histological subtype, and associated genetic mutations. Infiltrating duct carcinoma, frequently mutated genes like TP53 and PIK3CA, negatively influence survival via enhanced proliferation and invasion pathways. Sampling biases in genomic studies necessitate cautious interpretation to inform clinical decisions authentically. Survival improvement strategies hinge on personalized treatment approaches, particularly exploiting key gene mutations with targeted therapies. With a deepened understanding of these aspects, more precise prognostic and therapeutic measures can be employed, elevating patient survival outcomes in a disease as heterogeneous as breast carcinoma.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893809, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=934, prompt_tokens=461, total_tokens=1395, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 44/704...\n",
      "ChatCompletion(id='chatcmpl-BAiRdO7nhz4RAl5sstaT2QecZcFT4', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Breast NOS (Excludes Skin of Breast C44.5)\\n1. **Metastatic Patterns**: Breast Invasive Carcinoma primarily originates from breast tissue, excluding the skin (ICD-10: Breast NOS). This origin dictates its propensity to metastasize to organs such as bones, lungs, liver, and brain, significantly influencing patient survival. Metastasis to these areas is associated with poor prognosis and decreases survival rates.\\n   - **Biological Rationale**: The rich vascular and lymphatic network in breast tissues facilitates early dissemination of cancer cells.\\n   - **Influence on Survival**: Early detection and targeted therapy crucially impact survival, as metastatic spread substantially worsens outcomes.\\n\\n2. **Treatment Accessibility**: The classification as Breast NOS ensures treatment guidelines are well-established, allowing timely and appropriate interventions, positively affecting survival outcomes.\\n   - **Biological Rationale**: Established treatment regimens include surgery, chemotherapy, hormone therapy, and targeted biological agents that directly impact tumor growth and survival.\\n\\n### Histology: Infiltrating Duct Carcinoma, NOS\\n1. **Interaction with Mutation Profiles**: Infiltrating duct carcinoma (IDC), being the most common histological subtype, frequently exhibits specific genetic mutations such as in PIK3CA, TP53, and GATA3 that drive behavior and treatment responses.\\n   - **Biological Rationale**: Mutational landscapes in IDC can affect pathways like PI3K/AKT (proliferation), TP53 (genomic stability and apoptosis), influencing resistance and aggressiveness.\\n   - **Survival Impact**: Certain mutations portend resistance to therapies, modulating overall survival. For instance, PIK3CA mutations might predict better outcomes with targeted therapy.\\n\\n### Sampling Bias: Primary Tumor vs. Solid Tissue Normal\\n1. **Genomic Analysis Limitations**: Using genomic data from primary tumors and solid tissue normal controls can lead to biases in interpreting tumor-specific alterations.\\n   - **Potential Biases**: Tumor heterogeneity might not be fully captured if only the primary site is analyzed, missing subclones responsible for metastases. Solid tissue normal may harbor undetected genetic changes unrelated to the tumor.\\n   - **Impact on Survival Predictions**: This might result in incomplete prognostic models, affecting therapy choices and survival expectations.\\n\\n### Key Genes in Survival\\n1. **BRCA1/2**: Critical for DNA repair via homologous recombination. Mutations are associated with hereditary breast cancer, influencing treatment responsiveness (e.g., PARP inhibitors) and survival outcomes.\\n   - **Survival Impact**: Adverse, but targeted therapies can improve prognosis.\\n\\n2. **HER2 (ERBB2)**: Overexpression affects cell proliferation. HER2-positive cancers benefit from targeted therapies (e.g., Trastuzumab), significantly improving survival.\\n   - **Survival Influence**: Prioritizes tailored treatment, enhancing survival rates in positive cases.\\n\\n3. **TP53**: A tumor suppressor regulating cell cycle and apoptosis. Mutations lead to uncontrolled proliferation and poor prognosis.\\n   - **Survival Impact**: Often associated with aggressive phenotypes, diminishing survival.\\n\\n4. **PIK3CA**: Influences cell growth and survival pathways. Mutations can lead to pathway activation, affecting therapy response.\\n   - **Survival Effect**: Presence suggests potential benefit from PI3K inhibitors.\\n\\n5. **ESR1 (Estrogen Receptor Alpha)**: Drives hormone receptor-positive cancer growth, impacting therapies like anti-estrogen treatments.\\n   - **Survival Link**: Positive survival correlation due to treatment options.\\n\\n6. **AKT1**: Part of the signaling pathway impacting cell survival and metabolism.\\n   - **Survival Consequences**: Mutation can indicate benefits from pathway inhibitors.\\n\\n### Conclusion: Key Survival Risk Factors\\n- **Clinically Relevant Insights**: Metastatic behavior, histology-driven genetic impacts, and sampling biases are critical in formulating a survival prognosis. HER2 and ESR1 statuses allow for precise interventions that significantly improve outcomes, while BRCA mutations, despite their inherent risk, guide tailored therapies that potentially improve survival.\\n- **Patient Survival Impact**: Understanding these complex interactions allows clinicians to personalize treatment regimens, optimize early detection strategies, and improve precision in survival predictions, ultimately enhancing patient outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893825, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=887, prompt_tokens=461, total_tokens=1348, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 45/704...\n",
      "ChatCompletion(id='chatcmpl-BAiRm7RZaaGGxASqe5PMIA9fvrULR', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\nBreast invasive carcinoma, specifically categorized as Breast NOS (not otherwise specified), originates within the breast glandular tissue, discounting skin involvement. The origin is crucial because it determines the tumor’s biological behavior, influencing patterns of metastasis predominantly to bones, liver, lungs, and brain. These metastatic patterns significantly shape patient prognosis, often resulting in decreased survival rates when distant organs are involved.\\n\\n**Biological Rationale:**\\nThe origin within the breast glandular tissue suggests a strong propensity for hematogenous spread due to the rich vascularity of the breast, facilitating systemic dissemination of tumor cells. Recognizing these routes encourages targeted interventions to prevent metastasis.\\n\\n**Treatment Accessibility:**\\nGlobal disparities in healthcare access can influence survival. Facilities able to employ advanced diagnostic imaging and targeted therapies likely foster improved survival outcomes compared to underserviced regions where early detection rates are lower.\\n\\n**Potential Biases in Interpretation:**\\nThere may be biases inherent in classical histological categorizations such as NOS, potentially overlooking specific molecular subtypes that could yield more targeted therapeutic approaches.\\n\\n### Histology\\n\\n**Influence on Survival:**\\nIntraductal papillary adenocarcinoma with invasion, a subtype of breast cancer, interacts with specific mutation profiles (like PIK3CA or TP53 mutations) that can modify proliferative and invasive capacities, impacting survival outcomes.\\n\\n**Biological Rationale:**\\nThese tumors often involve papillary structures that enhance the interface between tumor and stromal tissue, facilitating mutations that drive further invasiveness and treatment resistance. The interaction between these histological features and specific genomic alterations (e.g., enhanced PI3K/Akt pathway activity due to PIK3CA mutations) underscores the aggressive nature of some variant tumors.\\n\\n**Potential Biases in Interpretation:**\\nDifferential histological examinations may not fully capture all molecular alterations, skewing treatment strategies that are overly reliant on histology without considering underlying molecular heterogeneity.\\n\\n### Sampling Bias\\n\\n**Limitations in Genomic Analysis:**\\n- **Blood Derived Normal:** Using blood-derived normal samples for comparisons in genomic studies can introduce biases, failing to capture the tumor microenvironment’s contributions to cancer biology.\\n  \\n- **Primary Tumor Sampling:** It may not represent the genetic diversity of metastatic sites. Metastatic clones may harbor additional mutations absent in the primary tumor that drive metastasis and influence treatment failure and survival detrimentally.\\n\\n**Impact on Interpretation:**\\nSuch biases can lead to inaccurate assessments of mutation-driven behaviors and expectations of treatment response, directly impacting patient management strategies.\\n\\n### Key Genes and Biological Mechanisms\\n\\n1. **TP53**: Essential in genome stability; its mutations can lead to treatment resistance and poorer outcomes by enabling unchecked proliferation and survival signaling.\\n   \\n2. **PIK3CA**: Part of the PI3K/Akt pathway that promotes cell growth and survival; its mutations are linked to increased breast cancer aggressiveness and reduced survival.\\n\\n3. **BRCA1/2**: Crucial for DNA repair; germline mutations often result in DNA repair deficiencies, leading to heightened genomic instability and aggressive cancer phenotypes.\\n\\n4. **ERBB2 (HER2)**: Overexpression is associated with aggressive growth and is a target for specific therapies, though untreated cases often show worse survival.\\n\\n5. **CDH1**: Linked with cell adhesion. Mutations can lead to increased invasiveness, promoting metastasis and negatively impacting survival.\\n\\n6. **PTEN**: Acts as a tumor suppressor; loss-of-function mutations result in unregulated cell survival and proliferation pathways enhancing tumor growth.\\n\\n**Biological Mechanisms:**\\nThese genes interact with pathways involved in proliferation, apoptosis regulation, and DNA damage response. Their alteration can predispose to aggressive behavior and negatively affect survival, impacting clinical outcomes significantly.\\n\\n### Conclusion\\n\\n**Synthesis of Key Survival Risk Factors:**\\nSurvival in breast invasive carcinoma is profoundly influenced by the interplay between tumor origin, histological characteristics, and genetic profile, compounded by a sampling bias that can obscure comprehensive genomic insights. Recognizing and overcoming such biases, alongside emphasizing understanding specific genomic mutations like those in TP53 and BRCA1/2, is pivotal for refining treatment strategies. Clinical insights into these multidimensional factors enable more nuanced prognostication and tailored therapies, fundamentally shaping patient survival outcomes and redefining treatment paradigms across different healthcare settings.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893834, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_8adc83c802', usage=CompletionUsage(completion_tokens=883, prompt_tokens=465, total_tokens=1348, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 46/704...\n",
      "ChatCompletion(id='chatcmpl-BAiS3WjDBFLM4xKzG5ZHczEjDhqZu', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n1. **Influence on Survival**\\n   - **Metastatic Patterns:** Breast invasive carcinoma, classified under Breast NOS, primarily metastasizes to bone, lungs, liver, and brain. This metastatic behavior directly impacts survival as it determines disease spread, treatment complexity, and the need for systemic therapy.\\n   - **Patient Survival:** The aggressive nature of metastatic patterns leads to a poorer prognosis, often resulting in decreased survival rates compared to localized cancers.\\n   - **Treatment Accessibility:** The exclusion of skin-origin breast cancer enhances precision in treatment strategies, as therapeutic approaches differ significantly based on tumor origin.\\n\\n2. **Biological Rationale**\\n   - Breast NOS ensures a focused clinical handling of truly breast originated tumors, thereby enabling better stratification of treatment protocols and patient monitoring. This focus enhances therapeutic precision and, consequently, survival outcomes.\\n\\n3. **Potential Biases**\\n   - Misclassification or delayed identification due to non-specific initial symptoms can bias early diagnosis and survival data, complicating longitudinal survival statistics.\\n\\n### Histology\\n\\n1. **Influence on Survival**\\n   - **Histology:** Invasive micropapillary carcinoma of the breast is associated with aggressive clinical behavior and higher rates of lymphovascular invasion, leading to a negative impact on survival.\\n   - **Mutation Profiles:** The presence of specific mutations may exacerbate invasive properties, influencing responsiveness to personalized therapies.\\n\\n2. **Biological Rationale**\\n   - This carcinoma subtype is characterized by small, tight clusters of cells within clear stromal spaces, increasing its metastatic potential and complicating treatment. These morphological features are often linked to certain mutations like PIK3CA or TP53, which can enhance tumor aggression.\\n\\n3. **Potential Biases**\\n   - Histological variability within sampled tumors may misrepresent genetic profiles if sampling is not precisely targeted, potentially skewing survival data.\\n\\n### Sampling Bias\\n\\n1. **Influence on Survival**\\n   - **Limitations of Sources:** Genomic analyses using blood-derived normals or primary tumors may not fully represent intra-tumoral heterogeneity or metastatic sites, affecting treatment choices and effectiveness.\\n   \\n2. **Biological Rationale**\\n   - Sampling bias leads to incomplete genomic datasets, potentially missing mutations present only in metastatic sites, which have critical roles in determining survival and treatment resistance.\\n\\n3. **Potential Biases**\\n   - Overreliance on primary tumors can result in overlooking clonal evolution that occurs in metastatic sites, thus impacting survival estimates and therapeutic strategies.\\n\\n### Key Genes Influencing Survival\\n\\n1. **TP53:** A crucial tumor suppressor involved in apoptosis and DNA repair. Mutations lead to unchecked cell proliferation and poor survival.\\n   \\n2. **PIK3CA:** Part of the PI3K/AKT pathway, often mutated in breast cancer, contributing to cell growth and survival. Targeted therapies improve outcomes.\\n\\n3. **ERBB2 (HER2):** Overexpression results in aggressive tumor growth. Targeted anti-HER2 therapies significantly improve survival.\\n\\n4. **BRCA1/2:** Pertains to DNA damage repair. Mutations increase susceptibility to breast/ovarian cancer, impacting survival negatively.\\n\\n5. **ESR1:** Estrogen receptor gene critical for hormone-driven tumors. Mutations might confer resistance to hormone therapy, affecting outcomes.\\n\\n6. **PTEN:** A tumor suppressor, its loss increases PI3K/AKT signaling, leading to poor prognosis and survival.\\n\\n### Conclusion\\n\\nBreast invasive carcinoma survival is intricately influenced by tumor origin, histological subtype, genetic mutations, and sampling biases. The understanding of metastatic patterns and histological aggressiveness provides strategic insights into patient management, while acknowledging sampling limitations can refine genomic interpretations. Key genes like TP53, PIK3CA, and HER2 are pivotal in tailoring treatments and predicting outcomes. Clinically, integrating these insights into tailored therapeutic strategies can significantly enhance patient survival, emphasizing the need for precision medicine and personalized oncology care.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893851, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=795, prompt_tokens=461, total_tokens=1256, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 47/704...\n",
      "ChatCompletion(id='chatcmpl-BAiSIq2jC4RfW44O0Zr67idZW6AuD', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin\\n\\n### Influence on Survival\\nBreast invasive carcinoma, specifically Breast NOS (not otherwise specified), excludes skin involvement and is relevant in understanding its metastatic behavior and subsequent survival impacts. Typically, these tumors originate in the ductal or lobular tissues, not the skin, which influences the lymphatic and blood vessel involvement, often leading to widespread dissemination.\\n\\n### Biological Rationale\\nThe origin directly impacts the metastatic spread; tumors originating from the breast parenchyma often metastasize to the bones, liver, lungs, and brain. This dissemination pathway is due to the rich vascular and lymphatic networks within the breast tissue, enabling the cancer cells to route efficiently to distant sites, thereby typically resulting in poorer survival outcomes post-metastasis.\\n\\n### Treatment Accessibility\\nTreatment options, including surgery, chemotherapy, radiation, and targeted biological therapies, are impacted by the tumor's receptor status (e.g., HER2, ER, PR status). HER2-positive and triple-negative cancers, often tied to more aggressive tumor biology inherent in Breast NOS, are linked with poorer prognosis but may respond to specific therapies like trastuzumab.\\n\\n## Histology\\n\\n### Medullary Carcinoma’s Impact\\nMedullary carcinoma, NOS (not otherwise specified), presents a distinct histological subtype of breast cancer that naturally exhibits a lower metastatic propensity and, thus, a relatively favorable survival outcome, despite often high-grade histological appearance.\\n\\n### Biological Rationale\\nThis carcinoma typically shows a rich lymphocytic stromal response indicative of robust immune engagement, which can correlate with better survival outcomes due to effective immune surveillance and control of local disease. Moreover, specific mutation profiles often associated with medullary carcinoma, such as BRCA1 mutations, can impact survival positively when coupled with prophylactic interventions or targeted treatments.\\n\\n## Sampling Bias\\n\\n### Impact in Genomic Analysis\\nWhen utilizing blood-derived normals or primary tumor samples for genomic profiling, there are inherent biases. Blood samples do not adequately represent the tumor's microenvironmental interactions, which can skew the understanding of the tumor's mutational burden or neoplastic cell behavior.\\n\\n### Biological Rationale\\nPrimary tumor sampling may over-represent detectable clonal populations while potentially missing subclonal, yet clinically significant, populations contributing to metastasis and treatment resistance. This bias can mislead therapeutic strategy development and survival prediction, particularly in advanced or treatment-resistant cases.\\n\\n## Key Genes\\n\\n### Survival-Associated Genes and Mechanisms\\n1. **TP53**: Often mutated in breast carcinomas, TP53 loss leads to disruption of apoptosis regulation, contributing to uncontrolled proliferation and poor prognosis.\\n   \\n2. **BRCA1/BRCA2**: Involved in DNA repair; mutations here significantly increase the risk of tumorigenesis and aggressive cancer phenotype, although offering targets for PARP-inhibitors which improve survival.\\n   \\n3. **PIK3CA**: Mutations activating the PI3K/AKT/mTOR pathway can drive cancer cell growth and survival, influencing resistance to several therapies.\\n   \\n4. **ERBB2 (HER2)**: Overexpression leads to aggressive tumor growth but targeted therapies like trastuzumab significantly improve survival.\\n   \\n5. **CDH1**: Loss of function mutations can lead to enhanced invasiveness and metastasis due to disrupted cell adhesion, worsening prognosis.\\n   \\n6. **ESR1**: Mutations in this gene can influence endocrine therapy resistance, primarily in ER-positive breast cancer, affecting long-term survival.\\n   \\n7. **AKT1**: Mutation affects signaling pathways critical for survival, promoting cancer cell proliferation and survival.\\n\\n## Conclusion\\n\\nSynthesizing these insights, breast invasive carcinoma’s impact on survival is multifaceted, hinging upon origins, histology, genetic makeup, and potential sampling biases. Clinically, the understanding of receptor status and specific mutational profiles guides personalized treatment, improving survival odds through targeted interventions. Continuous evolution in genomic techniques and integration of tumor microenvironment studies plays a crucial role in refining prognosis and therapeutic decisions to enhance survival outcomes. Focusing on careful interpretation of genomic data ensures strategies overcoming biases and addressing the heterogeneity of breast cancer at a molecular level, promoting precision medicine approaches for optimized patient care.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893866, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=845, prompt_tokens=459, total_tokens=1304, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 48/704...\n",
      "ChatCompletion(id='chatcmpl-BAiSXnm5EqggkwEbEHPTmwaCyQ1SW', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='## Breast Invasive Carcinoma and Survival Impact\\n\\n### Tumor Origin\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Breast invasive carcinoma typically originates in glandular epithelial tissue, influencing its propensity to metastasize primarily to bones, lungs, liver, and brain. This pattern is critical as metastatic spread significantly worsens survival outcomes.\\n- **Patient Survival and Treatment Accessibility:** Tumor origin in breast tissue often allows early detection through screening methods like mammography, positively impacting survival due to earlier, more effective intervention.\\n\\n**Biological Rationale:**\\n- Breast tissue characteristics, such as dense glandular structures, can facilitate tumor growth and subsequent dissemination through lymphatic and vascular channels, explaining the observed metastatic patterns.\\n- The accessibility of breast tissue for screening and early biopsy enhances the potential for early-stage treatment, directly affecting survival positively.\\n\\n**Potential Biases:**\\n- Most survival data comes from populations with accessible healthcare, potentially underestimating survival impacts in under-resourced regions with limited screening.\\n\\n### Histology: Medullary Carcinoma, NOS\\n**Influence on Survival:**\\n- **Mutation Profiles Interaction:** Medullary carcinoma of the breast, characterized by well-circumscribed tumors with prominent lymphocytic infiltration, often exhibits a unique mutation profile with an absence of lymphovascular invasion, typically leading to a better prognosis than other histological types.\\n\\n**Biological Rationale:**\\n- The interplay of a high-grade histological appearance with a generally favorable prognosis is linked to aggressive immune response due to lymphocytic infiltration, often associated with BRCA1 mutations.\\n\\n**Potential Biases:**\\n- Histological assessments can be subjective, and misclassification may lead to inaccurate survival data and treatment guideline development.\\n\\n### Sampling Bias\\n**Limitations:**\\n- **Primary Tumor Sampling:** Genetic analyses often rely on primary tumor samples, which may not reflect the mutational landscape of metastatic sites, leading to incomplete genomic insights.\\n- **Solid Tissue Normal Sampling:** Control samples often use adjacent normal tissue, which may already have early genetic alterations, skewing results.\\n\\n**Impact on Survival Understanding:**\\n- These biases can misinform treatment strategies by emphasizing prevailing mutations in primary sites without accounting for potential metastatic site heterogeneity.\\n\\n### Key Genes and Survival\\n**Influence on Survival:**\\n- **BRCA1/BRCA2:** Involved in DNA repair, mutations are linked to increased sensitivity to PARP inhibitors, offering a therapeutic advantage.\\n- **TP53:** A key regulator of apoptosis, TP53 mutations typically correlate with poorer prognosis due to deregulated cell cycle control.\\n- **PIK3CA:** Mutations can activate oncogenic pathways, impacting treatment resistance and patient survival adversely.\\n- **HER2:** Overexpression leads to aggressive tumor growth, but targeted therapies significantly improve outcomes.\\n- **ESR1:** Estrogen receptor mutations affect endocrine therapy effectiveness, pivotal in hormonal breast cancer management.\\n- **PTEN:** Tumor suppressor loss leads to unchecked AKT signaling, contributing to poor outcomes.\\n- **CDH1:** E-cadherin gene mutations can promote invasiveness, crucial in lobular carcinoma dynamics.\\n\\n**Biological Rationale:**\\n- These genes are involved in pathways regulating proliferation, apoptosis, and cell signaling—core survival determinants in cancer biology.\\n\\n**Potential Biases:**\\n- Studies often focus on high-prevalence gene mutations, potentially neglecting lower-frequency but clinically significant mutations.\\n\\n### Conclusion: Synthesis and Clinical Implications\\n- **Key Survival Factors:** Tumor origin and histological type significantly influence metastatic behavior and response to treatment. The genomic understanding can vary greatly due to sampling limitations and the inherent bias of focusing on accessible populations.\\n- **Clinical Impact:** The combination of genetic insights and histopathological data should guide personalized therapies, improving long-term survival. Emphasizing the heterogeneity across stages and sites, coupled with comprehensive access to diagnostic advancements, remains essential for optimizing patient outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893881, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=796, prompt_tokens=459, total_tokens=1255, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 49/704...\n",
      "ChatCompletion(id='chatcmpl-BAiSgWDWpum2gQoTwXIkKs6KhJpHf', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**  \\nBreast invasive carcinoma primarily arises in the ducts or lobules of the breast tissue. The exclusion of Skin of breast C44.5 ensures the primary concern is on deeper tissue origins, which often have different metastatic paths and prognoses.\\n\\n**Biological Rationale:**  \\n1. **Metastatic Patterns:** Breast cancer typically spreads to lymph nodes, bones, liver, lungs, and brain. The pattern depends on the location and molecular characteristics of the primary tumor, influencing survival based on the organ-specific proliferation capacity and the microenvironment.\\n2. **Patient Survival and Treatment Accessibility:** The deeper tissue involvement usually requires systemic therapies (chemotherapy, targeted therapies), affecting survival based on cancer stage at diagnosis and molecular subtype. Early-stage detection generally correlates with higher survival due to more localized disease amenable to curative treatment.\\n\\n**Potential Biases:**  \\nSampling from non-skin origins can miss some superficial lesions that have distinct biological behavior impacting pathways like signaling and proliferation, which are essential to accurately map for targeted therapy decisions.\\n\\n### Histology\\n\\n**Influence on Survival:**  \\nThe histological subtype, such as Lobular carcinoma, NOS, affects responses to treatment due to distinct biological characteristics, such as cellular adhesion and dissemination patterns.\\n\\n**Biological Rationale:**  \\n1. **Mutation Profiles:** Lobular carcinomas often have mutations in genes like CDH1, affecting cell adhesion and increasing the propensity for metastasis without forming primary masses easily detected by standard imaging. This can lead to delayed diagnosis affecting survival negatively.\\n2. **Outcomes:** Differences in genetic mutations influence therapeutic targets and chemoresistance, impacting survival. Lobular tumors are generally less responsive to chemotherapy, which can reduce survival expectations in advanced cases.\\n\\n**Potential Biases:**  \\nHistology-based assessments can overlook molecular data from non-tumor components or mixed histological patterns that significantly influence treatment response and survival.\\n\\n### Sampling Bias\\n\\n**Influence on Survival:**  \\nThe use of blood-derived normal and metastatic samples in genomic analysis can introduce biases, affecting the evaluation of tumor genomic landscapes and complicating therapeutic decisions.\\n\\n**Biological Rationale:**  \\n1. **Blood Derived Normal Samples:** These may not perfectly reflect tumor-mutational profiles, leading to potential underestimation of somatic mutations specific to tumors, affecting targeted therapy decisions.\\n2. **Metastatic Lesions:** Metastases often evolve distinct mutational profiles compared to primary tumors, which can lead to sampling bias if only metastatic tissue is evaluated, potentially omitting key survival-associated drivers present in the primary tumor.\\n\\n**Potential Biases:**  \\nBlood-derived samples are prone to contamination from non-tumor cells, skewing mutation analyses. Similarly, reliance on metastatic samples alone can miss variation present in primary tumors crucial for targeted treatment design.\\n\\n### Key Genes\\n\\n**Key Genes and Their Biological Mechanisms:**\\n\\n1. **TP53:** A critical tumor suppressor involved in DNA repair and apoptosis. Mutations in TP53 are associated with resistance to chemotherapy and poorer survival.\\n2. **PIK3CA:** Involved in cell proliferation and survival pathways. Mutations can lead to oncogenic activation and resistance to hormone therapies.\\n3. **GATA3:** Implicated in cellular differentiation and survival. Mutations can disrupt normal apoptosis signaling, impacting survival negatively.\\n4. **BRCA1/2:** Key in DNA repair, especially homologous recombination; mutations lead to genome instability and potential responsiveness to PARP inhibitors, offering varied survival impacts based on treatment.\\n5. **HER2 (ERBB2):** Drives cell cycle progression and proliferation; amplifications or mutations associate with aggressive phenotypes but also provide therapeutic targets, influencing survival positively in treated cases.\\n6. **CDH1:** Involved in cell adhesion; mutations in lobular carcinoma affect dissemination and metastatic potential adversely, impacting survival by influencing metastatic spread patterns.\\n7. **ESR1:** Estrogen receptor influencing hormonal regulation and survival; mutations can alter responsiveness to endocrine therapies impacting survival.\\n8. **PTEN:** Acts as a tumor suppressor controlling cell growth and survival pathways; loss of function mutations often correlate with poorer prognosis and aggressive disease.\\n\\n**Biological Mechanisms:**  \\n- **Proliferation and Cell Cycle Control:** Deregulated by TP53 and HER2.\\n- **DNA Repair and Genomic Stability:** Affected by BRCA1/2 and PTEN.\\n- **Apoptosis Regulation:** Altered TP53 mutations impair programmed cell death.\\n- **Immune Regulation:** Mutations in genes such as GATA3 might have roles in immune evasion mechanisms.\\n\\n### Conclusion\\n\\nThe synthesis of survival risk factors involves understanding the interplay between tumor origin, histological subtype, and genetic mutations, addressing key genes and potential biases in sampling methods. Clinically, early detection, understanding molecular profiles, and targeted therapy based on genetic insights are paramount for improving patient survival. Comprehensive genomic profiling while considering histological variances and sampling site biases remains integral to enhancing treatment precision, ultimately leading to improved survival outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893890, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1020, prompt_tokens=458, total_tokens=1478, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 50/704...\n",
      "ChatCompletion(id='chatcmpl-BAiT4GtTKPc2O6avpybEJTbiv5ftx', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To address the complex intersection of factors influencing survival in Breast invasive carcinoma (Breast NOS, excluding skin of breast C44.5), we\\'ll delve into several key components: tumor origin, histology, sampling biases, and genetic mutations. Let\\'s examine each of these factors in detail and synthesize their implications for patient survival.\\n\\n### Tumor Origin and Metastatic Patterns\\n1. **Influence on Survival**\\n   - Tumor origin, particularly Breast NOS, primarily influences metastatic patterns, as these tumors often spread to lymph nodes, bone, liver, and lungs.\\n   - Survival is negatively impacted when tumors are more likely to metastasize, as widespread dissemination can complicate treatment and reduce effectiveness.\\n\\n2. **Biological Rationale**\\n   - Breast epithelial cells, originating in glandular tissue, are prone to certain pathways that facilitate metastasis, including epithelial-mesenchymal transition (EMT). EMT confers cells with increased motility and invasiveness, crucial for dissemination.\\n\\n3. **Treatment Accessibility**\\n   - Breast NOS presents challenges due to its potentially broad classification, which might affect precision in targeting treatment, thus influencing survival negatively if misclassified initially.\\n\\n### Histology: Lobular Carcinoma, NOS\\n1. **Influence on Survival**\\n   - Lobular carcinoma, NOS, often has a distinctive spread pattern known as \"Indian file\" infiltration, which may elude detection until advanced stages, negatively impacting survival.\\n\\n2. **Interplay with Mutation Profiles**\\n   - Common mutations include loss of E-cadherin (CDH1 gene), which facilitates cell adhesion, and additional mutations may foster distinctive responses to hormonal therapies, influencing outcome variability.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n1. **Influence on Survival Interpretation**\\n   - Using blood-derived normal samples to assess genomic alterations versus primary tumors can misrepresent the genetic landscape and underestimate tumor heterogeneity.\\n\\n2. **Biological Rationale**\\n   - Blood samples lack the tumor microenvironment\\'s contextual genomic interactions, often leading to biases in mutation prevalence and prognostic assessments.\\n   - This can skew survival predictions if key mutations or expressions modifier factors are under-represented in sequencing data.\\n\\n### Key Genes and Survival Association\\n1. **Key Survival-Associated Genes**: TP53, PIK3CA, BRCA1/2, HER2, ESR1, PTEN, RB1\\n2. **Biological Mechanisms**\\n   - **TP53**: Tumor suppressor gene; mutations lead to faulty cell cycle control and apoptosis evasion, typically worsening prognosis.\\n   - **PIK3CA**: Part of the PI3K/AKT pathway; mutations activate pathways increasing proliferation and survival signaling.\\n   - **BRCA1/2**: Critical for DNA repair; mutations impair genomic stability, potentially improving survival in cases with targeted therapies (e.g., PARP inhibitors).\\n   - **HER2**: Amplification linked to aggressive tumor growth; targeted therapies (e.g., trastuzumab) improve survival for affected individuals.\\n   - **ESR1**: Mutations drive hormone resistance, influencing survival negatively when hormone therapies are compromised.\\n   - **PTEN**: Loss affects cell cycle regulation and apoptosis, typically correlating with poorer outcomes.\\n   - **RB1**: Regulates cell cycle progression; loss leads to unchecked cell division, worsening prognosis.\\n\\n### Synthesis: Key Survival Risk Factors\\nExamining Breast invasive carcinoma survival involves integrating multiple biological dimensions:\\n- **Tumor invasiveness and metastatic characteristics** greatly impact patients\\' trajectories.\\n- **Histological nuances** such as those in Lobular carcinoma require tailored therapeutic strategies, influencing outcome disparities.\\n- **Genomic insights**, while potent, necessitate careful interpretation of sampling sources to avoid analytical biases.\\n\\nIn conclusion, improving survival outcomes hinges on precision medicine approaches that address tumor biology, integrate histologic idiosyncrasies, and accurately interpret genomic data. Ensuring clinical relevance involves constantly updating therapeutic strategies to adapt to complex mutational landscapes and metastatic progressions. This holistic integration is pivotal to advancing patient management and survival in Breast invasive carcinoma.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893914, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=834, prompt_tokens=458, total_tokens=1292, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 51/704...\n",
      "ChatCompletion(id='chatcmpl-BAiTNCasRgStcW82eogbBmaqEH2QC', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin\\n\\n### Influence on Survival\\n\\n1. **Metastatic Patterns**: Breast invasive carcinoma not otherwise specified (NOS) generally has a propensity for metastasis to the bone, lungs, liver, and brain. This pattern is crucial as metastasis to vital organs significantly lowers survival rates.\\n2. **Patient Survival**: Survival is negatively impacted with advanced metastatic stages, where prognosis is poor due to limited effectiveness of current treatments in eradicating widespread disease.\\n3. **Treatment Accessibility**: Access to personalized and targeted therapy may improve survival because treatments like HER2 inhibitors and hormonal therapies can be very effective for certain subtypes of breast cancer. However, accessibility can vary by region and healthcare infrastructure, impacting outcomes.\\n\\n### Biological Rationale\\n\\n- **Epithelial-to-Mesenchymal Transition (EMT)**: Tumor cells gain motility and invasiveness through EMT, facilitating metastasis.\\n- **Vascular Invasion**: The highly vascular nature of breast tumors aids in dissemination through the bloodstream or lymphatic system.\\n\\n### Bias Consequences\\n\\n- **Misclassification**: Tumor origin, especially in NOS classifications, can lead to under-characterization, thus impeding tailored therapies that can enhance survival.\\n\\n## Histology\\n\\n### Influence on Survival\\n\\n1. **Lobular Carcinoma NOS**: This histological subtype is characterized by a high risk of late recurrence and diffuse infiltration, complicating surgical resections and leading to a more concealed metastatic spread.\\n   \\n### Biological Rationale\\n\\n- **Mutation Profiles**: Different histological patterns show variable genomic aberrations; lobular carcinomas often feature mutations like CDH1, affecting cohesion and invasiveness, resulting in worse clinical outcomes.\\n- **Hormonal Receptors**: Often hormone receptor-positive (ER and/or PR), leading to specific hormonal treatment regimens which can prolong survival.\\n\\n### Bias Consequences\\n\\n- **Sampling Bias**: Tumors like lobular cancer can be underrepresented in genomic studies due to difficulties in sampling diffusely infiltrative lesions, leading to incomplete mutational landscapes.\\n\\n## Sampling Bias\\n\\n### Influence on Survival\\n\\n1. **Primary Tumor vs. Metastasis**: Genomic analysis often focuses on primary tumors, ignoring the genomic changes that occur in metastatic sites, which are clinically most relevant for survival outcomes.\\n2. **Solid Tissue Normal**: Sampling biases can misrepresent the tumor's genomic landscape if non-tumor tissue contains significant alterations, leading to incorrect clinical assessments and treatment plans.\\n\\n### Biological Rationale\\n\\n- **Heterogeneity**: Intratumor heterogeneity means genomic profiles of primary and metastatic tumors can differ substantially, impacting treatment efficacy and survival.\\n\\n### Bias Consequences\\n\\n- **Genomic Interpretation**: Misleading genomic profiles can result from sampling inconsistencies, impacting therapeutic decisions and ultimately affecting patient survival.\\n\\n## Key Genes\\n\\n### Influence on Survival\\n\\n1. **TP53**: Critical in regulating apoptosis; mutations lead to unchecked cellular proliferation, correlating with poorer prognosis.\\n2. **PIK3CA**: Plays a role in cell growth and survival. Mutations can activate the PI3K/AKT pathway, often resulting in aggressive clinical behavior.\\n3. **BRCA1/2**: Associated with DNA damage repair; mutations increase susceptibility to DNA-damaging agents but also improve responsiveness to PARP inhibitors.\\n4. **ESR1**: Influences hormonal pathways; mutations contribute to endocrine resistance, impacting survival in hormone receptor-positive cases.\\n5. **HER2**: Amplification leads to aggressive growth, but responsiveness to targeted therapies can significantly improve survival.\\n6. **CDH1**: Its mutation disrupts cell adhesion, contributing to invasive spread and presenting challenges for early detection and treatment.\\n7. **KI-67**: Marker of proliferation; high levels correlate with poorer survival due to aggressive tumor growth.\\n8. **PTEN**: Loss of function activates survival pathways, leading to treatment resistance and tumor progression.\\n\\n### Biological Mechanisms\\n\\n- **Proliferation**: Driven by oncogenes like HER2 and KI-67, impacting growth rates and survival.\\n- **Apoptosis**: Genes like TP53 regulate programmed cell death; their dysfunction allows survival despite genetic damage.\\n- **Immune Response**: Mutations affecting the immune landscape can lead to immune evasion, affecting both prognosis and treatment response.\\n\\n### Bias Consequences\\n\\n- **Genomic Interpretation**: Context matters; poor representation due to sampling biases can obscure the role these genes play across tumor stages and types.\\n\\n## Conclusion\\n\\n**Synthesizing Key Survival Risk Factors:**\\n\\n- **Comprehensive Histopathological and Genomic Profiling**: Essential to capture genetic diversity, especially in metastatic lesions, to personalize treatment and improve survival outcomes.\\n- **Histology-Specific Management**: Understanding distinct metastatic patterns and mutational profiles in lobular vs ductal carcinomas can enhance prognostication and treatment.\\n- **Addressing Sampling Biases**: Improved sampling techniques and broader genomic analysis, including profiling of metastatic sites, will better inform clinical decision-making and therapy selection.\\n\\nIncorporating these insights into clinical practice is critical for enhancing patient survival, emphasizing the necessity of precision medicine in oncology.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893933, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=1055, prompt_tokens=458, total_tokens=1513, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 52/704...\n",
      "ChatCompletion(id='chatcmpl-BAiTcVOQloqGBVjUZno5Ov5g1a6jI', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin:\\n1. **Influence on Metastatic Patterns and Patient Survival:**\\n   - Breast invasive carcinoma often originates in the ducts or lobules, predisposing it to spread to regional lymph nodes and distant organs like bone, liver, lung, and brain. This metastatic spread is central to patient prognosis as systemic dissemination typically reduces survival rates.\\n   - Understanding the origin, identified as Breast NOS (excludes Skin of breast C44.5), helps refine treatment strategies by focusing on these high-risk metastatic sites, potentially improving survival through tailored intervention.\\n\\n2. **Treatment Accessibility:**\\n   - Origin-focused diagnostics aid in designing therapeutic approaches that target the most probable metastatic pathways. By predicting specific patterns, healthcare can prioritize systemic therapies (e.g., chemotherapy, hormonal therapy) that may extend survival, especially in cases where localized control has lower impact.\\n\\n### Histology:\\n1. **Interactions with Mutation Profiles and Outcome:**\\n   - Infiltrating ductal carcinoma (IDC) and lobular carcinoma differ histologically and genetically. IDC is more prevalent and tends to present with more aggressive genetic mutations such as TP53, influencing poorer outcomes.\\n   - Lobular carcinoma may exhibit mutations in CDH1, affecting the E-cadherin protein, which impacts cell adhesion and migration, contributing to diffuse metastasis patterns that affect survival differently.\\n\\n2. **Biological Rationale:**\\n   - The histological type influences treatment response due to varying growth patterns and mutation burdens. IDC's heterogeneous nature often shows resistance to therapies if driven by high mutation rates, thus complicating treatment and potentially reducing survival.\\n\\n### Sampling Bias:\\n1. **Limitations of Blood Derived Normal and Primary Tumor Samples:**\\n   - Blood-derived normals and primary tumor samples can under-represent tumor heterogeneity, especially in metastatic sites. This bias limits comprehensive mutation profiling, potentially overlooking subclonal mutations influencing prognosis.\\n   - The reliance on primary tumor data alone may inflate the importance of somatic mutations while missing the broader genomic landscape influencing survival, such as acquired resistance mechanisms observed only in metastatic samples.\\n\\n2. **Potential Biases:**\\n   - Such biases may lead to incomplete therapeutic targets, misrepresenting mutation-driven mechanisms affecting survival, and delaying effective, targeted treatment pathways.\\n\\n### Key Survival-Associated Genes:\\n1. **PIK3CA:**\\n   - Frequently mutated in breast cancer, influences cell growth and survival via the PI3K/AKT pathway. PIK3CA mutations often correlate with a favorable prognosis when targeted appropriately with PI3K inhibitors.\\n\\n2. **TP53:**\\n   - Known as the guardian of the genome, TP53 mutations lead to genomic instability, influencing poor outcomes due to resistance to apoptosis and continued proliferation.\\n\\n3. **BRCA1/BRCA2:**\\n   - Essential for DNA repair. Mutations in these genes are associated with higher risk of additional primary tumors, influencing not only initial treatment outcomes but also the need for ongoing surveillance and prophylactic approaches impacting survival.\\n\\n4. **ERBB2 (HER2):**\\n   - Overexpression or amplification leads to aggressive tumor behavior and poor outcomes if untreated. Targeted therapies like trastuzumab have positively impacted survival significantly.\\n\\n5. **CDH1:**\\n   - Loss-of-function mutations in lobular carcinomas lead to poor cell-cell adhesion, influencing diffuse metastasis and often hindering early diagnosis.\\n\\n6. **mTOR:**\\n   - Involved in cellular metabolism and growth. Alterations affecting this pathway can influence cell cycle progression and are potential targets providing improved survival when effectively inhibited.\\n\\n### Conclusion:\\nThe integration of tumor origin, histological subtype, mutation profiles, and genomic sampling considerations presents a complex picture impacting breast carcinoma survival. Precise diagnosis and tailored treatment focusing on gene-specific pathways can mitigate some risks associated with primary and metastatic diseases. These insights through the lens of molecular genetics emphasize individualized therapies, potentially improving survival outcomes by addressing the unique molecular architecture of each patient's disease. Understanding these dynamics is essential for advancing breast cancer management and enhancing survivability across diverse patient populations.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893948, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=818, prompt_tokens=462, total_tokens=1280, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 53/704...\n",
      "ChatCompletion(id='chatcmpl-BAiTrCMNryDd8lgy7gyaYzn2Lr7X4', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Influence on Survival\\n\\n1. **Metastatic Patterns**: Breast NOS, excluding skin of breast (C44.5), typically originates within breast ductal or lobular structures, affecting their propensity to metastasize primarily to regional lymph nodes, bones, lungs, and liver. Such metastatic spread results in variable survival outcomes, with bone metastases often correlating with better prognosis than visceral metastases.\\n\\n2. **Patient Survival**: Breast cancer's survival rates hinge on stage at diagnosis. Early-stage breast cancer generally has better outcomes. Tumors of lobular origin are known to present at later stages, partly due to diffuse growth patterns, which can complicate early detection and negatively impact survival.\\n\\n3. **Treatment Accessibility**: Access to systemic therapies like hormonal treatments varies based on tumor receptor status (e.g., ER, PR, HER2). Estrogen receptor-positive tumors, prevalent in breast cancer NOS, often exhibit better responses to hormone therapies, enhancing survival.\\n\\n### Histology: Interaction with Mutation Profiles\\n\\n1. **Infiltrating Ductal Carcinoma (IDC)**: The most common form, IDC, frequently harbors mutations in TP53 and PIK3CA. TP53 mutations are associated with high-grade tumors, poor differentiation, and lower survival due to impaired apoptosis regulation.\\n\\n2. **Infiltrating Lobular Carcinoma (ILC)**: Characterized often by CDH1 mutations, leading to E-cadherin dysfunction, promoting cell detachment and infiltration. While ILC often presents later and involves more extensive surgical treatment, it sometimes responds well to endocrine therapy, marginally balancing survival outcomes.\\n\\n3. **Outcome Influence**: Histological subtypes, intertwined with mutation profiles, tailor treatment approaches and prognoses, with IDC generally having varied prognoses based on genetic alterations compared to more uniform treatment pathways in ILC due to its hormonal sensitivity.\\n\\n### Sampling Bias: Genomic Analysis Limitations\\n\\n1. **Primary Tumor Bias**: Genomic analyses predominantly focus on primary tumors due to accessibility. This may not capture metastases' genetic landscape, leading to partial treatment insights and possible underestimation of aggressive secondary mutations affecting survival.\\n\\n2. **Solid Tissue Normal Bias**: Utilizing adjacent normal tissues as a genomic baseline can misrepresent true mutational backgrounds if tissues harbor pre-malignant changes unnoticed, skewing interpretation towards benign profiles and affecting the assessment of tumor-specific mutations.\\n\\n### Key Genes and Biological Mechanisms\\n\\n1. **TP53**: Critical for cell cycle regulation and apoptosis; mutations often signal aggressive cancers with poor prognosis.\\n\\n2. **PIK3CA**: Involved in proliferation and cell growth pathways; mutations can indicate potential benefit from targeted PI3K inhibitors, improving outcomes.\\n\\n3. **BRCA1/2**: Repair DNA double-strand breaks. Mutations heighten breast cancer risk but stratify patients for PARP inhibitor therapies, enhancing survival.\\n\\n4. **HER2**: Amplification drives proliferation; HER2-targeted therapies dramatically improve survival in biomarker-positive cancers.\\n\\n5. **ER (Estrogen Receptor)**: A positive status often correlates with favorable response to hormonal therapies, enhancing survival.\\n\\n6. **CDH1**: Loss of function leads to cell adhesion disruption in ILC, hinting at immune evasion and reduced apoptosis, impacting survival negatively.\\n\\n7. **KMT2C/D**: Involve chromatin remodeling; mutations are associated with improved effacement of proliferative restrictions, influencing chemotherapy responses.\\n\\n8. **AKT1**: Central in PI3K/AKT pathway; provides a target for inhibitors, showing promise in clinical trials for improving progression-free survival.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nSurvival in breast invasive carcinoma hinges on the tumor's origination and histological nuances which dictate metastasis patterns and initial treatment responses. Genetic profiling illustrates potential pathways for targeted therapies, yet is hampered by intrinsic biases from sampling methods. Clinically, understanding the interplay between tumor biology and genetic underpinnings informs personalized treatment strategies, directly impacting patient outcomes and survival probabilities by enabling precision medicine tailored to individual genomic and histopathological profiles.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893963, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=846, prompt_tokens=462, total_tokens=1308, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 54/704...\n",
      "ChatCompletion(id='chatcmpl-BAiU21nLIGEASLs3Eo4Ir30GWUgEM', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin: Breast NOS Influence on Metastatic Patterns and Survival**\\n\\nBreast invasive carcinoma, classified as Breast NOS, primarily originates within the breast tissue. Its classification, excluding skin involvement (C44.5), highlights its intramammary origin. This localization has specific implications for metastatic patterns, patient survival, and treatment pathways:\\n\\n1. **Metastatic Patterns**: The tumor's breast origin typically determines metastatic routes via axillary lymph nodes, with common sites including the bones, lungs, liver, and brain. Metastasis to these sites correlates with decreased survival due to treatment challenges and increased disease burden.\\n\\n2. **Patient Survival**: Survival is negatively impacted by early metastatic spread characteristic of breast cancer. However, early detection and treatment modalities such as hormone therapy and targeted therapies can mitigate these effects, improving survival rates.\\n\\n3. **Treatment Accessibility**: Due to its common occurrence and well-researched nature, treatment accessibility is generally high with multiple systemic therapies available, influencing survival positively by providing options for both early and advanced disease stages.\\n\\n**Histology: Impact of Infiltrating Ductal Carcinoma Mixed with Other Types**\\n\\nInvasive ductal carcinoma, often mixed with other histological types, interacts with genomic mutations influencing outcomes:\\n\\n1. **Combination with Other Types**: This histological heterogeneity can lead to varied progression patterns, as different cell types may harbor distinct genomic alterations. Mixed subtype tumors may have uncertain prognosis due to the unpredictability in growth and response to therapy.\\n\\n2. **Mutation Profiles and Outcomes**: The presence of mutations such as in PIK3CA, TP53, and others dictates growth dynamics. For instance, TP53 mutations often relate to poor differentiation and aggressive behavior, reducing survival chances, while PIK3CA mutations might suggest sensitivity to certain targeted treatments, potentially improving outcomes.\\n\\n**Sampling Bias: Blood-Derived Normal vs. Primary Tumor Genomic Analysis**\\n\\n1. **Limitations**: Blood-derived normals often present biases, as somatic mutations prevalent in tumor DNA may not reflect mutations present in blood. This provides a less representative genomic landscape of the tumor, potentially skewing data analysis.\\n\\n2. **Primary Tumor Sampling**: While more reflective of the cancer's true genomic status, sampling biases can arise from tumor heterogeneity, with primary lesions not fully representing metastatic sites or subclonal populations, leading to a partial understanding of actionable mutations.\\n\\n**Key Genes Affecting Survival**\\n\\n1. **BRCA1/2**: Mutations here increase risk but also guide therapy with PARP inhibitors, which improve outcomes due to their role in DNA repair pathway deficiencies.\\n   \\n2. **HER2 (ERBB2)**: A well-known oncogene; targeted treatments like trastuzumab directly improve survival by inhibiting proliferative signaling pathways.\\n\\n3. **TP53**: Frequently mutated, contributing to genomic instability and resistance to some chemotherapies, negatively impacting survival.\\n\\n4. **PIK3CA**: Involved in cell growth signaling; its mutation can suggest sensitivity to PI3K inhibitors, offering targeted treatment opportunities which can positively influence survival.\\n\\n5. **CDH1**: Encodes for E-cadherin, and its mutation or loss often leads to increased invasion and metastasis, negatively impacting survival.\\n\\n6. **ESR1**: Estrogen receptor alpha mutations guide hormone therapy, influencing survival by targeting estrogen-driven proliferative paths.\\n\\n**Synthesis of Key Survival Risk Factors**\\n\\nIn sum, the key factors impacting survival in breast invasive carcinoma include its primary anatomical and pathological characteristics, histological subtype interactions, identifying actionable mutations despite potential sampling biases, and utilizing knowledge of pivotal genes to tailor treatment strategies. By understanding these nuanced interactions, oncologists can more effectively target treatments to improve patient outcomes, highlighting the necessity of comprehensive genomic profiling and stratified therapeutic approaches.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893974, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=778, prompt_tokens=464, total_tokens=1242, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 55/704...\n",
      "ChatCompletion(id='chatcmpl-BAiUCoAWG8m4ImOLRcpcDectF1Rly', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin:**\\n\\n1. **Metastatic Patterns and Survival:**\\n   - **Influences on Metastatic Patterns:** Breast invasive carcinoma, especially when defined as Breast NOS, typically originates in the ductal or lobular tissues of the breast. This origin affects its propensity to metastasize to specific sites like the bone, liver, lungs, and brain. The exclusion of skin involvement is significant; skin involvement often suggests more advanced or atypical progression.\\n   - **Impact on Survival:** Metastasis to regions such as the bone or brain drastically worsens prognosis, as these sites are challenging to treat effectively due to anatomical and physiological barriers, impacting survival negatively.\\n   - **Treatment Accessibility:** Patients with breast NOS have more standardized access to treatment protocols like hormone therapy, targeted therapy, and chemotherapy, thereby improving survival prospects if caught early.\\n\\n2. **Biological Rationale:**\\n   - Ductal and lobular origins determine aggressiveness and response to hormone and targeted therapies. Since these cancers can retain hormone receptor positivity, they are more amenable to treatments such as tamoxifen or aromatase inhibitors, which can significantly improve survival.\\n\\n**Histology:**\\n\\n1. **Interaction with Mutation Profiles:**\\n   - **Infiltrating Duct Carcinoma Mixed with Other Types:** This mix can result in a heterogeneous tumor environment with complex mutation profiles that influence treatment responsiveness and metastatic capability.\\n   - **Effects on Outcomes:** The presence of mixed histological types can lead to both increased aggressiveness and variability in treatment response, potentially compromising survival if under or improperly treated.\\n\\n2. **Biological Explanation:**\\n   - Mixed histology typically indicates multiple clonal populations within the tumor, complicating treatment as these clones may harbor distinct mutations, some conferring resistance to specific therapies, thus impacting prognosis.\\n\\n**Sampling Bias:**\\n\\n1. **Limitations in Genomic Analysis:**\\n   - **Primary Tumor vs. Solid Tissue Normal:** Genomic analyses often rely on samples from the primary tumor and adjacent normal tissue. However, this may not capture the genomic diversity within metastatic lesions, nor the full spectrum of microenvironmental influences.\\n   \\n2. **Implications for Survival Analysis:**\\n   - **Biases in Interpretation:** This can lead to underestimation of mutation burden and clonal heterogeneity, resulting in an incomplete picture of aggressiveness and treatment resistance, skewing survival predictions.\\n\\n**Key Genes:**\\n\\n1. **Identifying Survival-Associated Genes:**\\n   - **TP53:** Mutations in this gene are commonly associated with poor survival due to dysfunctional regulation of cell cycle and apoptosis.\\n   - **PIK3CA:** Alterations can lead to enhanced proliferation signals and contribute to therapy resistance.\\n   - **BRCA1/2:** Germline mutations significantly increase risk and can influence responses to PARP inhibitors, illustrating potential for targeted treatment impact on survival.\\n   - **HER2 (ERBB2):** Amplification leads to aggressive disease courses but predicts responsiveness to targeted therapies like trastuzumab, improving outcomes.\\n   - **CDH1 (E-cadherin):** Loss mutations are associated with solid tumor invasiveness, impacting metastatic potential and thus survival negatively.\\n   - **ESR1 (Estrogen Receptor alpha):** Mutation or dysregulation affects hormonal therapy outcomes, a critical determinant for survival in hormone receptor-positive breast cancers.\\n   - **PTEN:** Loss often correlates with increased tumor growth and therapy resistance, impacting overall prognosis.\\n   - **Ki67:** Elevated levels are indicative of high proliferative activity, often correlating with poor prognosis; however, it can also mark sensitivity to proliferation-targeted therapies.\\n\\n**Synthesis:**\\n\\n- **Key Survival Risk Factors:** Tumor origin, specifically precise histological classification, and accurate genomic profiling, is crucial for prognosis. The interplay of histological diversity and genetic alterations predominantly dictates survival outcomes. However, effective treatment access and targeted therapy utilization, particularly addressing genetic vulnerabilities (e.g., hormone receptor status, HER2 amplification), can significantly alter prognosis. Identifying and mitigating sampling biases in genomic analysis by adopting comprehensive multi-region or circulating tumor DNA approaches can improve survival prediction accuracy and therapeutic targeting.\\n- **Clinically Relevant Insights:** An integrated understanding of the tumor’s origin, structural heterogeneity, and detailed genomic information is essential to optimize treatment approaches, ensuring consistent improvements in patient survival.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741893984, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=887, prompt_tokens=464, total_tokens=1351, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 56/704...\n",
      "ChatCompletion(id='chatcmpl-BAiUTRlr2fxI6SefBlsyJEqni4dlw', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Breast NOS (Excludes Skin of Breast C44.5)\\n\\n**Impact on Survival:**\\n\\n1. **Metastatic Patterns:**\\n   - **Influence:** Breast NOS tumors primarily metastasize to organs like bones, lungs, liver, and brain.\\n   - **Survival Impact:** These metastases impact survival negatively, with bone metastases often associated with a relatively better prognosis compared to brain or liver due to treatment challenges and aggressive disease progression in visceral organs.\\n   - **Treatment Accessibility:** Standard systemic treatments, such as hormone therapy and chemotherapy, tend to be accessible; however, metastatic sites like the brain challenge treatment due to the blood-brain barrier, potentially worsening outcomes.\\n\\n2. **Biological Rationale:**\\n   - Tumor cells display adaptability, with epithelial-mesenchymal transition facilitating dissemination and organotropism guiding specific metastatic sites.\\n\\n### Histology: Infiltrating Lobular Carcinoma (ILC), Mixed Types\\n\\n**Impact on Survival:**\\n\\n1. **Interaction with Mutation Profiles:**\\n   - **Influence:** ILC often lacks E-cadherin due to CDH1 mutations, leading to diffuse growth and less palpable tumors. When mixed with other carcinoma types, these features can alter survival outcomes.\\n   - **Survival Impact:** Lobular features often result in later-stage detection, traditionally linked to poorer outcomes compared to ductal types, despite an often indolent growth pattern that varies across mixed types.\\n\\n2. **Biological Rationale:**\\n   - Loss of cell adhesion mechanisms via CDH1 influences metastatic behavior and response to treatment. The diversity in histological characteristics within mixed types complicates this, modifying treatment responses and survival predictions.\\n\\n### Sampling Bias: Limitations of Blood-Derived Normal and Primary Tumor Samples\\n\\n**Impact on Survival Analysis:**\\n\\n1. **Blood-Derived Normal Samples:**\\n   - **Bias:** These may not accurately represent the microenvironment and mutations specific to the tumor site.\\n   - **Survival Impact:** Potential misinterpretation of mutation significance and tumor heterogeneity, affecting decisions in personalized therapy.\\n\\n2. **Primary Tumor Samples:**\\n   - **Bias:** Sampling from one part of the tumor may not capture its heterogeneity, leading to incomplete genetic profiles.\\n   - **Survival Impact:** Misguided treatment decisions if not all clonal populations are identified, possibly overlooking aggressive subclones.\\n\\n### Key Genes: Impact on Survival\\n\\n1. **TP53:**\\n   - **Mechanism:** Regulates cell cycle, DNA repair, and apoptosis; mutations lead to unchecked proliferation.\\n   - **Impact:** Poor prognosis, as loss of checkpoint controls results in aggressive disease.\\n\\n2. **ERBB2 (HER2):**\\n   - **Mechanism:** Drives proliferation via receptor tyrosine kinase signaling.\\n   - **Impact:** Amplification associated with poorer survival, but targeted by therapies like trastuzumab that significantly improve outcomes.\\n\\n3. **PIK3CA:**\\n   - **Mechanism:** Part of the PI3K/AKT pathway, affecting growth and survival signaling.\\n   - **Impact:** Mutations link with variable survival outcomes—context-dependent due to possible therapeutic targets.\\n\\n4. **BRCA1/2:**\\n   - **Mechanism:** DNA repair through homologous recombination; mutations increase genomic instability.\\n   - **Impact:** Linked with high-grade tumors but offer targeted treatment opportunities (e.g., PARP inhibitors).\\n\\n5. **ESR1:**\\n   - **Mechanism:** Hormonal regulation by estrogen receptor signaling.\\n   - **Impact:** Estrogen receptor positivity generally implies better prognosis due to treatment responsiveness, though mutations can indicate resistance.\\n\\n6. **CDH1:**\\n   - **Mechanism:** Cell adhesion molecule, critical in maintaining tissue architecture.\\n   - **Impact:** Loss facilitates lobular cancer, characterized by diffuse spread, challenging early detection, and variable outcomes.\\n\\n### Conclusion: Synthesis of Key Survival Risk Factors\\n\\n**Clinically Relevant Insights:**\\n\\n- **Genomic Complexity:** Breast cancer survival is markedly influenced by genetic variations within and between histological types, highlighting the need for precise genomic assessments.\\n- **Histological Diversity:** Mixed histology in lobular carcinoma demands individualized diagnosis and follow-up strategies due to varied biological behavior and treatment responses.\\n- **Sampling Considerations:** Comprehensive genomic profiling, considering inter-tumoral heterogeneity and leveraging advancements in single-cell sequencing, is vital for accurate survival predictions.\\n- **Targeted Therapies:** Understanding specific genetic aberrations offers pathways for personalized treatments, which are instrumental in improving patient survival outcomes, provided meticulous attention to resistance mutations and emerging therapeutic targets.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894001, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=946, prompt_tokens=465, total_tokens=1411, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 57/704...\n",
      "ChatCompletion(id='chatcmpl-BAiUmvGBOv6RxwlDtdYX6VRKgqsPb', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin: Breast NOS Impact on Survival**\\n\\n1. **Metastatic Patterns**: Breast NOS (not otherwise specified) denotes tumors within breast tissue but excludes those originating from the skin (C44.5). Such tumors commonly metastasize to axillary lymph nodes, bone, liver, lungs, and brain. Early detection and local containment directly correlate with better survival rates due to reduced metastatic spread.\\n\\n2. **Patient Survival and Treatment Accessibility**: Breast NOS impacts survival by determining initial treatment strategies and potential systemic therapies. Its classification guides personalized medicine approaches, especially in hormone receptor-positive subtypes, which benefit from hormone therapy, improving survival rates. Accessibility to targeted treatments like HER2 inhibitors in some geographic regions enhances survival outcomes.\\n\\n**Histology: Paget Disease and Infiltrating Duct Carcinoma's Influence**\\n\\n1. **Paget Disease**: This rare form involves the skin and often the ducts underneath. Its mere presence can indicate an underlying malignancy which, left unchecked, can infiltrate local nodes, affecting survival negatively.\\n\\n2. **Infiltrating Duct Carcinoma (IDC)**: IDC is the most common form of breast cancer and primarily affects survival through its growth patterns and mutation load. The interplay between its histological features and prevalent mutations, such as TP53 and PIK3CA, significantly influences prognosis by dictating aggressiveness and treatment resistance.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\n1. **Limitations of Blood Derived Normal**: When comparing tumor to normal tissues (often blood-derived), discrepancies can arise due to differences in mutation load and microenvironment, leading to potential misinterpretation of mutation impacts on survival.\\n\\n2. **Primary Tumor Sampling**: Sampling the primary tumor gives an initial mutation profile but may not represent subsequent mutations acquired in metastases, skewing survival predictions. This bias emphasizes the necessity for comprehensive multi-region sampling for accurate prognostication.\\n\\n**Key Genes Impacting Survival**\\n\\n1. **TP53**: Functions as a tumor suppressor, regulating cell cycle and apoptosis. Mutations are associated with poorer outcomes due to unchecked proliferation and chemoresistance.\\n\\n2. **PIK3CA**: Involved in cell growth and survival pathways; mutations lead to increased proliferation and have variable effects on survival, often based on concurrent mutations and therapy access.\\n\\n3. **BRCA1/2**: Critical for DNA repair; mutations result in genomic instability and increased pathogenesis but also render tumors susceptible to PARP inhibitors, improving survival in responsive subtypes.\\n\\n4. **HER2 (ERBB2)**: Its amplification promotes aggressive growth; treatment with HER2 inhibitors significantly improves survival in positive cases.\\n\\n5. **ESR1**: Estrogen receptor gene; mutations, particularly in hormone receptor-positive cancers, can drive recurrence and resistance to hormonal therapies, impacting survival.\\n\\n6. **PTEN**: Regulates cell cycle by suppressing AKT signaling; loss of function mutations correlate with aggressive phenotypes and reduced survival.\\n\\n7. **GATA3**: A transcription factor family member, involved in DNA binding and regulating gene expression; mutations can affect differentiation and hormone response, influencing outcomes based on subtype.\\n\\n8. **CDH1**: Encodes E-cadherin; loss leads to increased invasiveness and metastasis, complicating treatment and survival.\\n\\n**Synthesis of Survival Risk Factors**\\n\\nIn conclusion, breast cancer survival is influenced by a complex interplay of tumor origin, histological characteristics, and genomic alterations, each contributing to treatment response and metastatic propensity. Understanding these factors, particularly the role of key genes and sampling limitations, aids in optimizing treatment strategies and improving patient survival. Clinically, focusing on integrating precise genetic profiling with histological insights and addressing sampling biases can better predict survival outcomes and guide tailored therapeutic interventions.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894020, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=767, prompt_tokens=463, total_tokens=1230, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 58/704...\n",
      "ChatCompletion(id='chatcmpl-BAiUwTdLZ54OOCQvRPTbdmBbTdxKe', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Breast Invasive Carcinoma and Its Impact on Survival**\\n\\n1. **Tumor Origin and its Influence on Survival:**\\n   - **Metastatic Patterns:** Breast invasive carcinoma primarily arises from glandular tissues and has a propensity to metastasize to lymph nodes, bones, lungs, liver, and brain. The high metastatic potential generally leads to poorer survival rates due to complications from distant disease spread.\\n   - **Patient Survival:** Prognosis is heavily influenced by early detection. Tumors originating from the breast (excluding skin involvement) tend to demonstrate varied survival rates based on the molecular subtype and stage at diagnosis.\\n   - **Treatment Accessibility:** Tumors confined to the breast tend to respond better to localized treatments such as surgery and radiation. Access to hormonal therapies, targeted therapies (e.g., HER2 inhibitors), and chemotherapy also significantly affects outcomes. Geographic and economic barriers can limit these treatments, particularly in low-resource settings.\\n\\n2. **Histology:**\\n   - **Paget Disease and Interaction with Mutation Profiles:**\\n     - This rare form involves the nipple-areola complex and is often associated with underlying ductal carcinoma. Despite its distinct histological pattern, its coexistence with invasive ductal carcinoma may complicate treatment and reduce survival due to potential for deeper tissue invasion.\\n   - **Infiltrating Duct Carcinoma (IDC):**\\n     - As the most common histological subtype, IDC is characterized by ductal structures infiltrating surrounding stroma. Survival is influenced by the grade and extent of invasion. Mutational profiles often include PIK3CA, TP53, and GATA3 mutations.\\n   - **Mutation Impact:**\\n     - Different histological subtypes often exhibit distinct mutational landscapes that affect survival. For instance, triple-negative breast cancer (TNBC), lacking estrogen, progesterone, and HER2 receptor expression, generally shows aggressive behavior and poor outcomes due to limited targeted treatment options.\\n\\n3. **Sampling Bias:**\\n   - **Limitations of Primary Tumor and Solid Tissue Normal:**\\n     - Genomic analysis often relies on biopsy samples from primary tumors or adjacent normal tissue. This can introduce bias as metastases may harbor distinct mutations not present in primary sites, thereby skewing survival predictions.\\n   - **Impact on Genomic Interpretation:**\\n     - Without comprehensive profiling including metastatic sites, reliance solely on primary tumor data may underestimate the tumor's heterogeneity, limiting the identification of resistance mechanisms or targetable mutations.\\n\\n4. **Key Genes and Their Biological Mechanisms Affecting Survival:**\\n   - **BRCA1/2:** Critical for DNA repair; mutations lead to genomic instability and increased cancer susceptibility. PARP inhibitors have been successful in improving outcomes for patients with these mutations.\\n   - **HER2 (ERBB2):** Overexpression leads to aggressive disease but also provides a target for therapies like trastuzumab, significantly improving survival.\\n   - **TP53:** Functions as a tumor suppressor. Mutations often result in unchecked proliferation and poor prognosis.\\n   - **PIK3CA:** Involved in cell growth signaling; mutations can activate pathways that lead to tumorigenesis. PI3K inhibitors are emerging as targeted therapies.\\n   - **ESR1:** Provides growth signals mediated through estrogen. Alterations can lead to hormone therapy resistance but also guide endocrine therapy choices.\\n   - **PTEN:** Loss leads to activation of the PI3K/AKT pathway, enhancing survival and proliferation of cancer cells.\\n   - **CDH1 (E-cadherin):** Critical for cell adhesion. Loss promotes invasion and metastasis.\\n\\n**Synthesis and Conclusion:**\\nBreast invasive carcinoma survival is profoundly influenced by a multitude of factors including the site of origin and histological subtype, both of which dictate metastatic behavior and treatment options. Key genomic alterations provide insights into therapeutic vulnerabilities, though these insights can be limited by sampling biases primarily when analyzing primary tumors.\\n\\nSurvival risk is multifactorially determined, requiring an integrated approach to treatment, including genetic testing, personalized medicine strategies, and addressing disparities in treatment accessibility. Incorporating these insights into clinical practice will refine prognostication and improve patient outcomes by aligning therapeutic strategies with the biological behavior of individual tumors.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894030, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=850, prompt_tokens=463, total_tokens=1313, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 59/704...\n",
      "ChatCompletion(id='chatcmpl-BAiVE2Pohbgs9WZdQv01C6OPHJzDo', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To thoroughly analyze the survival impacts of Breast Invasive Carcinoma (specifically Breast NOS excluding Skin of breast C44.5), let\\'s explore the factors in detail:\\n\\n### Tumor Origin:\\nBreast invasive carcinomas commonly originate from the ductal or lobular epithelium but the specific notation \"Breast NOS\" generally refers to tumors that do not fit conventional classifications. \\n\\n**Influences on Survival:**\\n- **Metastatic Patterns:** Breast NOS carcinomas can have unpredictable metastatic behavior due to lack of specific origin categorization. This uncertainty can delay or complicate staging and treatment decisions, negatively impacting survival.\\n- **Patient Survival:** Due to unclear pathological origins, treatment regimens might not be as targeted or effective initially, often requiring broader-spectrum chemotherapy, impacting survival negatively.\\n- **Treatment Accessibility:** Without specific features tied to more common subtypes, patients might have limited access to clinical trials or targeted therapies benefiting defined subcategories.\\n\\n**Biological Rationale:**\\n- **Heterogeneity:** Their undefined epithelial origin suggests a heterogeneous group possibly comprising varied molecular subtypes, each with distinct prognoses and responses to treatment.\\n\\n**Potential Biases:**\\n- **Sample Categorization:** Incorrect or generalized classification could lead to misinterpretation of metastatic potential and treatment options.\\n\\n### Histology:\\nOne noted histological type is the Metaplastic Carcinoma, NOS.\\n\\n**Influences on Survival:**\\n- **Mutation Profiles:** These tumors often carry high mutational burdens but lack specific targeted treatment options, which might complicate treatment strategies, negatively affecting survival.\\n  \\n**Biological Rationale:**\\n- **Diverse Differentiation:** Metaplastic carcinomas often exhibit metaplasia – the transdifferentiation of cells, leading to aggressive behavior and poor therapeutic response due to mixed histological patterns.\\n\\n**Potential Biases:**\\n- **Variability in Definition:** Histological variability within NOS categories can result in inconsistent treatment responses and outcomes, challenging standardization in clinical settings.\\n\\n### Sampling Bias:\\nCommon samples for genomic analysis include blood-derived normal tissue and primary tumor tissues.\\n\\n**Influences on Survival:**\\n- **Limitations:** Blood-derived DNA may not accurately reflect tumor heterogeneity, leading to potential misinterpretation regarding mutations that drive tumor behavior.\\n\\n**Biological Rationale:**\\n- **Genomic Variability:** Tumor heterogeneity may not be captured when comparing with germline DNA due to inherent cancer cell diversity which influences survival by impacting treatment effectiveness.\\n\\n**Potential Biases:**\\n- **Sampling Artifacts:** Normal blood samples lack intratumoral genetic variability, possibly skewing mutation significance assessment for survival-related analyses.\\n\\n### Key Genes:\\nSeveral genes are associated with survival in breast carcinoma, such as TP53, ERBB2 (HER2), BRCA1/2, PIK3CA, ESR1, PTEN, MYC, and AKT1.\\n\\n**Influences on Survival:**\\n- **TP53:** A tumor suppressor gene, mutations are associated with poor prognosis due to loss of apoptosis regulation.\\n- **ERBB2 (HER2):** Overexpression correlates with aggressive breast cancer but can be targeted by therapies such as trastuzumab, improving survival.\\n- **BRCA1/2:** Germline mutations confer high risk; however, targeted therapies like PARP inhibitors offer survival benefits.\\n- **PIK3CA:** Mutations often lead to unchecked cell proliferation but are actionable with PI3K inhibitors, potentially improving outcomes.\\n- **ESR1:** Estrogen receptor mutations can influence response to endocrine therapy, affecting survival in hormone receptor-positive cancers.\\n- **PTEN:** Loss of function is linked to PI3K/AKT pathway dysregulation, promoting survival in a negative context.\\n- **MYC and AKT1:** These are involved in cell cycle regulation and survival signaling, with aberrations often leading to aggressive phenotypes.\\n\\n**Biological Mechanisms:**\\n- **Proliferation, Apoptosis, and Immune response:** All these genes are involved in regulation, where disruption can directly affect tumor growth, metastasis, and response to immunotherapy.\\n\\n**Potential Biases:**\\n- **Variability in Sample Quality:** Sampling biases, especially in diverse tumor types, may impact gene mutation interpretations and their correlation to survival.\\n\\n### Conclusion:\\nIn synthesizing these elements, survival in Breast NOS is largely influenced by the undefined nature and heterogeneous nature of the tumors, histological variability, sampling biases, and the actionable genetic landscape. Clinically, a better understanding of specific molecular signatures and adaptive treatment strategies targeting identified genetic mutations could enhance patient outcomes significantly. The integration of comprehensive genomic profiling, avoiding sampling biases, remains crucial in accurately directing targeted therapies that offer the potential to improve survival rates in this cancer group.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894048, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=964, prompt_tokens=459, total_tokens=1423, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 60/704...\n",
      "ChatCompletion(id='chatcmpl-BAiVTc8kzbYgTEqRJNNYoz6o6psaN', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin and Survival Impact**\\n\\nBreast invasive carcinoma originates primarily from the epithelial cells lining the breast ducts or lobules, excluding skin origins (ICD-10: Breast NOS, excludes Skin of breast C44.5). This distinction is critical because:\\n\\n1. **Metastatic Patterns**: Breast NOS tends to metastasize to the bone, lungs, liver, and brain. These sites significantly influence patient survival due to their essential functions and complexities in treatment management.\\n\\n2. **Survival Influence**: Metastasis to these distant organs often marks a poorer prognosis. For instance, bone metastases might be managed with bisphosphonates or denosumab, but brain metastases are particularly challenging due to the blood-brain barrier, limiting chemotherapeutic efficacy.\\n\\n3. **Treatment Accessibility**: Some metastatic sites are more accessible to local treatments (e.g., stereotactic radiosurgery for brain metastases), while others (e.g., liver) might require systemic approaches, affecting overall survival strategies.\\n\\n**Histology and Mutation Impact**\\n\\nPhyllodes tumors, particularly malignant ones, are rare but aggressive and affect survival through:\\n\\n1. **Mutation Profiles**: Malignant Phyllodes tumors often exhibit mutations in key growth and proliferation pathways. Unlike typical invasive ductal carcinomas, Phyllodes tumors might present KIT (CD117) mutations, contributing to unchecked growth.\\n\\n2. **Survival Outcomes**: Mutations amplify proliferative signaling, resulting in rapid growth, which may necessitate aggressive surgical management. The histological grade correlates with outcomes; high-grade variants show quick metastasis, reducing survival.\\n\\n3. **Histopathological Influence**: The fibro-epithelial components of Phyllodes tumors may obscure underlying mutations during genomic profiling, impacting the treatment selection and surveillance strategies.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\nThe utilization of **Blood Derived Normals** and **Primary Tumor Samples** presents certain challenges:\\n\\n1. **Tumor Heterogeneity**: Primary tumors display significant genetic heterogeneity. Sampling a singular section may not capture the full mutation spectrum, leading to potential oversight of critical driver mutations.\\n\\n2. **Blood Derived Normal**: This method serves as a control to identify somatic mutations, but it may miss circulating tumor DNA or rare subclones present in the blood, failing to reflect true tumor diversity.\\n\\n3. **Bias Impact on Survival Prognostication**: Misrepresentations of the tumor’s genetic landscape could result in suboptimal therapeutic targeting, thereby influencing survival outcomes adversely.\\n\\n**Key Genes and Survival**\\n\\nFocusing on survival-associated genes, the following influence breast cancer prognosis:\\n\\n1. **TP53**: Mutation often leads to loss of normal p53 function, impairing cell cycle arrest and apoptosis, thereby allowing cancer progression.\\n\\n2. **PIK3CA**: Frequently mutated in breast cancer, enhances cell proliferation via the PI3K/Akt pathway, implicating poorer survival outcomes in mutant variants.\\n\\n3. **BRCA1/2**: Germline mutations increase hereditary breast cancer risk, lead to homologous recombination repair defects, and define therapy choices like PARP inhibitors.\\n\\n4. **HER2**: Amplification leads to aggressive cancer phenotypes with initially poor prognosis; however, targeted therapies (e.g., trastuzumab) have significantly improved survival.\\n\\n5. **ESR1**: Hormone receptor status (ER+) determines hormonal management approaches. Mutations in ESR1 may result in endocrine therapy resistance, impacting survival.\\n\\n6. **CDH1**: Associated with loss of adhesion and increased metastatic potential, E-cadherin loss correlates with poor outcomes.\\n\\n7. **Ki-67**: High proliferation index suggests rapid tumor growth; often correlated with aggressive behavior but also predicts response to chemotherapy.\\n\\n**Conclusion**\\n\\nKey survival risk factors in breast invasive carcinoma include metastatic sites, tumor heterogeneity, histological aggressiveness, and genetic mutations. Clinically, integrating histological evaluation with comprehensive genomic profiling underpins personalized treatment plans. Recognizing sampling biases and leveraging genomic insights significantly impacts therapeutic decisions and thus survival rates. Improved patient outcomes hinge on accurate, holistic profiling and targeted, dynamic treatment strategies.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894063, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=845, prompt_tokens=459, total_tokens=1304, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 61/704...\n",
      "ChatCompletion(id='chatcmpl-BAiVfxql7ifkYolMYzsAQDLPD9jGF', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin: Breast NOS (Excludes Skin of Breast C44.5)**\\n\\n1. **Survival Influence**\\n   - Breast NOS represents breast tissue origin without specific histological subtype identification. This classification may suggest a delay or inappropriateness in tailored treatment approaches.\\n   - It influences metastatic patterns as tumors are categorized late, potentially leading to the spread to common sites such as bones, lungs, liver, and brain, often identified late in progression, negatively impacting survival.\\n\\n2. **Biological Rationale**\\n   - The unclear origin complicates early detection, resulting in delayed intervention and often worsened prognosis. \\n   - These tumors may lack distinct receptor statuses guiding therapies, such as HER2 or hormone receptor-targeted treatments, contributing to survival challenges.\\n\\n3. **Potential Biases in Genomic Interpretation**\\n   - Tumors categorized under NOS can suffer from sampling biases where genomic databases may not accurately capture their profiles due to heterogeneity.\\n   - Broad classifications may obscure molecular subtypes under-represented in genomic studies, affecting the interpretation of genomic data and survival projections.\\n\\n**Histology: Cribriform Carcinoma, NOS**\\n\\n1. **Survival Influence**\\n   - Cribriform carcinoma typically presents with favorable survival outcomes due to its indolent nature compared to more aggressive forms.\\n   - Mutations found in these tumors often align with less aggressive biological behavior, aiding in better prognosis.\\n\\n2. **Biological Rationale**\\n   - Often estrogen receptor-positive, cribriform carcinomas tend to proliferate under hormonal regulation rather than through aggressive mutations, thus responding well to hormone therapies.\\n\\n3. **Potential Biases in Genomic Interpretation**\\n   - Histological niche might be underrepresented in broader genomic surveys, introducing bias in the data due to a focus on more prevalent subtypes.\\n   - Misinterpretation risks may occur if sampling does not distinguish tissue architecture accurately.\\n\\n**Sampling Bias: Blood Derived Normal, Primary Tumor**\\n\\n1. **Survival Influence**\\n   - Sampling bias can skew genomic survival analyses, potentially misrepresenting mutation frequencies and pathways active in tumor promotion or suppression.\\n   - Blood-derived normals sometimes fail to capture tissue-specific mutations crucial for accurate survival prognostication.\\n\\n2. **Biological Rationale**\\n   - Tumors display intra-tumoral heterogeneity, leading to differing genomic landscapes within a single tumor mass.\\n   - Blood-derived normals might fail to account for the somatic mosaicism present only within tumor tissues.\\n\\n3. **Potential Biases in Genomic Interpretation**\\n   - Blood samples may not reflect tumor microenvironment dynamics accurately, failing to include stromal or immune component influences on cancer evolution and survival.\\n   - Comparative analysis can produce false negatives for tissue-specific mutations.\\n\\n**Key Genes Influencing Survival**\\n\\n1. **TP53**: Tumor suppressor involved in DNA repair and apoptosis. Mutations often result in poor survival due to lost cellular damage control.\\n   \\n2. **BRCA1/BRCA2**: Integral in DNA repair pathways. Mutations predispose to aggressive phenotypes and higher recurrence rates but can make tumors susceptible to PARP inhibitors.\\n\\n3. **PIK3CA**: Involved in cell growth signaling. Mutational impacts vary but can affect sensitivity to specific inhibitors and generally indicate a worse prognosis.\\n\\n4. **ERBB2 (HER2)**: Overexpression leads to aggressive tumor behavior but also targets for therapy, improving survival through HER2-targeted treatments.\\n\\n5. **PTEN**: Tumor suppression via regulatory pathways. Loss can result in unchecked growth signaling.\\n\\n6. **CDH1**: Encodes E-cadherin, crucial for cell adhesion. Mutations link to metastatic potential and poorer survival.\\n\\n7. **MYC**: Oncogene driving cell proliferation. Overexpression often signifies more aggressive, treatment-resistant cancers.\\n\\n8. **AKT1**: Participates in survival signaling, with mutations correlating to survival pathway alterations, providing rational targets for therapy.\\n\\n**Synthesis and Clinical Insights**\\n\\nThe survival impacts in breast cancer are profoundly linked to origin, histology, sampling approaches, and genetic underpinnings. Origin factors shape metastatic pathways and accessibility to the right treatment, while specific histological types determine biological behavior and pharmacological targeting. Sampling biases necessitate nuanced interpretation to ensure accuracy. Key genes markedly influence survival through pathways governing DNA repair, growth, and apoptosis. Acknowledging these factors provides strategies for personalized therapy, ensuring improved patient management and survival outcomes. The integration of such multifaceted insights into clinical practice furthers the potential for tailored interventions fostering longer, quality survivals.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894075, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=930, prompt_tokens=450, total_tokens=1380, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 62/704...\n",
      "ChatCompletion(id='chatcmpl-BAiVz7SIQnN6rQRjBMHNybyq8UJ9n', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"# Impact of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma on Survival\\n\\n## Tumor Origin\\n\\n### Influence on Survival\\n- **Endocervical adenocarcinoma**, origin in endocervical glands, shows differing metastatic patterns from squamous cell carcinoma, often spreading to pelvic lymph nodes and distant organs like the lungs more readily due to its glandular nature.\\n- This differential pattern affects survival negatively, as adenocarcinomas are often detected at a later stage compared to squamous cell carcinoma, which may remain local longer.\\n\\n### Biological Rationale\\n- Endocervical adenocarcinomas tend to develop deeper into cervical tissue, making initial identification challenging and leading to later diagnosis when metastasis has likely occurred.\\n- Accessibility to effective treatment diminishes as the disease advances beyond locoregional containment.\\n\\n### Potential Biases\\n- Sampling may not fully capture dynamic metastasis evolution, particularly if biopsy misses deeper, more aggressive areas within the tumor.\\n\\n## Histology\\n\\n### Influence on Survival\\n- **Squamous cell carcinoma, NOS (not otherwise specified)** has a variable mutation profile, which influences prognosis.\\n- High-grade transformations and the ability to evade immune detection due to genetic mutations tend to worsen survival outcomes.\\n\\n### Biological Rationale\\n- Histology affects the tumor microenvironment and its interaction with immune cells.\\n- Tumors with alterations in immune evasion pathways, like PD-L1 expression, can persist despite immune surveillance, complicating treatment and reducing survival.\\n\\n### Potential Biases\\n- Sampling from primary sites may not reflect heterogeneity; critical aggressive clones could be underrepresented if sampling is superficial.\\n\\n## Key Genes Impacting Survival\\n\\n1. **TP53**: A tumor suppressor critical in apoptosis regulation; mutations often lead to unregulated tumor growth and poor prognosis.\\n2. **PIK3CA**: Involved in signaling for cell proliferation; mutations correlate with aggressive cervical cancer phenotypes.\\n3. **HRAS**: Promotes cell division; mutations can increase invasiveness, reducing survival.\\n4. **EGFR**: Overexpression influences greater mitotic activity and resistance to apoptosis.\\n5. **CDKN2A (p16/INK4a)**: Typically inactivated, leading to uncontrolled cell cycle progression.\\n6. **PTEN**: Altered in cancerous tissues, it leads to disrupted cell cycle arrest mechanisms.\\n7. **BRCA1/2**: Though less common, mutations can affect DNA repair capabilities, leading to heightened genomic instability.\\n8. **PD-L1**: Immune checkpoint regulator; overexpression can allow tumor cells to escape immune surveillance, affecting treatment response and survival.\\n\\n### Biological Mechanisms\\n- Alterations in these genes affect not just the tumor cell's proliferative capacity but also interactions with the surrounding stroma and immune environment, crucially impacting therapeutic resistance and disease trajectory.\\n\\n### Potential Biases\\n- Blood-derived samples may not accurately capture tumor-specific mutations, causing potential misinterpretation of mutation burden and heterogeneity.\\n- Primary tumor samples might not reflect metastatic lesions' more aggressive genomic alterations, impacting treatment efficacy predictions.\\n\\n## Synthesis of Key Survival Risk Factors\\n\\n- **Early Detection and Histological Type**: Early-stage detection of squamous cell carcinoma generally offers better outcomes than adenocarcinomas due to their metastatic propensity and delayed detection.\\n- **Genetic Mutations and Expression Profiles**: The presence and type of mutations significantly dictate survival odds. Mutations in TP53, PIK3CA, or high PD-L1 expression often correlate with poorer outcomes.\\n- **Sampling and Genomic Interpretation**: Accuracy of genomic data requires careful sampling to reflect true tumor heterogeneity. Misguided by sampling bias, treatment decisions can lead to suboptimal management.\\n\\nOverall, a comprehensive understanding of the tumor's origin, precise histological classification, and detailed genomic profiling, while accounting for potential biases, are paramount in formulating effective, personalized treatment strategies to enhance survival outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894095, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=804, prompt_tokens=454, total_tokens=1258, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 63/704...\n",
      "ChatCompletion(id='chatcmpl-BAiWFH3DkGMYGIfiotKKcsringqg4', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin and Impact on Survival**\\n\\n**Endocervical Influence on Metastatic Patterns:**\\nEndocervical adenocarcinomas typically arise in the glandular cells lining the cervical canal. Their origin influences metastatic spread, often involving the lymphatic system more extensively than squamous cell types. This proclivity affects the staging at diagnosis, which is crucial given that advanced stages correlate with poorer survival rates.\\n\\n- **Survival Influence:** Tumors originating from the endocervix may have a more aggressive lymphatic spread, decreasing survival odds in cases with advanced metastatic disease.\\n\\n- **Biological Rationale:** The endocervical location enables easier access to the regional lymph nodes, enhancing the probability of metastasis. The rich vascular and lymphatic network supports quick dissemination and impacts the therapeutic approach, often necessitating more aggressive systemic treatments.\\n\\n- **Potential Biases:** Geographic and healthcare accessibility biases are prevalent, where regions with limited access to screening programs may diagnose these cancers at more advanced stages, influencing survival data.\\n\\n**Histology and Its Interaction with Mutation Profiles**\\n\\n**Endometrioid Adenocarcinoma, NOS:**\\nIn cervical cancers, endometrioid histology can often suggest a different molecular pathology. It may exhibit distinct mutational profiles compared to squamous histologies.\\n\\n- **Survival Influence:** The histologic subtype contributes to therapeutic decisions, where certain histologies like endometrioid might predict differing sensitivities to hormone-based therapies or specific chemotherapeutic agents, influencing survival.\\n\\n- **Biological Rationale:** The unique genomic mutations in endometrioid adenocarcinomas (e.g., PI3K/AKT/mTOR pathway alterations) can modify tumor behavior, affecting growth, resistance mechanisms, and ultimately patient outcomes.\\n\\n- **Potential Biases:** Sampling methods could miss mutations due to tumor heterogeneity, with endometrioid areas possibly having different genomic landscapes compared to other parts of the tumor.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\n**Blood-Derived Normal vs. Primary Tumor:**\\nGenomic analyses often compare tumor DNA with control samples from blood, assuming somatic mutations. However, this assumes the absence of germline mutations impacting tumor biology.\\n\\n- **Survival Influence:** If germline mutations affecting tumor-promoting pathways (like BRCA) are missed, treatment choices might not effectively target these pathways, impacting survival outcomes.\\n\\n- **Biological Rationale:** Blood-derived normals may not capture the full scope of inherited genetic susceptibilities, which could influence cancer behavior and patient resilience to therapies.\\n\\n- **Potential Biases:** Tumor heterogeneity means primary tumor downsamples might not represent the entire mutational load effectively, skewing survival predictions based on incomplete data.\\n\\n**Key Genes Influencing Survival**\\n\\n1. **TP53 (Proliferation and Apoptosis Regulation):** Often mutated in cervical cancers, leading to evasion of growth arrest and apoptosis, negatively affecting survival.\\n   \\n2. **PIK3CA (Pathway Activation in Cell Proliferation):** Activating mutations foster uncontrolled growth by enhancing AKT signaling, correlating with aggressive disease and poor survival.\\n\\n3. **MYC (Oncogene in Cell Cycle Regulation):** Amplification or overexpression promotes rapid cell division and is associated with advanced disease stages.\\n\\n4. **CDKN2A (Tumor Suppressor):** Loss or dysfunction leads to uncontrolled cell cycle progression, common in aggressive tumors, negatively impacting survival.\\n\\n5. **KRAS (Signal Transduction):** Mutations contribute to resistance against targeted therapies and chemotherapy, with significant survival implications in non-responsive cases.\\n\\n6. **FGFR3 (Growth Factor Receptor):** Alterations can lead to enhanced cell survival and proliferation, especially relevant in hormone-resistant pathways.\\n\\n7. **PD-L1 (Immune Evasion):** Overexpression enables cancer cells to escape immune surveillance, reducing effectiveness of immune-based therapies.\\n\\n8. **BRCA1/BRCA2 (DNA Repair):** Loss through mutation or epigenetic silencing reduces repair fidelity, sometimes exploited therapeutically but often leading to more aggressive tumors when unchecked.\\n\\n**Concluding Synthesis**\\n\\nCervical cancer survival is intricately linked to the interplay between tumor origin, histological subtype, genomic mutations, and subsequent therapeutic responses. Origin and histology influence metastatic potential and treatment pathways, while genetic mutations provide insight into targeted therapy options. Sampling biases must be addressed to ensure accurate mutation identification and corresponding treatment adaptations. Effective management requires integrating these biological insights to optimize patient outcomes, emphasizing personalized treatment strategies adapted to the unique risk profiles inherent in each patient's tumor biology.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894111, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=933, prompt_tokens=458, total_tokens=1391, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 64/704...\n",
      "ChatCompletion(id='chatcmpl-BAiWX548bhrE2p9SO7FILhnIAUikl', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Cervical squamous cell carcinoma often involves the human papillomavirus (HPV) and tends to metastasize locally to the pelvis before distant spread, affecting regional lymphatics. Endocervical adenocarcinoma, especially those of the gastric type, can have more aggressive distant metastatic behaviors. This impacts survival negatively due to earlier systemic progression.\\n- **Patient Survival:** Adenocarcinomas, particularly more aggressive subtypes like the gastric type, generally have a poorer prognosis compared to squamous cell types. This is partly due to their less predictable patterns of spread and resistance to certain therapies.\\n- **Treatment Accessibility:** Squamous cell carcinomas are often more amenable to conservative treatments (e.g., surgery and radiotherapy), while adenocarcinomas may present later and require more extensive systemic approaches.\\n\\n**Biological Rationale:**\\n- The origin in the endocervix and histological differences play a crucial role in progression due to exposure to different microenvironments and HPV types, influencing DNA repair and genetic mutation mechanisms.\\n\\n### Histology\\n\\n**Mucinous Carcinoma, Gastric Type:**\\n- **Interaction with Mutation Profiles:** These tumors often have unique mutation profiles, possibly involving KRAS and TP53 mutations. The biological pathways include cell growth signaling alterations.\\n- **Survival Outcomes:** Such histological subtypes exhibit resistance to standard chemotherapy, leading to poorer outcomes.\\n\\n**Biological Rationale:**\\n- Histological differences affect the tumor environment interactions and immune evasion capabilities. Gastric-type mucinous adenocarcinomas often resist apoptosis, which worsens prognosis.\\n\\n### Sampling Bias\\n\\n**Limitations in Genomic Analysis:**\\n- **Blood Derived Normal vs. Primary Tumor:** The use of blood-derived DNA as a comparison in genomic studies may fail to capture tumor-specific mutations that are highly localized, leading to oversight of crucial mutational landscapes.\\n- This bias impacts survival predictions as it might lead to over or under-estimation of certain aggressive signatures that are present predominantly in tumor tissues.\\n\\n**Biological Rationale:**\\n- Tumor heterogeneity is inadequately represented, which can skew predictive models for personalized treatment planning, thus influencing actual clinical outcomes.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes:**\\n\\n1. **TP53:** Mutations in TP53 are associated with poor survival due to delayed apoptosis and enhancement of genetic instability.\\n2. **PIK3CA:** Activating mutations lead to sustained proliferative signaling, hindered DNA repair, reducing survival.\\n3. **PTEN:** Loss of PTEN is linked to oncogenic signaling unopposed, especially in adenocarcinomas, adversely affecting prognosis.\\n4. **EGFR:** Overexpression or mutation enhances proliferative and survival pathways, contributing to therapy resistance.\\n5. **CDKN2A (p16):** Its loss or inactivation is often linked to uncontrolled cell cycle progression, common in HPV-related cancers.\\n6. **SMAD4:** Alterations here can disrupt TGF-β mediated cell cycle arrest and pro-apoptotic signals.\\n7. **BRCA1/2:** Mutations may confer sensitivity to specific DNA-damage-based therapies but generally indicate poor repair capabilities and thus worsened outcomes.\\n8. **KRAS:** Often mutated in gastric-type adenocarcinomas, leading to persistent proliferative signaling.\\n\\n**Biological Rationale:**\\n- These genes regulate critical pathways like cell cycle control, apoptosis, DNA repair, and cellular communication. Dysfunctional pathways significantly sway survival outcomes.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nThe intersection of tumor origin, histology, and molecular profiling constructs a complex landscape dictating cervical cancer survival. Histological subtleties play a substantial role in treatment responses. The genomic insights, while advancing, face challenges due to sampling biases impeding personalized oncology advances. Clinically, understanding these factors directs treatment stratification and might enhance prognostic accuracy.\\n\\nBy focusing on origin-specific metastatic potentials, histological aggressiveness, and pivotal genetic mutations, one can better tailor interventions, ultimately aiming to improve patient survival outcomes. The realization of these factors in clinical settings will enhance not only prognosis estimates but also guide impactful precision therapeutics.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894129, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=864, prompt_tokens=455, total_tokens=1319, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 65/704...\n",
      "ChatCompletion(id='chatcmpl-BAiWs1o5RRLe2dNkrrUwdueqYacPH', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Cervical squamous cell carcinoma (SCC) and endocervical adenocarcinoma** both originate from the cervix, but from distinct components: the exocervix and endocervix respectively. The exocervix's location typically results in earlier symptomatic presentation and accessibility to screening, potentially improving early detection rates and outcomes.\\n\\n**Metastatic Patterns:**\\n- **Squamous Cell Carcinoma:** Tends to remain localized longer compared to adenocarcinoma, which can exhibit a more aggressive spread pattern due to its glandular origin, potentially impacting survival negatively.\\n  \\n**Treatment Accessibility:**\\n- The exocervical location allows for easier access during procedures such as biopsies and surgical interventions, enhancing treatment responsiveness, especially in early stages.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n- **Squamous Cell Carcinoma, NOS (Not Otherwise Specified):** Histological subtype influences response to chemoradiotherapy. SCC is typically more sensitive to radiation due to the keratinizing nature of the cells, aiding in treatment effectiveness.\\n\\n**Mutation Profiles:**\\n- **Interaction with Mutation Profiles:** SCC is often associated with fewer actionable mutations compared to adenocarcinomas, where mutations might be more diverse, impacting targeted therapy viability and outcomes. SCC tends to have a better prognosis when caught early due to predictable treatment responses.\\n\\n### Sampling Bias\\n\\n**Limitations:**\\n- **Blood Derived Normal vs. Primary Tumor Samples:** Blood-derived samples might not capture the full mutational landscape of the primary tumor. This can lead to misinterpretation of tumor heterogeneity and underrepresentation of mutations crucial for targeted therapy.\\n\\n**Genomic Analysis Impact:**\\n- False negatives can occur if the primary biopsy sample doesn't capture areas of high mutation due to geographical heterogeneity. This affects the understanding of resistance mechanisms and leads to suboptimal treatment planning.\\n\\n### Key Genes\\n\\n1. **TP53**:\\n   - **Role:** Tumor suppressor involved in apoptosis regulation.\\n   - **Impact:** Mutations usually result in loss of cell cycle control, leading to unregulated cell proliferation, and thus, poorer survival outcomes.\\n\\n2. **PIK3CA**:\\n   - **Role:** Involved in the PI3K/AKT pathway, promoting cell growth and survival.\\n   - **Impact:** Mutations can drive oncogenesis, but targeted therapies (e.g., PI3K inhibitors) can improve outcomes in patients with these mutations.\\n\\n3. **CDKN2A (p16INK4a)**:\\n   - **Role:** Regulates the cell cycle by inhibiting cyclin-dependent kinase.\\n   - **Impact:** Loss or mutation leads to unchecked cell division, correlating with aggressive tumor behavior and survival impacts.\\n\\n4. **EGFR**:\\n   - **Role:** Promotes cell proliferation and survival via signaling cascade activation.\\n   - **Impact:** Overexpression can indicate poor prognosis, but EGFR inhibitors offer targeted treatment options.\\n\\n5. **BRCA1/BRCA2**:\\n   - **Role:** DNA repair.\\n   - **Impact:** Mutations can contribute to genomic instability, enhancing aggressiveness but providing avenues for PARP inhibitor therapies.\\n\\n6. **KRAS**:\\n   - **Role:** GTPase involved in cell signaling pathways.\\n   - **Impact:** Mutations are linked with aggressive behavior and resistance to certain chemotherapies.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n**Clinically Relevant Insights:**\\n- The tumor origin (exocervix) and the histology (SCC or adenocarcinoma) significantly influence clinical management and survival, emphasizing the need for tailored treatment strategies.\\n- Gene expression and mutation profiles highlight potential therapeutic targets, with implications for personalized medicine approach.\\n- Sampling biases underscore the necessity for comprehensive biopsy techniques to ensure representative genomic analyses.\\n\\n**Survival Impact:**\\n- Emphasizing early detection and accurate molecular characterization significantly enhances survival outcomes. Evolution of treatment strategies, focusing on genomic-tailored therapies, ensures improved prognosis and decreases mortality in cervical cancer, highlighting the importance of integrating genomic insights into clinical practice.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894150, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=842, prompt_tokens=454, total_tokens=1296, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 66/704...\n",
      "ChatCompletion(id='chatcmpl-BAiX4m1oXDch5Y6PqEiXIeAOJaEd7', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Certainly. Let's delve into the requested aspects of cervical squamous cell carcinoma (SCC) and endocervical adenocarcinoma as they relate to survival:\\n\\n### Tumor Origin\\n\\n**Influence on Survival:**\\n\\n1. **Metastatic Patterns:** \\n   - **Cervix Uteri Origin:** Cervical cancers, due to their anatomical position, often metastasize to regional lymph nodes and distant sites such as the lungs, liver, and bones. The presence of regional lymph node involvement is a significant negative prognostic marker that greatly diminishes survival rates.\\n\\n2. **Patient Survival:**\\n   - **Treatment Accessibility:** Cervical cancer, often influenced by socio-economic status, may affect access to early detection (e.g., Pap smears) and timely treatment. Socio-economic disparities significantly impact survival outcomes.\\n\\n3. **Biological Rationale:** \\n   - The cervix's role as a gateway for metastasis emphasizes the importance of lymph node surveillance in directing adjuvant therapy, potentially improving survival through early identification and treatment of metastases.\\n\\n### Histology\\n\\n**Interaction with Mutation Profiles:**\\n\\n1. **Papillary Squamous Cell Carcinoma:**\\n   - **Outcomes:**\\n     - This variant may exhibit aggressive behavior with high recurrence rates, directly impacting survival negatively. Its papillomatous architecture sometimes correlates with resistance to standard therapies.\\n\\n2. **Mutation Profiles:**\\n   - **Interrelation:**\\n     - Certain mutations, such as TP53 or CDKN2A alterations, common in SCC, interact with cellular pathways governing cell cycle and apoptosis, potentially leading to therapeutic resistance.\\n\\n**Biological Rationale:**\\n- Mutations affecting cell cycle regulators can lead to unchecked cellular proliferation and enhanced survival of cancer cells, complicating treatment.\\n\\n### Sampling Bias\\n\\n**Limitations in Genomic Analysis:**\\n\\n1. **Blood Derived Normal:**\\n   - The use of peripheral blood as a control for somatic mutation analysis may miss tumor-specific alterations, leading to underestimation of mutation burden or false negatives.\\n\\n2. **Primary Tumor Sampling:**\\n   - Biopsies may not capture the heterogeneity of the tumor, missing subclonal populations that hold prognostic significance, thereby potentially misguiding treatment strategies.\\n\\n**Potential Biases:**\\n- Such biases can lead to incomplete mutational assessments, altering prognostic predictions and responses to targeted therapies.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes:**\\n\\n1. **TP53:** \\n   - **Mechanism:** A critical tumor suppressor; mutations lead to genomic instability, impacting DNA repair mechanisms.\\n2. **PIK3CA:**\\n   - **Role in Proliferation:** Driving cellular growth and survival through the PI3K/AKT pathway; mutations are often associated with reduced responsiveness to PI3K inhibitors.\\n3. **CDKN2A:**\\n   - **Cell Cycle Regulation:** Acts as a regulator, and loss of function can lead to unchecked cell division.\\n4. **KMT2D:**\\n   - **Chromatin Modulation:** Involvement in epigenetic regulation affects gene expression profiles promoting oncogenesis.\\n5. **ERBB2 (HER2):**\\n   - **Growth Signal Modulation:** Overexpression or mutation can drive tumor progression and affects survival through aggressive growth patterns.\\n6. **FGFR3:**\\n   - **Signal Transduction:** Partners with growth factors in promoting malignant behavior.\\n\\n**Biological Rationale:**\\n- These genes regulate critical pathways in tumor biology, influencing proliferation, invasion, and apoptosis—key survival determinants.\\n\\n### Conclusion\\n\\n**Synthesis of Key Survival Risk Factors:**\\n\\n1. **Clinically Relevant Insights:**\\n   - The interplay between the tumor's original site, mutation profiles, and overarching histological characteristics provides a comprehensive insight into treatment modalities and survival outcomes.\\n   - Recognition of genomic intricacies and addressing sampling biases is crucial for accurate prognosis and tailored therapy strategies.\\n\\n2. **Impact on Patient Survival:**\\n   - A deep understanding of these molecular mechanisms augments personalized oncology practices, aiming to enhance patient survival through precision medicine approaches and improved early detection strategies. \\n\\nOverall, optimizing survival in cervical cancer hinges on integrating rigorous genomic and histopathological insights with clinical management protocols.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894162, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=861, prompt_tokens=454, total_tokens=1315, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 67/704...\n",
      "ChatCompletion(id='chatcmpl-BAiXP6gNxj7ebyqhEjhfvKEJkVDrK', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Certainly. Let's examine the impact of Cervical Squamous Cell Carcinoma (SCC) and Endocervical Adenocarcinoma on survival by dissecting the contributing factors step-by-step:\\n\\n### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns and Survival:**\\n   - **Cervix uteri origin:** This is critical as the cervical location impacts lymphatic spread. The cervix has rich lymphatic drainage, which predisposes to regional lymph node metastasis before distal hematogenous spread.\\n   - **Survival Impact:** Early lymphatic involvement correlates with poorer prognosis due to potential regional and distant metastasis. Timely detection and treatment often improve outcomes.\\n\\n2. **Treatment Accessibility:**\\n   - **Locale and Resources:** Patients in regions with limited healthcare access may face delayed diagnosis and treatment, contributing negatively to survival.\\n   - **Early Intervention:** Accessible screening programs, like the Pap smear and HPV testing, detect pre-cancerous changes enhancing early intervention and increasing survival rates.\\n\\n### Histology: Squamous Cell Carcinoma vs. Adenocarcinoma\\n\\n1. **Histological Differences:**\\n   - **Squamous Cell Carcinoma:** Typically originates from the ectocervix, often linked with HPV infection.\\n   - **Endocervical Adenocarcinoma:** Arises from glandular cells, may be less frequently associated with HPV, and presents more diagnostic challenges.\\n\\n2. **How Histology Affects Mutation Profiles and Outcomes:**\\n   - **Mutation Variability:** SCC is often characterized by mutations in tumor suppressor genes like TP53 and proto-oncogenes, while adenocarcinomas may harbor mutations in genes such as KRAS.\\n   - **Survival Outcomes:** SCC usually responds well to radiation therapy when diagnosed early, whereas adenocarcinoma can be more aggressive and resistant to some chemotherapy regimens, impacting survival negatively.\\n\\n### Sampling Bias\\n\\n1. **Blood Derived Normal vs. Primary Tumor:**\\n   - **Sample Types:** Blood-based samples might underestimate tumor heterogeneity, missing somatic mutations present only in the tumor.\\n   - **Bias Influence:** Primary tumors provide a more comprehensive genomic profile, but biopsy site and method can miss some cancerous regions, introducing bias in analysis.\\n\\n2. **Genomic Analysis Limitations:**\\n   - **Clonal Architecture:** Tumor biopsy sampling may not capture all subclones, leading to biased conclusions on mutation prevalence and resistance mechanisms, affecting treatment strategy decisions.\\n\\n### Key Genes and Biological Mechanisms\\n\\n1. **TP53:** Regulates DNA repair and apoptosis; mutations often lead to unchecked cell proliferation.\\n2. **PIK3CA:** Involved in cell growth pathways; mutations can drive aggressive behavior and poor survival.\\n3. **PTEN:** Tumor suppressor that regulates cell cycle progression; its loss can lead to uncontrolled cell division.\\n4. **CDKN2A (p16):** Frequently impacted in HPV-associated cancers; regulates cell cycle arrest, with mutations linked to poor prognosis.\\n5. **EGFR:** Often overexpressed, promoting cell proliferation; targeted therapies against it may improve outcomes.\\n6. **KRAS:** Mutations are more common in adenocarcinoma, complicating treatment and reducing survival prospects.\\n7. **BRCA1/2 (often more related to breast/ovarian, but overlap in repair pathways is relevant):** Involved in DNA repair, with mutations potentially enhancing sensitivity to certain treatments (e.g., PARP inhibitors).\\n\\n### Conclusion: Key Survival Risk Factors\\n\\n- **Early Detection and Treatment Access:** Strongest positive influence on survival, linked to effective screening and public health infrastructure.\\n- **Genomic Landscape:** Determines tailored treatment opportunities and prognostic predictions; focused therapies can mitigate poor prognostic implications of high-risk genotypes.\\n- **Histology and Tumor Biology:** Drive response to therapy, particularly important in differential treatment strategies between squamous and glandular origins.\\n- **Potential Sampling Biases:** Must be recognized in genomic data interpretation, emphasizing the need for comprehensive tissue analysis.\\n\\nIn summary, cervical cancer survival is critically impacted by genetic mutations, histological type, and healthcare accessibility. Targeted treatment based on precise genomic insights and early diagnosis are pivotal in improving outcomes. Recognizing biases and variability in tumor genetics plays a crucial role in creating accurate prognostic models and therapeutic approaches, ensuring an optimized, individualized treatment plan for each patient.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894183, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=893, prompt_tokens=454, total_tokens=1347, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 68/704...\n",
      "ChatCompletion(id='chatcmpl-BAiXgt14S9UOhDetzvRtiPHEMY8vJ', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Cervix Uteri and Metastatic Patterns:**\\n\\n- **Survival Impact:** The cervix uteri is anatomically positioned such that local disease can be constrained within the pelvic region initially, potentially slowing earlier metastatic spread. This localization can sometimes result in a better initial survival prognosis than other cancers that metastasize more aggressively from the primary site.\\n  \\n- **Biological Rationale:** The unique epithelial composition and vascular supply pattern can confine early disease progression. However, when metastasis occurs, common sites include the pelvic lymph nodes, lungs, and liver, reflecting patterns in lymphatic and hematogenous dissemination.\\n  \\n- **Treatment Accessibility:** The cervix is readily accessible for screening and biopsy, which allows for early detection and treatment, directly improving survival odds. Widespread implementation of HPV vaccination and Pap smears significantly impacts early detection, although disparities in access can cause survival variations among different populations.\\n\\n### Histology\\n\\n**Squamous Cell Carcinoma (SCC), NOS:**\\n\\n- **Survival Influence:** SCC of the cervix generally has distinct biological behavior characterized by a relatively more predictable local growth pattern compared to adenocarcinomas. This predictability allows for more standardized treatment approaches which can sometimes lead to better management outcomes.\\n  \\n- **Mutation Profiles:** Mutational patterns in SCC typically involve TP53 and PIK3CA mutations, contributing to cellular proliferation and tumor survival. Aberrations in these genes often lead to compromised apoptosis and unchecked tumor growth, negatively impacting survival.\\n  \\n- **Genomic Study Biases:** Sampling predominantly primary sites without concurrent metastatic samples can bias assessments of mutational load and potential treatment resistance, omitting insights into tumor evolution under treatment pressures.\\n\\n### Sampling Bias\\n\\n**Metastatic vs. Solid Tissue Normal:**\\n\\n- **Sampling Limitations:** Genomic profiling lacks comprehensive representation if limited to primary or non-representative metastatic sites. Differences between normal adjacent and the primary tumor tissue can lead to underestimation of mutation heterogeneity.\\n  \\n- **Survival Influence:** This biased genomic landscape can misinform treatment decisions, thereby affecting patient-specific therapeutic effectiveness and overall survival. Recognizing intratumor heterogeneity is crucial to developing resistance-averse treatment strategies.\\n\\n### Key Genes Associated with Survival\\n\\n1. **TP53:** Manages cell cycle and apoptosis. Mutations result in failed cell cycle checkpoints, leading to tumor survival advantages.\\n   \\n2. **PIK3CA:** Regulates cell growth pathways. Alterations can activate prosurvival PI3K/AKT signaling, often linked to poor survival outcomes.\\n   \\n3. **PTEN:** Tumor suppressor that inhibits PI3K/AKT pathway. Loss of its function exacerbates tumor progression via unchecked cellular proliferation.\\n   \\n4. **CDKN2A (p16):** Involved in cell cycle regulation. Its overexpression is a surrogate marker for HPV infection, impacting disease progression and therapy responsiveness.\\n   \\n5. **HRAS:** Gene typically mutated in cancer, influencing survival by driving cell proliferation and metastasis.\\n   \\n6. **KRAS:** Mutated KRAS can lead to continuous growth signals and resistance to apoptosis, negatively affecting survival rates.\\n   \\n7. **ARID1A:** Mutations in this chromatin remodeler can lead to epigenetic alterations and impaired DNA damage response, often worsening prognosis.\\n   \\n8. **NOTCH1:** Typically involved in cell differentiation; mutations can contribute to escape from growth control, aiding in oncogenesis.\\n\\n### Conclusion\\n\\nUnderstanding the interplay between tumor origin, histology, and genetic mutations in cervical cancers underscores the importance of early detection and intervention. The impact of genomic variations on treatment responses highlights the need for tailored management strategies to improve survival. Particular focus on genes like TP53, PIK3CA, and others offers pharmacogenomic insights into therapeutic avenues and resistance mechanisms. Overall, by integrating clinical, histological, and genetic frameworks, oncologists can refine prognosis and therapy, potentially enhancing survival outcomes for patients with cervical cancer.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894200, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=811, prompt_tokens=454, total_tokens=1265, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 69/704...\n",
      "ChatCompletion(id='chatcmpl-BAiXrkgVcioFl7E1HmHgOPT3mtTt5', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns:**\\n   - Cervical squamous cell carcinoma and endocervical adenocarcinoma originate from the cervix uteri. The cervix, due to its anatomical location, can lead to early local spread within the pelvic region and potentially to distant lymph nodes, influencing metastatic patterns. \\n   - **Biological Rationale:** The rich vascular and lymphatic networks surrounding the cervix facilitate regional dissemination before distant metastasis occurs.\\n   - **Impact on Survival:** Localized spread may permit early detection and intervention, potentially improving survival rates.\\n\\n2. **Patient Survival and Treatment Accessibility:**\\n   - Accessibility to prompt diagnosis and cervical cancer screening (e.g., Pap smear) directly affects survival outcomes. Early identification through screening allows for treatment at less advanced stages, which is crucial for higher survival rates.\\n   - **Biological Rationale:** Early stages have less extensive tumor development, leading to higher curability and better prognosis.\\n   - **Impact:** Areas with widespread screening programs typically see better survival outcomes compared to regions with limited access.\\n\\n### Histology\\n\\n1. **Interaction with Mutation Profiles:**\\n   - Squamous cell carcinoma, NOS, and endocervical adenocarcinoma have distinct histological features and mutation profiles. Histology directs treatment modalities and prognosis.\\n   - **Biological Rationale:** Squamous cell carcinomas often harbor mutations in tumor suppressor genes like TP53, while adenocarcinomas may show alterations in genes associated with hormonal pathways.\\n   - **Impact on Survival:** Specific mutations guide targeted therapies, influencing patient survival outcomes positively by personalizing treatment plans.\\n\\n### Sampling Bias\\n\\n1. **Limitations in Genomic Analysis:**\\n   - **Primary Tumor vs. Solid Tissue Normal:** Analyzing genomic data predominantly from primary tumors without comparative normal tissue can introduce biases in identifying truly tumor-specific alterations.\\n   - **Biological Rationale:** Normal variance in gene expression can be mistakenly attributed to tumor-specific changes if not contrasted against a healthy baseline.\\n   - **Impact on Survival:** Misinterpretation due to sampling bias may lead to incorrect targeting of pathways that are not genuinely implicated in cancer progression, potentially affecting treatment efficacy.\\n\\n### Key Genes\\n\\n1. **Genes Associated with Survival:**\\n   - **TP53:** Regulates cell cycle and apoptosis. Its mutation is often associated with poor prognosis due to deregulated cell death.\\n   - **PIK3CA:** Involved in cell growth and survival signaling pathways. Mutations may promote oncogenic activity but can be targeted by PI3K inhibitors.\\n   - **CDKN2A (p16):** Tumor suppressor that regulates cell cycle; its expression loss is a biomarker in HPV-related cervical cancers and indicates aggressive tumor behavior.\\n   - **ERBB2 (HER2):** Overexpression in some adenocarcinomas suggests use of targeted therapies, improving survival for those patients.\\n   - **BCL2:** Anti-apoptotic protein that contributes to cell survival. Elevated levels indicate therapy resistance.\\n   - **EGFR:** Its overexpression correlates with aggressive tumor growth, but it also presents an opportunity for EGFR-targeted therapies.\\n\\n2. **Biological Mechanisms:**\\n   - These genes influence survival through mechanisms involving proliferation, immune evasion, and apoptosis regulation, all critical to cancer progression and therapeutic response.\\n\\n### Conclusion: Key Survival Risk Factors\\n\\n1. **Synthesis:**\\n   - The origin of cervical cancer affects metastatic potential and early detection options, directly impacting survival. Histological differences and associated mutation profiles influence treatment pathways and outcomes. Sampling biases in genomic analyses can falsely direct therapeutic efforts, risking suboptimal patient management. A deeper understanding of key oncogenic and tumor suppressor genes informs targeted interventions.\\n\\n2. **Clinically Relevant Insights:**\\n   - The integration of histological, genetic, and sampling information provides a comprehensive outlook necessary for enhancing survival prospects in patients through precise diagnostic and therapeutic strategies. This multidimensional approach is essential for optimizing treatment and ultimately improving patient survival in cervical cancer.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894211, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=826, prompt_tokens=454, total_tokens=1280, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 70/704...\n",
      "ChatCompletion(id='chatcmpl-BAiY4CYOYCagDE8YB0kOEct76eYkk', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin and Its Influence on Survival\\n\\n**Metastatic Patterns and Patient Survival:**\\n1. **Tumor Origin**: Cervical cancer typically originates in the epithelial cells of the cervix (either squamous cells or glandular cells for adenocarcinomas). Its location at the junction between the uterus and vagina makes it prone to both local invasion and regional lymphatic spread.\\n   \\n2. **Influence on Metastatic Patterns**: Due to cervical cancer's location, early invasion to adjacent pelvic organs and pelvic lymph nodes is common, which can significantly impact survival. Patterns of distant metastasis often involve lungs, liver, and bones.\\n\\n3. **Implications for Treatment Accessibility**: Treatment approaches often include surgery (radical hysterectomy), radiation, and chemotherapy. Accessibility to these treatments varies substantially in different regions, affecting survival rates.\\n\\n4. **Survival Impact**: Early-stage detection and localized disease exhibit better prognosis, while advanced stages with extensive metastatic spread result in poorer survival outcomes.\\n\\n### Histology and Mutation Profiles in Survival Outcomes\\n\\n**Squamous Cell Carcinoma, Keratinizing, NOS:**\\n1. **Histological Insights**: Squamous cell carcinomas are generally more prevalent than adenocarcinomas in cervical cancer. The keratinizing subtype indicates a degree of tumor differentiation, influencing prognosis.\\n\\n2. **Mutation Profiles**: Common mutations in squamous cell carcinoma involve PIK3CA, TP53, and PTEN genes. These mutations affect cellular processes like proliferation and apoptosis, impacting tumor aggressiveness and response to therapy.\\n\\n3. **Survival Influence**: The presence of keratinization can be a factor for better differentiation and sometimes less aggressive behavior. However, specific mutation profiles can override these general tendencies, driving poorer outcomes.\\n\\n### Sampling Bias and Its Impact on Genomic Interpretation\\n\\n**Blood-Derived Normal vs. Primary Tumor Samples:**\\n1. **Source Bias**: Blood-derived normal samples may not fully represent the genetic background of the tumor environment, potentially missing tumor-specific mutations.\\n\\n2. **Primary Tumor Bias**: While analyzing primary tumors, intratumoral heterogeneity poses a challenge, potentially leading to underestimation of mutation diversity.\\n\\n3. **Impact on Survival Interpretation**: Sampling biases can distort genomic analyses, affecting the predicted survival outcomes based on genetic data. This can lead to challenges in individualized therapeutic decisions.\\n\\n### Key Genes Associated with Survival\\n\\n**Identifying Genes and Mechanisms:**\\n1. **TP53**: Key regulator of cell cycle, often mutated in carcinoma, leading to dysfunctional apoptosis and unchecked cell proliferation.\\n   \\n2. **PIK3CA**: Involved in the PI3K/AKT pathway, mutations contribute to increased cell growth and survival, often correlating with aggressive tumors.\\n\\n3. **PTEN**: Tumor suppressor that negatively regulates PI3K pathway; loss of function mutations lead to enhanced tumorigenicity.\\n\\n4. **CDKN2A (p16)**: Regulates cell cycle progression. Dysregulation is common in cervical cancer, influencing proliferation and survival.\\n\\n5. **EGFR**: Overexpression can promote oncogenic signaling, impacting prognosis, especially in squamous cell carcinoma.\\n\\n6. **CCND1 (Cyclin D1)**: Facilitates G1/S transition in cell cycle, overexpression may lead to unrestrained proliferation.\\n\\n7. **BCL2**: Anti-apoptotic gene; its expression prolongs cancer cell survival, affecting response to treatments.\\n\\n8. **BRCA1/2**: While less frequently mutated than in ovarian or breast cancers, their involvement in DNA repair pathways can impact treatment response.\\n\\n### Conclusion: Synthesis of Survival Risk Factors\\n\\nSurvival in cervical cancer is intricately linked to tumor origin, histological subtypes, genetic mutations, and biases inherent in genomic studies. Key drivers of prognosis include early detection, mutation burden, and specific genetic alterations, each influencing tumor behavior and therapy response. Clinically, understanding these factors assists in tailoring personalized treatment strategies, potentially improving patient survival rates. Emphasis on reducing biases in genomic interpretation through more comprehensive sampling and analysis can lead to more accurate prognostic predictions and better therapeutic targeting.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894224, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=853, prompt_tokens=458, total_tokens=1311, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 71/704...\n",
      "ChatCompletion(id='chatcmpl-BAiYQOj2Io4Ubg44V2BqVlHGecP64', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival**:  \\n- **Cervix uteri's Role**: The cervix is susceptible to infections by high-risk human papillomaviruses (HPVs), which are critical in the pathogenesis of cervical cancers. This anatomic origin supports a pattern of local invasion followed by potential pelvic and distant organ metastases, primarily driven by lymphatic spread.\\n- **Metastatic Patterns**: Cervical cancers predominantly metastasize to pelvic lymph nodes and can spread to distant sites like the lungs, liver, and bones. These patterns impact survival negatively, with prognosis dropping significantly once distal metastasis occurs.\\n\\n**Biological Rationale**:  \\n- **Tumor Proximity and Spread**: The cervix's anatomical features facilitate easy local invasion and lymphatic spread, explaining early metastasis in some cases, which correlates with poorer survival outcomes.\\n- **Treatment Accessibility**: Tumors localized to the cervix are more accessible to surgical intervention and radiotherapy, positively influencing survival if detected early.\\n\\n### Histology\\n\\n**Squamous Cell Carcinoma, Keratinizing, NOS**:\\n- **Influence on Survival**: The differentiation status and keratinization level in squamous cell carcinomas relate to how aggressive the cancer behaves. Well-differentiated, keratinizing types often have a more favorable prognosis compared to poorly differentiated ones.\\n- **Interaction with Mutation Profiles**: Mutations in PIK3CA, TP53, and CDKN2A (p16) often appear, influencing cell cycle dysregulation and apoptotic resistance, thereby driving the survival outcomes towards poorer prognostic implications.\\n\\n**Biological Rationale**:  \\n- **Mutation-Driven Aggression**: Genomic instability through mutations can lead to aggressive tumor phenotypes with high proliferation rates and resistance to apoptosis, translating to reduced survival.\\n- **Histological Features**: Keratinizing elements generally hint at more differentiated tumor states, which can be less aggressive and thus more manageable clinically.\\n\\n### Sampling Bias\\n\\n**Limitations of Primary Tumor, Solid Tissue Normal in Genomic Analysis**:  \\n- **Influence on Survival Insight**: Sampling biases can lead to incomplete genomic profiles, skewing understanding towards more prevalent mutations while under-representing sub-clonal variations that might influence prognostic pathways.\\n- **Potential Biases**: \\n  - **Normal Tissue Comparison**: Often, solid tissue normal samples do not accurately represent the background mutation rate of epithelial versus less relevant stromal cells, confounding true tumorigenic signals.\\n  - **Primary Site Sampling**: Focusing solely on primary tumor sites might overlook the genomic alterations that arise during metastasis, underestimating their impact on survival.\\n\\n**Biological Rationale**:\\n- **Heterogeneity Oversight**: Ignoring intra-tumoral and inter-tumoral heterogeneity might significantly affect the accuracy in predicting survival, due to variable treatment resistances not being accounted for.\\n\\n### Key Genes\\n\\n1. **PIK3CA**: Influences cell growth and survival by activating the PI3K/AKT pathway, often leading to enhanced proliferation and treatment resistance.\\n2. **TP53**: Acts as a tumor suppressor and its inactivation removes crucial cell cycle checkpoints, leading to unchecked cell proliferation.\\n3. **CDKN2A (p16)**: Regulates cell cycle progression; its disruption can lead to unscheduled cell cycle entry, enhancing malignancy.\\n4. **BRCA1/2**: Involved in DNA damage repair; mutations can increase susceptibility to genomic instability.\\n5. **EGFR**: When overactive, it promotes aggressive growth behaviors through enhanced receptor signaling.\\n6. **ERBB2 (HER2)**: Its overexpression associates with aggressive disease phenotypes, influencing proliferation.\\n7. **LKB1/STK11**: Tumor suppressor involved in metabolism regulation; alterations might drive energy-efficient cancer cell metabolism favoring survival.\\n\\n**Biological Rationale**:\\n- **Proliferation and Survival Mechanisms**: These genes impact fundamental processes like cell cycle control, apoptosis, and proliferation, thereby deeply affecting overall survival dynamics.\\n\\n### Conclusion\\n\\nKey survival risk factors for cervical cancer include effective early detection influenced by the accessibility of the cervical tumor, histological type, and specific genetic mutations that modulate cellular behavior. Limitations in sampling and potential biases can impact the interpretation of genomic data, emphasizing the necessity for comprehensive analysis strategies that account for heterogeneity. Identifying and targeting specific genomic alterations can optimize therapeutic approaches, potentially enhancing patient survival through precision medicine approaches. Understanding these complex interactions aids in personalized prognosis and highlights the critical need for early and accurate detection and intervention strategies.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894246, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=953, prompt_tokens=458, total_tokens=1411, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 72/704...\n",
      "ChatCompletion(id='chatcmpl-BAiYi2zU3clfzrCtDH7PVYoBHn85U', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n\\n- **Metastatic Patterns:** Tumors originating in the cervix uteri often exhibit specific metastatic trends, primarily spreading to the pelvic lymph nodes, lungs, liver, and bones. This pattern influences survival rates, with early detection in localized regions typically yielding better prognoses than distant metastases.\\n  \\n- **Survival Impact:** Early-stage detection is crucial for favorable outcomes, as localized cervical tumors are more amenable to surgical resection or radiation. Metastatic spread significantly diminishes survival prospects due to reduced response rates to systemic therapies.\\n\\n- **Treatment Accessibility:** Cervical cancer's detectability via routine screening (e.g., Pap smears) plays a pivotal role in early intervention. However, socioeconomic factors and healthcare accessibility disparities can affect survival, where limited access to screening and treatment reduces survival rates.\\n\\n**Biological Rationale:**\\n\\n- The cervix's location and its transitional zone (transforming squamous to glandular epithelium) predispose it to HPV infections—key oncogenic drivers promoting transformation.\\n\\n**Potential Biases:**\\n\\n- Screening biases can exist, where populations with better healthcare access might show artificially improved survival due to lead-time bias rather than a truly more positive prognosis.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n\\n- **Squamous Cell Carcinoma, Large Cell, Nonkeratinizing, NOS:** Typically, these tumors present distinct mutation profiles compared to adenocarcinomas, impacting their response to therapies.\\n\\n**Biological Rationale:**\\n\\n- Non-keratinizing variants often associate with high-risk HPV types, potentially leading to more aggressive biological behavior and poorer outcomes if not detected early. Their specific mutation profiles—such as alterations in PIK3CA or PTEN—affect cell cycle regulation and apoptosis.\\n\\n**Potential Biases:**\\n\\n- Histopathological sampling can miss mixed histology components if biopsies are non-representative, leading to misclassification and inappropriate treatment strategies.\\n\\n### Sampling Bias\\n\\n**Influence on Genomic Analysis:**\\n\\n- **Blood Derived Normal vs. Primary Tumor:** Utilizing blood-derived normal samples can miss somatic mutations present exclusively in the tumor, skewing mutation importance in survival analysis.\\n  \\n**Biological Rationale:**\\n\\n- Tumor heterogeneity effects may be underestimated when blood or single-site primary tumors are sampled, potentially misrepresenting the mutation spectrum and its impact on survival.\\n\\n**Potential Biases:**\\n\\n- Liquid biopsies may fail to capture the full intratumoral heterogeneity, especially when emergent resistant subclones are present only in metastatic sites, masking aggressive subpopulations that affect survival negatively.\\n\\n### Key Genes\\n\\n**Influence on Survival:**\\n\\n- **TP53, PIK3CA, PTEN, CDKN2A, LKB1 (STK11), EGFR, MYC, and HPV E6/E7 Oncoproteins:** These genes regulate cell proliferation, apoptosis, and immune evasion—all crucial for cancer progression and therapy resistance.\\n\\n**Biological Rationale:**\\n\\n- **TP53:** Mutations disrupt genomic stability and cell cycle control, worsening prognosis.\\n- **PIK3CA & PTEN:** Alterations promote unchecked cell growth and survival pathways, often indicating aggressive tumor behavior with poor therapeutic response.\\n- **CDKN2A:** Deletions halt senescence and apoptosis, allowing malignant proliferation.\\n- **LKB1 (STK11):** Implicated in metabolic regulation and epithelial integrity, mutations here exacerbate metastatic potential.\\n- **EGFR & MYC:** Overexpression or amplification enhances proliferative signaling pathways, correlating with resistance to multiple therapies.\\n\\n**Potential Biases:**\\n\\n- Detection biases may occur if subclonal mutations are selectively enriched or missed in single biopsies, leading to misjudgment of their relevance in guiding treatment decisions.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n**Clinically Relevant Insights and Impact:**\\n\\n- **Early Detection and Intervention:** Timely intervention remains the cornerstone of improved survival, heavily reliant on accessible healthcare and effective screening.\\n  \\n- **Targeted Therapies and Genomic Characterization:** Personalized treatment based on comprehensive genomic profiling can significantly enhance outcomes, especially for identifiable driver mutations. Survival can be improved by tailoring therapy to the tumor’s specific mutation landscape.\\n\\n- **Addressing Socioeconomic Disparities:** Efforts must focus on equalizing healthcare access to mitigate disparities observed in survival outcomes.\\n\\nOverall, cervical cancer survival is multifaceted, dictated by timely diagnosis, appropriate histological and genomic characterization, and equitable healthcare access, underscoring the necessity for integrated care approaches in oncology.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894264, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=936, prompt_tokens=462, total_tokens=1398, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 73/704...\n",
      "ChatCompletion(id='chatcmpl-BAiYv9oK8Is2LBgjdE0G6Qk8O4HKp', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns:**\\n   - **Cervix uteri** tumors primarily metastasize through local extension and lymphatic routes, initially affecting nearby pelvic structures and lymph nodes. Hematogenous spread is less common but can occur in advanced cases.\\n\\n2. **Impact on Patient Survival:**\\n   - **Survival Impact:** Early-stage detection corresponds to better survival rates due to localized disease. Advanced stages with distant metastasis drastically reduce survival rates due to limited treatment efficacy once the tumor has spread.\\n\\n3. **Treatment Accessibility:**\\n   - **Accessibility Factors:** This type of cancer benefits from screening and early detection programs (like Pap smears and HPV testing), significantly impacting survival by allowing for early intervention. Furthermore, the presence of local treatment facilities and resources contributes to improved patient outcomes.\\n\\n### Histology\\n\\n1. **Basaloid Squamous Cell Carcinoma:**\\n   - **Prognosis:** This subtype typically exhibits a more aggressive behavior compared to other histologies, with a tendency for rapid progression and poor differentiation, leading to worse survival outcomes.\\n\\n2. **Interaction with Mutation Profiles:**\\n   - **Mutational Dynamics:** Basaloid variants often harbor mutations in oncogenes and tumor suppressor genes that promote altered cell proliferation and evasion of apoptosis, contributing to aggressive clinical behavior. \\n\\n### Sampling Bias\\n\\n1. **Blood Derived Normal vs. Primary Tumor:**\\n   - **Limitations in Genomic Analysis:**\\n     - **Bias Impact:** Differences in genomic profiles from blood versus direct tumor samples can result in underrepresentation of specific mutational burdens, potentially leading to incomplete understanding of the tumor's genetic landscape.\\n\\n### Key Genes Associated with Survival\\n\\n1. **Genes:**\\n   - **TP53:** Mutations often lead to dysfunctional cell cycle regulation, promoting unchecked cell division, associated with poor prognosis.\\n   - **PIK3CA:** Aberrations in this gene activate survival pathways, contributing to resistance against apoptosis, thus negatively affecting survival.\\n   - **PTEN:** Loss of function can result in enhanced survival signaling, affecting tumor growth and dissemination.\\n   - **CDKN2A (p16):** Frequently inactivated, leading to disrupted cell cycle control, its loss correlates with poor differentiation and aggressive tumor behavior.\\n   - **EGFR:** Overexpression or mutation leads to enhanced tumor proliferation and poor survival, though it may offer targeted therapy avenues.\\n   - **NOTCH1:** Dysregulation often results in stromal interactions that promote tumor invasiveness and resistance.\\n   - **KRAS:** Mutations can activate downstream pathways vital for cellular proliferation, correlating with more aggressive disease and reduced survival.\\n\\n2. **Biological Mechanisms:**\\n   - **Proliferation and Apoptosis:** Alterations in these genes drive imbalance in cellular growth and survival, where enhanced proliferative signaling coupled with anti-apoptotic mechanisms can sustain aggressive tumor phenotypes.\\n\\n### Synthesis and Clinically Relevant Insights\\n\\n1. **Key Survival Risk Factors:**\\n   - **Stage and Histological Type:** The cancer stage and presence of aggressive histological features such as basaloid carcinoma strongly influence prognosis.\\n   - **Genetic Profiling:** Understanding the mutational landscape (e.g., PIK3CA, TP53) informs both targeted therapy decisions and overall prognostic expectations.\\n   - **Sampling Precision:** Accurate genomic analysis emphasizing both primary tumor characteristics and systemic (blood-based) markers improves personalized treatment approaches.\\n\\n2. **Clinical Implications:** \\n   - Early screening and correct histological classification remain pivotal in enhancing survival. Moreover, identifying genetic alterations provides treatment targets, potentially improving outcomes when applied in a timely and specific manner.\\n\\nThrough comprehensive understanding and intervention strategies, the complexity of cervical cancer survival can be addressed more effectively, ultimately improving patient outcomes across diverse clinical settings.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894277, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=780, prompt_tokens=455, total_tokens=1235, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 74/704...\n",
      "ChatCompletion(id='chatcmpl-BAiZB4ZvCuroEWrP11hv9J1UC70HZ', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Influence on Survival:**\\n1. **Cervical Anatomy**: The cervix's anatomical location plays a crucial role in its metastatic patterns. Located in the lower part of the uterus, tumors such as squamous cell carcinoma and adenocarcinoma can invade locally into adjacent tissues like the bladder and rectum, complicating treatment options.\\n2. **Lymphatic Spread**: The cervix's rich lymphatic network predisposes it to spread cancer cells to regional lymph nodes, influencing prognosis negatively.\\n3. **Distant Metastases**: Although less common, hematogenous spread can lead to distant metastases, affecting organs like the lungs and bones, drastically diminishing survival rates.\\n\\n**Biological Rationale:**\\n- Cervical tumors initially proliferate locally before potentially disseminating through lymphatics or bloodstream, contingent on the tumor's aggressiveness and genetic makeup.\\n- The accessibility of the cervix for early detection and treatment through Pap smears and HPV vaccinations offers varied survival outcomes.\\n\\n**Potential Genomic Bias:**\\n- Diagnosis and treatment are often more accessible, reflecting higher survival rates in developed regions compared to under-resourced areas where late presentation predominates.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n1. **Squamous Cell Carcinoma (SCC)**: Typically more common, SCC arises from the epithelial cells lining the cervix. It generally has a more indolent course but requires early detection for optimal outcomes.\\n2. **Adenocarcinoma, NOS**: Arising from glandular cells, this type presents more aggressively, often leading to a poorer prognosis compared to SCC due to its propensity for earlier metastatic spread.\\n   \\n**Biological Rationale:**\\n- Adenocarcinomas tend to be more aggressive, with molecular alterations such as K-RAS mutations driving oncogenic pathways, enhancing proliferation and metastatic potential.\\n\\n**Genomic Analysis Bias:**\\n- Histological distinctions may contribute to sampling bias, where less aggressive SCC may be overrepresented in genomic studies, skewing perceptions of survival causes.\\n\\n### Sampling Bias\\n\\n**Limitations:** \\n1. **Blood-Derived Normal vs. Primary Tumor**: Utilizing blood as a normal control in genomic studies can introduce bias, as germline variations may not precisely reflect the tissue-specific mutational landscape.\\n2. **Tumor Heterogeneity**: Primary tumors can display intra-tumoral heterogeneity, complicating genomic analyses and potentially leading to incomplete representations of the entire mutational spectrum.\\n\\n**Impact on Survival Analysis:**\\n- Accurate survival-related genomic insights require comprehensive sampling to encompass tumor heterogeneity, ensuring targeted treatments address all diverse subclonal populations within a tumor.\\n\\n### Key Genes\\n\\n1. **TP53**: Functions as a tumor suppressor, regulating cell cycle arrest and apoptosis. Mutations can result in unchecked proliferation and cancer progression, reducing survival.\\n2. **PIK3CA**: Involved in the PI3K/AKT signaling pathway that regulates cell growth and survival. Mutations enhance oncogenic signaling, linking to poorer prognosis.\\n3. **KRAS**: Mutated in various adenocarcinomas, driving cell proliferation and survival. Its presence correlates with aggressive progression and reduced survival.\\n4. **ERBB2 (HER2/neu)**: Overexpression leads to uncontrolled division and is associated with a subset of aggressive cervical adenocarcinomas.\\n5. **BRCA1/2**: Mutations are rare but highlight genomic instability factors that could influence treatment response and survival.\\n6. **CDKN2A**: Loss impacts cell cycle regulation, implicated in both SCC and adenocarcinoma forms.\\n7. **NOTCH1**: Plays roles in differentiation and cell fate. Its dysregulation is tied to increased invasion and a sharp survival decline.\\n8. **PTEN**: Loss leads to enhanced PI3K pathway activity, promoting survival, proliferation, and resistance to apoptosis.\\n\\n### Conclusion\\n\\n**Key Survival Risk Factors:**\\n- The integration of tumor origin, histology, and genetic landscape informs molecularly targeted treatments.\\n- HPV status, integration site in the genome, and the genomic instability signature compound outcome prognoses.\\n- Advances in genomics should focus on understanding clonal evolutions, such as chromosomal instability patterns, and how the tumor microenvironment and immune landscape impact therapeutic responses.\\n- Emphasis on personalized, biomarker-driven therapies holds potential to improve survival, but accessibility and early detection remain paramount challenges impacting global outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894293, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=912, prompt_tokens=454, total_tokens=1366, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 75/704...\n",
      "ChatCompletion(id='chatcmpl-BAiZY1Pz9GG9Glnqd4HSXpTLXxL21', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='## Tumor Origin\\n\\nCervical squamous cell carcinoma and endocervical adenocarcinoma originate from the cervix uteri, impacting metastatic patterns, patient survival, and treatment accessibility significantly.\\n\\n1. **Influence on Survival**: Both types of tumors are influenced by their local environment. Cervical cancers are known for their slower metastatic patterns compared to other malignancies, such as ovarian cancer. However, when metastasis does occur, common sites include lymph nodes, the pelvic region, and in advanced cases, distant organs like the lungs and liver. The prognosis worsens dramatically with distant metastases.\\n\\n2. **Biological Rationale**: The cervix uteri is heavily influenced by hormonal cycles and HPV infection, which contribute to carcinogenesis. HPV-induced DNA damage is a critical driver of cervical carcinogenesis, particularly in squamous cell carcinoma.\\n\\n3. **Biases**: Treatment accessibility can vary due to socio-economic factors, impacting survival statistics. Access to regular screening and HPV vaccination can significantly affect early detection rates and survival outcomes.\\n\\n## Histology\\n\\nHistological differences between cervical squamous cell carcinoma and endocervical adenocarcinoma affect prognosis and treatment response differently.\\n\\n1. **Influence on Survival**: Adenocarcinomas tend to have a worse prognosis compared to squamous cell carcinomas due to a more aggressive biological behavior and often being diagnosed at a more advanced stage.\\n\\n2. **Biological Rationale**: Adenocarcinoma cells, being glandular, tend to invade deeper into tissues than squamous cells, which can be reflected in their aggressive metastatic behavior.\\n\\n3. **Biases**: Diagnosis can be biased by histological similarities in poorly differentiated tumors, leading to challenges in accurate classification, which is vital for appropriate therapeutic strategies.\\n\\n## Sampling Bias\\n\\nConsiderations in genomic analysis involve potential sampling biases of primary tumors and solid tissue normals.\\n\\n1. **Influence on Survival**: Incorrect assumptions about the genetic landscape due to sampling errors can lead to misinformed therapeutic decisions impacting survival.\\n\\n2. **Biological Rationale**: Tumors are heterogeneous; sampling a non-representative section might miss crucial mutations that are actionable or prognostic.\\n\\n3. **Biases**: Sampling bias can obscure true mutational burdens or fail to capture tumor microenvironment interactions, leading to underestimated or overestimated risk assessments in a clinical setting.\\n\\n## Key Genes\\n\\nKey survival-associated genes in cervical cancer include:\\n\\n1. **TP53**: Regulates cell cycle and apoptosis. Mutations here can lead to uncontrolled cell proliferation, reducing survival rates.\\n2. **PIK3CA**: Involved in cell growth and survival pathways. Mutations can activate oncogenic signaling pathways, promoting tumor growth.\\n3. **KRAS**: Another gene in growth signaling pathways where mutations can lead to aggressive cancer phenotypes and chemoresistance.\\n4. **CDKN2A**: Encodes for p16 protein, a crucial cell cycle regulator. Loss-of-function mutations can impair cell cycle control.\\n5. **NOTCH1**: Plays roles in cell differentiation and apoptosis; mutations might lead to disrupted signaling and enhanced proliferation.\\n6. **PTEN**: Tumor suppressor involved in regulating PI3K pathways. Loss affects apoptosis and cell survival mechanisms.\\n7. **FGFR3**: Its mutations affect cell division, growth, and repair; alterations are linked with aggressive growth patterns.\\n8. **ERBB2 (HER2)**: Aberrant activation of this gene is associated with increased proliferation and survival, typically heralding a poor prognosis.\\n\\n## Conclusion\\n\\nThe survival impact of cervical squamous cell carcinoma and endocervical adenocarcinoma is intricately tied to factors including tumor origin, histology, genetic mutations, and sampling biases. Early detection through effective screening can drastically improve survival rates by catching the disease in its most treatable stages. Genomic interpretations can be skewed by sampling and classification errors, necessitating careful appraisal of molecular data and histological findings. The integration of genomic insights with clinical practice can enhance targeted treatment plans, emphasizing the importance of understanding individual genomic profiles toward increasing survival outcomes. Understanding key genetic mutations and their roles helps tailor therapy, potentially improving prognosis and managing disease progression more effectively.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894316, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=858, prompt_tokens=454, total_tokens=1312, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 76/704...\n",
      "ChatCompletion(id='chatcmpl-BAiZnlAkwzQONB1DKPP5Z3Z7DvlJK', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"## Tumor Origin: Cervix Uteri Influence\\n\\n### Step 1: Influence of Tumor Origin on Metastatic Patterns and Survival\\nThe cervix is strategically located at the junction of the upper and lower genital tract, which influences both local invasion and metastatic potential. Tumors of the cervix, such as squamous cell carcinoma and adenocarcinoma, often initially spread to regional lymphatics, such as the pelvic and para-aortic nodes.\\n\\n**Impact on Survival:**\\n- **Negative:** Early lymphatic dissemination can result in poorer prognosis if not caught early, as lymphatic involvement is a significant survival predictor.\\n- **Positive:** Detection of microinvasion and localized disease can lead to high survival rates with prompt surgical intervention or chemoradiotherapy.\\n\\n**Biological Rationale:**\\nThe architecture of the cervix consists of a transition zone vulnerable to HPV infection, a major precursor to cervical cancer, facilitating localized invasion before systemic metastasis.\\n\\n### Step 2: Treatment Accessibility\\nAccessibility to regular Pap smear screening and HPV vaccination greatly influences survival.\\n\\n**Positive Impact:** Early detection via screenings improves survival rates by facilitating early intervention.\\n\\n**Negative Impact:** In areas with limited access to these preventive services, detection occurs at later stages, reducing survival rates due to advanced regional invasion.\\n\\n## Histology: Endometrioid Adenocarcinoma, NOS\\n\\n### Step 3: Interaction with Mutation Profiles\\nHistological types like endometrioid adenocarcinoma exhibit unique mutation profiles affecting their behavior.\\n\\n**Impact on Survival:**\\n- **Negative:** Poor differentiation often associated with higher-grade lesions can lead to aggressive behavior and lower survival.\\n- **Positive:** Well-differentiated tumors generally have a favorable prognosis due to slower growth rates and responsiveness to treatment.\\n\\n**Biological Rationale:**\\nMutational profiles such as PIK3CA, PTEN loss, and ARID1A mutations are common. These mutations disrupt cell cycle control and apoptosis, enhancing tumor proliferation.\\n\\n### Step 4: Sampling Bias in Genomic Analysis\\n\\n**Blood Derived Normal (BDN):**\\n- **Limitation:** Blood-derived samples may not reflect tumor clonal heterogeneity, leading to underreported somatic mutations.\\n  \\n**Primary Tumor Sample:**\\n- **Limitation:** Tumor heterogeneity can lead to biased interpretations with underrepresentation of subclonal populations that affect survival predictions.\\n\\n**Impact on Studies:** Misinterpretation of survival data due to sampling biases can mislead treatment stratification.\\n\\n## Key Genes: Survival-Associated Genes\\n\\n### Step 5: Identification and Biological Mechanisms\\n\\n1. **TP53**:\\n   - **Function:** Regulates the cell cycle and apoptosis.\\n   - **Impact:** Mutation leads to unregulated cell proliferation and is associated with poorer outcomes.\\n\\n2. **PIK3CA**:\\n   - **Function:** Part of the PI3K/AKT pathway, promoting growth and survival.\\n   - **Impact:** Mutations can enhance proliferation, thus negatively influencing survival.\\n\\n3. **PTEN**:\\n   - **Function:** Tumor suppressor gene, antagonizing PI3K/AKT pathway.\\n   - **Impact:** Loss of function mutations lead to unchecked proliferation, reducing survival.\\n\\n4. **KMT2D**:\\n   - **Function:** Chromatin modifier, influences gene expression.\\n   - **Impact:** Mutations can lead to epigenetic dysregulation associated with poor outcomes.\\n\\n5. **ERBB2 (HER2)**:\\n   - **Function:** Receptor tyrosine kinase involved in growth signaling.\\n   - **Impact:** Overexpression is a targetable alteration, but correlates with aggressive cancer.\\n\\n6. **BRCA1/BRCA2**:\\n   - **Function:** DNA repair pathways.\\n   - **Impact:** Mutations contribute to genomic instability, worsens survival if untreated.\\n\\n## Conclusion: Key Survival Risk Factors\\n\\n### Survival Risk Factors Synthesis:\\nThe survival impact of cervical cancers is multifaceted, involving early detection benefits from screening, histological grade, and molecular alterations driving aggressiveness. Buoyed by knowledge on HPV's role, treatment development focuses on molecularly targeted therapies, aided by genomic understating.\\n\\n**Clinically Relevant Insights:**\\n- The emphasis on regular screening and preventive vaccines remains paramount in improving cervical cancer survival.\\n- Identification and targeting of key mutations (e.g., PIK3CA) are ongoing, improving stratification and personalized therapies.\\n- The clarification of histological and molecular profiles is essential to optimize therapeutic regimens and maximize patient survival.\\n\\nFocusing on clinical and genomic comprehensions can strategically combat cervical cancer's impact on survival, necessitating continuous research and healthcare accessibility improvement.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894331, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=947, prompt_tokens=458, total_tokens=1405, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 77/704...\n",
      "ChatCompletion(id='chatcmpl-BAiaE9cYOgYiRqr4loBOO3Uib3MFi', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Certainly, let's break down the impact of Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) on survival by examining the specific factors:\\n\\n### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns and Patient Survival:**\\n   - **Primary Site:** Cervical cancers originate in the cervix, with squamous cell carcinoma and endocervical adenocarcinoma being the most prevalent types. The anatomical location of the cervix within the pelvis allows for local spread to nearby urinary and reproductive organs.\\n   - **Metastasis:** The typical metastatic route for cervical cancers involves the pelvic lymph nodes. Due to this localized lymphatic spread, early-stage detection and intervention are critical to survival.\\n   - **Survival Impact:** Survival rates decrease significantly with metastasis beyond the pelvis, emphasizing the importance of early detection.\\n\\n2. **Treatment Accessibility:**\\n   - **Stage-Dependent Treatment Options:** Early-stage cervical cancer often amenable to surgical interventions and localized radiotherapy provides better prognoses. Advanced stages might necessitate systemic chemotherapy, which has variable accessibility and success depending on healthcare resources.\\n\\n### Histology\\n\\n1. **Adenocarcinoma, Endocervical Type:**\\n   - **Mutational Influence:** Endocervical adenocarcinomas often harbor different mutations compared to squamous cell carcinomas, such as mutations in PIK3CA, KRAS, and PTEN. These genetic differences influence treatment efficacy and outcomes.\\n   - **Impact on Outcomes:** Relevant mutations may confer resistance to certain therapies, like conventional chemotherapy, making the role of targeted therapies critical.\\n   - **Histological Differences:** Endocervical adenocarcinomas have a distinct glandular architecture which may lead to differences in tumor growth rate and patient responses to therapies.\\n\\n### Sampling Bias\\n\\n1. **Limitations with Blood Derived Normal and Primary Tumor Genomic Analysis:**\\n   - **Potential Bias:** Blood-derived normal samples may not accurately reflect the germline variations due to hematopoietic mosaicism. Therefore, caution is needed when interpreting genomic data from these sources.\\n   - **Primary Tumor Bias:** Genomic heterogeneity within primary tumors can result in sampling biases. Single biopsy samples may miss key mutations present in different tumor regions, potentially underrepresenting the true mutation burden.\\n\\n### Key Genes\\n\\n1. **Survival-Associated Genes:**\\n   - **TP53:** Critical for apoptosis regulation. Mutations often result in dysregulated cell growth and decreased apoptosis, leading to poor prognosis.\\n   - **PIK3CA:** Involved in cell proliferation and survival through the PI3K/AKT/mTOR pathway. Mutations or overexpressions are associated with worse outcomes.\\n   - **KRAS:** Modulates cellular proliferation; mutations often lead to uncontrolled cell growth and are associated with aggressive tumor phenotypes.\\n   - **PTEN:** Tumor suppressor that regulates cell cycle and prevents excessive cellular proliferation. Loss of function is linked to poor prognostic outcomes.\\n   - **CDKN2A:** Inhibits cell cycle progression. Loss or mutation correlates with higher malignancy and reduced survival.\\n   - **SMAD4:** Part of the TGF-beta signaling pathway, frequently altered, affecting growth and apoptosis pathways.\\n   - **BRCA1/2:** Though less common, mutations can lead to homologous recombination deficiency contributing to genomic instability and affecting sensitivity to certain therapies.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n- **Early Detection:** Crucial for improved survival; allows for localized treatment before metastatic spread.\\n- **Individualized Therapy:** Genetic and histological insights guide targeted therapies, enhancing treatment efficacy.\\n- **Healthcare Accessibility:** Access to comprehensive treatment options is a significant determinant of outcomes.\\n- **Genomic Insights:** Understanding of specific genetic mutations can combat treatment resistance and guide management strategies.\\n\\nIn conclusion, the survival of patients with cervical squamous cell carcinoma and endocervical adenocarcinoma is intricately linked to tumor origin, histological subtype, mutation profile, and systemic treatment access. Targeted therapies based on genomics hold promise but necessitate overcoming sampling and access barriers to translate potential into improved patient outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894358, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=849, prompt_tokens=458, total_tokens=1307, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 78/704...\n",
      "ChatCompletion(id='chatcmpl-BAiaau35cFbHgVyT3HOUOA3vrpx5P', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Metastatic Patterns and Patient Survival:**\\n- **Influence on Survival:** The anatomical location of the cervix impacts how cervical squamous cell carcinoma and endocervical adenocarcinoma spread. Generally, cervical cancer metastasizes to regional lymph nodes, pelvic structures, and, less commonly, to distant organs like the lungs.\\n- **Biological Rationale:** The rich lymphatic network in the cervix facilitates lymphatic spread. Tumor cells access these pathways early, influencing survival by increasing the likelihood of regional metastasis.\\n- **Treatment Accessibility:** Treatment options, including surgery, radiation, and chemotherapeutic regimens, are influenced by the early detection capabilities and cervical accessibility. Early-stage detection positively impacts survival through prompt local control.\\n\\n### Histology\\n\\n**Mucinous Adenocarcinoma and Mutation Profiles:**\\n- **Influence on Survival:** Mucinous adenocarcinomas typically present distinct clinicopathological features compared to squamous cell carcinomas. They show variation in response to therapy and exhibit different survival outcomes.\\n- **Biological Rationale:** Mucinous adenocarcinomas often harbor specific mutations in genes such as KRAS which are associated with distinct biological behaviors and therapy resistance.\\n- **Outcome Impact:** These mutations can lead to differential aggressiveness and tumor progression, potentially impacting survival negatively if they contribute to treatment resistance.\\n\\n### Sampling Bias\\n\\n**Limitations of Blood Derived Normal, Primary Tumor Analysis:**\\n- **Influence on Genomic Interpretation:** Blood-derived normal samples might not provide a comprehensive baseline for accurate genomic comparison against tumor DNA, potentially leading to bias in mutation detection.\\n- **Biological Rationale:** Blood can miss local somatic mutations present in the actual tumor microenvironment or reflect systemic variations unrelated to the cervical malignancy.\\n- **Impact on Genomic Analysis:** Such biases could skew survival predictions by overestimating or underestimating the role of specific genomic alterations.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes in Cervical Cancer:**\\n1. **TP53:** A tumor suppressor involved in cell cycle regulation and apoptosis. Mutations can lead to unchecked cell proliferation, negatively impacting survival.\\n2. **PIK3CA:** This oncogene influences cell growth and survival through the PI3K/AKT pathway. Mutations often result in enhanced proliferation and metastasis.\\n3. **KRAS:** Involved in cell signaling; mutations affect growth and survival, often found in mucinous subtypes with poorer responses to standard therapies.\\n4. **CDKN2A (p16):** Regulates cell cycle progression. Loss of function results in uncontrolled division, often correlating with aggressive tumor behavior.\\n5. **BRCA1/2:** Although more associated with breast and ovarian cancers, mutations can impact DNA repair mechanisms in cervical cancer, influencing treatment responses.\\n6. **EGFR:** Overexpression leads to enhanced cell proliferation and resistance to apoptosis, associated with poor prognosis.\\n7. **PTEN:** Tumor suppressor that negatively regulates the PI3K/AKT pathway; loss of function mutations result in uncontrolled cell growth.\\n\\n### Conclusion\\n\\nSynthesizing these elements:\\n\\n1. **Histological Variability:** The differentiation between squamous cell carcinoma and mucinous adenocarcinoma, coupled with the unique mutation profiles, critically influences treatment and survival outcomes.\\n2. **Genetic Insights:** Understanding key mutational landscapes, particularly in genes like TP53 and PIK3CA, informs targeted therapies and prognostication.\\n3. **Sampling Bias Consideration:** Accurate survival predictions require comprehensive genomic analyses that minimize biases inherent in sampling techniques.\\n4. **Clinical Implications:** Emphasizing early detection and tailored therapeutic regimens targeting specific genetic alterations can significantly impact patient survival.\\n\\nThese oncological and genomic factors collectively forge a complex survival landscape for cervical cancer, necessitating precise, individualized treatment strategies to optimize outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894380, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=790, prompt_tokens=455, total_tokens=1245, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 79/704...\n",
      "ChatCompletion(id='chatcmpl-BAiazeIVHD1DFMQPoraJXL5gttQ1C', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Tumor Origin**\\n\\n1. **Influence on Survival and Metastasis:**\\n   - Cervical squamous cell carcinoma and endocervical adenocarcinoma originate from the cervix uteri, which is critical due to its anatomical and cellular environments. The cervix functions as a barrier with high HPV exposure, leading to DNA damage and carcinogenesis predominantly in the squamous epithelial cells or glandular epithelial cells (in adenocarcinoma). Tumor origin largely influences how cancer cells invade surrounding tissues and distant organs. Cervical cancers commonly invade locally and primarily spread via lymphatics, impacting regional lymph nodes, which can affect survival negatively if metastasis occurs.\\n\\n2. **Biological Rationale:**\\n   - The transition zone of the cervix, where columnar epithelium meets squamous epithelium, is particularly vulnerable to HPV integration, leading to dysplastic changes. This creates fertile ground for cancer evolution. The depth of invasion and nodal metastasis greatly dictate prognosis, explaining why early detection is crucial for improved survival outcomes.\\n\\n3. **Treatment Accessibility:**\\n   - Geographic and socio-economic factors affect access to early screening and preventive care (like HPV vaccination), directly influencing survival. In areas with poor healthcare infrastructure, cervical cancer is often diagnosed at advanced stages, reducing treatment efficacy and survival rates.\\n\\n**Histology**\\n\\n1. **Interaction with Mutation Profiles:**\\n   - Mucinous carcinoma, particularly the gastric type, is less common but more aggressive, often presenting with unique mutant profiles that provide resistance to standard therapies. This histological subtype negatively impacts survival when resistant mutations render common treatments less effective.\\n\\n2. **Biological Rationale:**\\n   - Gastric-type mucinous adenocarcinomas often exhibit mutations such as TP53 and occasionally KRAS, which contribute to its aggressive nature by disrupting normal apoptotic pathways and enhancing cell survival and proliferation.\\n\\n**Sampling Bias**\\n\\n1. **Influence on Genomic Analysis:**\\n   - Genomic studies often rely on samples like Blood Derived Normal or Primary Tumor tissues. Using blood DNA can miss somatic mutations present only in tumor tissues, whereas primary tumor samples are subject to heterogeneity, potentially leading to incomplete genomic profiling.\\n\\n2. **Potential Biases:**\\n   - Sampling bias can lead to underreporting of intratumor heterogeneity or overemphasis on mutations found in bulk but not clonal populations, skewing survival predictions and therapeutic choices.\\n\\n**Key Genes**\\n\\n1. **Survival-Associated Genes:**\\n   - **TP53:** Critical for apoptotic regulation; mutations lead to unchecked cell proliferation and resistance to cell death, worsening survival.\\n   - **PTEN:** Tumor suppressor involved in signaling pathways; loss-of-function mutations lead to enhanced PI3K/AKT pathway activation, promoting survival and resistance to apoptosis.\\n   - **EGFR:** Overexpression or mutation leads to increased signaling for proliferation and reduced apoptosis, often correlating with poorer prognosis.\\n   - **PIK3CA:** Frequently mutated; contributes to oncogenic signaling, impacting proliferation and survival positively for the cancer cells.\\n   - **CDKN2A:** Inactivation leads to uncontrolled cell cycle progression, often seen in aggressive cervical cancers, negatively affecting survival.\\n   - **BRCA1/2:** Though less common, mutations invoke defective DNA repair mechanisms, contributing to genomic instability but sometimes offering targetable vulnerabilities with PARP inhibitors.\\n   - **PD-L1 (CD274):** Overexpression helps tumor cells evade immune detection, directly affecting immune response and survival outcomes.\\n\\n**Synthesis of Key Survival Risk Factors**\\n\\n- **Clinically Relevant Insights:**\\n  - Early detection and HPV vaccination remain the most effective strategies for improving survival in cervical cancers. Histological understanding aids in identifying high-risk, less responsive variants.\\n  - Genetic profiling must include a representative sample of the tumor's heterogeneity to accurately guide personalized therapies.\\n  - Socioeconomic factors greatly dictate disease outcomes, emphasizing the need for equitable healthcare access to improve overall survival rates globally.\\n\\nUnderstanding the integration of these factors offers opportunities for precision medicine approaches, highlighting the necessity of multidisciplinary care in managing cervical cancer.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894405, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=838, prompt_tokens=455, total_tokens=1293, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 80/704...\n",
      "ChatCompletion(id='chatcmpl-BAibCuZgU6YcndYNl4NlJrrOrpfd0', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Cervix Uteri\\n\\n1. **Influence on Metastatic Patterns and Survival:**\\n   - The cervix uteri, given its anatomical position, primarily shows early local metastasis to nearby tissues and later systemic spread. This contributes to higher local disease control but poses challenges once distant metastasis occurs.\\n   - **Survival Impact:** Localized disease generally has a better prognosis due to early detection and treatment effectiveness. However, once metastasis spreads, particularly to the liver or lungs, survival rates decrease significantly.\\n   - **Treatment Accessibility:** Cervical cancer, being a reproducible organ disease, is often amenable to surgery, radiation, and chemotherapy, which are more accessible compared to many other cancers.\\n\\n2. **Biological Rationale:**\\n   - The cervix is highly vascularized, facilitating localized spread more initially than distant metastasis. This impacts treatment strategy, with earlier stages favorable for surgical intervention and localized therapy, which can potentially improve survival rates.\\n\\n### Histology: Adenosquamous Carcinoma\\n\\n1. **Interaction with Mutation Profiles:**\\n   - Adenosquamous carcinoma combines features of both squamous cell carcinoma and adenocarcinoma. It often presents a diverse mutational landscape, including frequent mutations in the PIK3CA and KRAS genes.\\n   - **Survival Impact:** This dual histology often results in more aggressive tumor behavior compared to pure adenocarcinoma or squamous cell carcinoma alone, affecting survival negatively.\\n   \\n2. **Biological Rationale:**\\n   - The presence of both glandular and squamous elements may allow the carcinoma to exploit diverse proliferative and migratory pathways. The heterogeneity tends to confer resistance to standard treatments, thereby reducing overall survival chances.\\n\\n### Sampling Bias: Genomic Analysis\\n\\n1. **Limitations of Blood Derived Normal, Primary Tumor:**\\n   - When using blood-derived normal as a comparator in genomic studies, there can be a misunderstanding of mutational backgrounds, potentially indicating constitutional variants as somatic mutations.\\n   - **Survival Impact:** Misinterpretation can lead to incorrect treatment plans or prognostic stratifications if driver mutations are misidentified or overlooked.\\n   \\n2. **Biological Rationale:**\\n   - Normal blood-derived samples might not fully represent the true genetic landscape of contrast seen in a primary tumor, skewing mutation profiles and possibly affecting targeted therapy development.\\n\\n### Key Genes Associated with Survival\\n\\n1. **PIK3CA:**\\n   - **Mechanism:** Drives tumor proliferation and survival via the PI3K/AKT pathway, a critical pro-survival signaling cascade.\\n   - **Impact:** Frequently mutated in cervical cancer, leading to increased tumor growth and resistance to apoptosis, negatively influencing survival.\\n\\n2. **KRAS:**\\n   - **Mechanism:** Involved in the RAS/MAPK pathway, affecting cell proliferation and survival.\\n   - **Impact:** Mutations denote aggressive tumor behavior and poorer outcomes due to enhanced growth signaling.\\n\\n3. **TP53:**\\n   - **Mechanism:** Regulates DNA repair and apoptosis.\\n   - **Impact:** Mutations often lead to loss of tumor suppressive functions, enabling tumor progression and resistance to standard therapy.\\n\\n4. **ERBB2 (HER2):**\\n   - **Mechanism:** Promotes cell growth and division.\\n   - **Impact:** Overexpression or amplification linked to reduced survival due to aggressive disease course and therapeutic resistance.\\n\\n5. **CDKN2A (p16):**\\n   - **Mechanism:** Negative regulator of the cell cycle.\\n   - **Impact:** Loss through methylation or deletion correlates with unchecked cell division, contributing to poorer prognosis.\\n\\n6. **MYC:**\\n   - **Mechanism:** Controls cell cycle progression and apoptosis.\\n   - **Impact:** Amplification or overexpression often correlates with resistance to apoptosis and enhanced survival of malignant cells.\\n\\n7. **VEGF:**\\n   - **Mechanism:** Promotes angiogenesis.\\n   - **Impact:** Elevated levels facilitate tumor growth and metastasis, typically associated with decreased survival.\\n\\n### Conclusion: Key Survival Risk Factors\\n\\n- **Anatomical Origin:** Determines initial metastatic spread potential, primarily influencing early intervention success.\\n- **Histological Variety:** Mixed histologies carry diverse mutational burdens predisposing to aggressive disease.\\n- **Genomic Interpretation Biases:** Accurate genomic insights are essential. Incorrect individualized genomic interpretations can misguide therapeutic choices.\\n- **Gene Mutations:** Core survival-associated genes highlight critical pathways (PI3K/AKT, RAS/MAPK) with direct clinical implications on targeted treatments.\\n\\n**Clinically Relevant Insights:** These factors underscore the importance of precision medicine in treatment planning, where targeted therapies and tailored interventions based on accurate genomic profiling can significantly improve patient outcomes in cervical squamous cell carcinoma and related histological variants.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894418, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=976, prompt_tokens=453, total_tokens=1429, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 81/704...\n",
      "ChatCompletion(id='chatcmpl-BAibkhnxPHABcXVkF2TDZXKc1OB20', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Ovary Influence\\n\\n**Step-by-Step Impact on Survival:**\\n\\n1. **Metastatic Patterns:**\\n   - The origin of a tumor in the ovary can significantly influence its metastatic potential and patterns. Ovarian tumors often metastasize via peritoneal dissemination and lymphatic routes, potentially leading to widespread abdominal involvement. This method of spread is often less contained compared to hematogenous metastasis and can result in more extensive disease at presentation.\\n\\n2. **Patient Survival:**\\n   - Advanced metastatic patterns typically result in poorer survival because they can complicate surgical resection and limit effective therapeutic options. Extensive metastatic spread often correlates with advanced stage diagnosis, a critical determinant of prognosis.\\n\\n3. **Treatment Accessibility:**\\n   - Tumors originating in the ovary may be detected at later stages due to nonspecific symptoms, limiting early intervention possibilities. This can restrict prompt surgical and chemotherapeutic strategies, directly impacting survival negatively.\\n\\n**Biological Rationale:**\\n   - Ovarian cancers have high intratumoral heterogeneity. The diverse clonal populations can exhibit varied resistance to treatments, challenging therapeutic efficacy.\\n\\n**Potential Biases:**\\n   - Sampling from the primary site often predominates, potentially missing heterogeneity present in metastatic sites, leading to underestimation of metastatic potential and treatment resistance.\\n\\n### Histology: Interaction Between Squamous Cell Carcinoma, NOS, and Mutation Profiles\\n\\n**Step-by-Step Impact on Survival:**\\n\\n1. **Mutation Profile Implications:**\\n   - Squamous cell carcinoma of the cervix associated with limited genetic instability might restrict potential targeted therapy approaches. If key oncogenic drivers are non-targetable, survival can be adversely affected.\\n\\n2. **Impact on Outcomes:**\\n   - The histology type inherently influences proliferation and apoptotic pathways. Squamous histology may exhibit inherent resistance mechanisms to apoptosis, promoting survival and potentially worsening outcomes.\\n\\n**Biological Rationale:**\\n   - Squamous cell carcinomas often harbor mutations that affect cellular adhesion and integrity, promoting invasiveness and impacting therapeutic responses.\\n\\n**Potential Biases:**\\n   - Genomic studies may often preferentially collect samples during early stages, introducing bias by underrepresenting late-stage genomic alterations crucial for survival assessments.\\n\\n### Sampling Bias: Impact of Blood Derived Normal, Metastasis\\n\\n**Step-by-Step Impact on Survival:**\\n\\n1. **Genomic Variability:**\\n   - Blood-derived normal controls often fail to account for tumor-specific mutations that might be restricted to the tumor microenvironment, potentially skewing comparative oncogenomic analyses.\\n   \\n2. **Biological Interpretation Challenges:**\\n   - Metastatic samples may carry additional mutation burdens not present in primary tumors, reflecting survival-affecting resistance profiles that are unrecognized if under-sampled.\\n\\n**Potential Biases:**\\n   - Focusing on blood-derived samples may dilute the detection of critical somatic mutations, compromising the understanding of genomic drivers of survival.\\n\\n### Key Genes: Survival-Associated Genes\\n\\n- **TP53:** Crucial for regulating the cell cycle and apoptosis; mutations can lead to unchecked proliferation.\\n- **PIK3CA:** Alters cell growth pathways; mutations can drive cancer progression and affect survival.\\n- **BRCA1/2:** Involvement in DNA repair; mutations heighten genomic instability, influencing treatment response and survival.\\n- **APC:** Affects Wnt signaling and cellular adhesion; its mutation can lead to enhanced metastatic potential.\\n- **KRAS:** Mutations often drive aggressive phenotypes and resistance to therapy, impacting survival detrimentally.\\n- **CDKN2A:** Involved in cell cycle control; mutations disrupt growth regulation, affecting outcomes.\\n\\n**Biological Mechanisms:**\\n   - Each gene influences pathways critical for cancer cell survival, such as apoptosis, DNA repair, and cell proliferation.\\n\\n**Potential Biases:**\\n   - Genetic sampling biases can skew the frequency and impact of these gene mutations in survival assessment, often underestimating the heterogeneity of mutational impacts.\\n\\n### Conclusion: Synthesis of Key Survival Risk Factors\\n\\n**Clinical Insights:**\\n\\n- **Tumor Origin and Histologic Factors:** They heavily influence metastatic spread and treatment response, both being pivotal in tailoring treatment strategies.\\n- **Genomic Contributions and Sampling Biases:** An understanding of sampling limitations is crucial to refine prognostic tools and improve personalized therapy approaches.\\n- **Survival Impact of Genetic Drivers:** Identification of genetic mutations enables stratification of patients for targeted therapies, showing direct survival benefits.\\n\\nBy integrating these aspects into a comprehensive clinical assessment, we refine our ability to predict patient outcomes and enhance tailored treatment strategies, ultimately impacting survival positively.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894452, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=935, prompt_tokens=450, total_tokens=1385, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 82/704...\n",
      "ChatCompletion(id='chatcmpl-BAic8fyLC0rqT3dOsFVPvQ1SXc8I8', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To comprehensively analyze the survival impact of Cervical squamous cell carcinoma and endocervical adenocarcinoma concerning ovarian implication (ICD-10: Ovary), we must dissect each element methodically considering tumor origin, histology, sampling bias, and genetic factors. Here is how each component impacts survival:\\n\\n### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns and Survival:**\\n   - **Ovarian Impact:** Cervical cancer typically metastasizes locally to the pelvic lymph nodes and distal organs like the lungs. However, if ovarian involvement (often rare) is detected, it may indicate more aggressive metastatic behavior or synchronous primary tumors. This modification can adversely affect survival because metastasis complicates treatment and reduces efficacy, thereby worsening the prognosis.\\n\\n2. **Treatment Accessibility:**\\n   - **Priority Consideration:** Ovarian involvement may necessitate more comprehensive surgical approaches or aggressive chemotherapy regimens, enhancing complexity and treatment side effects, potentially limiting survival.\\n\\n3. **Biological Rationale:**\\n   - **Rationale for Poorer Outcomes:** The ovary\\'s proximity to the cervix can facilitate easier intraperitoneal spread of cancer cells, transitioning cancer from local to more systemic diseases, complicating management.\\n\\n### Histology\\n\\n1. **Impact of Squamous Cell Carcinoma Histology:**\\n   - **Survival Influence:** Squamous cell carcinoma of the cervix represents a significant proportion of cervical cancers and is generally considered more radiosensitive compared to adenocarcinomas, potentially leading to better outcomes if detected early.\\n\\n2. **Mutation Interaction:**\\n   - **NOS Variability:** The \"not otherwise specified\" nature leads to challenges in precisely tailoring therapies as mutation profiles may include variations not targeted by specific treatments, affecting survival unfavorably.\\n\\n3. **Biological Mechanisms:**\\n   - **Significance:** This histological type often exhibits disruption in pathways regulating proliferation and apoptosis, mediated by p53 mutations, potentially leading to aggressive growth and unpredictability in response to treatment.\\n\\n### Sampling Bias\\n\\n1. **Limitations of Sampling in Genomic Analysis:**\\n   - **Blood Derivation:** Normal cells sampled from the blood may not capture the genomic heterogeneity present in primary tumors, leading to an underestimation of actionable mutations and subsequent treatment efficacy.\\n   - **Primary Tumor Sampling:** While it captures the tumor genomic landscape, sampling may miss regional variations, like sub-clonal populations contributing to resistance, skewing survival predictions.\\n\\n2. **Impact on Interpretation:**\\n   - **Potential Inaccuracies:** Consequently, survival predictions based on incomplete genomic data might be misleading, especially if personalized medicine strategies are employed without comprehensive knowledge of genetic variability.\\n\\n### Key Genes\\n\\n1. **Survival-Associated Genes:**\\n   - **TP53:** Mutations lead to loss of cell cycle control, enhancing proliferation and reducing apoptosis, negatively impacting survival.\\n   - **PIK3CA:** Involved in cell growth pathways; mutations can signal aggressive tumor behavior and poor prognosis.\\n   - **CDKN2A:** Regulates cell cycle progression; loss of function can contribute to unchecked cellular proliferation.\\n   - **EGFR:** Overexpression may correlate with increased tumor aggressiveness and resistance to therapy.\\n   - **KRAS:** Mutations often drive growth factor-independent signal transduction, increasing metastatic potential.\\n   - **BRCA1/2:** Typically associated with double-strand DNA repair, alterations here can lead to genomic instability, though they may increase sensitivity to specific chemotherapeutics.\\n   - **HER2:** Presence can indicate more aggressive disease but also makes targeted therapies possible.\\n\\n2. **Biological Mechanisms:**\\n   - **Mechanisms Impacting Survival:** These genes orchestrate processes from cell cycle regulation to metabolic control and apoptosis. Their mutation profiles contribute to varying treatment responses and generally correlate with more aggressive phenotypes, detracting from survival rates.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nIn conclusion, the interplay of tumor origin, specific histological characteristics, and genomic sampling biases create a complex landscape impacting survival outcomes in cervical cancers. Key genetic mutations involved in proliferation, metastasis, and resistance pathways critically shape the survival prognosis. Clinically, understanding these nuanced factors can guide precision medicine approaches, potentially improving survival through tailored therapies that address both the genomic and histopathological complexity of each tumor. Recognizing and mitigating sampling biases alongside advanced genetic profiling remain pivotal in advancing treatment efficacy and overall patient survival.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894476, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=899, prompt_tokens=450, total_tokens=1349, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 83/704...\n",
      "ChatCompletion(id='chatcmpl-BAica8ZO2a4z1bfkS3Kh5HknHlzDM', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"**Cholangiocarcinoma and Survival Impact:**\\n\\n### Tumor Origin\\n\\n1. **Influence on Metastatic Patterns:**\\n   - **Liver as Primary Site:** Cholangiocarcinoma originates from the bile duct epithelium within the liver. The liver's extensive vascular architecture allows for hematogenous spread, predominantly to regional lymph nodes and the peritoneum, impacting survival negatively by enabling widespread metastasis.\\n   - **Local Invasion:** Given the liver's central role in systemic metabolism, tumors can quickly invade the hepatic vasculature, altering liver function and leading to complications like portal hypertension and hepatic failure.\\n\\n2. **Patient Survival and Treatment:**\\n   - **Prognosis:** The survival rates are low because primary cholangiocarcinomas are often asymptomatic until advanced stages. Due to the liver's essential functions, early diagnosis is critical but challenging.\\n   - **Treatment Accessibility:** Surgical resection is the main curative option; however, only a minority of cases qualify due to late-stage diagnosis. The liver's regenerative capability poses initial optimism post-resection, but recurrence rates remain high.\\n\\n### Histology and Mutation Interaction\\n\\n1. **Impact on Outcomes:**\\n   - **Histological Variability:** Cholangiocarcinoma is typically adenocarcinomatous in nature. The complex glandular structures are associated with distinct mutation profiles impacting survival variably.\\n   - **Mutation Profiles:** Common genetic mutations like KRAS, TP53, and IDH1 affect cellular processes like apoptosis and proliferation, with mutated TP53 leading to unchecked cell division and a worse prognosis.\\n\\n2. **Biological Mechanisms:**\\n   - **Oncogenic Mutations:** Mutations in IDH1/2 can disrupt normal cellular metabolism, fostering tumor growth. IDH mutations are linked with differentiation anomalies, influencing histologic heterogeneity, which correlates with variability in treatment responses and outcomes.\\n\\n### Sampling Bias\\n\\n1. **Limitations of Blood Derived Normal and Primary Tumor:**\\n   - **Genomic Analysis:** Blood-derived normal controls may not capture the somatic genomic landscape accurately due to systemic interaction in liver-driven illnesses. Comparing these with primary tumor samples may overlook intratumoral heterogeneity.\\n   - **Assessment Challenges:** Primary tumor samples might not reflect metastatic potential or genetic evolution, leading to biases in interpreting the tumor's aggressiveness or potential therapeutic targets.\\n\\n### Key Genes and Survival Mechanisms\\n\\n1. **Survival-Associated Genes:**\\n   - **TP53:** Regulates cell cycle and apoptosis; mutant TP53 results in impaired apoptosis, leading to increased survival of malignant cells — associated with poorer outcomes.\\n   - **KRAS:** Governs proliferative signaling; mutations lead to continuous cell division, enhancing metastatic risk and reducing response to targeted therapies.\\n   - **IDH1/2:** Altered activity affects cellular energetics and differentiation, contributing to aggressive tumor behavior.\\n   - **FGFR2:** Alterations in the FGFR2 pathway can contribute to angiogenesis and cell proliferation, affecting tumor growth and therapeutic resistance.\\n   - **BAP1:** Known for chromatin remodeling; loss affects DNA repair mechanisms, increasing genetic instability, and worsening prognosis.\\n   - **ARID1A:** Involved in chromatin remodeling; its loss can lead to enhanced tumor stemness and adaptability.\\n   - **BRCA1/2:** Tumor suppressor genes that, when inactivated, impair DNA repair, enhancing mutation rates within the tumor.\\n   - **HNF1A:** Implicated in bile duct formation and differentiation; mutations can further familial cholangiocarcinoma predisposition.\\n\\n2. **Biological Rationale and Impact on Survival:**\\n   - Many of these genes directly influence pathways involved in DNA repair, cellular proliferation, and apoptosis. Their function or dysfunction affects genetic stability and chemotherapeutic responsiveness.\\n\\n### Conclusion – Key Survival Risk Factors:\\n\\n1. **Synthesis of Influencing Elements:**\\n   - **Tumor Origin and Histology:** The hepatic origin promotes aggressive metastatic pathways, while the liver's unique environment aligns with specific histological features that tie back to mutation-driven malignancy.\\n   - **Genetic Landscape:** A combination of gene mutations (e.g., KRAS, TP53) dictates tumor behavior, influencing aggression and treatment responses — particularly affecting survival rates considerably.\\n   - **Sampling and Diagnostic Challenges:** Highlight the need for refined sampling techniques and more comprehensive genetic profiling to improve prognosis accuracy and therapy personalization.\\n\\nThese insights underscore the multifactorial nature of cholangiocarcinoma's impact on patient survival, emphasizing the clinical relevance of integrated diagnostic and therapeutic strategies tailored to genetic and histological profiles.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894504, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=943, prompt_tokens=437, total_tokens=1380, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 84/704...\n",
      "ChatCompletion(id='chatcmpl-BAid20rQNz39CAsM4VyCWgvLlAGqT', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Intrahepatic Bile Duct\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Intrahepatic cholangiocarcinoma (ICC) often spreads via hematogenous, lymphatic, and peritoneal routes. This complexity leads to early dissemination, challenging surgical resection and complicating management.\\n- **Patient Survival & Treatment Accessibility:** ICC is often diagnosed at advanced stages, with curative options like liver transplantation or resection being limited due to late detection. Survival rates are consequently lower compared to other liver cancers.\\n\\n**Biological Rationale:**\\n- **Metastasis:** The liver's dense vascularization facilitates hematogenous spread, while the proximity of bile ducts to lymphatics accelerates regional metastasis. This complex vascular environment complicates surgical margins, affecting the cure rate.\\n\\n**Biases in Genomic Interpretation:**\\n- Tumor heterogeneity based on location may skew genomic data, with more aggressive phenotypes underrepresented if sampling is biased towards accessible, less invasive lesions.\\n\\n### Histology and Mutation Profiles\\n\\n**Influence on Survival:**\\n- **Histological Subtypes:** Variants like mucinous or mixed ICC exhibit differing pathological behaviors, which influence prognosis and therapeutic responses.\\n- **Mutation Profiles:** Common mutations in ICC, such as IDH1/2, KRAS, and FGFR2 fusions, are tied to differential survival outcomes, reflecting on targeted therapy potential.\\n\\n**Biological Rationale:**\\n- **Differential Pathogenicity:** Molecular differences in histological subtypes can result in varied growth rates, angiogenesis (vascular mimicry in some ICC subtypes), and immune evasion. \\n\\n**Biases in Genomic Interpretation:**\\n- Histological assessment may lead to sampling that overlooks intratumor heterogeneity. Biopsies capturing only a portion of the tumor might miss significant driver mutations present in subclonal populations.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n**Influence on Survival:**\\n- Accurate genomic characterization is vital for treatment strategy. Blood-derived samples may fail to capture tumor-specific mutations, especially those not shedding into circulation (ctDNA).\\n\\n**Biological Rationale:**\\n- Blood samples can miss somatic mutations strictly present in the tumor’s microenvironment, leading to incomplete mutation profiles impacting targeted treatment efficacy.\\n\\n**Potential Biases:**\\n- Sampling errors may lead to misinterpretation of mutation significance, affecting prognosis and leading to suboptimal therapeutic choices if based on incomplete profiles.\\n\\n### Key Genes and Survival Impact\\n\\n1. **IDH1/2**: Mutations in these isocitrate dehydrogenase genes alter cellular metabolism and epigenetics, promoting oncogenesis and offering targets (e.g., ivosidenib). They generally suggest better prognosis when targetable therapies are utilized.\\n\\n2. **KRAS**: Mutations here drive poor prognosis due to aggressive tumor proliferation and chemo-resistance, emphasizing a need for novel inhibitors.\\n\\n3. **FGFR2 Fusions**: These promote oncogenic signaling pathways causing cell proliferation and survival. Targeted FGFR inhibitors can improve outcomes when these fusions are present.\\n\\n4. **TP53**: Mutations herald poor survival, common in advanced ICC, due to failure of apoptosis and cell cycle dysregulation.\\n\\n5. **ARID1A**: Loss-of-function mutations correlate with chromatin remodeling defects, influencing cell cycle progression.\\n\\n6. **BAP1**: Associated with chromatin structure alterations and poor prognosis, BAP1 mutations drive aggressive tumor behavior.\\n\\n**Biological Mechanisms:**\\n- Each mutation exhibits unique pathways affecting cellular differentiation, angiogenesis, immune interaction, and apoptosis, impacting overall survival.\\n\\n### Conclusion\\n\\n- **Key Survival Risk Factors:** Tumor origin (late-stage presentation due to early metastasis), molecular heterogeneity, and actionable tumor genetics like FGFR2 fusions profoundly influence survival rates.\\n- **Clinically Relevant Insights:** Targeted molecular diagnostics are imperative; comprehensive genomic profiles can direct precision therapy, offering the best prognosis.\\n- **Impact on Patient Survival:** Integrating molecular characteristics with early detection efforts could transition ICC management towards more effective, personalized strategies, enhancing survival and quality of life.\\n\\nA comprehensive, nuanced understanding of these factors provides a roadmap for utilizing molecular pathology in guiding therapeutic decisions and improving patient outcomes in ICC.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894532, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=876, prompt_tokens=447, total_tokens=1323, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 85/704...\n",
      "ChatCompletion(id='chatcmpl-BAidSlf6RBXh62fDub4CvyDhfd7wH', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n#### Influence on Survival\\nCholangiocarcinoma originates in the intrahepatic bile ducts, influencing metastatic patterns significantly. Its origin typically leads to early invasion of adjacent liver tissues and vasculature, resulting in a higher propensity for vascular invasion and distant metastasis, which directly impacts survival negatively.\\n\\n#### Biological Rationale\\nThe bile duct epithelium, where these tumors originate, has a complex vascular supply that facilitates dissemination of tumor cells. This vascularity leads to higher incidents of hematogenous metastasis, particularly to the liver and lungs. These metastatic patterns are often aggressive and challenging to treat, reducing overall survival.\\n\\n#### Treatment and Accessibility\\nMoreover, intrahepatic cholangiocarcinoma often presents at an advanced stage due to the asymptomatic nature of early lesions. This delays diagnosis and limits surgical options, as resection is only feasible in early stages and significantly impacts survival rates when not possible.\\n\\n### Histology and Mutation Profiles\\n\\n#### Influence on Survival\\nCholangiocarcinoma's histological diversity includes well to poorly differentiated adenocarcinomas, which align with varied mutation profiles such as alterations in KRAS, TP53, and IDH1. These mutations are crucial in determining the aggressiveness of the cancer and subsequently, patient prognosis.\\n\\n#### Biological Rationale\\nMutations in KRAS and TP53 are associated with uncontrolled cell proliferation and resistance to apoptosis, enhancing tumor progression and reducing survival. Alterations in IDH1 can lead to metabolic changes that promote tumor growth and environmental adaptability, complicating treatment responses.\\n\\n#### Potential Biases\\nThere are potential biases in sampling tumor tissues, as heterogeneity within and between tumors may lead to an underestimation of mutant alleles or overlooking critical mutations, affecting the accuracy of prognosis and personalized treatment planning.\\n\\n### Sampling Bias\\n\\n#### Limitations of Genomic Analysis\\nSampling from primary tumors or tissue normals might not accurately reflect the tumor’s heterogeneous nature. Variability in sampling techniques can lead to biases where critical mutations in subclonal populations are missed, potentially skewing genomic insights and impacting therapeutic decisions adversely. \\n\\n#### Influence on Survival\\nSuch omissions could lead to ineffective treatment regimes that ignore existing clonal expansions, leading to disease progression unchecked by therapy, ultimately affecting survival negatively.\\n\\n### Key Genes and Their Biological Mechanisms\\n\\n1. **KRAS**: Frequently mutated, KRAS influences cell-cycle progression and proliferation. Its alterations often correlate with aggressive tumor behavior and poor survival.\\n\\n2. **TP53**: A crucial tumor suppressor, mutations here result in impaired cell cycle control and resistance to cell death, leading to tumor growth and poorer patient outcomes.\\n\\n3. **IDH1**: Mutations often drive metabolic reprogramming in cells, supporting survival in hypoxic conditions and leading to increased malignancy.\\n\\n4. **BAP1**: Loss-of-function mutations are associated with genetic instability and enhanced cancer cell immortality, adversely affecting survival.\\n\\n5. **ARID1A**: Inactivation affects chromatin remodeling, altering gene expression patterns, often seen in more aggressive tumors.\\n\\n6. **FGFR2**: Gene fusions or mutations lead to constitutively active signaling pathways that promote proliferation and survival, associated with poor outcomes but also targeted therapy opportunities.\\n\\n7. **BRCA2**: Altered DNA repair mechanisms due to mutations elevate genomic instability, driving tumor progression.\\n\\n8. **HER2/ERBB2**: Overexpression or amplification can drive aggressive growth, though also offers potential targeting with specific therapeutic agents when identified.\\n\\n### Conclusion: Key Survival Risk Factors and Clinically Relevant Insights\\n\\n- **Aggressive Tumor Biology**: Driven by specific gene mutations, aggressive tumor histology, and inherent characteristics of its origin, cholangiocarcinoma tends to present late with advanced-stage disease. \\n- **Challenges in Early Detection**: Due to its silent course in early stages, late-stage diagnosis is common, limiting curative options and negatively impacting outcomes.\\n- **Complex Genomic Landscape**: Understanding genetic profiles and their phenotypic expressions remains critical in managing patient treatment plans, though achieving a comprehensive genomic understanding is hindered by sampling biases.\\n  \\nUltimately, the integrated understanding of these factors points to the need for enhanced molecular profiling and early detection methods to improve treatment specificity and patient survival outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894558, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=868, prompt_tokens=447, total_tokens=1315, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 86/704...\n",
      "ChatCompletion(id='chatcmpl-BAidsdB0yTW0ShMF3DmhianOIGSM6', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='To address the complex interplay of factors affecting survival in Cholangiocarcinoma, specifically the extrahepatic type, we need to delve into the tumor origin, histology, genetic mutations, and potential sampling biases systematically.\\n\\n### 1. Tumor Origin: Extrahepatic Bile Duct\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Extrahepatic cholangiocarcinoma, due to its anatomical proximity to the hepatic portal, can facilitate early dissemination to regional lymph nodes and potential seeding in distant organs. This contributes negatively to survival by complicating surgical interventions and facilitating systemic disease.\\n- **Patient Survival Impact:** Because of frequent late diagnosis and propensity for early metastasis, extrahepatic cholangiocarcinoma often presents at advanced stages, lowering overall survival rates compared to other forms. The five-year survival rate remains dismal due to late-stage detection.\\n- **Treatment Accessibility:** Anatomical concerns, such as proximity to vital structures (liver, pancreas, and major blood vessels), complicate surgical resection which is the primary curative option. Limited surgical candidates decrease survival odds significantly.\\n\\n**Biological Rationale:**\\n- The location contributes to aggressive behavior and limits effective early intervention, underscoring the importance of timely and precise diagnosis for improving prognostic outcomes.\\n\\n### 2. Histology: Interaction with Mutation Profiles\\n\\n**Influence on Survival:**\\n- **Histological Subtype Variations:** Cholangiocarcinoma can be classified histologically into well-differentiated, moderately-differentiated, and poorly-differentiated types. Poorly differentiated tumors typically exhibit more aggressive behavior and mutations associated with unfavorable outcomes, such as KRAS or P53 mutations.\\n\\n**Biological Rationale:**\\n- Histological differentiation affects tumor biology, influencing proliferation rates and apoptosis resistance pathways. The presence of certain mutations, such as those affecting the cell cycle regulation, further exacerbate these histologic tendencies.\\n\\n### 3. Sampling Bias: Limitations in Genomic Analysis\\n\\n**Influence on Survival:**\\n- **Blood vs. Tumor Sampling:** Reliance on blood-derived samples can introduce biases due to tumor heterogeneity. Primary tumor tissues provide more accurate snapshots of the mutational landscape directly affecting survival.\\n- **Methodological Constraints:** Blood-derived norms may underestimate intratumoral heterogeneity or miss unique mutations, potentially skewing predictions of patient outcomes and drug responsiveness.\\n\\n### 4. Key Genes (Survival-Associated)\\n\\n**Genes and Their Mechanisms:**\\n1. **KRAS:** Affects cell signaling pathways controlling growth and apoptosis. Mutations often result in resistance to apoptosis, enhancing survival discrepancies in tumor populations.\\n2. **TP53:** Tumor suppressor involved in DNA repair and apoptosis. Mutations normally result in unchecked cellular proliferation.\\n3. **IDH1/2:** These mutations alter essential metabolic pathways, impacting tumor microenvironment and survival outcomes.\\n4. **ARID1A:** Influences chromatin remodeling, affecting gene expression patterns crucial for tumor suppression.\\n5. **EGFR:** Overexpression or mutations can contribute to oncogenic signaling, impacting therapeutic targeting and drug resistance.\\n6. **FGFR2:** Mutations or fusions in FGFR2 enhance proliferation signals. Select FGFR inhibitors might offer improved survival in patients with these alterations.\\n\\n**Biological Rationale:**\\n- Each genetic alteration plays a distinct yet sometimes overlapping role in tumor progression through dysregulation of critical survival-related pathways.\\n\\n### Conclusion\\n\\nSynthesizing these factors, survival in extrahepatic cholangiocarcinoma is heavily dependent on early detection and characterization of both anatomical and genetic landscapes. Clinically, an emphasis on accurate tumor origin assessment combined with comprehensive genomic profiling could inform targeted therapeutic strategies, potentially improving survival rates. The interplay of tumor biology with surgical accessibility and personalized therapy outlines the complexity of survival risks, guiding both current and future treatment paradigms. Understanding these dynamics is crucial for developing effective interventions and improving patient outcomes.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894584, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=801, prompt_tokens=445, total_tokens=1246, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 87/704...\n",
      "ChatCompletion(id='chatcmpl-BAie8CctoGVZvkd1WfE32rndTSDI9', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Cecum Impact on Survival\\n\\n**Influence on Survival**\\n- **Metastatic Patterns**: Tumors originating in the cecum can metastasize to liver and regional lymph nodes earlier due to proximity and lymphatic drainage efficiency. This early spread typically correlates with poorer survival outcomes.\\n- **Patient Survival**: Survival likelihood decreases with earlier lymphatic involvement, as more advanced disease at diagnosis leads to fewer curative treatment options.\\n- **Treatment Accessibility**: Cancer treatments may vary based on tumor location, with cecal cancers potentially benefiting differently due to their specific pharmaceutical absorption or resection strategies.\\n\\n**Biological Rationale**\\n- **Lymphatic System Involvement**: Proximity of the cecum to key lymphatic pathways results in rapid tumor cell dissemination.\\n- **Biological Differences**: Cecal tumors might differ in their cell adhesion properties, facilitating early metastatic behavior compared to distal colon sites.\\n\\n**Bias in Genomic Interpretation**\\n- **Potential Overdiagnosis or Delayed Detection**: The anatomical location might influence diagnostic accuracy, skewing survival statistics by either overrepresenting certain gene expressions at advanced stages or missing early-stage cancers in genomic studies.\\n\\n### Histology: Adenocarcinoma, NOS Interaction with Mutation Profiles\\n\\n**Influence on Survival**\\n- **Prognosis and Treatment Responsiveness**: General adenocarcinoma, NOS, may display diverse behaviors depending on prevalent mutation profiles like KRAS, NRAS, and BRAF, directly affecting survival through altered therapeutic responses.\\n- **Outcomes Variation**: While some mutations herald poor prognosis (e.g., BRAF V600E), others might indicate more favorable treatment pathways or vulnerability to certain drugs.\\n\\n**Biological Rationale**\\n- **Mutation-Driven Aggressiveness**: Certain mutations hijack signaling pathways (e.g., MAPK) enhancing cellular proliferation and invasion, compounding survival challenges.\\n- **Histological Homogeneity**: Lack of specific differentiation in NOS (not otherwise specified) categorization means diverse mutation profiles that could unpredictably affect treatment efficacy.\\n\\n**Bias in Genomic Interpretation**\\n- **Histogram Representation**: Reliance on primary tumor samples might miss heterogeneity captured only with broader sampling techniques, leading to skewed mutation impact representation.\\n\\n### Sampling Bias: Blood Derived Normal vs. Primary Tumor\\n\\n**Influence on Survival**\\n- Misinterpretation of mutation frequency due to inadequate representation of tumor heterogeneity can misguide treatment approaches, potentially affecting survival negatively.\\n\\n**Biological Rationale**\\n- **Genomic Context**: Tumor samples often exhibit intratumoral heterogeneity not mirrored by blood-derived samples, leading to partial insights in bioinformatics analyses.\\n  \\n**Bias in Genomic Interpretation**\\n- **Confounded Allelic Distribution**: Blood samples might not capture crucial tumor-specific mutation signatures due to dilution effects or lack of tumor-derived cfDNA detection.\\n\\n### Key Genes: Survival-Associated Mutants\\n\\n**Influence on Survival**\\n- **APC, TP53, KRAS, BRAF, PIK3CA, and NRAS mutations** all crucially dictate adenocarcinoma survival by altering malignancy pathways.\\n\\n**Biological Rationale**\\n- **APC and TP53**: Tumor suppressor roles, with mutations likely disabling controls on proliferation and apoptosis.\\n- **KRAS, BRAF, NRAS**: Oncogenic drivers that, when mutated, can lead to relentless cell division and evasion of apoptosis.\\n- **PIK3CA**: Pathway involvement in metabolic reprogramming, affecting how tumors resist certain chemotherapies.\\n\\n**Bias in Genomic Interpretation**\\n- **Selection of Samples**: Tumor purity and methodological limitations can lead to partial mutation frequency errors affecting perceived survival impact of these genes.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nThe cecal origin of a tumor often predisposes individuals to earlier metastasis due to anatomical and lymphatic configurations, fundamentally altering survival dynamics. Mutation profiles at the genomic level, especially those influencing key signal transduction pathways (e.g., MAPK, PI3K), further dictate individualized prognoses and highlight the complexity of adenocarcinoma treatment and survival outcomes. Considering tumor heterogeneity and accurate genomic representation remains critical; optimal survival outcomes hinge on precise and early detection, comprehensive mutation profiling, and personalized treatment strategies leveraging genomic insights. Balancing these factors within clinical frameworks enhances potential survival pathways, underlining the need for innovation in diagnostics and targeted therapies.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894600, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=902, prompt_tokens=440, total_tokens=1342, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 88/704...\n",
      "ChatCompletion(id='chatcmpl-BAieTc6rcnWUoNHeNAePma8lyHsrb', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='**Tumor Origin: Cecum\\'s Influence on Survival**\\n\\n1. **Metastatic Patterns and Survival:**\\n   - **Influence**: Colon adenocarcinomas originating from the cecum exhibit distinct metastatic behavior. The cecum\\'s proximity to the lymphatic system often leads to early lymphatic spread.\\n   - **Rationale**: Due to its anatomical location at the beginning of the colon, tumors in the cecum may be advanced at diagnosis, contributing to poorer survival compared to left-sided colon cancers. The biological behavior, driven by both anatomical factors and distinct molecular pathways, increases the risk of distant metastases, particularly to the liver and lungs.\\n\\n2. **Treatment Accessibility:**\\n   - **Influence**: Cecum-derived tumors might have less surgical accessibility following lymphatic spread, complicating full surgical resection.\\n   - **Rationale**: Limited accessibility might stem from the intricate blood supply and the surrounding tissue structures, requiring more complex surgical techniques. This complexity can delay intervention, impacting survival adversely.\\n\\n**Histology: Adenocarcinoma, NOS and Mutation Profiles**\\n\\n1. **Histological Influence on Survival:**\\n   - **Influence**: The histological type \"Adenocarcinoma, NOS\" indicates a lack of specific differentiation, often linked to a more aggressive phenotype.\\n   - **Rationale**: This non-specific classification often harbors KRAS, BRAF, or microsatellite instability (MSI) mutations. Tumors with MSI tend to have a better prognosis due to heightened immunogenicity, making them more susceptible to immunotherapy, inversely contributing to improved survival when such therapies are applied.\\n\\n2. **Interaction with Genetic Mutations:**\\n   - **Influence**: Mutation profiles play a crucial role in determining patient outcomes.\\n   - **Rationale**: Mutations in key pathways like the Wnt signaling or upregulations such as EGFR can lead to pervasive cell proliferation, poor differentiation, and tumor invasion, generally correlating with worse survival outcomes.\\n\\n**Sampling Bias in Genomic Analysis**\\n\\n1. **Limitations of Sampling:**\\n   - **Influence**: Sampling from primary tumors without adjacent solid tissue normals can introduce bias in genomic analysis.\\n   - **Rationale**: Without appropriate comparators, mutations identified in tumor samples may include passenger mutations or be affected by intratumor heterogeneity, which can mislead treatment strategies and survival predictions by not capturing the full tumor genetic landscape.\\n\\n2. **Potential Consequences:**\\n   - **Influence**: This bias could lead to overestimating the prevalence of mutations thought to drive carcinogenesis or miss relevant mutations altogether.\\n   - **Rationale**: Comprehensive genomic profiling that accounts for heterogeneity is necessary to accurately project potential metastasis and tumor behavior, influencing survival if deviations are not corrected.\\n\\n**Key Genes Influencing Survival**\\n\\n1. **APC** (Adenomatous Polyposis Coli):\\n   - **Mechanism**: Dysregulation contributes to aberrant Wnt signaling, enhancing cell proliferation.\\n   - **Survival Impact**: Typically, mutations indicate poor prognosis due to increased cellular growth and division.\\n\\n2. **KRAS**:\\n   - **Mechanism**: Mutations activate cell signaling pathways related to growth and survival.\\n   - **Survival Impact**: Poorer response to anti-EGFR therapies, thus poorer survival.\\n\\n3. **BRAF**:\\n   - **Mechanism**: Activates mitogen-activated protein kinase pathway, increasing proliferation.\\n   - **Survival Impact**: Worse prognosis, particularly BRAF V600E mutation linked with aggressive disease.\\n\\n4. **PIK3CA**:\\n   - **Mechanism**: Mutations lead to heightened PI3K/AKT pathway activity, promoting survival and resistance.\\n   - **Survival Impact**: Certain mutations correlate with either favorable outcomes or therapeutic resistance.\\n\\n5. **TP53**:\\n   - **Mechanism**: Key regulator of the cell cycle, apoptosis.\\n   - **Survival Impact**: Mutant forms often suggest genomic instability, associated with poorer survival.\\n\\n6. **MSI-related genes (MLH1, MSH2, MSH6, PMS2)**:\\n   - **Mechanism**: Linked to impaired DNA repair, leading to a more unstable genome.\\n   - **Survival Impact**: Positive when considering immunotherapy options due to high mutation burden.\\n\\n**Synthesis of Key Survival Risk Factors**\\n\\nIn cecum origin colon adenocarcinomas, accurate initial staging and genomic profiling are paramount for survival prediction. High consideration for the spatial and histological variability that characterizes these tumors is essential. Understanding the genomic underpinnings by mitigating sampling biases enables a clearer picture of tumor behavior. Clinical implications include prioritizing comprehensive treatment planning incorporating targeted and immunotherapy approaches where applicable. The impact on patient survival heavily draws from integrating anatomical challenges with molecular insights, ensuring that treatment protocols align with specific genetic information. This holistic approach increases survival by tailoring interventions to the biological nuances of cecum-derived malignancies.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894621, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=1032, prompt_tokens=440, total_tokens=1472, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 89/704...\n",
      "ChatCompletion(id='chatcmpl-BAietWkQFayNqFoG2b6vQGlS6rNuE', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Cecum Impact on Metastatic Patterns and Survival\\n\\n1. **Influence on Survival**:\\n   - **Metastatic Patterns**: Tumors originating in the cecum often exhibit a distinct pattern of spread compared to other colon segments. Given their anatomical location near the terminal ileum, these tumors might metastasize differently, often being detected later due to non-specific symptoms, which can negatively impact survival rates.\\n   - **Biological Rationale**: The cecum's unique location implies its vascular and lymphatic connections, facilitating metastasis, particularly to regional lymph nodes and potentially distant organs (e.g., liver, peritoneum). \\n   - **Treatment Accessibility**: Cecum cancers can be harder to detect early through colonoscopy, as they may be less accessible during routine screenings. This contributes to later-stage diagnosis, negatively influencing outcomes.\\n\\n### Histology: Mucinous Adenocarcinoma and Mutation Interaction\\n\\n2. **Influence on Survival**:\\n   - **Histological Type**: Mucinous adenocarcinomas are characterized by abundant extracellular mucin. They often present with a more aggressive course and less favorable prognosis due to different responsiveness to standard chemotherapy.\\n   - **Biological Rationale**: Mucins facilitate tumor cell protection and metastasis by providing a barrier against immune cell infiltration. This histological subtype often correlates with specific mutations such as KRAS and BRAF, known for promoting cell proliferation and inhibiting apoptosis, ultimately driving poorer outcomes.\\n   - **Mutation Profiles and Outcomes**: These mutations contribute to therapeutic resistance, complicating treatment and impacting survival adversely.\\n\\n### Sampling Bias: Implications of Blood Derived Normal, Primary Tumor\\n\\n3. **Influence on Survival**:\\n   - **Genomic Analysis Limitations**: Most genomic studies use blood or primary tumor samples. Blood-derived normal DNA may not adequately reflect the tumor's specific mutation landscape, leading to biased interpretations.\\n   - **Biological Rationale**: Discrepancies between blood normal and tumor-specific mutations can lead to underestimating the prevalence of specific prognostic markers.\\n   - **Potential Bias**: Primary tumor samples may also introduce bias, as they don't account for intratumoral heterogeneity or the full extent of metastatic potential captured by circulating tumor DNA.\\n\\n### Key Genes: Survival-Associated Genes\\n\\n4. **Influence on Survival**:\\n   - **APC**: Critical in cell cycle control, mutations often inaugurate colon tumorigenesis, impacting early detection and overall prognosis negatively.\\n   - **TP53**: Gates against genomic instability; its loss leads to unchecked proliferation and resistance to apoptosis.\\n   - **KRAS**: Commonly mutated in colon cancer, driving cell proliferation and aiding in chemotherapy resistance.\\n   - **BRAF**: Mutations often represent more aggressive tumors, associated with poor prognosis and specific therapeutic challenges.\\n   - **PIK3CA**: Involved in signaling pathways that regulate growth, providing insights into targeted therapy options.\\n   - **SMAD4**: Loss impacts TGF-beta signaling, often correlating with advanced disease.\\n   - **MSI (Microsatellite Instability)**: Often linked with mismatch repair deficiency, MSI-H tumors may respond better to immunotherapy.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\n**Clinical Insights**:\\nIntegrating these elements, patient survival in colon adenocarcinoma (cecum origin) is heavily influenced by the tumor's location, histological characteristics, genetic makeup, and potential biases in genomic data interpretation. The aggressive nature of mucinous adenocarcinomas and complications in treating high-risk gene mutations underscore the importance of personalized treatment approaches. Precise mutation profiling and understanding anatomical influences on metastatic patterns can guide more effective interventional strategies, improving survival outcomes. Recognizing and addressing sampling biases is also essential for advancing genomic research and tailoring therapies based on true tumor biology.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894647, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=793, prompt_tokens=441, total_tokens=1234, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 90/704...\n",
      "ChatCompletion(id='chatcmpl-BAifEHNDc9Sn7petVUTXysHRyOV4n', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin\\n\\n**Cecum Influence on Metastatic Patterns and Survival:**\\n1. **Anatomical Location:** Cecal tumors, being part of the right-sided colon, often present more advanced stages at diagnosis due to their location causing late-onset symptoms.\\n2. **Metastatic Propensity:** Right-sided colon cancers (such as those in the cecum) are associated with a higher incidence of peritoneal metastasis and a distinct lymphatic spread pattern. These factors typically result in a poorer prognosis compared to left-sided tumors.\\n3. **Treatment Accessibility:** The anatomical location can sometimes complicate surgical access and resection, potentially limiting curative treatment options. Also, right-sided tumors might exhibit less responsiveness to certain chemotherapies.\\n \\n### Histology\\n\\n**Mucinous Adenocarcinoma Impact:**\\n1. **Survival Influence:** Mucinous adenocarcinomas possess a significant volume fraction of extracellular mucin, complicating the tumor microenvironment and often leading to poorer survival outcomes.\\n2. **Biological Rationale:** The high mucin content can impede effective immune response and drug penetration, leading to therapy resistance. Furthermore, these tumors often correlate with specific mutational profiles, including alterations in the KRAS and BRAF genes, which can further worsen prognosis.\\n3. **Mutation Interactions:** These histological subtypes often harbor specific gene mutation patterns that influence tumor aggressiveness and treatment response, predicting poorer responses to conventional therapies.\\n\\n### Sampling Bias\\n\\n**Limitations in Genomic Analysis:**\\n1. **Primary Tumor Bias:** Examining genomic variations solely from primary tumor sites may not capture the genetic heterogeneity or the clonal evolution occurring in metastatic or recurrent disease sites.\\n2. **Solid Tissue Normal Bias:** Comparative analysis with solid tissue normal can sometimes obscure mutational landscapes due to contamination with normal stromal or inflammatory cells, leading to under-estimation of certain mutation prevalences.\\n3. **Survival Bias:** Bias arising from sampling can skew survival studies by either diluting out relevant mutations or incorrectly attributing genomic changes to malignancy, complicating the conclusions on survival impact.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes:**\\n1. **APC:** Crucial in maintaining cell cycle regulation. Mutations result in dysregulation of Wnt signaling, promoting unregulated cell proliferation and contributing to poor survival.\\n2. **TP53:** Functions as a tumor suppressor. Loss-of-function mutations lead to failure in apoptosis regulation, permitting accumulation of further mutations, and generally correlate with worse outcomes.\\n3. **KRAS:** Involved in cell signaling pathways for cell growth and survival. Mutations often predict resistance to anti-EGFR therapies, leading to reduced survival prospects in metastatic settings.\\n4. **BRAF:** Mutant forms promote aggressive tumor phenotypes through the MAPK pathway, often indicative of poor prognosis.\\n5. **PIK3CA:** Participates in cellular growth signaling. Mutations can contribute to chemoresistance and variably affect survival.\\n6. **SMAD4:** A regulator in the TGF-beta signaling pathway, and its loss is associated with a more invasive phenotype and reduction in overall survival.\\n7. **MLH1:** A mismatch repair gene whose defect leads to microsatellite instability, with variable implications on prognosis and response to immunotherapy. \\n\\n### Synthesis and Clinical Insights\\n\\n**Key Survival Risk Factors:**\\nThe prognosis of colon adenocarcinoma originating from the cecum is integrally linked to its anatomical and molecular characteristics. Right-sided origin confers a negative survival impact due to advanced stage presentation and distinct metastatic tendencies. Histological characteristics, especially mucinous features, further exacerbate the poor outcomes due to both the biological properties of the tumor and its associated genomic mutations. The underlying gene mutations dramatically influence survival odds by dictating therapeutic responsiveness and progression. Recognizing sampling biases in genomic analyses is crucial, as they may misrepresent mutation prevalence, impacting treatment strategies. \\n\\n**Clinical Implication:** \\nFor optimal management, a comprehensive diagnostic approach combining histological, anatomical, and genetic assessments is vital. Tailoring therapeutic strategies to account for specific mutations (like KRAS or BRAF) can improve target-directed therapies' efficacy. Addressing these aspects collectively will enhance personalized treatment regimens, potentially improving survival outcomes for patients with cecal adenocarcinoma.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894668, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=882, prompt_tokens=441, total_tokens=1323, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 91/704...\n",
      "ChatCompletion(id='chatcmpl-BAifYrnuJ5vwOSg5WDD7YamTebBQr', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\n1. **Location and Metastatic Patterns:** The ascending colon, as part of the right colon, is associated with distinct metastatic patterns. Tumors originating here often metastasize to different regions, such as the liver and lungs, earlier than left-sided tumors. This can negatively impact survival due to more extensive disease progression at diagnosis.\\n   \\n2. **Patient Survival and Treatment Accessibility:** Right-sided colon cancers, such as those in the ascending colon, tend to have a worse prognosis compared to left-sided cancers. This is partly due to later presentation with symptoms and the biologically more aggressive nature of these tumors, which limits effective surgical resection opportunities, crucial for curative intent.\\n\\n3. **Biological Rationale:** The embryonic origin, biomechanical environment, and distinct genetic pathways activated (such as MSI-high or BRAF mutations) contribute to the differential survival impacts.\\n\\n**Biases in Interpretation:** Right-sided colon tumors often present at more advanced stages because of subtle symptoms, potentially skewing survival statistics when stratified by stage.\\n\\n### Histology\\n\\n**Influence on Survival:**\\n1. **Histological Features of Adenocarcinoma, NOS:** Typically characterized by glandular formation, adenocarcinoma of the colon is evaluated using parameters like grade, which impacts aggressiveness and survivability.\\n\\n2. **Mutation Profiles and Interactions:** Adenocarcinoma, NOS, frequently involves mutations in key genes like KRAS, BRAF, and PIK3CA, which influence survival. BRAF mutations, for instance, are associated with poorer outcomes.\\n\\n3. **Biological Rationale:** Mutation-driven pathway activations influence cell proliferation and apoptotic resistance, underpinning aggressive invasion and metastasis potential.\\n\\n**Biases in Interpretation:** Histology assessment can suffer from inter-observer variability; moreover, not accounting for subtypes like mucinous adenocarcinomas might bias survival data towards more systematic biological characteristics.\\n\\n### Sampling Bias\\n\\n**Influence on Genomic Analysis:**\\n1. **Blood Derived Normal Samples:** These serve as a reference but might not capture tumor-specific mutations effectively. \\n\\n2. **Primary Tumor Sampling:** Limited to accessible regions, potentially missing heterogeneous mutation landscapes within a single tumor or across metastatic sites.\\n\\n**Biological Rationale:** Tumor heterogeneity means that genomic analyses may overlook crucial mutations that drive disease in un-sampled areas, affecting the understanding of metastatic potential and treatment resistance.\\n\\n**Biases in Interpretation:** Sampling biases can lead to misinterpretations about treatment response predictability and might underestimate tumor adaptability.\\n\\n### Key Genes\\n\\n**Survival-Associated Genes:**\\n1. **TP53:** Mutations lead to disrupted cell cycle control, reducing apoptosis and enhancing survival negatively.\\n2. **APC:** Loss of function causes uninhibited cell division, especially when coupled with Wnt signaling pathways, reducing survival rates.\\n3. **KRAS:** Altered signaling via downstream MEK–ERK pathways supports aggressive growth, negatively impacting survival.\\n4. **BRAF:** Particularly V600E, associated with poor prognosis due to increased metastatic potential.\\n5. **PIK3CA:** Activates AKT pathway, enhancing survival and resistance to apoptosis.\\n6. **MLH1 (Mismatch Repair):** Deficiencies lead to microsatellite instability, influencing survival variably based on context and tumor adaptability.\\n7. **CTNNB1 (Beta-catenin):** Mutations linked to enhanced Wnt signaling can result in unchecked cell proliferation.\\n8. **SMAD4:** Loss affects TGF-beta signaling, contributing to metastasis and poor outcomes.\\n\\n**Biological Mechanisms:** These genes are involved in crucial pathways controlling cell cycle, apoptosis, and signaling, directly affecting tumor growth and metastasis.\\n\\n### Conclusion\\n\\nThe survival impact in ascending colon adenocarcinoma involves an intricate interplay between tumor origin, histology, genetic mutations, and procedural biases in genomic sampling. Clinically, recognizing distinct genetic profiles, particularly MSI status and BRAF mutation presence, can guide precision oncology strategies. Access to comprehensive genomic profiles is crucial, though interpretations must be made cautiously due to potential biases. These insights underscore the need for tailored interventions to improve outcomes, emphasizing right-sided tumor challenges and the pivotal role of early detection strategies.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894688, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=866, prompt_tokens=442, total_tokens=1308, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 92/704...\n",
      "ChatCompletion(id='chatcmpl-BAifpAmp8ra3ZJaYdTHKgA8IMt4u4', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Ascending Colon\\n\\n**Influence on Survival:**\\n\\n1. **Metastatic Patterns:**\\n   - **Biological Rationale:** Tumors originating in the ascending colon tend to have a higher propensity for spreading to the liver and peritoneum due to the venous drainage via the portal circulation. This predisposes patients to liver metastases, which can significantly worsen prognosis.\\n   - **Survival Impact:** These metastases are often challenging to treat, leading to poorer overall survival rates compared to tumors in other colon locations. \\n\\n2. **Treatment Accessibility:**\\n   - **Biological Rationale:** The deeper location of the ascending colon might delay detection through typical screening procedures like colonoscopy, which tends to detect more distal colon cancers earlier.\\n   - **Survival Impact:** Delayed diagnosis contributes to advanced staging at presentation, reducing survival rates due to advanced disease burden.\\n\\n### Histology: Adenocarcinoma, NOS\\n\\n**Influence on Survival:**\\n\\n1. **Mutation Profiles:**\\n   - **Biological Rationale:** Adenocarcinoma, NOS (not otherwise specified) is a common histological subtype that often exhibits genetic alterations in KRAS, NRAS, and BRAF genes. These mutations drive tumorigenesis by altering signaling pathways (e.g., MAPK and PI3K/AKT).\\n   - **Survival Impact:** Mutations in these pathways can lead to resistance to EGFR inhibitors, directly impacting treatment outcomes and reducing survival rates. The presence of these mutations often dictates specific targeted therapies or exclusion from certain biological treatments.\\n\\n### Sampling Bias: Limitations in Genomic Analysis\\n\\n**Influence on Survival:**\\n\\n1. **Primary Tumor vs. Solid Tissue Normal:**\\n   - **Biological Rationale:** Sampling from primary tumors may miss heterogeneity present in metastatic sites. Solid tissue normal, used as a control, could also differ genetically from individual tumor sites.\\n   - **Potential Bias:** This can lead to an incomplete understanding of the tumor genomics, potentially leading to less effective personalized treatment strategies.\\n\\n### Key Genes Associated with Survival\\n\\n1. **APC:**\\n   - **Role:** Regulates Wnt signaling pathway, crucial for cellular adhesion and proliferation control.\\n   - **Impact:** Mutations usually lead to uncontrolled cell division, contributing to tumorigenesis.\\n\\n2. **TP53:**\\n   - **Role:** Acts as a tumor suppressor, regulating the cell cycle and apoptosis.\\n   - **Impact:** Loss of function mutations are associated with increased genomic instability and resistance to therapies that induce apoptosis.\\n\\n3. **KRAS:**\\n   - **Role:** Involved in cell signaling pathways that control proliferation and differentiation.\\n   - **Impact:** Mutations are predictive of poor responses to anti-EGFR treatments.\\n\\n4. **NRAS:**\\n   - **Role:** Similar to KRAS, impacts cell signaling pathways.\\n   - **Impact:** Mutational status is used to guide therapeutic decisions in metastatic settings.\\n\\n5. **BRAF:**\\n   - **Role:** A part of the MAPK/ERK pathway, critical for responding to growth signals.\\n   - **Impact:** V600E mutation is associated with poor prognosis and necessitates different therapeutic approaches.\\n\\n6. **PIK3CA:**\\n   - **Role:** Engages in the PI3K/AKT signaling pathway, affecting cell growth and survival.\\n   - **Impact:** Mutations promote oncogenic signaling, contributing to cancer progression and therapy resistance.\\n\\n7. **SMAD4:**\\n   - **Role:** Involved in TGF-beta signaling pathways, largely regulating cell growth and apoptosis.\\n   - **Impact:** Its loss is correlated with advanced tumor stage and poor survival outcomes.\\n\\n### Conclusion: Synthesis of Key Survival Risk Factors\\n\\nCombining these insights, several significant survival risk factors emerge for ascending colon adenocarcinoma. The propensity for early metastasis, often to critical organs like the liver, combined with common mutations in key signaling pathways (e.g., KRAS, BRAF) that diminish treatment efficacy, profoundly impacts patient outcomes.\\n\\nFurther compounded by potential biases due to incomplete genomic sampling and histological uncertainties, accurately profiling these tumors remains a challenge. Nonetheless, understanding these mechanisms enables us to focus on developing targeted therapies and stratifying patients more effectively based on their unique genetic and histological profiles, ultimately striving to improve survival rates through personalized medicine.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894705, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_8adc83c802', usage=CompletionUsage(completion_tokens=890, prompt_tokens=442, total_tokens=1332, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 93/704...\n",
      "ChatCompletion(id='chatcmpl-BAig8RqsIYz7Emdw68gWuoFIuONOR', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin\\n\\n**Influence on Survival:**\\n- **Metastatic Patterns:** Ascending colon cancer often gives rise to liver, lung, and peritoneal metastases due to its proximity to the portal venous circulation, impacting survival negatively.\\n- **Patient Survival:** Generally shows poorer outcomes compared to distal colon cancers, partly due to delayed symptom onset leading to late-stage diagnosis.\\n- **Treatment Accessibility:** Right-sided colon cancers, including ascending colon origins, typically have less favorable responses to specific chemotherapies (e.g., anti-EGFR therapies) due to genetic differences.\\n\\n**Biological Rationale:**\\n- Tumor cells from the ascending colon often exhibit microsatellite instability and a high mutational burden, known to drive immune evasion and contribute to poor response rates to conventional therapies.\\n\\n**Biases/Considerations:**\\n- Geographic and demographic factors (e.g., increased incidence in Western populations) may influence survival pattern interpretations, potentially skewing data based on the population studied.\\n\\n### Histology: Papillary Adenocarcinoma, NOS\\n\\n**Influence on Survival:**\\n- **Interaction with Mutation Profiles:** This subtype often correlates with genetic alterations such as KRAS mutations, influencing survival negatively by predicting resistance to certain targeted therapies.\\n- **Outcome Determinants:** Histological grading (high-grade tumors being more aggressive) directly correlates with worse survival.\\n\\n**Biological Rationale:**\\n- Papillary structures may exacerbate invasive potential and metastasis due to variations in cellular architecture and interaction with the extracellular matrix.\\n\\n**Biases/Considerations:**\\n- Histological assessments are often subjective, with interobserver variability influencing prognosis estimations and treatment planning.\\n\\n### Sampling Bias\\n\\n**Influence on Survival:**\\n- **Blood Derived Normal vs. Primary Tumor:** Use of blood-derived normal controls can underestimate tumor genomic complexity, potentially missing microenvironmental and clonal heterogeneity seen in primary tumor analysis.\\n\\n**Biological Rationale:**\\n- Whole blood samples do not capture the full range of somatic mutations and epigenetic modifications, especially those acquired later in tumor progression.\\n\\n**Biases/Considerations:**\\n- Sampling mainly primary tumor tissues may overlook circulating tumor cells or DNA indicative of metastasis, affecting comprehensive survival analysis.\\n\\n### Key Genes\\n\\n**1. KRAS:** \\n- **Influence on Survival:** Mutations in KRAS are associated with resistance to anti-EGFR therapies, negatively impacting survival.\\n- **Biological Mechanism:** Drives cell proliferation via MAPK/PI3K pathways.\\n\\n**2. BRAF:** \\n- **Influence on Survival:** V600E mutations often predict poor survival due to aggressive tumor behavior.\\n- **Biological Mechanism:** Constitutive activation of the MAPK pathway augments tumor growth and progression.\\n\\n**3. PIK3CA:** \\n- **Influence on Survival:** Mutation can enhance cellular survival and proliferation, though associations with survival are complex.\\n- **Biological Mechanism:** Activates the PI3K-AKT-mTOR pathway, promoting cell growth and survival.\\n\\n**4. TP53:** \\n- **Influence on Survival:** Loss of function mutations frequently correlate with aggressive tumor phenotypes and poor prognosis.\\n- **Biological Mechanism:** Impairment in DNA damage repair and apoptosis regulation.\\n\\n**5. APC:** \\n- **Influence on Survival:** Mutations, often early events in colorectal carcinogenesis, portend lower survival by promoting β-catenin accumulation and proliferation.\\n- **Biological Mechanism:** Disruption of WNT signaling pathway, affecting transcriptional regulation.\\n\\n**6. MMR Genes (MLH1, MSH2):**\\n- **Influence on Survival:** Their inactivation underlies MSI-H tumors, which paradoxically may show improved survival due to better immune recognition.\\n- **Biological Mechanism:** Impaired DNA mismatch repair leads to increased mutability.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nIn summary, survival in colon adenocarcinoma, particularly with an ascending colon origin, is impacted by a confluence of anatomical, histological, and genetic factors. Right-sided tumors underline the prognostically adverse effects of late presentation and inherent genetic resistances. Papillary histology may exacerbate aggressiveness, while key genes such as KRAS, BRAF, and TP53 delineate survival through pathway-sharing that amplifies carcinogenicity or evades therapeutic interventions. Sampling biases in genomic evaluations need addressing to fully comprehend these risks. Clinically, understanding these dynamics aids in tailoring patient-specific therapeutic strategies, improving precision in survival predictions and potential life-saving interventions.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894724, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=928, prompt_tokens=444, total_tokens=1372, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 94/704...\n",
      "ChatCompletion(id='chatcmpl-BAigPjqdTuf3zQgrD0v5oLqBouqCe', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"### Tumor Origin: Ascending Colon's Influence\\n\\n1. **Metastatic Patterns**:\\n   - **Influence**: The ascending colon, part of the right colon, is more likely to metastasize to the liver and lungs due to its rich venous drainage through the portal circulation.\\n   - **Survival Impact**: Right-sided colonic cancers, including those originating in the ascending colon, often present at a later stage compared to left-sided ones, generally leading to poorer survival outcomes.\\n   - **Treatment Accessibility**: Surgery and subsequent treatments can be more complex due to potential extensive liver metastases, impacting overall prognosis.\\n\\n2. **Biological Rationale**:\\n   - The proximal location and blood supply allow cancer cells to access the liver more directly, increasing the likelihood of hepatic spread—often complicating treatment and decreasing survival time.\\n\\n3. **Biases**:\\n   - Detection often happens at a more advanced stage, skewing survival data towards poorer outcomes when left-sided counterparts are considered.\\n\\n### Histology: Mucinous Adenocarcinoma and Mutation Profiles\\n\\n1. **Survival Impact**:\\n   - **Influence**: Mucinous adenocarcinomas, a subtype of colorectal cancer, exhibit a distinct mutational profile often including KRAS mutations, which can confer resistance to certain targeted therapies.\\n   - **Outcomes**: Typically associated with worse prognosis due to aggressive behavior, delayed detection, and advanced stage at diagnosis.\\n\\n2. **Biological Rationale**:\\n   - High mucin production can hinder the immune system's ability to attack tumor cells and decrease the efficacy of treatments, thereby lowering survival rates.\\n\\n3. **Potential Genomic Bias**:\\n   - Difficulties in tissue sampling may lead to underrepresentation or misinterpretation of mucinous components in genomic datasets, potentially skewing data towards non-representative mutation profiles.\\n\\n### Sampling Bias: Genomic Analysis Limitations\\n\\n1. **Limitations**:\\n   - **Blood Derived Normal vs. Primary Tumor**: Blood derived DNA might not capture tumor heterogeneity or truly representative genetic mutations of primary tumors.\\n   - **Impact on Survival Interpretation**: Underestimation of intratumoral heterogeneity can lead to oversimplified treatment choices, impacting survival predictions.\\n\\n2. **Biological Rationale**:\\n   - The tumor microenvironment, including stromal interactions and heterogeneity, plays a significant role in survival outcomes, often missed in peripheral blood sampling.\\n\\n3. **Biases**:\\n   - Post-diagnostic selection biases can lead to an overrepresentation of early-stage disease in blood studies, skewing survival interpretations to appear more favorable.\\n\\n### Key Genes Influencing Survival\\n\\n1. **APC**:\\n   - **Mechanism**: Tumor suppressor gene; its mutation leads to unregulated Wnt signaling, promoting tumor growth.\\n   - **Survival Impact**: Early mutations can drive tumorigenesis, reducing overall survival.\\n\\n2. **KRAS**:\\n   - **Mechanism**: Oncogene; mutations can lead to resistance to EGFR inhibitors.\\n   - **Survival Impact**: Associated with less favorable response to targeted therapies; when mutated, leads to lower survival rates.\\n\\n3. **TP53**:\\n   - **Mechanism**: Tumor suppressor; alterations inhibit apoptosis, fostering tumor resilience against therapies.\\n   - **Survival Impact**: Loss of TP53 function correlates with poor prognosis and treatment resistance.\\n\\n4. **PIK3CA**:\\n   - **Mechanism**: Oncogene; involved in cell growth and survival pathways.\\n   - **Survival Impact**: Mutations may contribute to chemoresistance, influencing survival negatively.\\n\\n5. **BRAF**:\\n   - **Mechanism**: Oncogene; mutations (e.g., V600E) trigger unregulated MAPK pathway activation.\\n   - **Survival Impact**: BRAF-mutant cancers are typically aggressive with poor survival outcomes, requiring specific targeted interventions.\\n\\n6. **MSI (Microsatellite Instability) Status**:\\n   - **Mechanism**: High MSI indicates defects in DNA repair mechanisms.\\n   - **Survival Impact**: MSI-high status often predicts better response to immunotherapy, significantly improving survival.\\n\\n### Synthesis and Clinically Relevant Insights\\n\\n**Key Survival Risk Factors**:\\n- **Tumor Location**: Right-sided tumors like those in the ascending colon are often detected late and metastasize early, leading to poorer survival.\\n- **Histological Challenges**: Mucinous differentiation complicates detection and treatment, often indicating worse outcomes.\\n- **Genomic Insights**: Recognizing and understanding mutations such as KRAS, TP53, and MSI status in context enhances treatment personalization, directly impacting survival.\\n- **Interpreting Bias**: Awareness of sampling biases is critical to avoid misguiding treatment strategies and threatens accurate survival predictions.\\n\\n**Impact on Patient Survival**:\\nUnderstanding the intricate interplay between these factors allows for tailored therapeutic approaches, improving survival prospects through accurate prognostic assessments and personalized medicine solutions. By considering both biological underpinnings and potential biases, clinicians can better strategize patient management and improve survival outcomes in colon adenocarcinoma.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894741, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=1057, prompt_tokens=443, total_tokens=1500, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 95/704...\n",
      "ChatCompletion(id='chatcmpl-BAigpaZROTuNpPBpi5I9lbTokL2fg', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content='### Tumor Origin: Ascending Colon\\n\\n#### Influence on Metastatic Patterns:\\n1. **Survival Influence:**\\n   - Tumors originating in the ascending colon typically present at a more advanced stage due to their anatomical location and associated symptoms, which often remain silent until later in the disease progression.\\n   - This late presentation often leads to a more systemic disease spread before detection, negatively impacting survival.\\n\\n2. **Biological Rationale:**\\n   - The lymphatic drainage and vascular supply of the ascending colon facilitate early dissemination into the systemic circulation, particularly to the liver and lungs, promoting metastasis.\\n\\n3. **Treatment Accessibility:**\\n   - The location can affect resectability, complicating surgical intervention due to factors like proximity to major blood vessels and the need for extensive resections.\\n   - More advanced disease at diagnosis implies potential necessity for more aggressive chemotherapy regimens, complicating treatment plans.\\n\\n#### Potential Biases:\\n- **Stage of Detection:** More often detected at an advanced stage, which might skew survival data to reflect a worse prognosis than if detected earlier.\\n\\n### Histology: Mucinous Adenocarcinoma\\n\\n#### Interaction with Mutation Profiles:\\n1. **Survival Influence:**\\n   - Mucinous adenocarcinomas are often associated with a poorer prognosis compared to non-mucinous types, owing to their aggressive nature and resistance to standard therapies.\\n\\n2. **Biological Rationale:**\\n   - This subtype typically exhibits distinct genetic mutations, such as alterations in the KRAS and BRAF genes, contributing to aggressive behavior and therapy resistance.\\n\\n3. **Potential Biases:**\\n   - Mucinous histology might lead to misclassification if the mucinous component is small in core biopsies, affecting treatment decisions based on subtype behavior.\\n\\n### Sampling Bias: Limitations in Genomic Analysis\\n\\n1. **Influence on Survival:**\\n   - Sampling biases can lead to incomplete or non-representative genomic landscapes, influencing treatment decisions and prognostic accuracy.\\n\\n2. **Biological Rationale:**\\n   - Tumors exhibit heterogeneity; primary tumor sampling might not capture metastatic clones, potentially overlooking significant mutations driving aggressive phenotypes.\\n\\n3. **Bias Implications:**\\n   - Biopsies may represent only a subpopulation of cancer cells, underestimating the heterogeneity and resulting in potential therapeutic misguidance.\\n\\n### Key Genes Influencing Survival\\n\\n1. **TP53:**\\n   - **Influence:** Mutations in TP53 commonly lead to abrogation of apoptosis and increased genomic instability.\\n   - **Biological Mechanism:** Functions as a tumor suppressor by regulating the cell cycle and inducing apoptosis in response to DNA damage.\\n\\n2. **KRAS:**\\n   - **Influence:** Mutant KRAS is associated with resistance to EGFR-targeted therapies, negatively impacting progression-free survival.\\n   - **Biological Mechanism:** Promotes unchecked proliferation via constitutive RAS-MAPK pathway activation.\\n\\n3. **APC:**\\n   - **Influence:** Mutations lead to dysregulated Wnt signaling, promoting tumor initiation and growth.\\n   - **Biological Mechanism:** Normally inhibits cell proliferation by degrading β-catenin; mutations allow for transactivation of proliferation genes.\\n\\n4. **BRAF:**\\n   - **Influence:** BRAF mutations, especially V600E, are linked with poor prognosis and therapy resistance.\\n   - **Biological Mechanism:** BRAF is part of the RAS/MAPK pathway, where mutations lead to excess growth signal transduction.\\n\\n5. **PIK3CA:**\\n   - **Influence:** Mutations correlate with tumor progression and poor outcomes due to enhanced Akt signaling.\\n   - **Biological Mechanism:** Drives cancer cell survival and growth through the PI3K/AKT pathway.\\n\\n6. **Mismatch Repair Genes (MLH1, MSH2):**\\n   - **Influence:** Deficiencies lead to microsatellite instability (MSI), found in a subset with distinct prognostic and therapeutic implications (e.g., immunotherapy responsiveness).\\n   - **Biological Mechanism:** Contributes to genetic hypermutability and consequent neoantigen presence, affecting immune response.\\n\\n### Synthesis of Key Survival Risk Factors\\n\\nCombining the discussed factors, colon cancer originating from the ascending colon often presents late with unique histological and genetic profiles, complicating treatment approaches. Mucinous adenocarcinomas further aggravate survival odds due to aggressive behavior driven by specific genetic alterations. The limitations of sampling could mask clinically relevant mutations, emphasizing the need for comprehensive genomic profiling. An understanding of the genetic landscape helps tailor therapy, predicting resistance or susceptibility, directly influencing patient outcomes. Recognizing these nuanced factors can enhance prognostic accuracy and refine personalized treatment strategies, ultimately aiming to improve survival rates.', refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894767, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_f9f4fb6dbf', usage=CompletionUsage(completion_tokens=970, prompt_tokens=443, total_tokens=1413, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 96/704...\n",
      "ChatCompletion(id='chatcmpl-BAihAzKJkZSKqA0LTdXfEKx8iKq6p', choices=[Choice(finish_reason='stop', index=0, logprobs=None, message=ChatCompletionMessage(content=\"Certainly. Let's analyze colon adenocarcinoma, particularly originating in the ascending colon, by examining each factor systematically.\\n\\n### Tumor Origin and Survival\\n\\n1. **Influence on Metastatic Patterns**:\\n   - **Ascending Colon Characteristics**: Tumors in the ascending colon often exhibit different behaviors compared to distal colon cancers. Their location within the right-side of the colon means that they are more likely associated with specific genetic profiles like those having microsatellite instability (MSI) and mutations in mismatch repair genes.\\n   - **Survival Impact**: These genetic differences, particularly MSI-high status, generally correlate with a better prognosis and a distinctive metastatic pattern. Right-sided colon cancers such as those from the ascending colon may have a propensity to metastasize to the peritoneum or distant sites like the liver.\\n   - **Rationale**: The lymphatic drainage and vascularization of the ascending colon contribute to its metastatic behavior. Additionally, right-sided tumors are frequently more aggressive but respond differently to certain chemotherapy regimens due to their genetic makeup.\\n\\n2. **Treatment Accessibility**:\\n   - **Surgical Intervention**: Access to complete surgical resection can be technically challenging in right colon cancers due to their proximity to other visceral organs.\\n   - **Adjuvant Therapy Influence**: Tumors with MSI often show resistance to certain chemotherapy drugs but might respond better to immunotherapy, which directly affects the treatment strategy and prognosis.\\n\\n### Histology and Its Influence\\n\\n1. **Adenosquamous Carcinoma Histology**:\\n   - **Characteristics**: Adenosquamous carcinoma is a rare histological subtype of adenocarcinoma and is marked by components of both glandular and squamous cell carcinoma.\\n   - **Outcome Impact**: This subtype often has a poorer prognosis due to aggressive behavior and a complex mutation profile that might include KRAS, BRAF, or mismatch repair gene alterations.\\n   - **Mutation Interaction**: These mutations generally enhance the tumor's ability to grow and evade apoptosis, affecting overall patient survival negatively.\\n\\n### Sampling Bias in Genomic Analysis\\n\\n1. **Limitations of Blood Derived Normal and Primary Tumor Samples**:\\n   - **Sampling Issues**: The use of blood-derived normal tissues might not accurately capture tumor-specific mutations or the tumor microenvironment's influence on gene expression.\\n   - **Genomic Interpretation**: Biopsies of primary tumors can suffer from intratumoral heterogeneity, thereby not fully representing all sub-clonal populations, which might lead to underestimation of genomic diversity and heterogeneity.\\n   - **Impact**: These biases may result in an incomplete understanding of the oncogenic drivers influencing treatment responses and resistance patterns.\\n\\n### Key Genes and Survival\\n\\n1. **Key Survival-Associated Genes**:\\n   - **TP53**: Often mutated and leading to disrupted apoptosis and unchecked cellular proliferation.\\n   - **KRAS**: Mutations can lead to uncontrolled signaling for growth and survival via the MAPK pathway.\\n   - **APC**: Critical for WNT signaling pathways; mutations lead to cell proliferative advantages.\\n   - **BRAF**: V600E mutation correlates with poor prognosis, driving proliferation through MAPK signaling.\\n   - **PIK3CA**: Pertains to survival-associated pathways like PI3K/AKT, contributing to cellular growth and resistance to apoptosis.\\n   - **MSI-associated MMR genes**: High levels of MSI can induce a hyper-mutated state that fosters both an initial survival advantage and later vulnerability to immune checkpoint inhibitors.\\n   - **ATM**: Involved in DNA damage response with its mutation affecting genomic instability and influencing chemotherapeutic efficacy.\\n\\n### Conclusion and Synthesis\\n\\nIn conclusion, the impact on survival for colon adenocarcinomas, particularly from the ascending colon, is multifaceted. Tumor origin affects metastatic potential and treatment strategies through genetic predispositions such as MSI. The complex histological interactions of adenosquamous carcinoma can significantly worsen prognosis. Furthermore, genomic sampling bias highlights the challenges in fully understanding tumor biology, potentially compromising personalized treatment.\\n\\nKey genetic drivers have a profound influence on survival by modulating cellular processes such as proliferation, apoptosis, and immune response. Understanding these risks and biological mechanisms allows for better stratification of patients and the tailoring of therapy, most notably by exploiting differential responses to chemotherapy and immunotherapy strategies. These insights are critical for developing precise prognostic assessments and optimizing treatment approaches to improve patient outcomes.\", refusal=None, role='assistant', annotations=[], audio=None, function_call=None, tool_calls=None))], created=1741894788, model='gpt-4o-2024-08-06', object='chat.completion', service_tier='default', system_fingerprint='fp_eb9dce56a8', usage=CompletionUsage(completion_tokens=897, prompt_tokens=441, total_tokens=1338, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=0, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0)))\n",
      "Processing prompt 97/704...\n"
     ]
    },
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[90], line 6\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mProcessing prompt \u001b[39m\u001b[38;5;132;01m{\u001b[39;00midx\u001b[38;5;241m+\u001b[39m\u001b[38;5;241m1\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m/\u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mlen\u001b[39m(prompts)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m...\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m      5\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m----> 6\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mclient\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mchat\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcompletions\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcreate\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m      7\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmodel\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mgpt-4o\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m      8\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmessages\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\n\u001b[1;32m      9\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m     10\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43msystem\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     11\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[1;32m     12\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m     13\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     14\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mYou are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\n\u001b[1;32m     15\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[1;32m     16\u001b[0m \u001b[43m                \u001b[49m\u001b[43m]\u001b[49m\n\u001b[1;32m     17\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     18\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m     19\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrole\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     20\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mcontent\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\n\u001b[1;32m     21\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m     22\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     23\u001b[0m \u001b[43m                        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprompt\u001b[49m\n\u001b[1;32m     24\u001b[0m \u001b[43m                    \u001b[49m\u001b[43m}\u001b[49m\n\u001b[1;32m     25\u001b[0m \u001b[43m                \u001b[49m\u001b[43m]\u001b[49m\n\u001b[1;32m     26\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\n\u001b[1;32m     27\u001b[0m \u001b[43m        \u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     28\u001b[0m \u001b[43m        \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m{\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtype\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtext\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m     29\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     30\u001b[0m \u001b[43m        \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m2048\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     31\u001b[0m \u001b[43m        \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m1\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     32\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m     33\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;241;43m0\u001b[39;49m\n\u001b[1;32m     34\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m     35\u001b[0m     responses\u001b[38;5;241m.\u001b[39mappend(response)\n\u001b[1;32m     36\u001b[0m     \u001b[38;5;28mprint\u001b[39m(response)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/openai/_utils/_utils.py:279\u001b[0m, in \u001b[0;36mrequired_args.<locals>.inner.<locals>.wrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    277\u001b[0m             msg \u001b[38;5;241m=\u001b[39m \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mMissing required argument: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mquote(missing[\u001b[38;5;241m0\u001b[39m])\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    278\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m(msg)\n\u001b[0;32m--> 279\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/openai/resources/chat/completions/completions.py:914\u001b[0m, in \u001b[0;36mCompletions.create\u001b[0;34m(self, messages, model, audio, frequency_penalty, function_call, functions, logit_bias, logprobs, max_completion_tokens, max_tokens, metadata, modalities, n, parallel_tool_calls, prediction, presence_penalty, reasoning_effort, response_format, seed, service_tier, stop, store, stream, stream_options, temperature, tool_choice, tools, top_logprobs, top_p, user, web_search_options, extra_headers, extra_query, extra_body, timeout)\u001b[0m\n\u001b[1;32m    871\u001b[0m \u001b[38;5;129m@required_args\u001b[39m([\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m], [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmessages\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmodel\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mstream\u001b[39m\u001b[38;5;124m\"\u001b[39m])\n\u001b[1;32m    872\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mcreate\u001b[39m(\n\u001b[1;32m    873\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    911\u001b[0m     timeout: \u001b[38;5;28mfloat\u001b[39m \u001b[38;5;241m|\u001b[39m httpx\u001b[38;5;241m.\u001b[39mTimeout \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m|\u001b[39m NotGiven \u001b[38;5;241m=\u001b[39m NOT_GIVEN,\n\u001b[1;32m    912\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ChatCompletion \u001b[38;5;241m|\u001b[39m Stream[ChatCompletionChunk]:\n\u001b[1;32m    913\u001b[0m     validate_response_format(response_format)\n\u001b[0;32m--> 914\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_post\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    915\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/chat/completions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    916\u001b[0m \u001b[43m        \u001b[49m\u001b[43mbody\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmaybe_transform\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    917\u001b[0m \u001b[43m            \u001b[49m\u001b[43m{\u001b[49m\n\u001b[1;32m    918\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmessages\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmessages\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    919\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodel\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodel\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    920\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43maudio\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43maudio\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    921\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfrequency_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfrequency_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    922\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunction_call\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunction_call\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    923\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mfunctions\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mfunctions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    924\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogit_bias\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogit_bias\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    925\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mlogprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mlogprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    926\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_completion_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_completion_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    927\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmax_tokens\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmax_tokens\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    928\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmetadata\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmetadata\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    929\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mmodalities\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mmodalities\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    930\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mn\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mn\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    931\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mparallel_tool_calls\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mparallel_tool_calls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    932\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mprediction\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mprediction\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    933\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mpresence_penalty\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mpresence_penalty\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    934\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mreasoning_effort\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mreasoning_effort\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    935\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mresponse_format\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mresponse_format\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    936\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mseed\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mseed\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    937\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mservice_tier\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mservice_tier\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    938\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstop\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstop\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    939\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstore\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstore\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    940\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    941\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mstream_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    942\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtemperature\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtemperature\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    943\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtool_choice\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtool_choice\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    944\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtools\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtools\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    945\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_logprobs\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_logprobs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    946\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mtop_p\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mtop_p\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    947\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43muser\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43muser\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    948\u001b[0m \u001b[43m                \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mweb_search_options\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m:\u001b[49m\u001b[43m \u001b[49m\u001b[43mweb_search_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    949\u001b[0m \u001b[43m            \u001b[49m\u001b[43m}\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    950\u001b[0m \u001b[43m            \u001b[49m\u001b[43mcompletion_create_params\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mCompletionCreateParams\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    951\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    952\u001b[0m \u001b[43m        \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mmake_request_options\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    953\u001b[0m \u001b[43m            \u001b[49m\u001b[43mextra_headers\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_headers\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_query\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_query\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mextra_body\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mextra_body\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[1;32m    954\u001b[0m \u001b[43m        \u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    955\u001b[0m \u001b[43m        \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mChatCompletion\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    956\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    957\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mStream\u001b[49m\u001b[43m[\u001b[49m\u001b[43mChatCompletionChunk\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    958\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/openai/_base_client.py:1242\u001b[0m, in \u001b[0;36mSyncAPIClient.post\u001b[0;34m(self, path, cast_to, body, options, files, stream, stream_cls)\u001b[0m\n\u001b[1;32m   1228\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mpost\u001b[39m(\n\u001b[1;32m   1229\u001b[0m     \u001b[38;5;28mself\u001b[39m,\n\u001b[1;32m   1230\u001b[0m     path: \u001b[38;5;28mstr\u001b[39m,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   1237\u001b[0m     stream_cls: \u001b[38;5;28mtype\u001b[39m[_StreamT] \u001b[38;5;241m|\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m   1238\u001b[0m ) \u001b[38;5;241m-\u001b[39m\u001b[38;5;241m>\u001b[39m ResponseT \u001b[38;5;241m|\u001b[39m _StreamT:\n\u001b[1;32m   1239\u001b[0m     opts \u001b[38;5;241m=\u001b[39m FinalRequestOptions\u001b[38;5;241m.\u001b[39mconstruct(\n\u001b[1;32m   1240\u001b[0m         method\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mpost\u001b[39m\u001b[38;5;124m\"\u001b[39m, url\u001b[38;5;241m=\u001b[39mpath, json_data\u001b[38;5;241m=\u001b[39mbody, files\u001b[38;5;241m=\u001b[39mto_httpx_files(files), \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39moptions\n\u001b[1;32m   1241\u001b[0m     )\n\u001b[0;32m-> 1242\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m cast(ResponseT, \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mopts\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m)\u001b[49m)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/openai/_base_client.py:919\u001b[0m, in \u001b[0;36mSyncAPIClient.request\u001b[0;34m(self, cast_to, options, remaining_retries, stream, stream_cls)\u001b[0m\n\u001b[1;32m    916\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m    917\u001b[0m     retries_taken \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[0;32m--> 919\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    920\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcast_to\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcast_to\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    921\u001b[0m \u001b[43m    \u001b[49m\u001b[43moptions\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43moptions\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    922\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    923\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstream_cls\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream_cls\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    924\u001b[0m \u001b[43m    \u001b[49m\u001b[43mretries_taken\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mretries_taken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    925\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/openai/_base_client.py:955\u001b[0m, in \u001b[0;36mSyncAPIClient._request\u001b[0;34m(self, cast_to, options, retries_taken, stream, stream_cls)\u001b[0m\n\u001b[1;32m    952\u001b[0m log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mSending HTTP Request: \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m, request\u001b[38;5;241m.\u001b[39mmethod, request\u001b[38;5;241m.\u001b[39murl)\n\u001b[1;32m    954\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 955\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_client\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43msend\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    956\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    957\u001b[0m \u001b[43m        \u001b[49m\u001b[43mstream\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstream\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mor\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_should_stream_response_body\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    958\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    959\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    960\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m httpx\u001b[38;5;241m.\u001b[39mTimeoutException \u001b[38;5;28;01mas\u001b[39;00m err:\n\u001b[1;32m    961\u001b[0m     log\u001b[38;5;241m.\u001b[39mdebug(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mEncountered httpx.TimeoutException\u001b[39m\u001b[38;5;124m\"\u001b[39m, exc_info\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpx/_client.py:914\u001b[0m, in \u001b[0;36mClient.send\u001b[0;34m(self, request, stream, auth, follow_redirects)\u001b[0m\n\u001b[1;32m    910\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_set_timeout(request)\n\u001b[1;32m    912\u001b[0m auth \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_build_request_auth(request, auth)\n\u001b[0;32m--> 914\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_auth\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    915\u001b[0m \u001b[43m    \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    916\u001b[0m \u001b[43m    \u001b[49m\u001b[43mauth\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mauth\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    917\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    918\u001b[0m \u001b[43m    \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43m[\u001b[49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    919\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    920\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    921\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m stream:\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpx/_client.py:942\u001b[0m, in \u001b[0;36mClient._send_handling_auth\u001b[0;34m(self, request, auth, follow_redirects, history)\u001b[0m\n\u001b[1;32m    939\u001b[0m request \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mnext\u001b[39m(auth_flow)\n\u001b[1;32m    941\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 942\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_handling_redirects\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    943\u001b[0m \u001b[43m        \u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    944\u001b[0m \u001b[43m        \u001b[49m\u001b[43mfollow_redirects\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfollow_redirects\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    945\u001b[0m \u001b[43m        \u001b[49m\u001b[43mhistory\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mhistory\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    946\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    947\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    948\u001b[0m         \u001b[38;5;28;01mtry\u001b[39;00m:\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpx/_client.py:979\u001b[0m, in \u001b[0;36mClient._send_handling_redirects\u001b[0;34m(self, request, follow_redirects, history)\u001b[0m\n\u001b[1;32m    976\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mrequest\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n\u001b[1;32m    977\u001b[0m     hook(request)\n\u001b[0;32m--> 979\u001b[0m response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_send_single_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    980\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    981\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m hook \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_event_hooks[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpx/_client.py:1014\u001b[0m, in \u001b[0;36mClient._send_single_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m   1009\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[1;32m   1010\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAttempted to send an async request with a sync Client instance.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1011\u001b[0m     )\n\u001b[1;32m   1013\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m request_context(request\u001b[38;5;241m=\u001b[39mrequest):\n\u001b[0;32m-> 1014\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mtransport\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1016\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, SyncByteStream)\n\u001b[1;32m   1018\u001b[0m response\u001b[38;5;241m.\u001b[39mrequest \u001b[38;5;241m=\u001b[39m request\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpx/_transports/default.py:250\u001b[0m, in \u001b[0;36mHTTPTransport.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    237\u001b[0m req \u001b[38;5;241m=\u001b[39m httpcore\u001b[38;5;241m.\u001b[39mRequest(\n\u001b[1;32m    238\u001b[0m     method\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mmethod,\n\u001b[1;32m    239\u001b[0m     url\u001b[38;5;241m=\u001b[39mhttpcore\u001b[38;5;241m.\u001b[39mURL(\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    247\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mrequest\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    248\u001b[0m )\n\u001b[1;32m    249\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_httpcore_exceptions():\n\u001b[0;32m--> 250\u001b[0m     resp \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_pool\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mreq\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    252\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(resp\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n\u001b[1;32m    254\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m Response(\n\u001b[1;32m    255\u001b[0m     status_code\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mstatus,\n\u001b[1;32m    256\u001b[0m     headers\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mheaders,\n\u001b[1;32m    257\u001b[0m     stream\u001b[38;5;241m=\u001b[39mResponseStream(resp\u001b[38;5;241m.\u001b[39mstream),\n\u001b[1;32m    258\u001b[0m     extensions\u001b[38;5;241m=\u001b[39mresp\u001b[38;5;241m.\u001b[39mextensions,\n\u001b[1;32m    259\u001b[0m )\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/connection_pool.py:256\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    253\u001b[0m         closing \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_assign_requests_to_connections()\n\u001b[1;32m    255\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_close_connections(closing)\n\u001b[0;32m--> 256\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    258\u001b[0m \u001b[38;5;66;03m# Return the response. Note that in this case we still have to manage\u001b[39;00m\n\u001b[1;32m    259\u001b[0m \u001b[38;5;66;03m# the point at which the response is closed.\u001b[39;00m\n\u001b[1;32m    260\u001b[0m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(response\u001b[38;5;241m.\u001b[39mstream, typing\u001b[38;5;241m.\u001b[39mIterable)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/connection_pool.py:236\u001b[0m, in \u001b[0;36mConnectionPool.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    232\u001b[0m connection \u001b[38;5;241m=\u001b[39m pool_request\u001b[38;5;241m.\u001b[39mwait_for_connection(timeout\u001b[38;5;241m=\u001b[39mtimeout)\n\u001b[1;32m    234\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m    235\u001b[0m     \u001b[38;5;66;03m# Send the request on the assigned connection.\u001b[39;00m\n\u001b[0;32m--> 236\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43mconnection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    237\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpool_request\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrequest\u001b[49m\n\u001b[1;32m    238\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    239\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m ConnectionNotAvailable:\n\u001b[1;32m    240\u001b[0m     \u001b[38;5;66;03m# In some cases a connection may initially be available to\u001b[39;00m\n\u001b[1;32m    241\u001b[0m     \u001b[38;5;66;03m# handle a request, but then become unavailable.\u001b[39;00m\n\u001b[1;32m    242\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    243\u001b[0m     \u001b[38;5;66;03m# In this case we clear the connection and try again.\u001b[39;00m\n\u001b[1;32m    244\u001b[0m     pool_request\u001b[38;5;241m.\u001b[39mclear_connection()\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/connection.py:103\u001b[0m, in \u001b[0;36mHTTPConnection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    100\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_connect_failed \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[1;32m    101\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exc\n\u001b[0;32m--> 103\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_connection\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mhandle_request\u001b[49m\u001b[43m(\u001b[49m\u001b[43mrequest\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/http11.py:136\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    134\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m Trace(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mresponse_closed\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    135\u001b[0m         \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_response_closed()\n\u001b[0;32m--> 136\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m exc\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/http11.py:106\u001b[0m, in \u001b[0;36mHTTP11Connection.handle_request\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m     95\u001b[0m     \u001b[38;5;28;01mpass\u001b[39;00m\n\u001b[1;32m     97\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m Trace(\n\u001b[1;32m     98\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mreceive_response_headers\u001b[39m\u001b[38;5;124m\"\u001b[39m, logger, request, kwargs\n\u001b[1;32m     99\u001b[0m ) \u001b[38;5;28;01mas\u001b[39;00m trace:\n\u001b[1;32m    100\u001b[0m     (\n\u001b[1;32m    101\u001b[0m         http_version,\n\u001b[1;32m    102\u001b[0m         status,\n\u001b[1;32m    103\u001b[0m         reason_phrase,\n\u001b[1;32m    104\u001b[0m         headers,\n\u001b[1;32m    105\u001b[0m         trailing_data,\n\u001b[0;32m--> 106\u001b[0m     ) \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_response_headers\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    107\u001b[0m     trace\u001b[38;5;241m.\u001b[39mreturn_value \u001b[38;5;241m=\u001b[39m (\n\u001b[1;32m    108\u001b[0m         http_version,\n\u001b[1;32m    109\u001b[0m         status,\n\u001b[1;32m    110\u001b[0m         reason_phrase,\n\u001b[1;32m    111\u001b[0m         headers,\n\u001b[1;32m    112\u001b[0m     )\n\u001b[1;32m    114\u001b[0m network_stream \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_network_stream\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/http11.py:177\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_response_headers\u001b[0;34m(self, request)\u001b[0m\n\u001b[1;32m    174\u001b[0m timeout \u001b[38;5;241m=\u001b[39m timeouts\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mread\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m)\n\u001b[1;32m    176\u001b[0m \u001b[38;5;28;01mwhile\u001b[39;00m \u001b[38;5;28;01mTrue\u001b[39;00m:\n\u001b[0;32m--> 177\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_receive_event\u001b[49m\u001b[43m(\u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    178\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(event, h11\u001b[38;5;241m.\u001b[39mResponse):\n\u001b[1;32m    179\u001b[0m         \u001b[38;5;28;01mbreak\u001b[39;00m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_sync/http11.py:217\u001b[0m, in \u001b[0;36mHTTP11Connection._receive_event\u001b[0;34m(self, timeout)\u001b[0m\n\u001b[1;32m    214\u001b[0m     event \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mnext_event()\n\u001b[1;32m    216\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m event \u001b[38;5;129;01mis\u001b[39;00m h11\u001b[38;5;241m.\u001b[39mNEED_DATA:\n\u001b[0;32m--> 217\u001b[0m     data \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_network_stream\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    218\u001b[0m \u001b[43m        \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mREAD_NUM_BYTES\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mtimeout\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtimeout\u001b[49m\n\u001b[1;32m    219\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    221\u001b[0m     \u001b[38;5;66;03m# If we feed this case through h11 we'll raise an exception like:\u001b[39;00m\n\u001b[1;32m    222\u001b[0m     \u001b[38;5;66;03m#\u001b[39;00m\n\u001b[1;32m    223\u001b[0m     \u001b[38;5;66;03m#     httpcore.RemoteProtocolError: can't handle event type\u001b[39;00m\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    227\u001b[0m     \u001b[38;5;66;03m# perspective. Instead we handle this case distinctly and treat\u001b[39;00m\n\u001b[1;32m    228\u001b[0m     \u001b[38;5;66;03m# it as a ConnectError.\u001b[39;00m\n\u001b[1;32m    229\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m data \u001b[38;5;241m==\u001b[39m \u001b[38;5;124mb\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_h11_state\u001b[38;5;241m.\u001b[39mtheir_state \u001b[38;5;241m==\u001b[39m h11\u001b[38;5;241m.\u001b[39mSEND_RESPONSE:\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/httpcore/_backends/sync.py:128\u001b[0m, in \u001b[0;36mSyncStream.read\u001b[0;34m(self, max_bytes, timeout)\u001b[0m\n\u001b[1;32m    126\u001b[0m \u001b[38;5;28;01mwith\u001b[39;00m map_exceptions(exc_map):\n\u001b[1;32m    127\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sock\u001b[38;5;241m.\u001b[39msettimeout(timeout)\n\u001b[0;32m--> 128\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sock\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrecv\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmax_bytes\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/ssl.py:1232\u001b[0m, in \u001b[0;36mSSLSocket.recv\u001b[0;34m(self, buflen, flags)\u001b[0m\n\u001b[1;32m   1228\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m flags \u001b[38;5;241m!=\u001b[39m \u001b[38;5;241m0\u001b[39m:\n\u001b[1;32m   1229\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m   1230\u001b[0m             \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mnon-zero flags not allowed in calls to recv() on \u001b[39m\u001b[38;5;132;01m%s\u001b[39;00m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;241m%\u001b[39m\n\u001b[1;32m   1231\u001b[0m             \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m)\n\u001b[0;32m-> 1232\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[43mbuflen\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1233\u001b[0m \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m   1234\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28msuper\u001b[39m()\u001b[38;5;241m.\u001b[39mrecv(buflen, flags)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/ssl.py:1105\u001b[0m, in \u001b[0;36mSSLSocket.read\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m   1103\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_sslobj\u001b[38;5;241m.\u001b[39mread(\u001b[38;5;28mlen\u001b[39m, buffer)\n\u001b[1;32m   1104\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 1105\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_sslobj\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mread\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mlen\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[1;32m   1106\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m SSLError \u001b[38;5;28;01mas\u001b[39;00m x:\n\u001b[1;32m   1107\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m x\u001b[38;5;241m.\u001b[39margs[\u001b[38;5;241m0\u001b[39m] \u001b[38;5;241m==\u001b[39m SSL_ERROR_EOF \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39msuppress_ragged_eofs:\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "# responses = []\n",
    "\n",
    "# for idx, prompt in enumerate(prompts):\n",
    "#     print(f\"Processing prompt {idx+1}/{len(prompts)}...\")\n",
    "#     try:\n",
    "#         response = client.chat.completions.create(\n",
    "#             model=\"gpt-4o\",\n",
    "#             messages=[\n",
    "#                 {\n",
    "#                     \"role\": \"system\",\n",
    "#                     \"content\": [\n",
    "#                         {\n",
    "#                             \"type\": \"text\",\n",
    "#                             \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
    "#                         }\n",
    "#                     ]\n",
    "#                 },\n",
    "#                 {\n",
    "#                     \"role\": \"user\",\n",
    "#                     \"content\": [\n",
    "#                         {\n",
    "#                             \"type\": \"text\",\n",
    "#                             \"text\": prompt\n",
    "#                         }\n",
    "#                     ]\n",
    "#                 }\n",
    "#             ],\n",
    "#             response_format={\"type\": \"text\"},\n",
    "#             temperature=1,\n",
    "#             max_completion_tokens=2048,\n",
    "#             top_p=1,\n",
    "#             frequency_penalty=0,\n",
    "#             presence_penalty=0\n",
    "#         )\n",
    "#         responses.append(response)\n",
    "#         print(response)\n",
    "#     except Exception as e:\n",
    "#         print(f\"Error processing prompt {idx+1}: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "# data = []\n",
    "# for prompt, resp in zip(prompts, responses):\n",
    "#     try:\n",
    "#         # Extract the text answer from the ChatCompletion object\n",
    "#         answer_text = resp.choices[0].message.content\n",
    "#     except Exception as e:\n",
    "#         answer_text = None\n",
    "#         print(f\"Error extracting answer: {e}\")\n",
    "#     data.append({\n",
    "#         \"prompt\": prompt,\n",
    "#         \"response\": answer_text\n",
    "#     })\n",
    "\n",
    "# # Create a DataFrame from the collected data\n",
    "# df_responses = pd.DataFrame(data)\n",
    "\n",
    "# csv_path = \"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/location_description/chat_responses.csv\"\n",
    "# parquet_path = \"/home/chb3333/yulab/chb3333/data_extraction/sample_location_tumor_description/location_description/chat_responses.parquet\"\n",
    "\n",
    "# # Save the DataFrame as a CSV file\n",
    "# df_responses.to_csv(csv_path, index=False)\n",
    "# print(f\"Responses saved to {csv_path}\")\n",
    "\n",
    "# # Save the DataFrame as a Parquet file (requires pyarrow or fastparquet)\n",
    "# df_responses.to_parquet(parquet_path, index=False)\n",
    "# print(f\"Responses saved to {parquet_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
